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i 
ABSTRACT 
 Psychiatric illnesses are disorders that affect millions worldwide. 
Evidence from quantitative and molecular genetics analysis suggests a strong 
genetic component to these disorders. There is also evidence that embryonic 
neurodevelopment is a key period in the progression schizophrenia. The aim of 
the present study was to use post-mortem human hippocampus from subjects 
of a variety of psychiatric phenotypes to investigate neurodevelopmentally-
relevant gene expression in this region of the adult human brain. Particular 
interest is paid to schizophrenia risk gene DISC1; it has been shown to exhibit 
linkage and association to schizophrenia and is highly involved in embryonic 
and post natal neurodevelopmental processes. The results reported in this 
study indicate that DISC1 binding partners, and genes used to mark 
neurogenesis, can be found aberrantly expressed in schizophrenia and bipolar 
disorder, relative to controls. The results also suggest that DISC1 genotype may 
predict expression patterns of DISC1 binding partners and neurogenesis 
markers, irrespective of diagnosis. This may provide clues to the timing and 
nature of abnormal brain development in this illness and aid in development of 
treatment strategies. 
 
 
 
Keywords:  
Psychiatry, Gene Expression, Neurodevelopment, Dentate Gyrus 
 
iii 
ACKNOWLEDGEMENTS 
 I would like to thank my family for their infinite patience during the course 
of all my studies and especially during this thesis. Without their support I would 
not be submitting this piece of work. 
 I would also like to thank my supervisor Dr Carla Toro for giving me this 
opportunity. She has provided the right balance of guidance and freedom, which 
I believe has enabled me to gain the utmost from the experience. 
 Thanks go to all the staff and students at Cranfield University who in 
anyway helped me during the course of this project. Special mentions are 
reserved for: Dr. Sheila Govind, without whom I would still be in the lab running 
standard curves! Dr. Clare Humphries, you introduced to me a much easier life 
managing my Word documents (and also Twitter). Dr. Emmanuel Matas, you 
were always a reliable shoulder to ‘man-cry’ on and our time spent together as 
a neuropsychiatry team was invaluable. Thanks again to everyone; all the 
people who provided inspiration during the deep dark hours of toil and labour 
were greatly appreciated. 
 This work was supported by the Engineering and Physical Sciences 
Research Council and the Margaret Temple Award from the British Medical 
Association to Dr. Carla Toro. Postmortem brain tissue was donated by The 
Stanley Medical Research Institute Brain Collection courtesy of Drs. Michael B. 
Knable, E. Fuller Torrey, Maree J. Webster, and Robert H. Yolken. 
 I would like to dedicate this thesis to a dear friend, Zoe Anderson, who 
passed whilst I was studying at Cranfield. Here’s to you! 
 
v 
TABLE OF CONTENTS 
ABSTRACT ......................................................................................................... i 
ACKNOWLEDGEMENTS................................................................................... iii 
LIST OF FIGURES ........................................................................................... viii 
LIST OF TABLES .............................................................................................. xx 
1 INTRODUCTION ............................................................................................. 1 
1.1 Schizophrenia and Other Major Psychiatric Disorders .............................. 1 
1.2 Neurobiological Findings ........................................................................... 2 
1.3 Genetic Literature ..................................................................................... 7 
1.3.1 Quantitative Genetics ......................................................................... 7 
1.3.2 Molecular Genetics............................................................................. 9 
1.3.3 Genetic Contribution To Disease ..................................................... 14 
1.4 Evidence of a Neurodevelopmental Component ..................................... 15 
1.4.1 Cytoarchitectural, Neuroanatomical and Structural Findings ............ 15 
1.4.2 Environmental Factors ..................................................................... 16 
1.4.3 Premorbid Findings .......................................................................... 16 
1.4.4 Neurogenesis and Schizophrenia .................................................... 17 
1.5 Adult Neurogenesis................................................................................. 18 
1.5.1 Adult Olfactory Neurogenesis ........................................................... 19 
1.5.2 Adult Hippocampal Neurogenesis .................................................... 20 
1.5.3 Immunohistological Markers ............................................................. 20 
1.6 Dentate Gyrus Gene Expression ............................................................ 23 
1.6.1 Neurodevelopmental Genes ............................................................. 24 
1.6.2 Hormone Receptors ......................................................................... 25 
1.6.3 Regulators of Neurotransmission ..................................................... 25 
1.6.4 Synaptic Markers ............................................................................. 28 
1.7 The Duality of Adult and Embryonic Neurogenesis ................................. 29 
1.7.1 Molecular Overlap ............................................................................ 30 
1.7.2 Functional and Morphological Overlap ............................................. 32 
1.8 Disrupted-in-schizophrenia- (DISC1) ...................................................... 33 
1.8.1 DISC1 Expression ............................................................................ 34 
1.8.2 DISC1 Function ................................................................................ 35 
1.8.3 DISC1 Binding Partners ................................................................... 38 
2 RATIONALE AND AIMS ................................................................................ 43 
2.1 Rationale ................................................................................................. 43 
2.2 Aims ........................................................................................................ 43 
2.3 Hypotheses ............................................................................................. 44 
2.4 Objectives ............................................................................................... 44 
3 MATERIALS AND METHODS ....................................................................... 47 
3.1 Subjects .................................................................................................. 47 
3.2 Dentate Dissections ................................................................................ 47 
vi 
3.3 Extraction Procedures ............................................................................. 49 
3.4 Quantitative Polymerase Chain Reaction (qPCR) .................................. 50 
3.4.1 Enzyme Selection ............................................................................ 52 
3.4.2 Standard Curves .............................................................................. 54 
3.5 Allelic Discrimination ............................................................................... 65 
3.6 Immunohistochemistry (IHC) .................................................................. 67 
3.6.1 DAB Antibody Trials ......................................................................... 68 
3.6.2 Near-IR IHC ..................................................................................... 75 
3.7 Statistical Analysis .................................................................................. 78 
3.7.1 Outlier Removal ............................................................................... 79 
3.7.2 Confounding Factor Detection ........................................................ 112 
4 GENOTYPE ANALYSIS .............................................................................. 125 
4.1 DISC1 Locus ......................................................................................... 126 
4.1.1 rs3738401 ...................................................................................... 126 
4.1.2 rs6675281 ...................................................................................... 131 
4.1.3 rs3737597 ...................................................................................... 136 
4.1.4 rs821616 ........................................................................................ 140 
4.2 Schizophrenia-susceptibility Genes ...................................................... 146 
4.2.1 Regulatory-associated Protein of MTOR (RPTOR) SNP 
rs2289759 ............................................................................................... 146 
4.2.2 Brain-derived Neurotrophic Factor (BDNF) SNP rs6265 ................ 150 
5 QUANTITATIVE PCR (qPCR) ..................................................................... 157 
5.1 DISC1 Binding Partners ........................................................................ 165 
5.1.1 DPYSL2 ......................................................................................... 165 
5.1.2 FEZ1 .............................................................................................. 171 
5.1.3 NDEL1 ............................................................................................ 180 
5.1.4 PDE4B ........................................................................................... 183 
5.2 Neurogenesis-related Genes ................................................................ 187 
5.2.1 DCX ................................................................................................ 187 
5.2.2 NEUROD1 ...................................................................................... 195 
5.3 Regional Analysis ................................................................................. 199 
6 QUANTITATIVE IMMUNOHISTOCHEMISTRY .......................................... 201 
6.1 FEZ1 Protein Density ............................................................................ 205 
6.1.1 DISC1 rs821616 ............................................................................. 207 
6.2 NEUROD1 Protein Density ................................................................... 209 
7 DISCUSSION .............................................................................................. 215 
7.1 Genotype Analysis ................................................................................ 215 
7.2 Gene Expression .................................................................................. 216 
7.2.1 DCX ................................................................................................ 216 
7.2.2 FEZ1 .............................................................................................. 220 
7.2.3 NEUROD1 and DISC1 ................................................................... 228 
7.2.4 Other Effects .................................................................................. 231 
vii 
7.3 Limitations ............................................................................................. 232 
7.4 Conclusions .......................................................................................... 234 
8 REFERENCES ............................................................................................ 237 
9 APPENDICES ............................................................................................. 273 
Appendix A Dentate Gyrus Gene Expression ............................................. 273 
Appendix B Anterior Hippocampus Coronal Sections ................................. 325 
Appendix C Parallel Outlier Analyses ......................................................... 331 
Continuous Variables: Non-Parametric Correlations (w/ Outliers Incl.) .......... 331 
Dichotomous Variables: Non-Parametric Tests (w/ Outliers Incl.) .................. 335 
 
 
viii 
LIST OF FIGURES  
1-1 From Seeman et al.19 A graph demonstrating the correlation between D2 
receptor affinity and clinical potency of first-generation antipsychotic 
medication. The x-axis shows the recommended clinical dosage; the y-axis 
describes the half maximal inhibitory concentration. ................................... 4 
1-2 From Eastwood and Harrrrison39 Immunoautradiograph of the synaptic 
marker protein, synaptophysin in the hippocampus. In this study, the 
control subjects had on average more of this protein than did the patients 
with schizophrenia reflected in the paler second image. ............................. 6 
1-3 From Kirov et al.45 Risk of developing schizophrenia in relatives of 
probands. The data are based on the review of studies compiled by 
Gottesman42. ............................................................................................... 8 
1-4 Adapted from Kirov et al.45 A diagram depicting the human karyotype; 
rectangular bars and black arrows highlight a selection of chromosomal loci 
with reported linkage to schizophrenia. ..................................................... 14 
1-5 Adapted from the Society for Neuroscience website (www.sfn.org) Diagram 
showing critical regions in the brain for adult neurogenesis. ..................... 20 
1-6 From Von Bohlen and Halbach138 A diagram showing the generation and 
development of new neurons within the granular layer of the DG divided 
into five stages. At each stage, different specific molecules are expressed 
in the developing neuron, some of these markers have the potential to be 
used to quantify and qualify adult neurogenesis[NeuN = neuron-specific 
nuclear protein; GFAP = glial fibrillary acidic protein; PSA-NCAM = 
polysialylated neural cell adhesion molecule; TUC-4 = CRMP4 (collapsin 
response-mediated protein4); Tuj-1 = class III β-tubulin]. ......................... 21 
1-7 Taken from St. Clair et al.84 and Blackwood et al.205 A pedigree showing the 
co-segregation of a balanced t(1:11) translocation with psychiatric illness 34 
1-8 From Camargo et al.213 DISC1 network of protein-protein interactions. 
Underlined in red are proteins that interact with DISC1 and were used in 
further yeast-two hybrid (Y2H) screens to derive the protein interaction 
network. Connecting lines indicate an interaction between molecules. In 
boxes are proteins that interact with the protein screened in further Y2H 
screens. A black asterisk indicates a protein that is located in a 
schizophrenia risk locus. A purple asterisk indicates a protein that is found 
in regions where chromosomal abnormalities have been linked to 
schizophrenia ............................................................................................ 36 
1-9 From Lipska et al.204 Graph to show the expression of DISC1 and its binding 
partners RNA in the DLPFC and the hippocampus in brains of 
schizophrenic patients as percentages of the average expression of normal 
controls. NUDEL = NDEL1, asterisks denote significance, P<0.05 ........... 37 
ix 
1-10 Annotated DISC1 protein. Grey area denotes reported FEZ1 binding 
region, red arrows show relative position of non-synonymous 
polymorphisms. ......................................................................................... 39 
1-11 Annotated DISC1 protein. Grey area denotes reported NDEL1 binding 
region, red arrows show relative positions of non-synonymous 
polymorphisms. ......................................................................................... 40 
1-12 Annotated DISC1 protein. Grey area denotes reported PDE4B/D binding 
region, red arrows show relative positions of non-synonymous 
polymorphisms. ......................................................................................... 41 
3-1 Picture of anterior hippocampus coronal section with dissected regions 
annotated (DG = dentate gyrus molecular layer, CA1 = cornu ammonis 1, 
CA2 = cornu ammonis 2, CA3 = cornu ammonis 3 ................................... 48 
3-2 Picture of anterior hippocampus coronal section without annotations ........ 48 
3-3 Graph showing real-time amplification of a DISC1 locus using a TaqMan 
assay with VIC probe. The 3 sets of curves represent the 3 Taq 
polymerase enzymes tested; Roche = Roche Universal Probe Master 
(#04913957001), ABI = TaqMan Universal Mastermix (#4364341), 
PrimerDesign = PrimerDesign Precision Mastermix (#Precision) ............. 53 
3-4 Graph showing the average threshold cycle (cq) number from 20ng DNA, 
obtained using DNA polymerase from a variety of suppliers. Roche = 
Roche Universal Probe Master (#04913957001), ABI = TaqMan Universal 
Mastermix (#4364341), PrimerDesign = PrimerDesign Precision Mastermix 
(#Precision) ............................................................................................... 54 
3-5 3% agarose gel with 25bp ladder comparing size of PCR products obtained 
from the gene expression assay for DCX, DPYSL2, and FEZ1, NEUROD1. 
Image is annotated with estimated amplicon sizes ................................... 56 
3-6 3% agarose gel, with 25bp ladder, comparing size of PCR products 
obtained from the gene expression assays for NDEL1 and PDE4B. Image 
is annotated with estimated amplicon sizes .............................................. 56 
3-7 Standard curve of DCX assay representing the threshold cycles of standard 
dilutions prepared from a synthetic oligonucleotide designed from the DCX 
gene .......................................................................................................... 58 
3-8 Standard curve of DPYSL2 assay representing the threshold cycles of 
standard dilutions prepared from a synthetic oligonucleotide designed from 
the DPYSL2 gene ..................................................................................... 59 
3-9 Standard curve of FEZ1 assay representing the threshold cycles of 
standard dilutions prepared from a synthetic oligonucleotide designed from 
the FEZ1 gene .......................................................................................... 60 
3-10 Standard curve of HMBS assay representing the threshold cycles of 
standard dilutions prepared from pooled anterior hippocampus cDNA. .... 61 
x 
3-11 Standard curve of NDEL1 assay representing the threshold cycles of 
standard dilutions prepared from a synthetic oligonucleotide designed from 
the NDEL1 gene ........................................................................................ 62 
3-12 Standard curve of NEUROD1 assay representing the threshold cycles of 
standard dilutions prepared from a synthetic oligonucleotide designed from 
the NEUROD1 gene .................................................................................. 63 
3-13 Standard curve of PDE4B assay representing the threshold cycles of 
standard dilutions prepared from a synthetic oligonucleotide designed from 
the PDE4B gene ....................................................................................... 64 
3-14 Standard curve of SDHA assay representing the threshold cycles of 
standard dilutions prepared from pooled anterior hippocampus cDNA ..... 65 
3-15 The 5’ Nuclease process from the ABI TaqMan SNP Genotyping Assays 
Protocol (4332856C) ................................................................................. 66 
3-16 DAB Immunoreactivity of FEZ1 antibody conjugate in coronal sections of 
dorsolateral prefrontal cortex grey matter. Staining highlights neurite 
extensions (small black arrows) and mainly pyramidal-shaped neuronal 
somata (large black arrows). ..................................................................... 69 
3-17 DAB Immunoreactivity of NEUROD1 antibody conjugate in coronal 
sections of anterior hippocampus. Staining highlights the dentate gyrus 
(small black arrows) and the appearance of sporadic staining of spheroid 
staining in the hilus (CA4) large black arrows). ......................................... 70 
3-18 DAB Immunoreactivity of NEUROD1 antibody conjugate in the dentate 
gyrus granule cell layer. Staining highlights the mainly pyramidal-shaped 
somata stained (large black arrows) and their process (small black arrows)
 .................................................................................................................. 71 
3-19 DAB Immunoreactivity of PDE4B antibody conjugate in sections of anterior 
hippocampus. The clear lack of discrete cellular staining is highlighted by 
comparisons with NEUROD1 staining trials in the same region of the 
hippocampus where staining of the dentate gyrus can be observed (inset, 
small black arrows) ................................................................................... 72 
3-20 DAB Immunoreactivity of PDE4B antibody conjugate in the hilus (CA4). 
The appearance of sparse staining of spheroid cell somata can be 
observed (large black arrows) ................................................................... 73 
3-21 DAB Immunoreactivity of DPYSL2 antibody conjugate in coronal sections 
of dorsolateral prefrontal cortex (white matter). The apparent staining of 
spheroid cell somata (large black arrows) is largely obscured by high non-
specific staining in the neuropil. ................................................................ 74 
3-22 DAB Immunoreactivity of DPYSL2 antibody conjugate in coronal sections 
of dorsolateral prefrontal cortex (white matter) counter-stained with 
haematoxylin. The sparse spheroid staining can be clearly attributed to 
xi 
somata counter-stained with haematoxylin, though this is still obscured by 
non-specific staining. ................................................................................. 75 
3-23 Images of FEZ1 and NEUROD1 double immuno-labelling (A, Grey matter 
ROI = Dashed white line, White matter ROI = dashed black line, Dentate 
gyrus ROI = solid white line); NEUROD1 immuno-labelling (B); FEZ1 
immuno-labelling. No primary antibody negative controls for NEUROD1 
and FEZ double immuno-labelling (D), NEUROD1 (E), and FEZ1 (F) ...... 77 
3-24 Box-plots showing distributions of DCX mRNA transcript levels in the 
anterior parahippocampal region and the identified outliers. Asterisk 
denotes outliers identified using Tukey Outlier Labelling Rule (g = 3); circle 
indicates (g = 1.5). All of the indicated Tukey outliers were also highlighted 
by the ‘2.5 standard deviations from the mean’ test. NRQ = Normalised 
Relative Quantity, bpd = Bipolar Disorder, mdd = Major Depressive 
Disorder, scz = Schizophrenia, con = controls, ......................................... 80 
3-25 Box-plots showing distributions of DCX mRNA transcript levels in the 
anterior parahippocampal region after the initial removal of labelled outliers. 
Asterisk denotes outliers identified using Tukey Outlier Labelling Rule (g = 
3); circle indicates (g = 1.5). All of the indicated Tukey outliers were also 
highlighted by the ‘2.5 standard deviations from the mean’ test. NRQ = 
Normalised Relative Quantity, bpd = Bipolar Disorder, mdd = Major 
Depressive Disorder, scz = Schizophrenia, con = controls, ...................... 80 
3-26 Scatter plot showing DCX mRNA transcript levels in the anterior 
parahippocampal region after Tukey outlier removal. Black arrows indicate 
removed outliers that were still highlighted by the ‘2.5 standard deviations 
from the mean’ test. NRQ = Normalised Relative Quantity, bpd = Bipolar 
Disorder, mdd = Major Depressive Disorder, scz = Schizophrenia, con = 
controls...................................................................................................... 81 
3-27 Scatter plot showing DCX mRNA transcript levels in the non-neurogenic 
hippocampal formation. Black arrows indicate removed outliers highlighted 
by the ‘2.5 standard deviations from the mean’ test. NRQ = Normalised 
Relative Quantity, bpd = Bipolar Disorder, mdd = Major Depressive 
Disorder, scz = Schizophrenia. ................................................................. 82 
3-28 Box-plots showing distributions of DPYSL2 mRNA transcript levels in the 
anterior parahippocampal region and the identified outliers. Asterisk 
denotes outliers identified using Tukey Outlier Labelling Rule (g = 3); circle 
indicates (g = 1.5). All of the indicated Tukey outliers were also highlighted 
by the ‘2.5 standard deviations from the mean’ test. NRQ = Normalised 
Relative Quantity, bpd = Bipolar Disorder, mdd = Major Depressive 
Disorder, scz = Schizophrenia, con = controls, ......................................... 83 
3-29 Box-plots showing distributions of DPYSL2 mRNA transcript levels in the 
anterior parahippocampal region after the initial removal of labelled outliers. 
Circles denote outliers identified using Tukey Outlier Labelling Rule (g = 
1.5). All of the indicated Tukey outliers were also highlighted by the ‘2.5 
standard deviations from the mean’ test. NRQ = Normalised Relative 
xii 
Quantity, bpd = Bipolar Disorder, mdd = Major Depressive Disorder, scz = 
Schizophrenia, con = controls, .................................................................. 84 
3-30 Scatter plot showing DPYSL2 mRNA transcript levels in the anterior 
parahippocampal region after Tukey outlier removal. NRQ = Normalised 
Relative Quantity, bpd = Bipolar Disorder, mdd = Major Depressive 
Disorder, scz = Schizophrenia, con = controls. ......................................... 85 
3-31 Scatter plot showing DPYSL2 mRNA transcript levels in the non-
neurogenic hippocampal formation. No outliers were identified. NRQ = 
Normalised Relative Quantity, bpd = Bipolar Disorder, mdd = Major 
Depressive Disorder, scz = Schizophrenia. ............................................... 86 
3-32 Box-plots showing distributions of FEZ1 mRNA transcript levels in the 
anterior parahippocampal region and the identified outliers. Asterisk 
denotes outliers identified using Tukey Outlier Labelling Rule (g = 3); circle 
indicates (g = 1.5). All of the indicated Tukey outliers were also highlighted 
by the ‘2.5 standard deviations from the mean’ test. NRQ = Normalised 
Relative Quantity, bpd = Bipolar Disorder, mdd = Major Depressive 
Disorder, scz = Schizophrenia, con = controls, ......................................... 87 
3-33 Box-plots showing distributions of FEZ1 mRNA transcript levels in the 
anterior parahippocampal region after the initial removal of labelled outliers. 
Asterisk denotes outliers identified using Tukey Outlier Labelling Rule (g = 
3); circle indicates (g = 1.5). All of the indicated Tukey outliers were also 
highlighted by the ‘2.5 standard deviations from the mean’ test. NRQ = 
Normalised Relative Quantity, bpd = Bipolar Disorder, mdd = Major 
Depressive Disorder, scz = Schizophrenia, con = controls, ...................... 88 
3-34 Scatter plot showing FEZ1 mRNA transcript levels in the anterior 
parahippocampal region after Tukey outlier removal. NRQ = Normalised 
Relative Quantity, bpd = Bipolar Disorder, mdd = Major Depressive 
Disorder, scz = Schizophrenia, con = controls. ......................................... 89 
3-35 Scatter plot showing FEZ1 mRNA transcript levels in the non-neurogenic 
hippocampal formation. Black arrows indicate removed outliers highlighted 
by the ‘2.5 standard deviations from the mean’ test. NRQ = Normalised 
Relative Quantity, bpd = Bipolar Disorder, mdd = Major Depressive 
Disorder, scz = Schizophrenia. ................................................................. 90 
3-36 Box-plots showing distributions of FEZ1 protein density levels across the 
anterior parahippocampal grey matter and the identified outliers. Circles 
denote outliers identified using Tukey Outlier Labelling Rule (g = 1.5). In 
this case, the indicated Tukey outliers were not also highlighted by the ‘2.5 
standard deviations from the mean’ test, they were therefore not removed. 
Isi = Mean Specific Intensity, bpd = Bipolar Disorder, mdd = Major 
Depressive Disorder, scz = Schizophrenia, con = controls, ...................... 91 
3-37 Scatter plot showing FEZ1 protein density levels across the anterior 
parahippocampal grey matter after Tukey outlier removal. Isi = Mean 
xiii 
Specific Intensity, bpd = Bipolar Disorder, mdd = Major Depressive 
Disorder, scz = Schizophrenia, con = controls. ......................................... 92 
3-38 Box-plots showing distributions of FEZ1 protein density levels across the 
anterior parahippocampal white matter and the identified outliers. Circles 
denote outliers identified using Tukey Outlier Labelling Rule (g = 1.5). All of 
the indicated Tukey outliers were also highlighted by the ‘2.5 standard 
deviations from the mean’ test. Isi = Mean Specific Intensity, bpd = Bipolar 
Disorder, mdd = Major Depressive Disorder, scz = Schizophrenia, con = 
controls,..................................................................................................... 93 
3-39 Scatter plot showing FEZ1 protein density levels across the anterior 
parahippocampal white matter after Tukey outlier removal. Isi = Mean 
Specific Intensity, bpd = Bipolar Disorder, mdd = Major Depressive 
Disorder, scz = Schizophrenia, con = controls. ......................................... 94 
3-40 Box-plots showing distributions of FEZ1 protein density levels in the 
dentate gyrus. No outliers were identified. Isi = Mean Specific Intensity, bpd 
= Bipolar Disorder, mdd = Major Depressive Disorder, scz = Schizophrenia, 
con = controls, ........................................................................................... 95 
3-41 Scatter plot showing FEZ1 protein density levels in the dentate gyrus. No 
identifiers were identified in this region. Isi = Mean Specific Intensity, bpd = 
Bipolar Disorder, mdd = Major Depressive Disorder, scz = Schizophrenia, 
con = controls. ........................................................................................... 96 
3-42 Box-plots showing distributions of NDEL1 mRNA transcript levels in the 
anterior parahippocampal region and the identified outliers. Asterisk 
denotes outliers identified using Tukey Outlier Labelling Rule (g = 3); circle 
indicates (g = 1.5). All of the indicated Tukey outliers were also highlighted 
by the ‘2.5 standard deviations from the mean’ test. NRQ = Normalised 
Relative Quantity, bpd = Bipolar Disorder, mdd = Major Depressive 
Disorder, scz = Schizophrenia, con = controls, ......................................... 97 
3-43 Box-plots showing distributions of NDEL1 mRNA transcript levels in the 
anterior parahippocampal region after the initial removal of labelled outliers. 
Circles denote outliers identified using Tukey Outlier Labelling Rule (g = 
1.5). All of the indicated Tukey outliers were also highlighted by the ‘2.5 
standard deviations from the mean’ test. NRQ = Normalised Relative 
Quantity, bpd = Bipolar Disorder, mdd = Major Depressive Disorder, scz = 
Schizophrenia, con = controls, .................................................................. 98 
3-44 Scatter plot showing NDEL1 mRNA transcript levels in the anterior 
parahippocampal region after Tukey outlier removal. NRQ = Normalised 
Relative Quantity, bpd = Bipolar Disorder, mdd = Major Depressive 
Disorder, scz = Schizophrenia, con = controls. ......................................... 99 
3-45 Scatter plot showing NDEL1 mRNA transcript levels in the non-neurogenic 
hippocampal formation. No outliers were identified. NRQ = Normalised 
Relative Quantity, bpd = Bipolar Disorder, mdd = Major Depressive 
Disorder, scz = Schizophrenia. ............................................................... 100 
xiv 
3-46 Box-plots showing distributions of NEUROD1 mRNA transcript levels in 
the anterior parahippocampal region and the identified outliers. Circle 
denotes outliers identified using Tukey Outlier Labelling Rule (g = 1.5). All 
of the indicated Tukey outliers were also highlighted by the ‘2.5 standard 
deviations from the mean’ test. NRQ = Normalised Relative Quantity, bpd = 
Bipolar Disorder, mdd = Major Depressive Disorder, scz = Schizophrenia, 
con = controls, ......................................................................................... 101 
3-47 Scatter plot showing NEUROD1 mRNA transcript levels in the anterior 
parahippocampal region after Tukey outlier removal. NRQ = Normalised 
Relative Quantity, bpd = Bipolar Disorder, mdd = Major Depressive 
Disorder, scz = Schizophrenia, con = controls. ....................................... 102 
3-48 Scatter plot showing NEUROD1 mRNA transcript levels in the non-
neurogenic hippocampal formation. Black arrow indicates removed outliers 
highlighted by the ‘2.5 standard deviations from the mean’ test. NRQ = 
Normalised Relative Quantity, bpd = Bipolar Disorder, mdd = Major 
Depressive Disorder, scz = Schizophrenia. ............................................. 103 
3-49 Box-plots showing distributions of NEUROD1 protein density levels across 
the anterior parahippocampal grey matter and the identified outliers. Circles 
denote outliers identified using Tukey Outlier Labelling Rule (g = 1.5). All of 
the indicated Tukey outliers were also highlighted by the ‘2.5 standard 
deviations from the mean’ test. Isi = Mean Specific Intensity, bpd = Bipolar 
Disorder, mdd = Major Depressive Disorder, scz = Schizophrenia, con = 
controls,................................................................................................... 104 
3-50 Scatter plot showing NEUROD1 protein density levels across the anterior 
parahippocampal grey matter after Tukey outlier removal. Isi = Mean 
Specific Intensity, bpd = Bipolar Disorder, mdd = Major Depressive 
Disorder, scz = Schizophrenia, con = controls. ....................................... 105 
3-51 Box-plots showing distributions of NEUROD1 protein density levels across 
the anterior parahippocampal white matter and the identified outliers. 
Circles denote outliers identified using Tukey Outlier Labelling Rule (g = 
1.5). All of the indicated Tukey outliers were also highlighted by the ‘2.5 
standard deviations from the mean’ test. Isi = Mean Specific Intensity, bpd = 
Bipolar Disorder, mdd = Major Depressive Disorder, scz = Schizophrenia, 
con = controls, ......................................................................................... 106 
3-52 Scatter plot showing NEUROD1 protein density levels across the anterior 
parahippocampal white matter after Tukey outlier removal. Isi = Mean 
Specific Intensity, bpd = Bipolar Disorder, mdd = Major Depressive 
Disorder, scz = Schizophrenia, con = controls. ....................................... 107 
3-53 Box-plots showing distributions of FEZ1 protein density levels in the 
dentate gyrus. No outliers were identified. Isi = Mean Specific Intensity, bpd 
= Bipolar Disorder, mdd = Major Depressive Disorder, scz = Schizophrenia, 
con = controls, ......................................................................................... 108 
xv 
3-54 Scatter plot showing FEZ1 protein density levels in the dentate gyrus. No 
identified in this region. Isi = Mean Specific Intensity, bpd = Bipolar 
Disorder, mdd = Major Depressive Disorder, scz = Schizophrenia, con = 
controls.................................................................................................... 109 
3-55 Box-plots showing distributions of PDE4B mRNA transcript levels in the 
anterior parahippocampal region and the identified outliers. Circle denotes 
outliers identified using Tukey Outlier Labelling Rule (g = 1.5). All of the 
indicated Tukey outliers were also highlighted by the ‘2.5 standard 
deviations from the mean’ test. NRQ = Normalised Relative Quantity, bpd = 
Bipolar Disorder, mdd = Major Depressive Disorder, scz = Schizophrenia, 
con = controls, ......................................................................................... 110 
3-56 Scatter plot showing PDE4B mRNA transcript levels in the anterior 
parahippocampal region after Tukey outlier removal. NRQ = Normalised 
Relative Quantity, bpd = Bipolar Disorder, mdd = Major Depressive 
Disorder, scz = Schizophrenia, con = controls. ....................................... 111 
3-57 Scatter plot showing PDE4B mRNA transcript levels in the non-neurogenic 
hippocampal formation. Black arrows indicate removed outliers highlighted 
by the ‘2.5 standard deviations from the mean’ test. NRQ = Normalised 
Relative Quantity, bpd = Bipolar Disorder, mdd = Major Depressive 
Disorder, scz = Schizophrenia. ............................................................... 112 
4-1 Adapted from Livak et al.250 Formula for normalizing RFUs for the purposes 
of allelic discrimination using the 5’ nuclease assay. .............................. 125 
4-2 Scatter plot of the raw data obtained from the 1st analysis of the DISC1 
rs3738401 SNP. The normalised relative fluorescence unit (NRFU) at cycle 
45 is demonstrated for each fluorophore. ................................................ 127 
4-3 Scatter plot of the raw data obtained from the 2nd analysis of the DISC1 
rs3738401. The normalised relative fluorescence unit (NRFU) at cycle 45 is 
demonstrated for each fluorophore. ........................................................ 128 
4-4 Scatter plot of the raw data obtained from the 3rd analysis of the DISC1 
rs3738401. The normalised relative fluorescence unit (NRFU) at cycle 45 is 
demonstrated for each fluorophore. ........................................................ 128 
4-5 Scatter plot of the raw data obtained from the analysis of DISC1 rs3738401 
in samples missing from the 1st experiment. Each previously missing 
sample was run in duplicate, the normalised relative fluorescence unit 
(NRFU) at cycle 45 is demonstrated for each fluorophore. ..................... 129 
4-6 Scatter plot of the raw data obtained from the 1st analysis of DISC1 
rs6675281. The normalised relative fluorescence unit (NRFU) at cycle 45 is 
demonstrated for each fluorophore. ........................................................ 132 
4-7 Scatter plot of the raw data obtained from the 2nd analysis of DISC1 
rs6675281. Threshold Cycles (Cq) are demonstrated for each fluorophore.
 ................................................................................................................ 133 
xvi 
4-8 Scatter plot of the raw data obtained from the 3rd  analysis of DISC1 
rs6675281. The normalised relative fluorescence unit (NRFU) at cycle 45 is 
demonstrated for each fluorophore. ........................................................ 133 
4-9 Scatter plot of the raw data obtained from the analysis of DISC1 rs6675281 
in samples missing from the 1st experiment. Each previously missing 
sample was run in duplicate, the normalised relative fluorescence unit 
(NRFU) at cycle 45 is demonstrated for each fluorophore.. .................... 134 
4-10 Scatter plot of the raw data obtained from the 1st analysis of DISC1 
rs3737597. The normalised relative fluorescence unit (NRFU) at cycle 45 is 
demonstrated for each fluorophore. ........................................................ 137 
4-11 Scatter plot of the raw data obtained from the 2nd analysis of DISC1 
rs3737597. The normalised relative fluorescence unit (NRFU) at cycle 45 is 
demonstrated for each fluorophore. ........................................................ 138 
4-12 Scatter plot of the raw data obtained from the 1st analysis of DISC1 
rs821616. The normalised relative fluorescence unit (NRFU) at cycle 45 is 
demonstrated for each fluorophore. ........................................................ 141 
4-13 Scatter plot of the raw data obtained from the 2nd analysis of DISC1 
rs821616. The normalised relative fluorescence unit (NRFU) at cycle 45 is 
demonstrated for each fluorophore. ........................................................ 142 
4-14 Scatter plot of the raw data obtained from the 3rd analysis of DISC1 
rs821616. The normalised relative fluorescence unit (NRFU) at cycle 45 is 
demonstrated for each fluorophore. ........................................................ 142 
4-15 Scatter plot of the raw data obtained from the analysis of DISC1 rs821616 
in samples missing from the 1st experiment. Each previously missing 
sample was run in duplicate, the normalised relative fluorescence unit 
(NRFU) at cycle 45 is demonstrated for each fluorophore. ..................... 143 
4-16 Scatter plot of the raw data obtained from the 1st analysis of RPTOR 
rs2289759. The normalised relative fluorescence unit (NRFU) at cycle 45 is 
demonstrated for each fluorophore. ........................................................ 146 
4-17 Scatter plot of the raw data obtained from the 2nd analysis of RPTOR 
rs2289759. The normalised relative fluorescence unit (NRFU) at cycle 45 is 
demonstrated for each fluorophore. ........................................................ 147 
4-18 Scatter plot of the raw data obtained from the analysis of RPTOR 
rs2289759 in samples missing from the 1st experiment. Each previously 
missing sample was run in duplicate, the normalised relative fluorescence 
unit (NRFU) at cycle 45 is demonstrated for each fluorophore................ 148 
4-19 Scatter plot of the raw data obtained from the 1st analysis of BDNF rs6265. 
The normalised relative fluorescence unit (NRFU) at cycle 45 is 
demonstrated for each fluorophore. Large annotated bold shapes surround 
data clusters used to make allele calls. ................................................... 151 
xvii 
4-20 Scatter plot of the raw data obtained from the 2nd analysis of BDNF 
rs6265. The normalised relative fluorescence unit (NRFU) at cycle 45 is 
demonstrated for each fluorophore. Large annotated bold shapes surround 
data clusters used to make allele calls. ................................................... 151 
4-21 Scatter plot of the raw data obtained from the 3rd analysis of BDNF rs6265. 
The normalised relative fluorescence unit (NRFU) at cycle 45 is 
demonstrated for each fluorophore. Large annotated bold shapes surround 
data clusters used to make allele calls. ................................................... 152 
4-22 Scatter plot of the raw data obtained from the analysis of BDNF rs6265 in 
samples missing from the 1st experiment. Each previously missing sample 
was run in duplicate, the normalised relative fluorescence unit (NRFU) at 
cycle 45 is demonstrated for each fluorophore. Large annotated bold 
shapes surround data clusters used to make allele calls. ....................... 153 
5-1 Bar graph showing DPYSL2 mRNA transcript levels across diagnosis in the 
anterior parahippocampal region. † denotes LSD p < .1; †† denotes LSD p 
< .05. BPD = Bipolar Disorder (N = 8), MDD = Major Depressive Disorder 
(N = 7), SCZ = Schizophrenia (N = 8), CON = controls (N = 9). .............. 167 
5-2 Bar graph showing DPYSL2 mRNA transcript levels across diagnosis in the 
non-neurogenic hippocampal formation. BPD = Bipolar Disorder (N = 4), 
MDD = Major Depressive Disorder (N = 4), SCZ = Schizophrenia (N = 4), 
CON = controls (N = 5). .......................................................................... 168 
5-3 Scatter plot showing the DPYSL2 mRNA transcript levels of rs821616 minor 
allele carriers in the anterior parahippocampal region ............................. 169 
5-4 Scatter plot showing the DPYSL2 mRNA transcript levels of rs3738401 
minor allele carriers in the non-neurogenic hippocampal formation ........ 170 
5-5 Scatter plot showing the DPYSL2 mRNA transcript levels of BDNF rs6265 
minor allele carriers in the non-neurogenic hippocampal formation ........ 171 
5-6 Bar graph showing FEZ1 mRNA transcript levels across diagnosis in the 
anterior parahippocampal region. ** denotes p < .05 (Bonferroni-adjusted) 
when controlling for the effects of confounding variables; ‡‡ denotes p < 
.05 (Bonferroni-adjusted). BPD = Bipolar Disorder (N = 7), MDD = Major 
Depressive Disorder (N = 6), SCZ = Schizophrenia (N = 8), CON = controls 
(N = 9). .................................................................................................... 175 
5-7 Bar graph showing FEZ1 mRNA transcript levels across diagnosis in the 
non-neurogenic hippocampal formation. †† denotes Mann-Whitney U and 
post hoc  ANOVA LSD  p < .05. BPD = Bipolar Disorder (N = 4), MDD = 
Major Depressive Disorder (N = 4), SCZ = Schizophrenia (N = 4), CON = 
controls (N = 4)........................................................................................ 176 
5-8 Bar graph showing FEZ1 mRNA transcript levels in the anterior 
parahippocampal region and history of psychosis. ** denotes p < .05 
(Bonferroni-adjusted) when controlling for the effects of disease onset. With 
psychosis (N = 15), without psychosis (N = 15). ..................................... 177 
xviii 
5-9 Scatter plot of FEZ1 mRNA transcript levels in rs3738401 minor allele 
carriers in the anterior parahippocampal region ...................................... 178 
5-10 Scatter plot of FEZ1 mRNA transcript levels in RAPTOR rs32289759 
minor allele carriers in the anterior parahippocampal region ................... 179 
5-11 Scatter plot of FEZ1 mRNA transcript levels in RAPTOR rs2289759 minor 
allele carriers in the non-neurogenic hippocampal formation .................. 180 
5-12 Bar graph showing NDEL11 mRNA transcript levels across diagnosis in 
the anterior parahippocampal region. BPD = Bipolar Disorder (N = 9), MDD 
= Major Depressive Disorder (N = 6), SCZ = Schizophrenia (N = 8), CON = 
controls (N = 7)........................................................................................ 182 
5-13 Bar graph showing NDEL1 mRNA transcript levels across diagnosis in the 
non-neurogenic hippocampal formation. BPD = Bipolar Disorder (N = 4), 
MDD = Major Depressive Disorder (N = 4), SCZ = Schizophrenia (N = 4), 
CON = controls (N = 5). .......................................................................... 183 
5-14 Bar graph showing PDE4B mRNA transcript levels across diagnosis in the 
anterior parahippocampal region. BPD = Bipolar Disorder (N = 10), MDD = 
Major Depressive Disorder (N = 6), SCZ = Schizophrenia (N = 7), CON = 
controls (N = 9)........................................................................................ 185 
5-15 Bar graph showing PDE4B mRNA transcript levels across diagnosis in the 
non-neurogenic hippocampal formation. BPD = Bipolar Disorder (N = 3), 
MDD = Major Depressive Disorder (N = 4), SCZ = Schizophrenia (N = 3), 
CON = controls (N = 5). .......................................................................... 186 
5-16 Scatter plot showing the PDE4B mRNA transcript levels of rs821616 minor 
allele carriers in the anterior parahippocampal region ............................. 187 
5-17 Bar graph showing DCX mRNA transcript levels across diagnosis in the 
anterior parahippocampal region. *** denotes p < .05 (Bonferroni-adjusted) 
against all groups when controlling for the effects of confounding variables. 
BPD = Bipolar Disorder (N = 8), MDD = Major Depressive Disorder (N = 5), 
SCZ = Schizophrenia (N = 9), CON = controls (N = 7). ........................... 191 
5-18 Bar graph showing DCX mRNA transcript levels across diagnosis in the 
non-neurogenic hippocampal formation. ‡ denotes p < .1 (Bonferroni-
adjusted), ‡‡ denotes p < .05 (Bonferroni-adjusted). BPD = Bipolar 
Disorder (N = 3), MDD = Major Depressive Disorder (N = 4), SCZ = 
Schizophrenia (N = 3), CON = controls (N = 5). ...................................... 192 
5-19 Scatter plot of DCX mRNA transcript levels in BDNF rs6265 minor allele 
carriers in the non-neurogenic hippocampal formation ........................... 193 
5-20 Scatter plot of DCX mRNA transcript levels in RAPTOR rs2289759 minor 
allele carriers in the non-neurogenic hippocampal formation .................. 194 
5-21 Bar graph showing NEUROD1 mRNA transcript levels across diagnosis in 
the anterior parahippocampal region. BPD = Bipolar Disorder (N = 10), 
xix 
MDD = Major Depressive Disorder (N = 6), SCZ = Schizophrenia (N = 7), 
CON = controls (N = 8). .......................................................................... 197 
5-22 Bar graph showing NEUROD1 mRNA transcript levels across diagnosis in 
the non-neurogenic hippocampal formation. BPD = Bipolar Disorder (N = 
3), MDD = Major Depressive Disorder (N = 3), SCZ = Schizophrenia (N = 
4), CON = controls (N = 5). ..................................................................... 197 
5-23 Scatter plot showing the NEUROD1 mRNA transcript levels of rs3738401 
minor allele carriers in the non-neurogenic hippocampal formation ........ 199 
5-24 Graph showing mRNA transcript levels of DCX, DPYSL2, FEZ1, NDEL1 
NEUROD1 and PDE4B mRNA in the anterior parahippocampal (APh) 
region and the non-neurogenic hippocampal formation (HF). †† denotes p 
< .05, NRQ = normalised relative quantity............................................... 200 
6-1 Bar graph showing the results of the within-group comparisons of grey 
matter FEZ1 protein density levels across DISC1 rs821616 minor allele 
carrier status from slides of anterior hippocampus. * denotes p < .05 (t-tests 
within groups); BPD = Bipolar Disorder (N, carriers = 6, non-carriers = 9), 
MDD = Major Depressive Disorder (N, carriers = 5, non-carriers = 5), SCZ 
= Schizophrenia (N, carriers = 6, non-carriers = 7), CON = controls (N, 
carriers = 5, non=carriers = 7) ................................................................. 208 
6-2 Bar graph showing the results of the within-group comparisons of dentate 
gyrus FEZ1 protein density levels across DISC1 rs821616 minor allele 
carrier status from slides of anterior hippocampus. * denotes p < .05 (t-tests 
within groups); BPD = Bipolar Disorder (N, carriers = 5, non-carriers = 9), 
MDD = Major Depressive Disorder (N, carriers = 5, non-carriers = 5), SCZ 
= Schizophrenia (N, carriers = 6, non-carriers = 7), CON = controls (N, 
carriers = 5, non=carriers = 7) ................................................................. 209 
6-3 Scatter plot showing the NEUROD1 protein density levels in the anterior 
parahippocampal grey matter of DISC1 rs6675281 minor allele carriers 
from slides of anterior hippocampus ....................................................... 210 
6-4 Scatter plot showing the NEUROD1 protein density levels in the anterior 
parahippocampal grey matter of DISC1 rs821616 minor allele carriers from 
slides of anterior hippocampus ................................................................ 211 
6-5 Scatter plot showing the NEUROD1 protein density levels in the anterior 
parahippocampal white matter of DISC1 rs821616 minor allele carriers 
from slides of anterior hippocampus ....................................................... 212 
 
 
xx 
LIST OF TABLES 
3-A Table showing qPCR assay information .................................................... 50 
3-B Schematic representation of the 96-well gene-maximised qPCR plate 
design (CO = calibrator oligonucleotide, NTC = non template control) ..... 52 
3-C Table showing the results of the calibrator oligonucleotide design. 
Estimated amplicon sizes were derived from gel electrophoresis 
experiments, calibrator oligonucleotide sequences equal the 25bp context 
sequence (highlighted in red) extended at both the 5’ and 3’ ends in 
accordance with the estimated amplicon size estimations. Extensions of the 
calibrator oligonucleotides were rounded up to the nearest 25bp to provide 
required oligonucleotide size values, sequence information can be found at 
www.ncbi.nlm.nih.gov/genbank. ................................................................ 57 
3-D Schematic representation of the 96-well plate setup for allelic discrimination 
analysis of each SNP. Samples are numbered 1-60 based on an AL 
identification number (NTC = Non-template control) ................................. 67 
3-E Table of the Spearman’s rank correlations of demographic and clinical 
variables with the gene expression normalised relative quantities in the 
anterior parahippocampal region. Asterisk indicates p < 01, double asterisk 
indicates, p < 05 ...................................................................................... 113 
3-F Table showing the results of Mann-Whitney U testing of dichotomous 
demographic and clinical variables for effects on the gene expression 
normalised relative quantities in the anterior parahippocampal region .... 115 
3-G Table of the Spearman’s rank correlations of demographic and clinical 
variables with the gene expression normalised relative quantities in the 
non-neurogenic hippocampal formation. Asterisk indicates p < 01, double 
asterisk indicates, p < 05 ......................................................................... 116 
3-H Table showing the results of Mann-Whitney U testing of dichotomous 
demographic and clinical variables for effects on the gene expression 
normalised relative quantities in the anterior parahippocampal region .... 119 
3-I Table of the Spearman’s rank correlations of demographic and clinical 
variables with the protein density values in sections of anterior 
hippocampus. Asterisk indicates p < 01, double asterisk indicates, p < 05
 ................................................................................................................ 120 
3-J Table showing the results of Mann-Whitney U testing of dichotomous 
demographic and clinical variables for effects on protein density values in 
section of anterior hippocampus. ............................................................ 122 
4-A Table demonstrating the genotype calls from each experiment for DISC1 
rs3738401, samples that were missing from the 1st experiment are 
highlighted in grey ................................................................................... 129 
xxi 
4-B Table showing the Stanley Consortium allele frequency Hardy-Weinberg 
equilibrium data for DISC1 rs3738401 .................................................... 131 
4-C Table showing the HapMap allele frequency Hardy-Weinberg equilibrium 
data for DISC1 rs3738401....................................................................... 131 
4-D Table demonstrating the genotype calls from each experiment for DISC1 
rs6675281, samples that were missing from the 1st experiment are 
highlighted in grey ................................................................................... 134 
4-E Table showing the Stanley Consortium allele frequency Hardy-Weinberg 
equilibrium data for DISC1 rs6675281 .................................................... 136 
4-F Table the HapMap allele frequency Hardy-Weinberg equilibrium data for 
DISC1 rs6675281 .................................................................................... 136 
4-G Table demonstrating the genotype calls from each experiment for DISC1 
rs3737597, samples that were missing from the 1st experiment are 
highlighted in grey ................................................................................... 138 
4-H Table showing the Stanley Consortium allele frequency Hardy-Weinberg 
equilibrium data for DISC1 rs3737597 .................................................... 140 
4-I Table showing the HapMap allele frequency Hardy-Weinberg equilibrium 
data for DISC1 rs3737597....................................................................... 140 
4-J Table demonstrating the genotype calls from each experiment for DISC1 
rs821616, samples that were missing from the 1st experiment are 
highlighted in grey ................................................................................... 143 
4-K Table showing the Stanley Consortium allele frequency Hardy-Weinberg 
equilibrium data for DISC1 rs821616 ...................................................... 145 
4-L Table showing the HapMap allele frequency Hardy-Weinberg equilibrium 
data for DISC1 rs821616......................................................................... 145 
4-M Table demonstrating the genotype calls from each experiment for RPTOR 
rs2289759, samples that were missing from the 1st experiment are 
highlighted in grey ................................................................................... 148 
4-N Table showing the Stanley Consortium allele frequency Hardy-Weinberg 
equilibrium data for RPTOR rs2289759 .................................................. 149 
4-O Table showing the HapMap allele frequency Hardy-Weinberg equilibrium 
data for RPTOR rs2289759. .................................................................... 150 
4-P Table demonstrating the genotype calls from each experiment for BDNF 
rs6265, samples that were missing from the 1st experiment are highlighted 
in grey ..................................................................................................... 153 
4-Q Table showing the Stanley Consortium allele frequency Hardy-Weinberg 
equilibrium data for BDNF rs6265 ........................................................... 155 
xxii 
4-R Table showing the HapMap allele frequency Hardy-Weinberg equilibrium 
data for BDNF SNP rs6265 ..................................................................... 155 
5-A Table of the anterior parahippocampal normalised relative quantity data 
from each diagnostic category. Asterisk indicates where the Levene’s Test 
of Equality of Error Variances was violated (p < 05), double asterisk 
indicates, p < 05 when controlling for demographic and clinical variables.; 
bpd = bipolar disorder, mdd = major depressive disorder, con = controls, 
scz = schizophrenia ................................................................................. 157 
5-B Table of the anterior parahippocampal normalised relative quantity data 
from each diagnostic category. Asterisk indicates where the Levene’s Test 
of Equality of Error Variances was violated (p < 05), double asterisk 
indicates, p < 05 when controlling for demographic and clinical variables.; 
bpd = bipolar disorder, mdd = major depressive disorder, con = controls, 
scz = schizophrenia ................................................................................. 158 
5-C Table showing the results of the non-parametric testing of minor carrier 
allele status effects on mRNA transcript levels in the anterior 
parahippocampal region .......................................................................... 160 
5-D Table showing the results of the non-parametric testing of minor carrier 
allele status effects on mRNA transcript levels in the non-neurogenic 
hippocampal formation ............................................................................ 163 
6-A Table of the anterior hippocampus protein density levels from each 
diagnostic category. Asterisk indicates where the Levene’s Test of Equality 
of Error Variances was violated (p < 05), double asterisk indicates, p < 05 
when controlling for demographic and clinical variables.; bpd = bipolar 
disorder, mdd = major depressive disorder, con = controls, scz = 
schizophrenia .......................................................................................... 201 
6-B Table showing the results of the non-parametric testing of minor carrier 
allele status effects on protein density levels in sections of anterior 
hippocampus ........................................................................................... 203 
9-A Table showing recent investigations into dentate gyrus gene expression 
(pharmacological investigations are shaded grey). ................................. 273 
9-B Table of the Spearman’s rank correlations of demographic and clinical 
variables with the gene expression normalised relative quantities (italic 
headings) in the anterior parahippocampal region (APh), the non-
neurogenic hippocampal formation (HF) and protein density levels from 
sections of anterior hippocampus. Asterisk indicates p < 01, double asterisk 
indicates, p < 05 ...................................................................................... 331 
9-C Table showing the results of Mann-Whitney U testing of dichotomous 
demographic and clinical variables for effects on the gene expression 
normalised relative quantities (italic headings) in the anterior 
parahippocampal region (APh), the non-neurogenic hippocampal formation 
(HF) and protein density levels from section of anterior hippocampus .... 335 
xxiii 
 
 
 1 
1 INTRODUCTION 
1.1 Schizophrenia and Other Major Psychiatric Disorders 
The term ‘schizophrenia’ was introduced into the psychiatric lexicon by 
Paul Eugen Bleuler to describe what he saw as a psychiatric condition 
characterised by a splitting of psychic functions1. Originally conceived as 
dementia praecox, a mental illness of deterioration and abnormal behaviour 
characterised by an early onset, Bleuler developed on the earlier ideas 
proposed by Benedict A. Morel and Emil Kraeplin by envisaging a group of 
syndromes of mental dysfunction distinct from dementias2. In doing so, Bleuler 
used the term schizophrenia to progress from the observational to a more 
explanatory terminology. When translated from the ancient Greek, 
schizophrenia alludes to a splitting of the mind. It is believed that this ‘splitting’ 
is a reference to a loss of coherence and co-ordination between aspects of 
mental function, i.e. the cognitive and the affective2. 
Schizophrenia has since become the term used to describe a disease 
that is estimated to affect millions of people worldwide with a point prevalence 
of 0.46%3,4. Schizophrenia has a complex symptomatology. Symptoms can 
range from delusions to depression, apathy to anhedonia and lethargy to loss of 
insight, all encompassed within a spectrum of positive and negative symptoms. 
The positive symptoms are those that indicate a supra-normal behavioural state 
i.e. beyond the range of what is deemed normal (delusions, hallucinations, 
thought disorders etc.). The negative symptoms are those characterised by a 
behavioural deficit (anhedonia, alogia, aboulia etc.). 
 Diagnosis of schizophrenia requires symptom manifestation over a 
minimum period of 6 months. This must be to such an extent that it impairs 
one’s ability to lead a productive lifestyle. At least one of the core positive 
symptoms, i.e. hallucinations, delusions or disorganised speech, must be 
present. These core symptoms can present at varying degree of severity, but at 
least one other symptom must also be present over the 6 month period 
(Diagnostic and Statistical Manual of Mental Disorders-V, DSM-V). 
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 The most recent DSM eliminated schizophrenia subtypes and the special 
exceptions for ‘bizarre delusions’ and ‘schneiderian first-rank auditory 
hallucinations’, which were previously accepted alone as sufficient for 
diagnosis. 
 DSM-V also made further considerations in the delineation between the 
major psychiatric disorders, bipolar disorder (BPD) and major depression 
disorder (MDD, also known as unipolar depressive disorder). Major depressive 
disorder (10-15% lifetime prevalence5) is a debilitating disorder of recurring 
major depressive episodes with a high mortality and morbidity6. Depression is 
required to sustain for 2 weeks, impinging significantly on the patient’s life, for 
the clinical classification as a major depressive episode (DSM-V). 
 Bipolar disorder is a recurring pathological mood disorder, of manic and 
hypomania. Mood and activity, over the period of a week, are accepted 
specifiers for the manic and hypomanic episodes, however cognitive 
disturbances and psychosis also feature. Bipolar subtypes include depressive 
symptoms with either; mania (Subtype I) or hypomania (Subtype II), bipolar type 
schizoaffective disorder is now only diagnosed if either mania or hypomania are 
present for the majority of the schizophrenia illness. The recent addition of 
‘other specified bipolar and related disorder’ accounts for cases where the 
bipolar symptoms are not sufficient for a bipolar disorder diagnosis (DSM-V). 
1.2 Neurobiological Findings 
In an attempt to extend our knowledge of schizophrenia, researchers 
have sought to identify its neuroanatomical, neurochemical and 
cytoarchitectural correlates. Though there has been no distinct diagnostic 
pathology found to date, there are some neurobiological findings that have 
proven quite robust when studying the brains of patients with schizophrenia. 
A general reduction in brain volume and an increase in ventricle size 
were reported in the initial attempts to find an anatomical basis for 
schizophrenia through pneumoencephalography7. With the development of 
imaging techniques such as magnetic resonance imaging (MRI) a greater 
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degree of detail has now become available. While providing more evidence for 
the earlier volumetric findings, imaging studies have also enabled researchers 
to particularise brain volume reductions to structures such as the prefrontal and 
superior temporal gyri5, the hippocampus8 and the thalamus9. The amygdala 
has also been shown to exhibit significant reductions in patients10 while the third 
and lateral ventricles have been shown to be significantly increased11. Cerebral 
asymmetry has also been reported12. 
Some more recent studies have attempted to correlate these 
neuroanatomical alterations to the specific neurocognitive deficits sometimes 
seen in schizophrenia13. Nevertheless, it is important to remember that many of 
the neuroanatomical alterations reported in schizophrenia are extremely subtle, 
showing considerable overlap with non-psychiatric controls. For example, Steen 
and colleagues14 reported the average reduction in the brain volume of 
schizophrenia patients to be only 3%; this was only just above the resolution 
limits of detection for the MRI methods of the time. 
Neuroanatomical abnormalities have also proven an important correlate 
of major depressive disorder. The dorsolateral prefrontal cortex (DLPFC), the 
anterior cingulated cortex (ACC), the lateral orbital prefrontal cortex, the ventral 
striatum and the nucleus accumbens are all brain regions where 
neuroanatomical abnormalities have been shown to persist in brains of major 
depressive disorder patients15; 16. A full review of the early neuroanatomical 
reports concerning major depressive and bipolar disorders was compiled by P. 
Harrison17. 
An increase in dopaminergic signalling has been proposed as a 
neurochemical feature of schizophrenia on the basis of pharmacological 
findings (e.g. Carlsson, 197818). Seeman and colleagues19 found that the first 
generation antipsychotics treated schizophrenia with a clinical potency that 
directly correlated to dopamine receptor D2 blockade (see Figure 1-1). An 
important role for dopamine in schizophrenia is supported by Laruelle and 
colleagues20 who used Single Photon Emission Tomography (SPET) to show 
that patients with schizophrenia exhibited a significantly greater level of 
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dopamine release in response to an amphetamine challenge. These findings 
helped to provide the rationale for the dopamine hypothesis of schizophrenia21. 
Contrary to first generation antipsychotics, second generation 
antipsychotics do not have such high affinity for D2 receptors but have 
comparable clinical potencies. Ergo, other neurotransmitter systems have been 
implicated in schizophrenia pathophysiology22. The evidence for a role of 
glutamatergic neurotransmission includes Krystal and colleagues23 who 
reported that the symptoms seen in subjects treated with a non-competitive N-
methyl-D-aspartate (NMDA) antagonist resembled much of schizophrenia’s 
positive and negative symptomatology. There have also been reports of 
decreased levels of glutamate in the cerebrospinal fluid of patients with 
schizophrenia24. 
 
1-1 From Seeman et al.19 A graph demonstrating the correlation between D2 receptor affinity 
and clinical potency of first-generation antipsychotic medication. The x-axis shows the 
recommended clinical dosage; the y-axis describes the half maximal inhibitory concentration. 
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Numerous neurotransmitters abnormalities have been reported in the 
brains of bipolar disorder patients. Elevated levels of noradrenaline turnover 
have been particularised to the frontal and occipital cortices as well the 
thalamus25. Contrarily, the researchers also detected reductions in metabolites 
associated with serotonin neurotransmission25. For major depressive disorder, 
prominent amongst the neurochemical findings has been data implicating the 
brain-derived neurotrophic factor (BDNF). Animal studies simulating stress have 
reported reductions in BDNF mRNA expression26, sera levels of BDNF have 
been demonstrated to undergo reductions in untreated patients27 and post-
mortem analyses have reported reduced BDNF and neurotrophin 3 (NT-3) 
expression levels in the brains of subjects who commit suicide in comparison to 
non-suicide counterparts26. 
The cytoarchitectural changes that have been observed in schizophrenic 
patients include aberrant clustering of neurons in neocortical white matter28 and 
in the entorhinal cortex (especially in lamina II)29; 30. Neuronal size reductions in 
the neocortex31 and the hippocampus32 have also been reported, along with a 
reduction in the number of dendritic spines33 and oligodendrocytes present34. 
Additionally, reductions in the abundance of synaptic markers such as 
synaptophysin35, synaptosomal-associated protein 25 (SNAP-25)35 and 
complexin II36 have been shown to be present in the brains of patients suffering 
from schizophrenia (see Figure 1-2). This has proven consistent with The 
Feinberg hypothesis which states that schizophrenia is induced by aberrant 
synaptic pruning. First episodes of schizophrenia usually present in the late 
puberty / early adulthood37,38, this coincides with the synaptic maturational 
process of cortical pruning. 
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1-2 From Eastwood and Harrrrison39 Immunoautradiograph of the synaptic marker protein, 
synaptophysin in the hippocampus. In this study, the control subjects had on average more of 
this protein than did the patients with schizophrenia reflected in the paler second image. 
 Both bipolar disorder and major depressive disorder have been 
demonstrated to associate with reductions in glial density40. However, cortical 
neuron numbers, which have been demonstrated to be relatively stable in 
bipolar disorder, have been shown to be reduced in Brodmann areas (BA) 6 
and 47 in major depressive disorder40. Regarding bipolar disorder, recent 
reports have intimated that reduced white matter integrity may serve as an 
endophenotype in this illness41. 
 It is important to always consider that neurobiological findings of this 
nature may represent adaptive changes caused by the disorder and not be 
causative of the disorder. Many of these measures may also be liable to 
confounds such as pharmacological intervention. Consequently, the study of 
genes at the molecular level is likely to provide a unique insight into the 
aetiology of schizophrenia. The genetic code is conserved throughout the 
course of an individual’s life, irrespective of disease progression. Consequently, 
variations in the genome that can be statistically associated to schizophrenia 
can be directly attributed causative, though not necessarily deterministic, status. 
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1.3 Genetic Literature 
1.3.1 Quantitative Genetics 
Genetic epidemiological studies suggest that in comparison with the 
general population, there is a 10-fold increase in the risk of developing 
schizophrenia for the children and dizygotic siblings of schizophrenia patients 
(Fig. 1-3). Furthermore, a review of the epidemiological data performed by 
Gottesman42 estimated the average monozygotic concordance rate at 48% as 
opposed to the dizygotic concordance rate of 17%. Adoption studies have 
shown this risk to be significantly maintained even when the twins undergo 
separate upbringings43. 
Current estimates now put the heritability at around 80%44. Among the 
non-Mendelian genetic disorders it is thought that schizophrenia has one of the 
highest heritabilities45. As well as supporting the idea of schizophrenia’s strong 
genetic component, the epidemiological data also suggests that there are other 
influences impacting on schizophrenia’s manifestation. The environmental 
contribution is made implicit by the aforementioned monozygotic twin 
concordance being estimated at considerably less than 100%. 
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1-3 From Kirov et al.45 Risk of developing schizophrenia in relatives of probands. The data are 
based on the review of studies compiled by Gottesman
42. 
For major depressive disorder, heritability has been estimated at 37%, 
with a 2-4-fold increase in the risk of developing the disorder for first degree 
relatives of probands46. There is also the evidence of a gender-difference in the 
prevalence of the disorder, with females twice as more likely to present with 
symptoms than males47; 48. The epidemiology also strongly suggests a genetic 
component to bipolar disorder. Patients commonly belong to families with a 
history of psychiatric illness, and the family history has proven an important 
clinical predictor of disease progression49. Twin and adoption studies evidence 
a bipolar disorder monozygotic concordance of 40-70%49. 
The manifestation of complex disorders such as schizophrenia and 
bipolar disorder is now understood to be the result of a complex interplay 
between environmental influences and numerous genes of small contributory 
effect50; 51. These genes are thought to have a combined effect lowering the 
threshold with which environmental influences are able elicit disease onset; an 
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increased susceptibility theory. The total numbers of genes that play a role are 
as of yet unknown. 
 Unlike Huntington’s and the familial form of Alzheimer’s, the hereditary 
pattern of major psychiatric disorders do not conform to Mendelian patterns of 
inheritance; the molecular genetic studies have failed to produce a single 
genetic marker for disease. Risch52 concluded that, for schizophrenia, the 
probability of a genetic locus conferring a sibling relative risk (λ) of more the 3 
was unlikely on the basis of the epidemiological findings. 
1.3.2 Molecular Genetics 
The proposition of a gene as a candidate for genetic association with 
psychiatric disorders is generally made on the following bases; functional 
candidate genes are proposed due to the nature of the protein product, 
cytogenetic candidate genes are proposed through their connection to a 
chromosomal abnormality that has been linked to disease, while positional 
candidate genes are proposed on the basis of linkage studies45. 
For a disorder such as schizophrenia, where limited aetiological 
information is available, linkage studies have proven informative in determining 
which chromosomal loci contain susceptibility genes. This is because they 
require no extra knowledge of the disorder other than its potential genetic basis. 
Furthermore, a particular type of linkage study, the nonparametric linkage 
analysis, makes no assumptions about the nature of the genetic inheritance. 
Model-free linkage studies use multigenerational genetic data from 
families with numerous affected individuals to investigate the coinheritance 
between cases. These analyses hypothesise that genomic loci containing one 
or more susceptibility genes will be consistently inherited by affected relatives. 
These loci are demarcated by polymorphic markers, usually microsatellites, 
spaced a minimum of 10cM apart53. 
In keeping with the polygenic theory proposed by Gottesman and 
Shields54, initial linkage analysis failed to produce any results of statistical 
significance. This failure is likely to be due to small sample sizes and 
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inadequate genetic marker density, all conferring insufficient statistical power on 
the studies. However, in the early 2000s two meta-analyses were published 
with greatly increased sample bases allowing for more rigorous statistical 
analysis55,56. Unfortunately there was minimal convergence in the genomic 
areas that these two papers proposed as susceptibility loci. Two loci that were 
both put forward by both papers were 8p and 22q. 
Association studies offer a means detecting genes of smaller effect sizes 
than is possible with linkage analysis. They ascribe disease association to 
individual polymorphisms or haplotypes, comparing the alleles of affected and 
unaffected individuals in either population samples (case-control studies) or 
families (transmission disequilibrium tests, TDT). A significant difference in the 2 
groups regarding the frequency of any particular allele or haplotype is deemed 
suggestive of an association between the allele and the disease. This means 
that the marker allele, or a marker in close linkage disequilibrium, confers a risk 
of disease upon carriers. 
Of the positional candidates, Dysbindin-1 (DTNBP1) was found to 
contain several single nucleotide polymorphisms (SNPs) associated to 
schizophrenia after association mapping of the putative linkage region 6p22.357. 
Associated SNPs were also found in D-amino acid oxidase activator (DAOA) 
after mapping in the 13q22-34 linkage region57. The region of linkage on 
chromosome 8p was found to contain the gene Neuregulin-1 (NRG1), a gene 
which has also exhibited associations to schizophrenia58. 
Some of the functional candidate genes include the neurotransmitter 
receptor genes dopamine receptor D3 (DRD3), dopamine receptor D2 (DRD2) 
and 5-hydroxytryptamine receptor 2A (HTR2A). The meta-analyses conducted 
by Glatt59, Jonsson60, Abdolmaleky61, and their respective colleagues suggest 
that these genes are implicated in schizophrenia susceptibility. Though the odds 
ratios are small (< 1.2), the data suggest that variants within these genetic loci 
contribute to schizophrenia susceptibility. A recently implicated functional 
candidate gene is glutamate receptor, metabotropic 3 (GRM3). This gene codes 
for a G protein-linked glutamatergic receptor. Egan and colleagues62 reported 
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over-transmission of a GRM3 haplotype to schizophrenia cases versus controls. 
They also detected a weak association between a SNP marker and 
schizophrenia. Though these findings were unsubstantiated in a repeat sample; 
the authors reported that this added to the evidence for altered glutamatergic 
neurotransmission in schizophrenia. 
Genome wide association studies (GWAS) extend the principle of 
association mapping. They treat the whole genome as a single chromosomal 
locus, investigating multiple markers simultaneously across the genome; as 
such they are hypothesis-free63. A sex-specific association of reelin (RELN) to 
schizophrenia has been suggested by a genome wide scan64. Recent genome 
wide association studies have implicated zinc finger protein 804A (ZNF804A) as 
a schizophrenia susceptibility gene65, along with neurogranin (NRGN), 
Transcription Factor 4 (TCF4) and loci in the major histocompatibility complex 
(MHC) region on chromosome 666. Further GWAS studies with increased 
statistical power are serving to increase our knowledge of the disorder, 
including quantifying the extent to which common polygenic variation 
contributes to schizophrenia and bipolar disorder risk67. 
Whole genome scans have also allowed researchers to identify 
uncommon (<5%) mutations existing below the resolution of light microscopy in 
disease populations. These mutations, generally copy number variants, have 
been found in greater numbers in schizophrenia68 and autism69, with effect 
sizes that are highly variable70, The investigation of these uncommon, and 
sometimes rare (<1%) variants, has added much to our understanding of the 
genetic architecture of psychiatric disorders. Foremost has been the 
reconciliation of hypotheses focussing singularly on either common or rare 
variants71. CNV studies have also highlighted several chromosomal loci as 
important in psychiatric disorders, including 3q2972, 17q1273, 16p13.174, 
16p11.275 15q11-q1376, as well as the vasoactive intestinal receptor 2 (VIPR2)77 
and neurexin (NRXN1)78 genes. 
Mutations above the resolution of light microscopy (cytogenetic 
abnormalities) have also implicated genes in schizophrenia. These include 
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catechol-o-methytransferase (COMT), proline dehydrogenase (PRODH) and 
disrupted-in-schizophrenia-1 (DISC1) and disrupted-in-schizophrenia-2 
(DISC2). The 22q11 chromosomal locus is deleted in patients with Velo-Cardio-
Facial Syndrome. Patients with deletions in this locus have a higher risk of 
developing schizophrenia than the general population79. COMT, PRODH and 
zinc finger, DHHC-Type Containing 8 (ZDHHC8) are genes which map to this 
region. Association studies have also suggested that COMT may contribute to 
schizophrenia risk80. The existence of a PRODH schizophrenia susceptibility 
variant has been proposed due to animal data suggesting that it regulates 
reductions in prepulse inhibition similar to those seen in human patients with 
schizophrenia81. There have also been positive schizophrenia association 
findings from studies on both PRODH82 and ZDNNC883. 
A t(1:11) translocation within an extended Scottish pedigree was 
reported to co-segregate with schizophrenia, bipolar disorder or depression84. It 
was found that this translocation disrupted 2 genes; DISC1 and DISC2. There is 
now also evidence for association between DISC1 and psychiatric disorders in 
multiple population sets85. 
For major depressive disorder, linkage studies have largely failed 
produce consistent reports; although the 15q locus produced a linkage signal of 
relative note86. The investigations of candidate genes, such as brain-derived 
neurotrophic factor (BDNF); Solute Carrier Family 6 (Neurotransmitter 
Transporter), Member 4 (SLC6A4); 5-hydroxytryptamine receptor (HTR2A) and 
Tryptophan hydroxylase 2 (TPH2); produced similarly mixed results87. Initial 
GWAS studies also failed to identify loci of genome wide significance, though 
piccolo pre-synaptic cytomatrix protein (PCLO)88 and cyclin D2 (CCND2)89 were 
highlighted as genes worthy of further consideration. More interesting have 
been the reports of a joint increased risk for both major depressive and bipolar 
disorder linked to the chromosomal loci of 12q2390 and 18q91. Further to this, a 
study jointly investigating major depressive and bipolar disorder identified 15 
SNPs in a 248kb high linkage disequilibrium block on 3p21.1 as exhibiting 
linkage92. 
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For bipolar disorder, linkage studies and candidate gene studies again 
failed to produce clear and consistent results. Some have argued that this may 
be due to poor SNP / gene choices and low sample sizes93. The GWAS have 
implicated numerous genomic regions; however the largest GWAS with an 
initial sample size of 16,731 and a replication sample of 46,912 subjects, 
detected a genome wide significance of one previously indicated gene 
(CACNA1C) and implicated another for the first time (ODZ4), a member of the 
teneurins family, thought to be involved in cell surface signalling and neuronal 
pathfinding94. Using this cohort, researchers have used an aggregated effect of 
risk variants to estimate the common polygenic variation of bipolar disorder to 
be 20-30%67; 95. Furthermore, pathway analysis of this cohort implicated the 
gene ontology category of 0015270, which relates to voltage gated calcium 
channel activity96. 
Recent data indicates an overlap in the genetic susceptibility for bipolar 
disorder and schizophrenia67; 97. In an interesting example of this overlap, family 
studies have reported an increased risk of bipolar spectrum disorders with the 
22q11 deletion linked to schizophrenia98. Other notable evidences of a role for 
CNVs in the bipolar disorder include the reported risk conferred by the 3q29 
locus, and the 4.8-fold increase in de novo CNVs in bipolar subjects99. Though 
SNPs and rare CNVs appear to be main contributory factors in bipolar disorder 
risk, dynamic mutations, mitochondrial DNA (mtDNA) and epigenetic variation 
have all also been implicated100. 
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1-4 Adapted from Kirov et al.45 A diagram depicting the human karyotype; rectangular bars and 
black arrows highlight a selection of chromosomal loci with reported linkage to schizophrenia. 
1.3.3 Genetic Contribution To Disease 
“Simplistically, genetic variation affects disease susceptibility in one of two 
ways. Either it changes the structure of the encoded protein (e.g. by an amino-
acid substitution of frame-shift mutation) or it alters the expression of the gene 
(e.g. by altering some parameter of transcription or translation) and thereby the 
amount or distribution of the protein”101 
Point mutations, such as SNPs, that have no effect on the amino acid 
sequence of the resultant protein are known as silent mutations. Many silent 
mutations occur within introns. When present within exons they exist on 
degenerate sites of triplet codons; this means that though the mature 
messenger RNA (mRNA) transcript will harbour the point mutation, it will have 
no effect on the amino acid sequence of the protein produced. These silent 
mutations are known as synonymous silent mutations. Conversely, non-
synonymous (also known as missense) mutations can have a marked effect on 
protein structure as they alter the amino acid sequence of the protein. When 
non-synonymous mutations are associated to a disease, they are thought to 
confer disease susceptibility in large part due to an effect on the protein 
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structure and consequent function. When silent mutations are associated to 
disease they are thought to act wholly through an effect on gene expression. 
The majority of genetic associations to schizophrenia are intronic. 
1.4 Evidence of a Neurodevelopmental Component 
1.4.1 Cytoarchitectural, Neuroanatomical and Structural Findings 
Important in the perceived neurodevelopmental component to psychiatric 
illness has been the lack of any consistent findings of neurodegenerative 
markers reported in the cytoarchitectural literature. Prominent amongst the 
subtle abnormalities found in the neuroanatomy of schizophrenia patients are 
the general and regionalised volumetric reductions (1.2 Neurobiological 
Findings). Without neurodegeneration to explain these abnormalities, 
researchers have proposed that they are the result of disturbances in the 
neurodevelopmental process102. 
 There is now also growing evidence that points to a disproportionate 
number of minor physical abnormalities in schizophrenic patients103. These 
structural abnormalities, of which the minor craniofacial malformations figure 
prominently, develop during the gestational process. These premorbid findings 
predict that indicators of illness presage schizophrenia onset, suggesting a 
neurodevelopmental aspect to schizophrenia aetiology. The following will focus 
on a full account of some of the factors which suggest a schizophrenia 
neurodevelopmental model. 
 The neurodevelopmental component of bipolar and major depressive 
disorder is less clear, some of the neurodevelopmentally-relevant environmental 
risk factors for schizophrenia, do not appear to operate on bipolar risk. 
Additionally, children who later go on to develop bipolar perform similar to the 
general population in neuromotor and cognitive tests104. This has led 
researchers to broach the possibility that whereas schizophrenia may associate 
with neurodevelopmental abnormalities, bipolar disorder may not104. For major 
depressive disorder, researchers continue to argue that a better understanding 
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of disease neurobiology can be reached with a full appreciation of the proposed 
neurodevelopmental models of the disorder105. 
1.4.2 Environmental Factors 
Obstetric complications (OCs) have been found to produce a small but 
significant increase in schizophrenia risk. Meta-analysis of the available data 
has concluded that the obstetric complications with the highest schizophrenia 
risk ratios were diabetes in pregnancy, low (<2000g) birth weight and 
emergency caesarean section (p<0.03)106. More recent retrospective studies 
have identified significant increases in the number of obstetric complications in 
the histories of high-risk individuals who later go on to develop schizophrenia107. 
 Nevertheless, as with neurobiological findings, obstetric complications 
represent multi-factorial events that may not be directly contributory to 
schizophrenia but serve only to mark an underlying causative process. Thusly, 
researchers have also sought to identify the molecular mechanism behind this 
putative risk. It has been proposed that certain obstetric complications can 
promote foetal hypoxia and/or elevate maternal cytokine levels, attenuating the 
neurodevelopmental process and imbuing schizophrenia risk108; 109. 
1.4.3 Premorbid Findings 
 Retrospective studies have suggested that there are significant 
behavioural and cognitive disturbances in the childhoods of patients who later 
go on to develop schizophrenia. Premorbid deficits in cognitive performance, 
reductions in academic performance, lower IQ scores and a higher prevalence 
of attentional deficit disorders have all been reported110;111. The premorbid 
social skills of schizophrenia patients have also been shown to suffer significant 
deficits; anti-social behaviour and social withdrawal are significantly more 
prevalent in the childhoods of schizophrenia cases when compared to non 
schizophrenia controls110. 
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1.4.4 Neurogenesis and Schizophrenia 
 In concordance with the theory of schizophrenia as a developmental 
disorder, connections between neurogenesis, and the genes involved in its 
regulation, have been reported with schizophrenia. For example, lithium, a 
mood stabilising drug used in psychiatric therapy, has been shown to stimulate 
neurogenesis112. 
1.4.4.1 Wingless-Type MMTV Integration Site Family (WNT)/β-catenin 
The WNT family of secreted glycoproteins are involved in a variety of 
developmental processes in both vertebrates and invertebrates. There is 
growing evidence as to their specific importance to neurogenesis. Hall and 
colleagues113 showed WNT7A to be involved in numerous processes including 
axonal modelling and synaptic differentiation. β-catenin, a downstream effector 
of WNT in the canonical WNT signalling pathway, has been shown to promote 
undifferentiated precursor cell proliferation and the development of dendrites114. 
It is also thought to recruit scaffolding molecules to developing synapses in 
order to aid in synaptic development115. 
 Components of WNT signalling pathways have been reported as 
exhibiting distorted expression levels in schizophrenia. Reductions in glycogen 
synthase kinase-3β (GSK-3β), a downstream effector of WNT in the canonical 
signalling pathway, have been reported in the cerebrospinal fluid (CSF)116, 
hippocampus117 and also the prefrontal cortex118 of schizophrenia patients when 
compared to controls. 
1.4.4.2 Reelin 
Reelin is an extracellular matrix glycoprotein expressed during embryonic 
corticogenesis. It is synthesised by Cajal-Retzius cells in the cortical marginal 
zone of the telencephalon and external granule cells119. During development, 
reelin has been shown to be involved in neural migration120, laminar 
positioning121 and dendritic development122. In adulthood, reelin is synthesised 
and secreted by almost all cortical and hippocampal γ-aminobutyric acid 
 18 
(GABA) interneurons. It is postulated to modulate neurotransmission, memory 
formation and synaptic plasticity122. 
 In schizophrenic patients, post-mortem reelin mRNA and protein levels 
have been found reduced by 50% in the hippocampus, temporal lobe and 
cortex123,124. DNA analyses of the RLN promoter have found an increased 
occurrence of methylation at positions 134 and 139 in schizophrenics as 
opposed to controls125. This has been corroborated by findings of increased 
expression of the methylating enzyme DNA methyltransferase 1 (DNMT1) in 
schizophrenic patients126. A direct genetic association of RLN with 
schizophrenia has also been suggested on the basis of case-control and TDT 
association studies127; 128. 
1.4.4.3 Retinoids 
Since before the 1950s, vitamin A has been implicated in 
neurodevelopment129. In the early 1980s vitamin A’s acid derivative, retinoic 
acid, was discovered to be an inducing signal in the chick embryo130. The 
retinoids have now been accepted as key regulators of the neurodevelopment 
process, acting on members of the steroid / thyroid hormone receptor 
superfamily. These activated receptors act as transcription factors to regulate 
the expression of other neurodevelopmental genes, including sonic hedgehog 
(SHH) and homeobox (HOX), playing a central role in aspects of 
neurodevelopment ranging from neurogenesis to axon extension131. 
There is evidence of abnormal retinoid receptor levels in the dentate 
gyrus (see 1.6.1). Furthermore, the clinical and pathological anomalies 
observed in patients suffering retinoid dysfunction are similar to those seen in 
schizophrenia132. 
1.5 Adult Neurogenesis 
 By the time a psychiatric diagnosis is made, much of neurogenesis has 
expired. This is a considerable hindrance to attempts to analyse the role of 
neurogenesis in schizophrenia. Originally described by Altman and 
colleagues133, adult neurogenesis refers to the process by which multipotent 
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neural precursor pools produce fully mature neurons in the adult brain. These 
precursor pools are preserved in two neurogenic ‘niches’ of the post-natal 
mammalian brain; the subependymal zone (SEZ) and the subgranular zone 
(SGZ). The developing neurons display differing migration dynamics contingent 
upon, though not necessarily determined by, the niche from which they derive. 
These neurons integrate into the neural circuitry, contributing to the brain’s 
neural architecture over an individual’s life and offering a means of potentially 
investigating neurogenesis in schizophrenic patients post-diagnosis. 
1.5.1 Adult Olfactory Neurogenesis 
The subependymal zone lines the anterior portion of the lateral 
ventricles; it is a region immediately apical to the ependymal cell bodies lining 
the ventricular space. Neuroblasts deriving from the SEZ migrate along 
channels collectively known as the rostral migratory stream (RMS). This stream 
traverses the SEZ to the olfactory bulb and is defined by a subgroup of 
specialized glial cells, the elongated walls of which form the channels 
developing neuroblasts migrate along. Upon reaching the olfactory bulb the 
developing neurons differentiate into interneurons, integrating into the local 
circuitry134. 
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1-5 Adapted from the Society for Neuroscience website (www.sfn.org) Diagram showing critical 
regions in the brain for adult neurogenesis. 
1.5.2 Adult Hippocampal Neurogenesis 
 Adult hippocampal neurogenesis occurs with the dentate gyrus which is 
a subfield of the hippocampal formation. The subgranular zone (SGZ) is a thin 
layer of cells approximately 3 nuclei in thickness between the granule layer and 
the hilus of the dentate gyrus135. These cells give rise to dentate granule cells 
which, having migrated tangentially as neuroblasts, elaborate processes, 
including axons extending to the cornu ammonis 3 (CA3) layer of the 
hippocampus. 
1.5.3 Immunohistological Markers 
 With the development of thymidine analog incorporation techniques 136, 
researchers were able to label cells undergoing mitosis, indicating erstwhile 
instances of neurogenesis in animal tissue. However, this technique is 
prohibited from use in schizophrenia patients due to the inherent mutagenic 
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properties of the utilised analogues. They also indiscriminately mark neurons 
and glia, further limiting their use experimentally. 
 When using tissue from post-mortem samples, immunohistological 
markers are used to indicate neurogenesis (Appendix A.3). These markers are 
preferably proteins that are expressed transiently during adult neurogenesis 
only; and not in either mature neurons or neurons regenerating after injury. 
Though numerous proteins have been used as neurogenesis markers, 
researchers caution against the use of any single marker as a sole determinant 
of neurogenesis 137. 
 
1-6 From Von Bohlen and Halbach138 A diagram showing the generation and development of 
new neurons within the granular layer of the DG divided into five stages. At each stage, different 
specific molecules are expressed in the developing neuron, some of these markers have the 
potential to be used to quantify and qualify adult neurogenesis[NeuN = neuron-specific nuclear 
protein; GFAP = glial fibrillary acidic protein; PSA-NCAM = polysialylated neural cell adhesion 
molecule; TUC-4 = CRMP4 (collapsin response-mediated protein4); Tuj-1 = class III β-tubulin]. 
 22 
1.5.3.1 Doublecortin (DCX) 
 Doublecortin is the founding member of a superfamily of genes which 
includes doublecortin-like kinase (DCLK) genes DCLK1, DCLK2 and DCLK3, 
retinitis pigmentosa-1 (RP1) and doublecortin-domain containing 2 (DCDC2). 
The common feature between all DCX superfamily members are microtubule-
binding properties of the gene products conferred by their DCX domain. Though 
the primary function of this domain is microtubule association139, the 
superfamily gene products are involved in a variety of cellular processes; 
DCLKs are proteins with kinase activity, RP1 is a photoreceptor linked to the 
retinitis pigmentosa disease and DCDC2 is linked to dyslexia. 
 The founding DCX gene is located on the X chromosome, it encodes a 
product 360 amino acids (aa) in length and contains two DCX domains and a 
serine, threonine and proline-rich (SP-rich) domain.  As determined by its 
molecular domain, the DCX gene product is a microtubule-associated protein 
(MAP). Classic MAPs bind using a random coil structure, whereas DCX-domain 
containing proteins utilise ubiquitin-like folding patterns. The DCX domains are 
80 amino acids in length and at least two are required for sufficient microtubule 
binding function140. Upon binding, DCX has been demonstrated to stabilise 
microtubules, counteracting their dynamic depolymerisation. 
 DCX is thought to function transiently in the extremities of migrating 
neurons. Its cellular expression has been localised to migrating neurons of the 
RMS and tangentially migrating neurons of the developing embryonic cortex141. 
It is transiently expressed in immature post-mitotic migrating neurons. 
Expression begins 1 day after the process of mitosis ceases and lasts for a 
period of approximately 2-3 weeks, at this point the abundance of the protein in 
the cell begins to subside142. It is on this basis that DCX has been proposed as 
an endogenous marker of neurogenesis. 
1.5.3.2 Neurogenic Differentiation Factor 1 (NeuroD1) 
 The NEUROD1 gene codes for a member the basic-helix-loop-helix 
(bHLH) family of transcription factors, characterised by the structural motif 
which shares its name. NEUROD1 has been demonstrated to be proneural, 
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transiently-expressed, and critical to normal neurodevelopment, especially in 
hippocampal and cerebellar granule cell development143; 144. In adult 
hippocampal neurogenesis, NEUROD1 expression is enough to promote 
neuronal differentiation and to some degree maintain newborn neuron 
numbers145. 
 The NEUROD1 gene contains transcription factor / lymphoid enhancer-
binding factor (TCF/LEF) regulatory elements, downstream effectors of the 
WNT pathway. WNTs are also a regulators of neurogenesis146. Nevertheless, 
until recently an interaction between WNT and NEUROD1 had yet to be 
characterised. NEUROD1 activation is now understood to reflect the WNT 
regulation of intracellular β-catenin, accumulation of which leads directly to the 
transcription of NEUROD1 via its TCF/LEF elements147. 
 Furthermore, Gao and colleagues145 presented evidence for the direct 
interaction of β-catenin with NEUROD1 regulatory elements. β-catenin and/or 
NEUROD1 silencing also produced similar effects on the generation and 
survival of newborn neurons. Upon NEUROD1 silencing, an absence of WNT-
mediated neurogenesis was also observed. 
1.6 Dentate Gyrus Gene Expression 
 Adult hippocampal neurogenesis is of particular relevance psychiatric 
research. The hippocampus harbours some of the particularised volumetric 
reductions associated with schizophrenia. It also plays a role in memory and 
behaviour, neuropsychological indices shown to exhibit marked deficits in 
affected individuals148. The hippocampal size reductions have been observed in 
both prodromal and first episode cases; somewhat suggestive of a relevance to 
the primary aetiology involved. A full review into the role of the hippocampus in 
psychiatric illness is provided by Harrison149. 
 Though much of this focus on the hippocampus in schizophrenia 
research is borne out of a perceived active contribution to disease, some 
researchers have sought to identify more subtle mechanisms by which this 
region may contribute to the disease state. Using a novel approach to analyse 
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the role of the hippocampus in schizophrenia, Altar and colleagues150 utilised 
laser-capture micro-dissection to isolate populations of dentate granule 
neurons. The authors demonstrated reductions in the expression of genes 
associated with “protein turnover and mitochondrial energy metabolism” in the 
brains of patients with schizophrenia. 
 Interestingly, they were also able to report reductions in genes involved 
in “neurite extension, and synaptic plasticity”. These results suggest that, at 
least to some degree, schizophrenia patients are subject to significant 
disturbances in postnatal neurodevelopmental processes. It is an intriguing 
possibility that this also applies to the embryonic neurodevelopment process 
(see 9Appendix A). 
1.6.1 Neurodevelopmental Genes 
 POU domain, class 3, transcription factor 1 (POU3F1, also known as 
Oct-6), is a developmentally active POU-III domain transcription factor. Best 
known for its role in Schwann cell myelination, Oct-6 is expressed in the central 
nervous system during neuronal identity specification. Ilia and colleagues151 
reported a drastic increase in the Oct-6 immunoreactivity of neurons in the 
granule cell layer of the dentate gyrus when comparing schizophrenics to 
normal controls, which displayed “little or no staining”. This expression disparity 
also extended to the CA3 region, where the pyramidal neurons of the 
schizophrenic cohort exhibited clear immunoreactivity, in stark contrast to their 
control counterparts. Western blots from the temporal cortex extracts of an 
independent sample further corroborated this expression disparity. 
 As aforementioned, the retinoids are a group of molecules that are 
crucial to the neurodevelopmental process. Rioux and Arnold131 demonstrated a 
twofold increase in the proportion of granule cells expressing retinoic acid 
receptor subtype alpha (RARα) protein in schizophrenia. Further to this, 
Miyaoka and colleagues152 present data suggestive of a significant 2.5 times 
increase in the WNT1 immunoreactive cell density levels in CA3 region of 
patients with schizophrenia. A member of the aforementioned WNT family of 
secreted glycoproteins, WNT1 specifically, has been implicated in cell adhesion 
 25 
and synaptic plasticity. Miyoaka and colleagues152 also found WNT1 cell density 
levels in the neighbouring non-neurogenic CA4 region to also be significantly 
increased. 
1.6.2 Hormone Receptors 
 The expression of genes involved in endocrine signalling has also been 
found to be dysregulated in this neurogenic region of the hippocampus in 
schizophrenia. Oestrogen signalling is thought to influence the growth, 
maturation and differentiation of a variety of tissues including the central 
nervous system153. In situ hybridization (ISH) analysis has revealed significant 
reductions in the dentate gyrus expression of oestrogen receptor-α (ERα) 
mRNA in slides from schizophrenia patients are compared with controls154. This 
would appear to cohere with oestrogen’s status as an environmental risk-factor 
for schizophrenia in utero155; especially as higher-than-normal levels of 
oestrogen during development are thought to predict aberrant ERα 
expression156. 
 In another ISH study, Webster and colleagues157 also found the mRNA 
expression of the nuclear receptor subfamily 3 member, glucocorticoid receptor 
(GR), to be reduced in dentate gyrus, CA3, frontal cortex and inferior temporal 
cortex of schizophrenia patients. This is intriguing as glucocorticoids, such as 
cortisol, are molecules primarily elicited as part of the physiological stress 
response which has been tentatively linked to schizophrenia as both a 
developmental and non-developmental risk factor. This correlates with the 
findings of reduced GR mRNA expression in both neurogenic and non-
neurogenic regions. 
1.6.3 Regulators of Neurotransmission 
 Pro-psychotic and neuroleptic drug activity has provided much of the 
rationale for the neurotransmitter theories of schizophrenia. Both glutamate 
NMDA receptor antagonists and dopamine agonists have been shown to 
produce effects similar to those seen in schizophrenia patients. Gene 
expression findings in the dentate gyrus implicate neurotransmission in the 
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post-natal neurodevelopmental context. For example, an ISH study found 
dopamine type 1 receptor (DRD1) mRNA to be decreased by 21% in the CA3 
brain region of subjects with schizophrenia158. 
 A variety of glutamate receptor subtypes and subunits have also been 
shown to exhibit aberrant expression levels in the postnatal neurogenic brain 
regions of schizophrenia sufferers. Kerwin and colleagues159 used quantitative 
auto-radiographic analysis of slides from schizophrenia patients and controls to 
identify differences in expression of glutamate receptor binding sites. From this 
study they were able to report bilateral reductions in kainate receptor levels (via 
kainic acid binding) in the dentate gyrus and CA3 of schizophrenia patients. 
These reports of reduced kainite receptor-binding levels were supported by 
findings at the mRNA level. Porter and colleagues160 demonstrate that mRNAs 
corresponding to glutamate receptor, ionotropic kainate 5 (KA2) and glutamate 
receptor, ionotropic kainate 2 (GluR6) both exhibit significant reductions in the 
dentate gyrus and CA3 of schizophrenia patients. 
 AMPA glutamate receptor subunits (GluR1-2) have also been to shown 
exhibit schizophrenia-related expression disturbances in the neurogenic 
context. Both GluR1 and GluR2 subunit mRNAs have been shown to undergo 
reductions of approximately 50% or more in the dentate gyrus and CA3161. For 
GluR1, these reductions were also found to be significant as a measure of 
abundance per neuron. The same applies for the analysis of NMDA receptor 
subunit 1 mRNA (NMDAR1) which Law and colleagues162 have found to exhibit 
lateralised reductions in left side dentate gyrus and CA3 in schizophrenia. 
 Other participants in glutamate neurotransmission include vesicular 
glutamate transporters (VGLUTs); responsible for maintaining glutamate pools 
in the vesicles of pre-synaptic terminals. Type 1 VGLUT has been shown, by 
use of regionalized immunohistochemical analysis, to exhibit an 84% increase 
in the post-mortem dentate gyrus of schizophrenic patients163. 
 Reductions in the expression of other glutamate processing molecules 
have also been observed. Glutamic acid decarboxylases (GADs) are the 
signature molecules of GABAergic interneurons in the dentate gyrus; 
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responsible for the conversion of glutamate into GABA in inhibitory pre-synaptic 
terminals. The expression of the GAD67 isoform, encoded by the GAD1 gene, 
was shown to be reduced by 22% in the dentate gyrus of schizophrenia 
sufferers when compared to controls164. 
 Another study into the cellular expression of both GAD mRNA isoforms 
(GAD65 and GAD67) failed to detect any differences between schizophrenia 
sufferers and controls in the dentate gyrus; it is important to note that this study 
did find significant decreases in the density of GAD65 mRNA stained neurons in 
the dentate and a combination of the CA2/3 regions when comparing controls 
with bipolar disorder sufferers165. 
 Other receptors shown to exhibit abnormal expression levels in the 
dentate gyrus of patients with schizophrenia include acetylcholinergic receptors. 
Crook and colleagues166 used radio-labelled binding assays to measure the 
abundance of cholinergic receptor, muscarinic 1 (M1) and cholinergic receptor, 
muscarinic 4 (M4) receptor binding sites and thus receptor levels. They reported 
a decrease in muscarinic receptor expression levels in the dentate gyrus and 
CA3. 
 These results were substantiated in 2007 by Scarr and colleagues167, 
who also found expression reductions in this neurogenic region of the postnatal 
brain. They were able to show, using quantitative auto-radiographic analysis 
and in situ hybridization of post-mortem slides, concurrent reductions in M4 
mRNA across whole sections and M1/4 receptor binding sites in CA3 and 
dentate gyrus (molecular and polymorphic layers, delineated by high resolution 
specific binding readings). 
 Other cholinergic receptors that have been analysed in the dentate 
include low-affinity nicotinic acetylcholinergic receptors that bind α-bungarotoxin 
(i.e. Homomeric CNS-type (α7)5 nicotinic receptors). As a proxy measure of the 
expression of these receptors, radio-labelled α-bungarotoxin binding was found 
to be decreased in the CA3 region of patients with schizophrenia168. 
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 Dean and colleagues169 investigated signalling molecules operating 
downstream from G-protein coupled receptors. After analysing the radio-ligand 
binding capacity of sections taken from individuals with schizophrenia, they 
reported a trend towards a decrease in protein kinase C expression and a 
significant decrease in the expression of adenylate cyclase in the dentate gyrus; 
no significant differences were observed in CA3. 
 Growth-associated protein 43 (GAP43), a substrate of protein kinase C, 
has been shown to exhibit reduced expression in the dentate gyrus. Two 
studies analysing the expression of this protein170,171, using slides from controls 
and patients with schizophrenia, compared antibody labelling intensities. Tian 
and colleagues170 revealed a trend towards a correlation between a 
schizophrenia diagnosis and reduced GAP43 levels in the dentate gyrus. 
Chambers and colleagues171 found that optical density readings for GAP43 
antibody were reduced when the inner molecular layer of the dentate gyrus was 
analysed separately. 
1.6.4 Synaptic Markers 
 Theories connecting schizophrenia and the synapse have endured, at 
least in part, on the basis of neurobiological findings, such as those highlighted 
by Harrison and Eastwood172. A possible role for synaptic abnormalities in a 
neurodevelopmental phase of schizophrenia aetiology has also been 
proposed173. Synaptophysin, a putative synaptic marker, has been shown to 
exhibit lateralized decreases in the dentate gyrus of schizophrenia patients39. 
 When Young and colleagues35 looked at synaptophysin and another 
synaptic protein, 2SNAP-25, they also reported expression disturbances. 
However, they reported an increase in the dentate gyrus granule cell layer 
expression of synaptophysin in schizophrenia; contrary to the findings of 
Eastwood and colleagues39, and a specific reduction of SNAP-25. The findings 
of reduced SNAP25 expression were specific in that they remained significant 
even when the synaptophysin expression levels were used as a covariate. 
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 Nevertheless, the findings of Eastwood and colleagues39 have since 
been substantiated by Chambers and colleagues171 . In their study they 
demonstrate synaptophysin protein levels to be decreased in both the inner and 
outer layers of the dentate gyrus. This is concordant with the additional reports 
of reduced synaptic protein levels in patients with schizophrenia. For example, 
Nowakowski and colleagues174 report the expression of synapse I, a protein 
associated with synaptic vesicles, to be reduced in the inner and outer layers of 
the dentate gyrus in schizophrenia. 
 Weickert and colleagues175 demonstrated that the expression of 
Dysbindin-1; protein is decreased in the dentate of schizophrenics. Dysbindin is 
a constituent of the dystrophin-associated protein complex concentrated at the 
postsynaptic density. Weickert and colleagues175 present data demonstrating 
that, in the brain of subjects with schizophrenia, the mRNA expression of 
Dysbindin-1 is decreased by 25% in the dentate gyrus, and 39% in CA3, when 
compared with healthy controls. 
 At the protein level, a similar decrease in expression was reported. 
Talbot and colleagues163 found that Dysbindin-1 protein neuropil 
immunoreactivity was reduced by 42% in the inner molecular layer of the 
dentate gyrus. This decrease was 14% in the parent cells of neurons 
responsible for the intrinsic glutamatergic input in the inner molecular layer. 
Decreases in Dysbindin-1 expression were also reported when CA2 and CA3 
regions were pooled; a 30% decrease in the stratum oriens and 37% in the 
stratum radiatum. 
1.7 The Duality of Adult and Embryonic Neurogenesis 
 A role for adult neurogenesis in the recovery from illness has been 
previously proposed as it is increased in response to brain injury176 and 
antidepressant stimulation177. In schizophrenia research, adult neurogenesis 
may also prove to be informative as an indicator of abnormalities with bearings 
upon neurodevelopmental processes of the ante- and peri-natal state. This 
requires the assumption that any analogy between adult and embryonic 
neurogenesis is valid. Gene expression disturbances can be highly dependent 
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on context, whether regional, temporal or otherwise. Disturbances observed in 
postnatal neurogenesis may, at best, only hint at clues to the nature of the 
embryonic neurodevelopmental abnormalities. Nevertheless, the mechanisms 
underpinning both adult and embryonic neurogenesis have been shown to 
exhibit intriguing similarities. 
1.7.1 Molecular Overlap 
The expression of genes, that are integral to the development and 
characterisation of neurons, can help elucidate the link between adult and 
embryonic neurogenesis. Researchers have found many of the transcription 
factors and guidance molecules that are active in embryonic neurogenesis to be 
expressed post-natally in developing neural precursors. In part, this can be 
interpreted as evidence of a conserved developmental program. 
1.7.1.1 Transcription Factors 
1.7.1.1.1 Empty Spiracles Homeobox1 and 2 (Emx1 and Emx2) 
 There is evidence to suggest that these transcription factors, postulated 
to play a role in forebrain regionalization, are also involved in adult 
neurogenesis. Adult Emx1 mutants have been shown to exhibit reduced levels 
of adult hippocampal neurogenesis; they exhibit smaller dentate gyri with fewer 
proliferating cells178. These observations may be a reflection the developmental 
impact of Emx1 expression depletion. Kohwi and colleagues179 provide more 
evidence of a role for Emx1 in postnatal neurogenesis; in their studies they 
found that Emx1 lineage-derived embryonic progenitors were able to produce 
GABAergic olfactory bulb interneurons when transplanted into adult mouse 
brain SEZ. 
 Emx2 is also thought to play a role in forebrain regionalization; however it 
has also been suggested to be involved in area patterning and the maintenance 
of progenitor pools in the embryonic brain. There is also evidence to suggest 
that Emx2 is involved in adult neurogenesis. Emx2 was found to be up-
regulated in the SEZ of adult monkeys, concomitant with increased levels of 
neurogenesis180. The neurogenesis was stimulated by transient global cerebral 
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ischemia and confirmed by bromodeoxyuridine (BrdU) staining. An up-
regulation of numerous other developmental transcription factors, including 
Ngn1, was observed. 
1.7.1.1.2 Neurogenin 1 and 2 (Ngn1 and Ngn2) 
 The neurogenin genes are thought to influence neural differentiation, 
marking the dorsal telencephalon during embryonic development. Numbers of 
Ngn1-expressing cells were found to be increased in adult monkeys in response 
to transient global cerebral ischemia by Tonchev and colleagues180. However, 
Vergano-Vera and colleagues181 found that embryonic adult olfactory bulb 
precursor cells expressed Ngn1 and Ngn2 while their adult counterparts 
expressed very little. This is suggestive of a neurogenic role that is biased 
towards embryonic neurogenesis. 
1.7.1.1.3 Hairy and Enhancer of Split (Hes) Genes 
 This family of genes are activated by Notch signalling and have been 
postulated to play a role in the proliferation and maintenance of progenitor pools 
in embryonic neurodevelopment. Hes1 and Hes5 expression has been found to 
be increased in the adult rat/mouse hippocampus in response to increased 
hippocampal neurogenesis182. In this instance, neurogenesis was stimulated by 
chronic fluoxetine administration and validated by immunohistochemistry. 
However, Hes gene up-regulation has also been detected upon an increase in 
neurogenesis stimulated by mild stress183 and simulated stroke184. 
1.7.1.1.4 Inhibitor Of DNA Binding 1, Dominant Negative Helix-Loop-Helix (Id) 
Genes and Paired Box 6 (Pax6) 
 Similar to the Hes genes, the Id family are thought to be involved in the 
proliferation of progenitor pools and differentiation suppression. There is 
however evidence to suggest that members the Id gene family play varying 
roles in neurogenesis dependent on the type of cell in which they are 
expressed185. 
 Pax6 is a multi-functional regulator of neurodevelopment found to be 
active in embryonic and post-natal neurogenesis. It is quite conceivable that its 
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pre-natal function is maintained in the neurogenic regions of the adult brain; 
Osumi and colleagues186 present a review that provides a convincing rationale 
for this hypothesis. 
1.7.1.1.5 NeuroD1; T-box, Brain, 1 and 2 (Tbr1 and Tbr2) 
 These transcription factors have also been shown to be involved in the 
neurogenesis observed post-natally and in the developing mammalian 
neocortex187,188. The aforementioned NeuroD1 (see 1.5.3.2) is a bHLH 
transcription factor thought to play a critical role in neural differentiation. Tbr1 is 
a T-box transcription factor involved in layer-related differentiation. 
 Also known as EOMES, Tbr2 is also expressed in the developing 
embryonic cortex. There has been evidence to suggest that it is involved in 
radial glial diifferention189. Intriguingly, mutated Tbr2 has been shown to evoke 
an abrogation of adult neurogenesis in the adult dentate gyrus190. Thusly, not 
only is Tbr2 expressed post-natally191 but the evidence suggests that it is critical 
to the process in the adult dentate. 
1.7.1.2 Guidance Molecules 
1.7.1.2.1  Polysialylated Neural Cell Adhesion Molecule (PSA-NCAM) 
 PSA-NCAM is a developmental cell surface marker, key to neural 
adhesion and involved in events such as neurite outgrowth192. Seki and 
colleagues193 investigated its expression in young and adult mice injected with 
BrdU. They found co-expression of both PSA-NCAM and BrdU in the 
hippocampus of rats aged 2-3 months and 15 months, with no qualitative 
difference in the morphology of the presumptive developing neurons. This is 
suggestive of a similar role for PSA-NCAM in adult and embryonic 
neurogenesis. 
1.7.2 Functional and Morphological Overlap 
The similarities in genes expressed during adult and embryonic 
neurogenesis are indicative of a well-conserved process. These similarities 
notwithstanding, there is still scope for these expression profiles to represent 
divergent processes. Transcription factor expression is postulated to be context-
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dependent194. This suggests that the observance of a gene being expressed in 
both instances of neurogenesis is not enough to confirm a genuine 
homogeneity of process. 
 The temporal profile of gene expression in adult and embryonic 
neurogenesis has also been shown to exhibit intriguing similarities. Immuno-
labelling of the inside-out laminal progression of the mouse neocortex has 
allowed researchers to characterize the sequence of transcription factor 
expression at the embryonic cortical plate. 
 This has proven to be directly parallel to the transcription factor 
expression sequence observed during the hippocampal neurogenesis of adult 
mice. Transcription factor expression during mouse embryonic neurogenesis 
has been shown to proceed from Pax6 to Tbr2, then NeuroD and finally Tbr1195. 
The same sequence been observed during adult neurogenesis studied in the 
dentate196. In total, the evidence is highly suggestive of adult neurogenesis 
recapitulating much of what is observed during embryonic neurodevelopment. 
1.8 Disrupted-in-schizophrenia- (DISC1) 
DISC1 became a gene of particular interest in schizophrenia research 
when its truncation was observed in a balanced translocation of loci 1q42 and 
11q14.3 which co-segregated with major psychiatric disorders in an extended 
Scottish family84; 197. Genetic association of DISC1 to schizophrenia has since 
been demonstrated in Finnish198, North American199, Chinese200 and 
Japanese201 population samples. Nevertheless, a recent meta-analysis has 
indicated no overall association of common polymorphisms with 
schizophrenia202. Chubb and colleagues85 present a full review into the role of 
the DISC1 locus in psychiatric disorders. 
DISC1 expression has been shown to be significantly reduced in 
lymphoblastoid cell lines from members of the original DISC1 translocation 
family 203. However these results have not been supported by studies analysing 
expression in brain. Lipska and colleagues204 presented data suggesting a trend 
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towards reduced DISC1 protein expression in the brains of schizophrenic 
individuals. However, these results did not reach a statistical significance. 
1-7 Taken from St. Clair et al.84 and Blackwood et al.205 A pedigree showing the co-segregation 
of a balanced t(1:11) translocation with psychiatric illness 
The DISC1 gene produces an immature mRNA transcript of 414457 
nucleotides; the translation of which produces a protein that is 854aa in length. 
This corresponds to the full-length L isoform DISC1 protein. There are 4 
isoforms consistently reported, though recent data has suggested the existence 
of further alternative splice variants206. 
 The full-length DISC1 protein contains a number of domains that have 
been characterised. Leliveld and colleagues207 show that its N-terminus region, 
up to approximately amino acid 320, is mostly non-structured. From amino acid 
320 to the C-terminal region, the DISC1 protein contains numerous binding 
domains that have been described in the literature 85. A self-association domain 
has been described and four predicted coiled-coil domains (CCDs) are reported 
as existing between residues 400-830207. 
1.8.1 DISC1 Expression 
 DISC1 is generally expressed at higher levels during embryonic and 
perinatal periods than in adulthood204. As a neurodevelopmentally active 
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schizophrenia risk gene, DISC1 has been investigated for roles in 
neurogenesis. One of the sub-cellular locations where DISC1 expression is 
pronounced is the growth cone of developing neurites 208. It is also expressed at 
the centrosome209 and is thought to be critical to neurite outgrowth and neuronal 
migration210. The cortical neurons of mice designed to express a truncated 
DISC1 protein were shown to exhibit significantly less well developed 
dendrites211. These findings have led researchers to propose that DISC1 is a 
positive regulator of the neurogenic process. 
 Intriguingly, when DISC1 has been analysed for roles in adult 
neurogenesis, results divergent from those seen during embryonic 
neurogenesis have been observed. DISC1 knockdown in the adult mammalian 
hippocampus has been shown to increase neuronal migration and 
arborisation212. Morphological and physiological signs of precocious synaptic 
maturation were also observed. This is strongly suggestive of a negative 
regulatory role for DISC1 in adult neurogenesis, as opposed to its positive 
embryonic regulatory role. The data appears to present evidence of a context-
dependent role for DISC1 in neurogenesis. 
1.8.2 DISC1 Function 
 DISC1 requires particular attention, not only because of its 
aforementioned neurodevelopmental role, but it has also been described as a 
protein that acts as a ‘molecular hub’ for many other neurodevelopmental 
proteins213. Camargo and colleagues213 identified numerous DISC1-interacting 
proteins using iterative yeast-two hybrid (Y2H) screens. They also conducted 
pathway and functional analyses of the observed ‘DISC1 interactors’; upon 
which the biological processes over-represented included 
regulation/organisation of actin and microtubule cytoskeleton (neurite 
morphology), cell cycle, cell division (neurogenesis) and intracellular transport 
(communication). These are highly  significant processes in neurodevelopment, 
and supplement the previously described evidence of DISC1’s role in the 
developing nervous system. 
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1-8 From Camargo et al.213 DISC1 network of protein-protein interactions. Underlined in red are 
proteins that interact with DISC1 and were used in further yeast-two hybrid (Y2H) screens to 
derive the protein interaction network. Connecting lines indicate an interaction between 
molecules. In boxes are proteins that interact with the protein screened in further Y2H screens. 
A black asterisk indicates a protein that is located in a schizophrenia risk locus. A purple 
asterisk indicates a protein that is found in regions where chromosomal abnormalities have 
been linked to schizophrenia 
Accumulating evidence suggests that DISC1 acts in a facilitatory capacity. 
For example, it regulates neuronal migration through its interaction with 
Lissencephaly-1 (LIS1, also known as Platelet-Activating Factor 
Acetylhydrolase 1b, Regulatory Subunit 1, 45kDa; PAFAH1B1) and NudE 
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Neurodevelopment Protein 1-Like 1 (NDEL1) proteins. DISC1 co-localises with 
NDEL1 and LIS1 at the centrosome and mutations in LIS1 and NudE 
Neurodevelopment Protein 1 (NDE1) can precipitate defects in neurogenesis 
and neuronal migration214; 215. DISC1 is also thought to facilitate growth cone 
extension. It co-localizes with LIS1, NDEL1, kinesin-1 and 14-3-3ε at the 
developing growth cone in a functional complex that is critical to the successful 
development of axons.  
An association between DISC1 genotype and the expression of DISC1 
binding partners was recently demonstrated in a study by Lipska and 
colleagues 204. Post-mortem tissue from the hippocampus and dorsolateral 
prefrontal cortex (DLPFC) of 43 schizophrenia patients and 79 controls was 
dissected. Gene expression was analysed using real-time polymerase chain 
reaction (PCR). The authors found the expression of the DISC1 binding 
partners NDEL1, fasciculation and elongation protein Zeta-1 (FEZ1)and LIS1 to 
be significantly reduced in the schizophrenia patients in comparison to the 
controls. This reduced expression was found in both brain regions; except in 
NUDEL’s case where the reduction in the DLPFC mRNA was not found to be 
significant. 
1-9 From Lipska et al.204 Graph to show the expression of DISC1 and its binding partners RNA 
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in the DLPFC and the hippocampus in brains of schizophrenic patients as percentages of the 
average expression of normal controls. NUDEL = NDEL1, asterisks denote significance, P<0.05 
 Intriguingly, they also found an effect of DISC1 genotype on the 
expression of NUDEL, FEZ1 and LIS1. Reductions in the hippocampal 
expression of the DISC1 binding partners were predicted by homozygosity for 
the DISC1 risk SNPs hCV219779, rs821597 and rs821616. Even more 
intriguingly, this effect was not found to be as robust in the DLPFC. 
 Somewhat surprisingly, two of these risk variants (hCV219779 and 
rs821597) are produced by silent mutations. This suggests that, in the case of 
hCV219779 and rs821597, the associations with reduced expression are likely 
the result of regulatory variants and not the result of a change in protein 
structure. Further interrogations of the molecular processes with which DISC1 is 
involved are only likely to contribute to our understanding of schizophrenia 
aetiology. This will potentially aid in the development of therapies and 
diagnostic capabilities. 
1.8.3 DISC1 Binding Partners 
 The following chapters offer a partial focus on schizophrenia. For a full 
review into DISC1 binding partners in psychiatric disorders readers are directed 
to the recent paper by Bradshaw and Porteous216. 
1.8.3.1 Fasciculation and elongation protein Zeta-1 (FEZ1) 
 Fez1 is the mammalian orthologue of the Unc76 of the nematode worm 
Caenorhabditis elegans. Unc76 has been shown to be involved in the 
development and elongation of worm axons217. It appears that this role is 
conserved in Fez1; rat phaeochromocytoma PC12 cells subjected to Fez1 RNA 
interference exhibit reduced neurite outgrowth218. FEZ1 protein has also been 
shown to be involved in microtubule transport, complexing with the microtubule 
motor protein kinesin218. It is thought that this function is critical to FEZ1’s role in 
neurite development219. 
 FEZ1 is a protein of 392 amino acids in length. Small angle X-ray 
analysis of FEZ1 suggests that it is mainly an unfolded protein and exists as a 
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stable dimer220. Lanza and colleagues220 confirms FEZ1’s C-terminal coiled-coil 
domain as critical for protein-protein interactions. This concords with the 
findings that a large number of the proteins postulated as FEZ1 binding partners 
have been found to associate with this C-terminal coiled-coil region221. The N-
terminal region appears to be important for the protein dimerisation and this had 
led to speculation that FEZ1 acts as a bivalent transport adaptor protein220. 
 FEZ1 has been show to associate with schizophrenia independently of 
DISC1222. However further association analyses have failed to corroborate 
these findings223; 224. FEZ1 is thought to bind to DISC1 close to the DISC 
translocation point; this suggests the possibility that the interruption of the 
FEZ1-DISC1 interaction plays a role in the molecular mechanism of 
Schizophrenia225. The postulated binding region of FEZ1 on the DISC1 protein 
is interrupted by the non-synonymous SNP rs6675281. 
 
1-10 Annotated DISC1 protein. Grey area denotes reported FEZ1 binding region, 
red arrows show relative position of non-synonymous polymorphisms. 
1.8.3.2 NudE Neurodevelopment Protein 1-Like 1 (NDEL1) 
 Two mammalian orthologs of the nuclear distribution pathway first 
identified in Aspergillus nidulans are Nde1 and Ndel1. NDEL1 codes for the 
Nuclear Distribution Factor E Homolog 1 which localises at the centrosome226. It 
is thought to play a role in the positioning of the nucleus and has been shown to 
be critical for neuronal migration and neurite outgrowth227. Located within 
chromosome locus of 16p13.11, the gene codes for a protein of 345aa. Splice 
variants have been recently described228. 
 There is evidence indicating that NDEL1 impacts on schizophrenia risk 
through its interaction with DISC1229. A reduction in NDEL1 expression in the 
brains of schizophrenics has also been suggested204. Furthermore, the 
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interaction between NDEL1 and DISC1 would appear to be critical to neuronal 
integration in the adult hippocampus212. 
 NDEL1 has been postulated to bind to amino acids 598-696 of the 
DISC1 protein230. This region is interrupted by the non-synonymous DISC1 SNP 
rs6675281. However, the binding domain more consistently reported spans the 
amino acids 802-835 of DISC1 protein 227. It is possible that both binding 
domains are valid. 
 
1-11 Annotated DISC1 protein. Grey area denotes reported NDEL1 binding 
region, red arrows show relative positions of non-synonymous polymorphisms. 
1.8.3.3 Phosphodiesterase-4B (PDE4B) 
 The genes that code for the phosphodiesterase 4 family of genes are 
mammalian orthologs of the Drosophila melanogaster Dunce gene. The 
phosphodiesterase 4 family consists of 4 members; A-D. They all have intrinsic 
cAMP hydrolytic activity. Dunce is thought to play important roles in both 
learning and memory in D.melanogaster. Inhibition of PDE4s has been 
demonstrated to enhance cognition231. PDE4s have also been shown to partake 
in axon regeneration after injury232. 
 The 4 family members are responsible for over 16 different isoforms; all 
containing 1 or both of 2 different domains, upstream conserved regions (UCR1 
and UCR2). UCRs perform key regulatory functions on the catalytic unit of the 
PDE4 enzyme. UCR2 is also thought to harbour a DISC1 binding region203. A 
sex-specific effect of 4 PDE4B tagSNPs in female schizophrenia patients has 
been reported233. Direct binding of PDE4B/D to DISC1 has been described; the 
regions of DISC1 thought to be critical to this binding include amino acids 191-
230 and 611-650234. This postulated binding region of the PDE4s lies in close 
proximity to the non-synonymous SNP rs6675281. 
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1-12 Annotated DISC1 protein. Grey area denotes reported PDE4B/D binding 
region, red arrows show relative positions of non-synonymous polymorphisms. 
1.8.3.4 Dihydropyrimidinase-like 2 (DPYSL2) 
 DPYSL2 codes for a dihydropyrimidinase related protein. This is a 
member of the DPYSL family of proteins. Though the binding of DPYSL2 with 
DISC1 protein has been reported213, the potential binding region is yet to be 
described, The yeast-two hybrid (Y2H) screen in which it was indicated 
elucidated a detailed protein-protein interaction network of proteins binding both 
with DISC1, and each other. The DPYSL2 protein was identified as binding only 
to the DISC1 bait protein. DYPSL2 has been shown to have >95% homology 
with chick CRMP2 (collapsing response mediator protein), mouse Ulip-2 (Unc-
33 like phosphoprotein 2) and rat TOAD-64235. These orthologs have all been 
reported as being mediators of axonal outgrowth236,237. 
 DPYSL2 is a gene of 14 exons and approximately 100kbp encoding a 
protein of 572 amino acids. Though the chicken ortholog (CRMP62) is neuron 
specific, DPYSL2 is thought to be expressed in a wide variety of tissues 
including brain235. The chromosomal loci of 8p21, in which DPYSL2 resides, is a 
putative schizophrenia risk loci238,239. Furthermore, numerous studies have 
identified significant SNP associations with schizophrenia in Japanese240 and 
Caucasian241 populations. 
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2 RATIONALE AND AIMS 
2.1 Rationale 
 In the context of the postnatal neurogenic niche, post-mortem analysis of 
gene expression has the potential to provide novel insights. The data presented 
by Lipska and colleagues204 shows that the expression of DISC1’s binding 
partners can be affected by mutations in the DISC1 gene. They also present 
evidence to suggest that this effect varies in the context of brain region. In the 
Lipska study, the effect of DISC1 genotype was manifest in the hippocampus. 
This brain region contains the subgranular neurogenic niche. It is intriguing to 
speculate as to whether this effect will endure when the neurogenic niche is 
specifically targeted. 
 The Lipska study analysed a set of 12 single nucleotide polymorphisms. 
Two of these polymorphisms were non-synonymous in nature. Of these two 
non-synonymous SNPs, one was found to affect DISC1 binding partner 
expression. Non-synonymous SNPs have a particular relevance to indirect 
effects on gene expression; that is to say effects not on the expression of the 
genomic locus, but on the binding partners of gene products. However, it is also 
intriguing to speculate that any previously undetected effect of DISC1 SNPs 
(non-synonymous or otherwise) may be revealed by the specific targeting of 
neurogenic regions of the brain. 
2.2 Aims 
 The potential for post-mortem studies to investigate neurogenic gene 
expression requires either; the accurate targeting of tissue, and/or 
measurements of neurogenesis marker expression. This project therefore aims 
to measure the effect of diagnosis and DISC1 genotype on the expression of 
DISC1 binding partners and neurogenesis genes in hippocampal subfield 
dissections. The genes chosen for this study are: 
Gene Rationale 
DCX  A MAP which has proven useful in marking neurogenesis
142. 
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DPYSL2  A putative DISC1 binding partner identified by a Y2H screen
213. 
 Independent evidence of genetic association to 
schizophrenia240. 
FEZ1  A DISC1 protein binding partner strongly indicated by Y2H
208. 
 Independent evidence of genetic association to 
schizophrenia222. 
NDEL1  A DISC1 protein binding partner indicated by both Y2H
213 and 
co-immunoprecipitation (Co-IP)230. 
 Evidence of an epistatic interaction with DISC1 in schizophrenia 
risk229. 
NEUROD1  A putative immunohistological marker of adult neurogenesis
138. 
PDE4B  A DISC1 protein binding partner indicated by both Y2H
213 and 
Co-IP234. 
 A pharmacological target of rolipram, which has been 
demonstrated to enhance long term potentiation231. 
2.3 Hypotheses 
i. The expression of DISC1 binding partners and genes used to mark 
neurogenesis will be aberrant relative to controls in the brains of 
schizophrenics. 
ii. DISC1 genotype will affect the expression of DISC1 binding partners 
and the neurogenesis markers, irrespective of diagnosis. 
2.4 Objectives 
The key steps in this process can be summarised as follows: 
i. Extract DNA and perform allelic discrimination analyses on DISC1 SNPs 
associated to schizophrenia and/or residing on reported binding regions 
for DISC1 binding partners. 
ii. Dissect dentate region from hippocampal sections and extract RNA 
iii. Measure gene expression in schizophrenia for DISC1 binding partners. 
iv. Measure expression of postulated markers of neurogenesis. 
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v. Assess the cellular expression of the utilised neurogenesis markers 
through immunohistochemistry. 
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3 MATERIALS AND METHODS 
3.1 Subjects 
 Post-mortem brain samples from the Stanley Consortium were used for 
the present study. This sample consists of 60 subjects with mixed diagnostic 
statuses (based on DSM-IV criteria) at time of death; 15 suffering from major 
depressive disorder (MDD), 15 suffering from bipolar disorder (BPD), 15 
suffering from schizophrenia (SCZ) and 15 controls with no history of mental 
illness (CON). Frozen sections (10um) of anterior hippocampus were used for 
gene expression studies and immunohistochemistry, paraffin-embedded fixed 
sections (14um) of frontal cortex were used for immunohistochemistry pilot 
studies. Frozen blocks of cerebellum were used for DNA extraction and 
subsequent genotype analysis. All experiments were performed blind to 
diagnosis. The availability of all tissue for the proposed study was approved by 
The Stanley Medical Research Institute. 
3.2 Dentate Dissections 
 Dentate dissection protocol consisted of air drying the slides, immersing 
the tissue in RNAlater stabilisation reagent (AM7024M, Ambion, 
www.ambion.com) to increase pliancy, then scraping desired region into an 
aliquot of RNA later using a sterile scalpel. Using enlarged images of Nissl 
stained sections for guidance, frozen sections of anterior hippocampus were 
manually dissected into three regions. The hippocampal formation (HF, also 
described as the pes hippocampi) was identified and dissected in two portions; 
a neurogenic portion (the dentate gyrus and CA3) and a non-neurogenic portion 
(CA1, CA2, and the subiculum). The remainder of the slides, largely 
encompassing the anterior part of the parahippocampal gyrus, was also 
dissected separately. 
 Frozen slides of anterior hippocampus were not available for 9 of the 60 
samples requested for analysis. Of the 51 samples dissected, variations in size 
and position on the antero-posterior axis necessitated the graphical recording of 
each dissection. Scans of haematoxylin and eosin stained slides, comprised of 
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each Stanley Consortium subject, were annotated for this purpose (Fig 3-1). 
These coronal sections were contiguous with the frozen sections of anterior 
hippocampus used in the current study. 
 
3-1 Picture of anterior hippocampus coronal section with dissected regions annotated 
(DG = dentate gyrus molecular layer, CA1 = cornu ammonis 1, CA2 = cornu ammonis 2, 
CA3 = cornu ammonis 3 
 
3-2 Picture of anterior hippocampus coronal section without annotations 
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3.3 Extraction Procedures 
 DNA was extracted from the frozen blocks of cerebellum using a variant 
of standard phenol-chloroform extraction procedures outlined in Freeman and 
colleagues 242. Yield and quality, indicated by the absorbance ratio (1.7 ≤ 
A260/A280 ≤ 1.9), was assessed via a Picodrop® spectrophotometer (Picodrop 
Ltd., Cambridge Bioscience, Cambridge, UK). 
 The RNA was extracted from the dissected tissues with TRIzol reagent 
(#VX15596-026, Life Technologies Inc., Grand Island, NY, USA) and Qiagen 
RNeasy mini kits (#74106, QIAgen, UK). Tissues were pelleted prior to 
pulverization in TRIzol reagent and the chloroform phase separation step was 
conducted. The resulting aqueous phase was then mixed with an equal volume 
of 70% and purified using Qiagen RNeasy mini kits (Qiagen Ltd., Manchester, 
UK). Extractions provided an average yield per mg staring tissue of 0.20µg ± 
0.07; the maximum expected yield per mg starting tissue is 1.5µg. During the 
dentate dissection procedure, tissues subjected to RNAlater treatment 
produced an average yield of 0.14µg ± 0.04 per mg starting tissue. This 
translated to an average yield of 1.76µg ± 0.43 per whole slide. 
 Quality control (QC) assessment of the micro-dissected hippocampal 
RNA was performed using the Picodrop® spectrophotometer (RNA: 1.9 ≤ 
A260/A280 ≤ 2.1) and a micro-scale electrophoresis system, the Bio-Rad 
Experion® (Bio-Rad, Hercules, CA, USA). Electropherograms of each RNA 
extract enabled the assessment of RNA quality using the proprietary RNA 
Quality Indicator (RQI) analysis metric. Extracts of RQI ≥ 3.8 were required for 
downstream applications204. Of the 51 samples dissected, 27 satisfied the RNA 
quality threshold. However, insufficient RNA yield prevented the accurate 
determination of RQI in the neurogenic HF extractions; precluding further 
analysis in this region. 
 RNA extracts from each region were diluted to standard concentrations 
and treated with TURBO DNA-free kit (Applied Biosystems, Cheshire, UK) in 
order to remove trace amounts of DNA. Reverse transcription experiments were 
conducted, 22.5 - 180ng RNA in 20μl reactions, using a mixture of oligo dT and 
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random primers in the nanoScript reverse transcriptase system (PrimerDesign, 
Southampton, UK). DNA extractions were performed on the frozen blocks of 
cerebellum using a phenol-chloroform extraction procedure outlined by 
Freeman and colleagues242. Nucleic acid yield and purity was assessed using 
the Picodrop spectrophotometer (DNA: 1.7 ≤ A260/A280 ≤ 1.9). 
3.4 Quantitative Polymerase Chain Reaction (qPCR) 
 The expression of target genes of interest (GOIs) were assessed via pre-
designed TaqMan assays (Applied Biosystems). Assays for Reference (REF) 
genes; hydroxymethylbilane synthase (HMBS) and succinate dehydrogenase 
complex, subunit A (SDHA); were custom-designed via the Roche 
ProbeLibrary® (available at www.universalprobelibrary.com). REF genes were 
pre-validated across diagnostic categories from a panel of 8 candidate REF 
genes using the Genorm software as described by Vandesompele and 
colleagues243. The software highlighted that these two reference genes were 
necessary and sufficient for normalisation of target gene data. Probes for the 
custom-designed assays were purchased from Roche (Hertfordshire, UK); 
primers were purchased separately (Invitrogen, Life Technologies, Paisley, UK 
). The qPCR plate design (see Table 3-B) followed the gene maximisation 
method243 and incorporated 3 technical replicates from which mean Cq values 
for each case were derived (SD < 0.2). Experiments were performed on the 
BIO-RAD CFX96 Real Time System. 
3-A Table showing qPCR assay information 
Gene Assay Info. (ABI Assay 
ID / Primer-probe details) 
Isoform 
coverage 
RefSeq Ids 
DPYSL2 Hs00265851_m1 3/3 NM_001197293.2, 
NM_001244604.1, 
NM_001386.5 
DCX Hs00167057_m1 5/5 NM_000555.3, 
NM_001195553.1, 
NM_178151.2, NM_178152.2, 
 51 
NM_178153.3 
NEUROD1 Hs00159598_m1 1/1 NM_002500.4 
FEZ1 Hs00192714_m1 1/1 NM_005103.4 
NDEL1 Hs01092620_m1 2/2 NM_001025579, 
NM_030808.4 
PDE4B Hs00277080_m1 4/4 NM_0010324116.1, 
NM_001037340.1, 
NM_001037341.1, 
NM_002600.3 
SDHA Primer(L): 
aagtccctccaattaaaccaaac 
Primer(R): 
gcagcatgattttgcattga 
Roche Probe 60 Cat No.: 
04688589001 
1/1 NM_004168.2 
HMBS Primer(L): 
caccacaggggacaagattc 
Primer(R): 
gtgaacaaccaggtccacttc 
Roche Probe 37 Cat No.: 
04687957001 
3/3 NM_001258209.1, 
NM_000190.3, 
NM_001258208.1 
 Based on Applied Biosystems’ assay re-evaluations in August 2010, a 
synonymous PDE4B SNP (rs34492439) was found to be located under the 
PDE4B assay probe/primer sequence. The NCBI website (dbSNP) reports the 
heterozygosity of this SNP to be 0.027, with the minor allele frequency 
undetermined. Furthermore, the latest genome build (Genome Build 
GRCh37.1), determined that the NDEL1 assay may detect NDEL1 genomic 
DNA. Due to experimental constraints, the possible impact of these findings on 
the data was not evaluated, 
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 Normalised relative quantity (NRQ) values were obtained by calculating 
the ratio of the GOI copy number to the geometric mean of REF gene copy 
numbers243. Copy numbers were extrapolated from the assay reaction efficiency 
and the mean Cq value of samples, relative to a calibrator oligonucleotide. 
Amplification efficiencies were verified by plotting standard curves for each 
primer pair using serial dilutions of the calibrator oligonucleotides (see 3.4.2.2). 
Calibrator oligonucleotides were synthetic template oligonucleotides, of known 
concentration, used to protect against the inter-run variability inherent across 
qPCR plates. Specific calibrator oligonucleotides required for each assay, and 
run across all qPCR plates (see 3.4.2.1). 
3-B Schematic representation of the 96-well gene-maximised qPCR plate design 
(CO = calibrator oligonucleotide, NTC = non template control) 
  1st SUBJECT 2nd SUBJECT 3rd SUBJECT CO NTC 
  1 2 3 4 5 6 7 8 9 10 11 12 
DCX A             
DPYSL2 B             
FEZ1 C             
PDE4B D             
NDEL1 E             
NEUROD1 F             
HMBS G             
SDHA H             
 
3.4.1 Enzyme Selection 
 During qPCR allelic discrimination experiments, sub-optimal efficiencies 
were observed. These did not affect the qualitative genotype assays, however 
they were prohibitive to qPCR. Therefore, comparisons of the commercially 
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available enzymes were performed. Across all the assays analysed, the Taq 
Polymerase supplied by Roche produced the most effective amplification. This 
is evidenced by an increased inclination of the sigmoid curves (Fig 3-3), 
increased maximum fluorescence, and slightly lower Cq value (Fig 3-4), all 
indicating increased reaction efficacy. 
 
3-3 Graph showing real-time amplification of a DISC1 locus using a TaqMan assay with VIC 
probe. The 3 sets of curves represent the 3 Taq polymerase enzymes tested; Roche = Roche 
Universal Probe Master (#04913957001), ABI = TaqMan Universal Mastermix (#4364341), 
PrimerDesign = PrimerDesign Precision Mastermix (#Precision) 
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3-4 Graph showing the average threshold cycle (cq) number from 20ng DNA, obtained using 
DNA polymerase from a variety of suppliers. Roche = Roche Universal Probe Master 
(#04913957001), ABI = TaqMan Universal Mastermix (#4364341), PrimerDesign = 
PrimerDesign Precision Mastermix (#Precision) 
3.4.2 Standard Curves 
 Quantification of genes of interest (GOIs) with qPCR requires the 
simultaneous measurement of either; a stably expressed reference gene, or a 
control sample with a known number of copies of the gene (or gene locus) in 
question. In absolute quantification, standard curves, serial dilutions of known 
quantities, are used as a comparative tool to estimate quantity. In relative 
quantification studies, they are used to calculate the efficiency of a reaction and 
determine whether the assay is suitable for further analysis. This study utilized a 
combination of both absolute and relative quantification strategies. Standard 
curves were used to validate calibrator oligonucleotides. This allowed 
expression levels to be quantified relative to a known sample (a form of 
absolute quantification). Standard curves were also used to determine the 
amplification efficiencies for each assay, therefore allowing expression levels to 
be further normalised by REF genes (relative quantification). 
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3.4.2.1 Calibrator Oligonucleotide Design 
 Calibrator oligonucleotides were designed to replicate qPCR assay 
amplicon sequences. For the REF gene assays, amplicon sequences were 
provided by the Roche ProbeLibrary® software. For the predesigned assays, 
very limited sequence information was available except for a ‘context sequence’ 
(a selected 25bp sequence from the predicted amplicon). Agarose gels were 
therefore utilised to reveal the actual size of GOI amplicons (Figs. 3-5, 3-6). 
This allowed the lengths of the designed GOI calibrators to reflect the possibility 
that the context sequence maybe positioned at either the 5’ or 3’ end of the 
amplicon (3-C Table). 
 Consequently, the sequence of the GOI calibrators represent; the context 
sequence, plus the necessary flanking sequence information from the gene 
(available from www.ncbi.nlm.nih.gov/genbank ). Due to their size, GOI 
calibrator oligonucleotides were purchased from Integrated DNA Technologies 
(Ultramer DNA, IDT, Coralville, IA ). REF gene calibrator oligonucleotides 
(<100bp) were procured from Invitrogen®. 
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3-5 3% agarose gel with 25bp ladder comparing size of PCR products obtained from the gene 
expression assay for DCX, DPYSL2, and FEZ1, NEUROD1. Image is annotated with estimated 
amplicon sizes 
 
3-6 3% agarose gel, with 25bp ladder, comparing size of PCR products obtained from the gene 
expression assays for NDEL1 and PDE4B. Image is annotated with estimated amplicon sizes 
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3-C Table showing the results of the calibrator oligonucleotide design. Estimated amplicon 
sizes were derived from gel electrophoresis experiments, calibrator oligonucleotide sequences 
equal the 25bp context sequence (highlighted in red) extended at both the 5’ and 3’ ends in 
accordance with the estimated amplicon size estimations. Extensions of the calibrator 
oligonucleotides were rounded up to the nearest 25bp to provide required oligonucleotide size 
values, sequence information can be found at www.ncbi.nlm.nih.gov/genbank. 
Gene Estimated 
Amplicon 
Size (bp) 
Required 
Oligonucleotide 
Size (bp) 
Calibrator Oligonucleotide 
Sequence (25bp context sequence 
highlighted in red) 
DPYSL2 70 125 GGACATCAGTGAGTGGCATAAGGGCATCCAG
GAGGAGATGGAAGCGCTTGTGAAGGATCACG
GGGTAAATTCCTTCCTCGTGTACATGGCTTTC
AAAGATCGCTTCCAGCTAACGGATTGCCAGA 
DCX 80 175 GATTTCTTTGGTGATGATGATGTGTTTATTGCC
TGTGGTCCTGAAAAATTTCGCTATGCTCAGGA
TGATTTTTCTCTGGATGAAAATGAATGCCGAG
TCATGAAGGGAAACCCATCAGCCACAGCTGG
CCCAAAGGCATCCCCAACACCTCAGAAGACTT
CAGCCAAGAGCCCTG 
NEUROD1 80 175 GAGGAATTCGCCCACGCAGGAGGCGCGGCG
TCCGGAGGCCCCAGGGTTATGAGACTATCAC
TGCTCAGGACCTACTAACAACAAAGGAAATC
GAAACATGACCAAATCGTACAGCGAGAGTGG
GCTGATGGGCGAGCCTCAGCCCCAAGGTCCT
CCAAGCTGGACAGACGAGTGT 
FEZ1 75 125 ACCTAGCTCCCGTGAAGAACCAGTTACAGATC
CAAGAGGAGGAGGAGACCCTTCAGGACGAG
GAGGTTTGGGATGCTCTGACAGACAATTACAT
CCCTTCACTCTCAGAAGACTGGAGGGATCCA 
NDEL1 80 175 AGTTGGAGGCACAATTAGTACAGGCTGAACAA
AGAAATAGAGACTTGCAGGCTGATAACCAAAG
ACTGAAATATGAAGTGGAGGCATTAAAGGAG
AAGCTAGAGCATCAATATGCACAGAGCTATAA
GCAGGTCTCAGTGTTAGAAGATGATTTAAGTC
AGACTCGGGCCATTAA 
PDE4B 75 175 TGGCAGACCTGAAGACAATGGTAGAAACGAA
GAAAGTTACAAGTTCAGGCGTTCTTCTCCTAG
ACAACTATACCGATCGCATTCAGGTCCTTCGC
AACATGGTACACTGTGCAGACCTGAGCAACC
CCACCAAGTCCTTGGAATTGTATCGGCAATGG
ACAGACCGCATCATGGA 
3.4.2.2 Reaction Efficiencies 
 The exponential nature of a PCR reaction predicts that the quantity of the 
target locus present in the reaction will be increased by a factor of 2 with every 
cycle. Simply put, the reaction efficiency (E) is a percentage calibration of the 
amplification success rate; 100% indicating successful target duplication each 
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cycle. In order to accurately quantify expression of genes across all samples, a 
PCR must demonstrate an optimal efficiency (90%≤E≤110%, R2≥0.980). 
3.4.2.2.1 DCX 
 A sufficient reaction efficiency was observed for the assay designed to 
measure the expression of the DCX gene (E = 108.3%, R2 = .983). 
 
3-7 Standard curve of DCX assay representing the threshold cycles of standard dilutions 
prepared from a synthetic oligonucleotide designed from the DCX gene 
3.4.2.2.2 DPYSL2 
 A sufficient reaction efficiency was observed for the assay designed to 
measure the expression of the DPYSL2 gene (E = 96.0%, R2= .995). 
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3-8 Standard curve of DPYSL2 assay representing the threshold cycles of standard dilutions 
prepared from a synthetic oligonucleotide designed from the DPYSL2 gene 
3.4.2.2.3 FEZ1 
 A sufficient reaction efficiency was observed for the assay designed to 
measure the expression of the FEZ1 gene (E = 105.9%, R2 = .982). 
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3-9 Standard curve of FEZ1 assay representing the threshold cycles of standard dilutions 
prepared from a synthetic oligonucleotide designed from the FEZ1 gene 
3.4.2.2.4 HMBS 
 A sufficient reaction efficiency was observed for the assay designed to 
measure the expression of the reference gene, HMBS (E = 102.6%, R2 = .980). 
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3-10 Standard curve of HMBS assay representing the threshold cycles of standard dilutions 
prepared from pooled anterior hippocampus cDNA. 
3.4.2.2.5 NDEL1 
 A sufficient reaction efficiency was observed for the assay designed to 
measure the expression of the NDEL1 gene (E = 92.4%, R2 = .981). 
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3-11 Standard curve of NDEL1 assay representing the threshold cycles of standard dilutions 
prepared from a synthetic oligonucleotide designed from the NDEL1 gene 
3.4.2.2.6 NEUROD1 
 A sufficient reaction efficiency was observed for the assay designed to 
measure the expression of the NEUROD1 gene (E = 90.2%, R2 = .998). 
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3-12 Standard curve of NEUROD1 assay representing the threshold cycles of standard 
dilutions prepared from a synthetic oligonucleotide designed from the NEUROD1 gene 
3.4.2.2.7 PDE4B 
 A sufficient reaction efficiency was observed for the assay designed to 
measure the expression of the PDE4B gene (E = 100.4%, R2 = .980). 
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3-13 Standard curve of PDE4B assay representing the threshold cycles of standard dilutions 
prepared from a synthetic oligonucleotide designed from the PDE4B gene 
3.4.2.2.8 SDHA 
 A sufficient reaction efficiency was observed for the assay designed to 
measure the expression of the SDHA gene (E = 90.4%, R2 = .988). 
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3-14 Standard curve of SDHA assay representing the threshold cycles of standard dilutions 
prepared from pooled anterior hippocampus cDNA 
3.5 Allelic Discrimination 
 Allelic discrimination was carried out (as previously described –Dunham 
and colleagues244) using genomic DNA extracted from Stanley consortium 
samples and selected TaqMan SNP 5’ nuclease assays (4351379, Applied 
Biosystems, Life Technologies, UK); targeting DISC1 SNPs rs3738401 
(C__25803261_10), rs821616 (C___1433135_20), rs6675281 
(C___1650667_10), rs3737597 (C___2747617_30), also SCZ susceptibility 
gene SNPs BDNF rs6265 (C__11592758_10) and RAPTOR rs2289759 
(C__15882533_10). Experiments were performed on the BIO-RAD CFX96 
Real-Time System. A control SNP, previously analysed in the sample by a 
separate laboratory (data not shown), was utilised to fully establish confidence 
in the genotype determination. The results obtained for this BDNF SNP rs6265 
were in 100% concordance with the previously produced results. 
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 The 5’ nuclease assay utilises PCR technology to amplify loci harbouring 
target SNPs. Quenched reporter probes complimentary to each allelic variant 
are present with fluorophores attached in an allele-specific manner. The probe 
fluorophores are cleaved from the quencher during the PCR amplification, 
increasing fluorescence in an allele-specific manner. 
 
3-15 The 5’ Nuclease process from the ABI TaqMan SNP Genotyping Assays Protocol 
(4332856C) 
 In this regard, genotype calls were made on the basis of a minimum of 3 
experiments. Post-optimisation, the protocol used for completing the genotype 
data collection involved dispensing 1µl of wet gDNA, diluted to approximately 
40ng/µl, into a 14µl PCR Cocktail for thermo-cycling. The constituent cocktail 
reagents and thermo-cycling parameters were as follows: 
Genotype Thermocycle 
1. Closed lid: Lid temperature of 105°C 
2. Temperature step: 95°C for 10 min 
3. 65 repetitions of 3 steps: a) 92°C for 15 sec 
    b) 60.4 for 50 sec 
 67 
    c) Plate read 
PCR Cocktail Reagent 
Concentration Volume (µl) 
 
FastStart Universal Probe Master 
(04913957001, Roche, Hertfordshire, 
UK) 
 
X2 
 
6.25 
SNP Assay X20 0.625 
Water 
 
- 7.125 
Total  14 
 
 Sample arrangement on each analysis plate is displayed in Fig 3-D, 
numbers in boxes refer to Stanley Consortium ‘AL’ identification numbers: 
3-D Schematic representation of the 96-well plate setup for allelic discrimination 
analysis of each SNP. Samples are numbered 1-60 based on an AL identification 
number (NTC = Non-template control) 
 01 02 03 04 05 06 07 08 09 10 11 12 
A 1 2 3 4 5 6 7 8     
B 9 10 11 12 13 14 15 16     
C 17 18 19 20 21 22 23 24     
D 25 26 27 28 29 30 31 32     
E 33 34 35 36 37 38 39 40     
F 41 42 43 44 45 46 47 48     
G 49 50 51 52 53 54 55 56     
H 57 58 59 60 NTC NTC NTC NTC     
 
3.6 Immunohistochemistry (IHC) 
A selection of commercial antibodies for DISC1 binding partners (FEZ1, 
PDE4B and DPYSL2) and a marker of new-born neurons (NEUROD1) were 
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tested in tissue sections of hippocampus from Stanley Consortium brains to 
determine the cellular expression. Due to experimental constraints, only these 
antibodies were tested. Qualitative assessment was carried out via 
diaminobenzidine (DAB) immunohistochemistry (VECTASTAIN® ABC kit; 
VECTOR Laboratories) to determine the types of cells in the dentate 
hippocampus region expressing these markers. Quantitative assessment of 
successfully-trialled antibodies were achieved via near-infrared (IR) imaging of 
slides (LI-COR Odyssey). 
3.6.1 DAB Antibody Trials 
 FFPE tissue sections from the Stanley Consortium were utilised to 
demonstrate the binding specificity of the selected primary antibodies. Sections 
were deparaffinised in xylene (twice for 15 min) and rehydrated in an ethanol 
series (100% ethanol twice for 3 min, 95% ethanol twice for 3 min, 80% for 3 
min, 70% for 3 min, then ddH20 twice for 3 min). For antigen retrieval, sections 
were microwaved in citrate buffer (pH 6.0) for 20 min, left to cool until the buffer 
reached 60°C), then microwaved for a further 5 min. Sections were then 
incubated in 3% hydrogen peroxide in 0.1 M phosphate-buffered saline (PBS) 
for 30 min to quench endogenous peroxidise activity. Non-specific binding was 
blocked using a 10% normal serum in 0.1M PBS for 1.5 h. This was followed by 
application of the primary antibody diluted in 0.1 M PBS with 1% serum and 
0.3% Triton X-100 at 4°C for 20 h. 
Sections were then washed in 0.1 M PBS (3 × 10 min) before and after 
being incubated at room temperature with a biotinylated secondary antibody for 
1.5 h. The VECTASTAIN Elite ABC kit (PK-6200, VECTOR Laboratories) was 
used according to the supplier’s instructions to visualise antibody binding. 
Sections were then dehydrated with ethanol dilutions (ddH20 for 1 min, 70% for 
1 min, 80% for 1 min, 95% ethanol for 1 min and 100% ethanol for 1 min) before 
being mounted on coverslips. Negative control sections were obtained by 
omitting the primary antibody. 
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3.6.1.1 FEZ1 Antibody 
 FEZ1 immunoreactivity was detected in sections of dorsolateral 
prefrontal cortex using 1/500 Goat anti-Human FEZ1 antibody (NB100-53816, 
Novus Biologicus) as a primary antibody and 1/200 biotinylated Rabbit anti-
Goat IgG (BA-5000, VECTOR Laboratories) for the secondary antibody. Non-
specific binding of the FEZ1 antibody was blocked using 10% normal Rabbit 
serum (NRS). Discrete cellular FEZ1 staining was observed in both grey and 
white matter; the labelling of axons and pyramidal-shaped somata (Fig 3-16). 
corresponded well with previously reported cytosolic expression patterns219. 
 
3-16 DAB Immunoreactivity of FEZ1 antibody conjugate in coronal sections of dorsolateral 
prefrontal cortex grey matter. Staining highlights neurite extensions (small black arrows) and 
mainly pyramidal-shaped neuronal somata (large black arrows). 
3.6.1.2 NEUROD1 Antibody 
 NEUROD1 immunoreactivity was detected in sections of anterior 
hippocampus using 1/200 Mouse anti-Human NEUROD1 antibody (ab60704, 
abcam, Cambridge, UK) as a primary antibody and a 1/100 dilution of a 
proprietary biotinylated secondary antibody mix of Horse anti-Mouse and Horse 
anti-Rabbit IgG supplied as part of the VECTASTAIN Elite ABC kit. Non-specific 
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binding of the NEUROD1 antibody was blocked using 10% normal Horse serum 
(NHS). Distinct NEUROD1 immunoreactivity was detected in the dentate gyrus 
granular layer, with sporadic staining in the hilus (CA4) (Fig 3-17). The 
morphology of labelled cells was in the granular layer was primarily pyramidal 
(Fig 3-18). This was consistent with the previous reports of NEUROD1 
expression in the dentate gyrus245; as well as the expected expression pattern 
of a putative marker of neurogenesis. 
 
3-17 DAB Immunoreactivity of NEUROD1 antibody conjugate in coronal sections of anterior 
hippocampus. Staining highlights the dentate gyrus (small black arrows) and the appearance of 
sporadic staining of spheroid staining in the hilus (CA4) large black arrows). 
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3-18 DAB Immunoreactivity of NEUROD1 antibody conjugate in the dentate gyrus granule cell 
layer. Staining highlights the mainly pyramidal-shaped somata stained (large black arrows) and 
their process (small black arrows) 
3.6.1.3 PDE4B Antibody 
 PDE4B immunoreactivity was detected in sections of anterior 
hippocampus using a 1/100 dilution of Rabbit anti-Human PDE4B antibody 
(Ab14611, Abcam)1 and a 1/100 dilution of the proprietary mix of biotinylated 
secondary antibodies (Horse anti-Mouse and Horse anti-Rabbit IgG) supplied 
as part of the VECTASTAIN Elite ABC kit. This antibody was not selected for 
quantitative analysis. This was because no discrete staining was observed to 
would allow for accurate quantification (Fig 3-19, 3-20). Furthermore, the lack of 
obvious staining in the anterior hippocampal sections ran in direct contradiction 
to the previous reports of widespread distribution in the hippocampus246. The 
limited quantitative IHC resources were therefore redirected to the analysis of 
more effective primary antibodies. 
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3-19 DAB Immunoreactivity of PDE4B antibody conjugate in sections of anterior 
hippocampus. The clear lack of discrete cellular staining is highlighted by comparisons 
with NEUROD1 staining trials in the same region of the hippocampus where staining of 
the dentate gyrus can be observed (inset, small black arrows) 
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3-20 DAB Immunoreactivity of PDE4B antibody conjugate in the hilus (CA4). The 
appearance of sparse staining of spheroid cell somata can be observed (large black 
arrows) 
3.6.1.4 DPYSL2 Antibody 
 Detection of the DPYSL2 immunoreactivity was conducted in sections of 
dorsolateral prefrontal cortex using a 1/200 dilution of Goat anti-Human CRMP2 
(AB9892, Millipore UK, Watford, UK) as a primary antibody; and a 1/200 of 
Rabbit anti-Goat Biotinylated IgG for the secondary. Expression was expected 
to be specific to neuronal populations with the capacity for differentiation and 
neuroplasticity modifications247. During the optimisation of the IHC assay, it was 
determined that the staining produced by the antibody was mainly non-specific 
especially in the white matter (Fig. 3-21). This was investigated further by 
counter-staining with a Harris modified haematoxylin solution (HHS32, Sigma-
Aldrich) for 7 min to stain nuclei, the underside of sections were then run under 
cold tap water for 1 min) before mounting. Counter-staining was performed after 
secondary antibody wash steps This demonstrated that stained neurons were 
sparsely populated in the white matter, and the staining intensity was effectively 
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masked by the non-specific staining in the neuropil (Fig. 3-22). Quantitative IHC 
resources were therefore redirected accordingly. 
 
3-21 DAB Immunoreactivity of DPYSL2 antibody conjugate in coronal sections of 
dorsolateral prefrontal cortex (white matter). The apparent staining of spheroid cell 
somata (large black arrows) is largely obscured by high non-specific staining in the 
neuropil. 
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3-22 DAB Immunoreactivity of DPYSL2 antibody conjugate in coronal sections of 
dorsolateral prefrontal cortex (white matter) counter-stained with haematoxylin. The 
sparse spheroid staining can be clearly attributed to somata counter-stained with 
haematoxylin, though this is still obscured by non-specific staining. 
3.6.2 Near-IR IHC 
 As FEZ1 and NEUROD1 antibodies were successfully trialled, 
quantitative assessments of antibody binding in frozen slides of anterior 
hippocampus were conducted. Quantitative assessment of FEZ1 protein density 
was conducted twice (an initial and a repeat experiment). Due to experimental 
constraints NEUROD1 assessments were carried out once only. In both cases, 
sections were fixed in 4% paraformaldeyhde (9.5 min), washed in 0.1M PBS (2 
× 5 min), and non-specific binding blocked with 10% normal Donkey serum 
(NDS) in 0.1M PBS for 1.5 h. Primary antibody incubations were performed in 
0.1 M PBS and 0.3% Triton X-100, but with 1% NDS at 4°C for 20 h. Sections 
were then washed in 0.1 M PBS (3 × 10 min) before and after being incubated 
with a near infrared dye-conjugated secondary antibodies for 1.5 h. Sections 
were then dehydrated with ethanol dilutions. 
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 FEZ1 expression was estimated using a 1/200 primary antibody dilution 
and signal intensities emitted from 1:200 dilution of secondary antibody (Donkey 
anti-Goat IgG, Alexa Fluor® 647 Conjugate, AP180SA6, Millipore, UK). The 
FEZ1 signal intensity was strongest in the white matter. NEUROD1 expression 
was estimated using a 1/210 primary antibody dilution and a 1:200 dilution of 
secondary antibody (IRDye® 800CW Donkey Anti-Mouse IgG (H+L), Highly 
Cross Adsorbed (926-32212, LI-COR Biosciences). NEUROD1 labelling was 
primarily located in the dentate gyrus and surrounding grey matter tissue (Fig 
3-23). 
 The fluorescent immuno-complexes were detected with the LI-COR 
Odyssey (Fig. 2B; 169 μm resolution, 0.9mm offset with high quality). The 
700nm channel sensitivity was optimised for each set of stained sections, with 5 
being found to be most optimal. Using the associated Odyssey software, 
regions of interest (ROIs) were defined (Fig 3-23) and independent protein 
densities (or mean specific intensities, lsi), were calculated for the anterior 
parahippocampal grey matter, white matter and dentate gyrus separately. lsi = li 
– bi, where bi = non-specific and background intensity and li = overall mean 
intensity; bi was derived from negative primary antibody controls. These 
calculations were performed according to the Odyssey operating instructions. In 
short, the protein density reflects the average specific signal intensity of the 
secondary antibody within the defined ROI. 
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3-23 Images of FEZ1 and NEUROD1 double immuno-labelling (A, Grey matter ROI = Dashed 
white line, White matter ROI = dashed black line, Dentate gyrus ROI = solid white line); 
NEUROD1 immuno-labelling (B); FEZ1 immuno-labelling. No primary antibody negative controls 
for NEUROD1 and FEZ double immuno-labelling (D), NEUROD1 (E), and FEZ1 (F) 
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3.7 Statistical Analysis 
 All statistical analyses were performed using the IBM SPSS statistics 
package. NRQs and lsi values were grouped on the basis of diagnosis for outlier 
removal prior to statistical testing. Univariate ANOVAs were performed to 
compare expression levels across diagnostic categories248. When Levene’s test 
for Homogeneity of Variance was violated (p < .05), in some cases the F value 
was predicted to undergo a reduction due to sample size, thus making the 
ANOVA test more conservative. In these cases parametric testing was 
concluded. Otherwise, when the Levene’s Test was violated Kruskal-Wallis 
testing was utilised; and the non-parametric equivalent of the Levene’s test 
applied. 
For analysis of genotyping data, the dominant effect model was used by 
grouping homozygous and heterozygous for the minor allele and comparing 
with subjects homozygous for the major allele via Mann-Whitney U testing. 
Gene expression data associated with genotype was then further assessed, 
where possible, using repeated-measures ANOVA (between-subjects factor 
being genotype) to avoid artefacts of multiple comparisons. 
 Assessments of demographic and clinical variables were carried out 
using Mann Whitney U tests (dichotomous variables) and Spearman’s rank-
order correlations (continuous variables). To identify potential dichotomous 
coviariates; IHC and mRNA data variable were compared between groups of 
gender, psychosis, and brain hemisphere using Mann Whitney U tests. To 
identify potential continuous covariates, age, pH, PMI, drugs and RQI were 
correlated with mRNA and IHC variables using Spearman’s rank-order 
correlations (see 3.7.2). Those showing significant correlations were retained as 
covariates in comparisons between schizophrenia, bipolar disorder, major 
depressive disorder and controls using Univariate ANCOVAs. Unless stated 
otherwise, all ANCOVA tests performed conformed to the homogeneity of 
regression model. 
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3.7.1 Outlier Removal 
 Outliers were removed using the Tukey outlier labelling rule249, (g = 1.5). 
Sample size precluded the use of Tukey outlier labelling for non-neurogenic HF 
qPCR, so in this region the limit of 2.5 standard deviations from the mean was 
utilised instead. In order to maintain outlier removal consistency, a subsequent 
re-test of all outliers was performed using this ‘standard deviation from the 
mean’ rule. These results were in concordance with Tukey outlier labelling. Due 
to ongoing concerns regarding sample size and statistical power, outlier 
removal was recorded and detailed below (Figs.3-24 to 3-57) and parallel tests, 
with outliers maintained, were performed (see 5-A Table, 6-A Table, and 
9Appendix C). 
3.7.1.1 DCX qPCR Plots 
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3-24 Box-plots showing distributions of DCX mRNA transcript levels in the 
anterior parahippocampal region and the identified outliers. Asterisk denotes 
outliers identified using Tukey Outlier Labelling Rule (g = 3); circle indicates (g = 
1.5). All of the indicated Tukey outliers were also highlighted by the ‘2.5 standard 
deviations from the mean’ test. NRQ = Normalised Relative Quantity, bpd = 
Bipolar Disorder, mdd = Major Depressive Disorder, scz = Schizophrenia, con = 
controls, 
 
3-25 Box-plots showing distributions of DCX mRNA transcript levels in the 
anterior parahippocampal region after the initial removal of labelled outliers. 
Asterisk denotes outliers identified using Tukey Outlier Labelling Rule (g = 3); 
circle indicates (g = 1.5). All of the indicated Tukey outliers were also highlighted 
by the ‘2.5 standard deviations from the mean’ test. NRQ = Normalised Relative 
Quantity, bpd = Bipolar Disorder, mdd = Major Depressive Disorder, scz = 
Schizophrenia, con = controls, 
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3-26 Scatter plot showing DCX mRNA transcript levels in the anterior 
parahippocampal region after Tukey outlier removal. Black arrows indicate 
removed outliers that were still highlighted by the ‘2.5 standard deviations from 
the mean’ test. NRQ = Normalised Relative Quantity, bpd = Bipolar Disorder, mdd 
= Major Depressive Disorder, scz = Schizophrenia, con = controls. 
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3-27 Scatter plot showing DCX mRNA transcript levels in the non-neurogenic 
hippocampal formation. Black arrows indicate removed outliers highlighted by 
the ‘2.5 standard deviations from the mean’ test. NRQ = Normalised Relative 
Quantity, bpd = Bipolar Disorder, mdd = Major Depressive Disorder, scz = 
Schizophrenia. 
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3.7.1.2 DPYSL2 qPCR Plots 
 
3-28 Box-plots showing distributions of DPYSL2 mRNA transcript levels in the 
anterior parahippocampal region and the identified outliers. Asterisk denotes 
outliers identified using Tukey Outlier Labelling Rule (g = 3); circle indicates (g = 
1.5). All of the indicated Tukey outliers were also highlighted by the ‘2.5 standard 
deviations from the mean’ test. NRQ = Normalised Relative Quantity, bpd = 
Bipolar Disorder, mdd = Major Depressive Disorder, scz = Schizophrenia, con = 
controls, 
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3-29 Box-plots showing distributions of DPYSL2 mRNA transcript levels in the 
anterior parahippocampal region after the initial removal of labelled outliers. 
Circles denote outliers identified using Tukey Outlier Labelling Rule (g = 1.5). All 
of the indicated Tukey outliers were also highlighted by the ‘2.5 standard 
deviations from the mean’ test. NRQ = Normalised Relative Quantity, bpd = 
Bipolar Disorder, mdd = Major Depressive Disorder, scz = Schizophrenia, con = 
controls, 
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3-30 Scatter plot showing DPYSL2 mRNA transcript levels in the anterior 
parahippocampal region after Tukey outlier removal. NRQ = Normalised Relative 
Quantity, bpd = Bipolar Disorder, mdd = Major Depressive Disorder, scz = 
Schizophrenia, con = controls. 
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3-31 Scatter plot showing DPYSL2 mRNA transcript levels in the non-neurogenic 
hippocampal formation. No outliers were identified. NRQ = Normalised Relative 
Quantity, bpd = Bipolar Disorder, mdd = Major Depressive Disorder, scz = 
Schizophrenia. 
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3.7.1.3 FEZ1 qPCR Plots 
 
3-32 Box-plots showing distributions of FEZ1 mRNA transcript levels in the 
anterior parahippocampal region and the identified outliers. Asterisk denotes 
outliers identified using Tukey Outlier Labelling Rule (g = 3); circle indicates (g = 
1.5). All of the indicated Tukey outliers were also highlighted by the ‘2.5 standard 
deviations from the mean’ test. NRQ = Normalised Relative Quantity, bpd = 
Bipolar Disorder, mdd = Major Depressive Disorder, scz = Schizophrenia, con = 
controls, 
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3-33 Box-plots showing distributions of FEZ1 mRNA transcript levels in the 
anterior parahippocampal region after the initial removal of labelled outliers. 
Asterisk denotes outliers identified using Tukey Outlier Labelling Rule (g = 3); 
circle indicates (g = 1.5). All of the indicated Tukey outliers were also highlighted 
by the ‘2.5 standard deviations from the mean’ test. NRQ = Normalised Relative 
Quantity, bpd = Bipolar Disorder, mdd = Major Depressive Disorder, scz = 
Schizophrenia, con = controls, 
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3-34 Scatter plot showing FEZ1 mRNA transcript levels in the anterior 
parahippocampal region after Tukey outlier removal. NRQ = Normalised Relative 
Quantity, bpd = Bipolar Disorder, mdd = Major Depressive Disorder, scz = 
Schizophrenia, con = controls. 
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3-35 Scatter plot showing FEZ1 mRNA transcript levels in the non-neurogenic 
hippocampal formation. Black arrows indicate removed outliers highlighted by 
the ‘2.5 standard deviations from the mean’ test. NRQ = Normalised Relative 
Quantity, bpd = Bipolar Disorder, mdd = Major Depressive Disorder, scz = 
Schizophrenia. 
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3.7.1.4 FEZ1 IHC Plots 
 
3-36 Box-plots showing distributions of FEZ1 protein density levels across the 
anterior parahippocampal grey matter and the identified outliers. Circles denote 
outliers identified using Tukey Outlier Labelling Rule (g = 1.5). In this case, the 
indicated Tukey outliers were not also highlighted by the ‘2.5 standard 
deviations from the mean’ test, they were therefore not removed. Isi = Mean 
Specific Intensity, bpd = Bipolar Disorder, mdd = Major Depressive Disorder, scz 
= Schizophrenia, con = controls, 
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3-37 Scatter plot showing FEZ1 protein density levels across the anterior 
parahippocampal grey matter after Tukey outlier removal. Isi = Mean Specific 
Intensity, bpd = Bipolar Disorder, mdd = Major Depressive Disorder, scz = 
Schizophrenia, con = controls. 
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3-38 Box-plots showing distributions of FEZ1 protein density levels across the 
anterior parahippocampal white matter and the identified outliers. Circles denote 
outliers identified using Tukey Outlier Labelling Rule (g = 1.5). All of the indicated 
Tukey outliers were also highlighted by the ‘2.5 standard deviations from the 
mean’ test. Isi = Mean Specific Intensity, bpd = Bipolar Disorder, mdd = Major 
Depressive Disorder, scz = Schizophrenia, con = controls, 
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3-39 Scatter plot showing FEZ1 protein density levels across the anterior 
parahippocampal white matter after Tukey outlier removal. Isi = Mean Specific 
Intensity, bpd = Bipolar Disorder, mdd = Major Depressive Disorder, scz = 
Schizophrenia, con = controls. 
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3-40 Box-plots showing distributions of FEZ1 protein density levels in the 
dentate gyrus. No outliers were identified. Isi = Mean Specific Intensity, bpd = 
Bipolar Disorder, mdd = Major Depressive Disorder, scz = Schizophrenia, con = 
controls, 
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3-41 Scatter plot showing FEZ1 protein density levels in the dentate gyrus. No 
identifiers were identified in this region. Isi = Mean Specific Intensity, bpd = 
Bipolar Disorder, mdd = Major Depressive Disorder, scz = Schizophrenia, con = 
controls. 
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3.7.1.5 NDEL1 qPCR Plots 
 
3-42 Box-plots showing distributions of NDEL1 mRNA transcript levels in the 
anterior parahippocampal region and the identified outliers. Asterisk denotes 
outliers identified using Tukey Outlier Labelling Rule (g = 3); circle indicates (g = 
1.5). All of the indicated Tukey outliers were also highlighted by the ‘2.5 standard 
deviations from the mean’ test. NRQ = Normalised Relative Quantity, bpd = 
Bipolar Disorder, mdd = Major Depressive Disorder, scz = Schizophrenia, con = 
controls, 
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3-43 Box-plots showing distributions of NDEL1 mRNA transcript levels in the 
anterior parahippocampal region after the initial removal of labelled outliers. 
Circles denote outliers identified using Tukey Outlier Labelling Rule (g = 1.5). All 
of the indicated Tukey outliers were also highlighted by the ‘2.5 standard 
deviations from the mean’ test. NRQ = Normalised Relative Quantity, bpd = 
Bipolar Disorder, mdd = Major Depressive Disorder, scz = Schizophrenia, con = 
controls, 
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3-44 Scatter plot showing NDEL1 mRNA transcript levels in the anterior 
parahippocampal region after Tukey outlier removal. NRQ = Normalised Relative 
Quantity, bpd = Bipolar Disorder, mdd = Major Depressive Disorder, scz = 
Schizophrenia, con = controls. 
 100 
 
3-45 Scatter plot showing NDEL1 mRNA transcript levels in the non-neurogenic 
hippocampal formation. No outliers were identified. NRQ = Normalised Relative 
Quantity, bpd = Bipolar Disorder, mdd = Major Depressive Disorder, scz = 
Schizophrenia. 
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3.7.1.6 NEUROD1 qPCR Plots 
 
3-46 Box-plots showing distributions of NEUROD1 mRNA transcript levels in the 
anterior parahippocampal region and the identified outliers. Circle denotes 
outliers identified using Tukey Outlier Labelling Rule (g = 1.5). All of the indicated 
Tukey outliers were also highlighted by the ‘2.5 standard deviations from the 
mean’ test. NRQ = Normalised Relative Quantity, bpd = Bipolar Disorder, mdd = 
Major Depressive Disorder, scz = Schizophrenia, con = controls, 
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3-47 Scatter plot showing NEUROD1 mRNA transcript levels in the anterior 
parahippocampal region after Tukey outlier removal. NRQ = Normalised Relative 
Quantity, bpd = Bipolar Disorder, mdd = Major Depressive Disorder, scz = 
Schizophrenia, con = controls. 
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3-48 Scatter plot showing NEUROD1 mRNA transcript levels in the non-
neurogenic hippocampal formation. Black arrow indicates removed outliers 
highlighted by the ‘2.5 standard deviations from the mean’ test. NRQ = 
Normalised Relative Quantity, bpd = Bipolar Disorder, mdd = Major Depressive 
Disorder, scz = Schizophrenia. 
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3.7.1.7 NEUROD1 IHC Plots 
 
3-49 Box-plots showing distributions of NEUROD1 protein density levels across 
the anterior parahippocampal grey matter and the identified outliers. Circles 
denote outliers identified using Tukey Outlier Labelling Rule (g = 1.5). All of the 
indicated Tukey outliers were also highlighted by the ‘2.5 standard deviations 
from the mean’ test. Isi = Mean Specific Intensity, bpd = Bipolar Disorder, mdd = 
Major Depressive Disorder, scz = Schizophrenia, con = controls, 
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3-50 Scatter plot showing NEUROD1 protein density levels across the anterior 
parahippocampal grey matter after Tukey outlier removal. Isi = Mean Specific 
Intensity, bpd = Bipolar Disorder, mdd = Major Depressive Disorder, scz = 
Schizophrenia, con = controls. 
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3-51 Box-plots showing distributions of NEUROD1 protein density levels across 
the anterior parahippocampal white matter and the identified outliers. Circles 
denote outliers identified using Tukey Outlier Labelling Rule (g = 1.5). All of the 
indicated Tukey outliers were also highlighted by the ‘2.5 standard deviations 
from the mean’ test. Isi = Mean Specific Intensity, bpd = Bipolar Disorder, mdd = 
Major Depressive Disorder, scz = Schizophrenia, con = controls, 
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3-52 Scatter plot showing NEUROD1 protein density levels across the anterior 
parahippocampal white matter after Tukey outlier removal. Isi = Mean Specific 
Intensity, bpd = Bipolar Disorder, mdd = Major Depressive Disorder, scz = 
Schizophrenia, con = controls. 
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3-53 Box-plots showing distributions of FEZ1 protein density levels in the 
dentate gyrus. No outliers were identified. Isi = Mean Specific Intensity, bpd = 
Bipolar Disorder, mdd = Major Depressive Disorder, scz = Schizophrenia, con = 
controls, 
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3-54 Scatter plot showing FEZ1 protein density levels in the dentate gyrus. No 
identified in this region. Isi = Mean Specific Intensity, bpd = Bipolar Disorder, mdd 
= Major Depressive Disorder, scz = Schizophrenia, con = controls. 
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3.7.1.8 PDE4B qPCR Plots 
 
3-55 Box-plots showing distributions of PDE4B mRNA transcript levels in the 
anterior parahippocampal region and the identified outliers. Circle denotes 
outliers identified using Tukey Outlier Labelling Rule (g = 1.5). All of the indicated 
Tukey outliers were also highlighted by the ‘2.5 standard deviations from the 
mean’ test. NRQ = Normalised Relative Quantity, bpd = Bipolar Disorder, mdd = 
Major Depressive Disorder, scz = Schizophrenia, con = controls, 
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3-56 Scatter plot showing PDE4B mRNA transcript levels in the anterior 
parahippocampal region after Tukey outlier removal. NRQ = Normalised Relative 
Quantity, bpd = Bipolar Disorder, mdd = Major Depressive Disorder, scz = 
Schizophrenia, con = controls. 
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3-57 Scatter plot showing PDE4B mRNA transcript levels in the non-neurogenic 
hippocampal formation. Black arrows indicate removed outliers highlighted by 
the ‘2.5 standard deviations from the mean’ test. NRQ = Normalised Relative 
Quantity, bpd = Bipolar Disorder, mdd = Major Depressive Disorder, scz = 
Schizophrenia. 
3.7.2 Confounding Factor Detection 
 In order to control for the effect of potential confounding factors, 
assessments of demographic and clinical variables were carried out using Mann 
Whitney U tests (dichotomous variables) and Spearman’s rank-order 
correlations (continuous variables). Those demonstrating a significant effect 
were retained as covariates for the comparisons between diagnostic groups. 
The full results of the tests are recorded here. 
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3.7.2.1 Anterior Parahippocampal Data 
3-E Table of the Spearman’s rank correlations of demographic and clinical 
variables with the gene expression normalised relative quantities in the anterior 
parahippocampal region. Asterisk indicates p < 01, double asterisk indicates, p < 
05 
Continuous Variables: qPCR Non-Parametric Correlations (anterior parahippocampal region) 
 Spearman’s rho DCX DPYSL2 FEZ1 NDEL1 NEUROD1 PDE4B 
  qPCR Plate Correlation 
Coefficient 
-.175 -.329 -.092 .140 -.001 -.378
*
 
P (2-tailed) .364 .066 .628 .460 .996 .027 
N 29 32 30 30 31 34 
RQI Correlation 
Coefficient 
-.313 -.048 -.182 -.506
**
 -.123 -.276 
P (2-tailed) .105 .797 .345 .004 .519 .120 
N 28 31 29 30 30 33 
age at death 
(years) 
Correlation 
Coefficient 
-.067 .098 .053 .104 -.161 .129 
P (2-tailed) .729 .592 .782 .583 .387 .467 
N 29 32 30 30 31 34 
age of onset 
of disease 
(years) 
Correlation 
Coefficient 
.130 -.198 -.409
*
 .272 .220 .031 
P (2-tailed) .502 .278 .025 .146 .234 .862 
N 29 32 30 30 31 34 
duration of 
disease 
(years) 
Correlation 
Coefficient 
.133 -.346 -.562
**
 .264 -.008 -.041 
P (2-tailed) .491 .053 .001 .159 .967 .816 
N 29 32 30 30 31 34 
lifetime 
quantity of 
fluphenazine 
or 
Correlation 
Coefficient 
.359 -.307 -.600
**
 .135 .062 -.128 
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Continuous Variables: qPCR Non-Parametric Correlations (anterior parahippocampal region) 
 Spearman’s rho DCX DPYSL2 FEZ1 NDEL1 NEUROD1 PDE4B 
equivalent 
(mg) 
P (2-tailed) .056 .087 .000 .478 .739 .472 
N 29 32 30 30 31 34 
severity of 
substance 
abuse 
Correlation 
Coefficient 
-.073 -.153 -.238 -.201 .159 -.173 
P (2-tailed) .708 .403 .206 .287 .394 .327 
N 29 32 30 30 31 34 
severity of 
alcohol 
abuse 
Correlation 
Coefficient 
-.069 .109 -.155 -.166 .375
*
 -.170 
P (2-tailed) .721 .551 .414 .381 .038 .336 
N 29 32 30 30 31 34 
PH Correlation 
Coefficient 
-.186 .186 .001 -.368
*
 -.369
*
 -.127 
P (2-tailed) .334 .308 .994 .045 .041 .474 
N 29 32 30 30 31 34 
mass of 
brain (g) 
Correlation 
Coefficient 
.067 .054 .219 -.043 .288 .048 
P (2-tailed) .732 .769 .245 .823 .117 .789 
N 29 32 30 30 31 34 
post-mortem 
interval 
(hours) 
Correlation 
Coefficient 
.278 -.097 .118 .345 -.044 .198 
P (2-tailed) .145 .598 .536 .062 .814 .262 
N 29 32 30 30 31 34 
STORAGE 
(DAYS) 
Correlation 
Coefficient 
.359 -.233 -.442
*
 .501
**
 -.190 -.037 
P (2-tailed) .056 .199 .014 .005 .307 .835 
N 29 32 30 30 31 34 
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3-F Table showing the results of Mann-Whitney U testing of dichotomous 
demographic and clinical variables for effects on the gene expression 
normalised relative quantities in the anterior parahippocampal region 
Dichotomous Variables: qPCR Non-Parametric Testing (anterior parahippocampal region) 
  DCX DPYSL2 FEZ1 NDEL1 NEUROD1 PDE4B 
female N 11 15 12 13 14 14 
Mean 
Rank 
14.18 14.33 15.17 14.46 14.64 19.29 
Sum of 
Ranks 
156.00 215.00 182.00 188.00 205.00 270.00 
male N 18 17 18 17 17 20 
Mean 
Rank 
15.50 18.41 15.72 16.29 17.12 16.25 
Sum of 
Ranks 
279.00 313.00 283.00 277.00 291.00 325.00 
Total N 29 32 30 30 31 34 
 
Mann-
Whitney 
U 
90.000 95.000 104.000 97.000 100.000 115.000 
 
Wilcoxon 
W 
156.000 215.000 182.000 188.000 205.000 325.000 
 
Z -.405 -1.227 -.169 -.565 -.754 -.875 
 
p (2-
tailed) 
.686 .220 .866 .572 .451 .382 
Death by 
suicide: yes 
N 7 9 8 8 8 8 
Mean 
Rank 
12.43 12.78 13.00 14.63 14.25 14.63 
Sum of 
Ranks 
87.00 115.00 104.00 117.00 114.00 117.00 
no N 22 23 22 22 23 26 
Mean 
Rank 
15.82 17.96 16.41 15.82 16.61 18.38 
Sum of 
Ranks 
348.00 413.00 361.00 348.00 382.00 478.00 
Total N 29 32 30 30 31 34 
 
Mann-
Whitney 
U 
59.000 70.000 68.000 81.000 78.000 81.000 
 
Wilcoxon 
W 
87.000 115.000 104.000 117.000 114.000 117.000 
 
Z -.917 -1.404 -.938 -.328 -.632 -.934 
 
p (2-
tailed) 
.359 .160 .348 .743 .527 .350 
With 
Psychosis 
N 17 15 15 15 15 17 
Mean 
Rank 
17.35 13.20 10.00 15.73 15.47 15.35 
Sum of 
Ranks 
295.00 198.00 150.00 236.00 232.00 261.00 
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Dichotomous Variables: qPCR Non-Parametric Testing (anterior parahippocampal region) 
  DCX DPYSL2 FEZ1 NDEL1 NEUROD1 PDE4B 
Without 
Psychosis 
N 12 17 15 15 16 17 
Mean 
Rank 
11.67 19.41 21.00 15.27 16.50 19.65 
Sum of 
Ranks 
140.00 330.00 315.00 229.00 264.00 334.00 
Total N 29 32 30 30 31 34 
 
Mann-
Whitney 
U 
62.000 78.000 30.000 109.000 112.000 108.000 
 
Wilcoxon 
W 
140.000 198.000 150.000 229.000 232.000 261.000 
 
Z -1.771 -1.869 -3.422 -.145 -.316 -1.257 
 
p (2-
tailed) 
.077 .062 .001 .885 .752 .209 
Hemisphere: 
right 
N 11 11 11 13 12 13 
Mean 
Rank 
13.64 14.82 10.18 17.62 12.00 13.62 
Sum of 
Ranks 
150.00 163.00 112.00 229.00 144.00 177.00 
left N 18 21 19 17 19 21 
Mean 
Rank 
15.83 17.38 18.58 13.88 18.53 19.90 
Sum of 
Ranks 
285.00 365.00 353.00 236.00 352.00 418.00 
Total N 29 32 30 30 31 34 
 
Mann-
Whitney 
U 
84.000 97.000 46.000 83.000 66.000 86.000 
 
Wilcoxon 
W 
150.000 163.000 112.000 236.000 144.000 177.000 
 
Z -.674 -.734 -2.518 -1.151 -1.947 -1.790 
  
p (2-
tailed) 
.500 .463 .012 .250 .052 .074 
3.7.2.2  Non-neurogenic Hippocampal Formation Data 
3-G Table of the Spearman’s rank correlations of demographic and clinical 
variables with the gene expression normalised relative quantities in the non-
neurogenic hippocampal formation. Asterisk indicates p < 01, double asterisk 
indicates, p < 05 
Continuous Variables: qPCR Non-Parametric Correlations (non-neurogenic hippocampal 
formation) 
  DCX DPYSL2 FEZ1 NDEL1 NEUROD1 PDE4B 
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Continuous Variables: qPCR Non-Parametric Correlations (non-neurogenic hippocampal 
formation) 
  DCX DPYSL2 FEZ1 NDEL1 NEUROD1 PDE4B 
  qPCR Plate Correlation 
Coefficient 
.928
**
 -.119 -.391 -.089 -.532
*
 .397 
P (2-tailed) .000 .649 .134 .733 .041 .143 
N 15 17 16 17 15 15 
RQI Correlation 
Coefficient 
-.226 -.303 -.404 .004 -.142 -.442 
P (2-tailed) .417 .237 .121 .989 .614 .099 
N 15 17 16 17 15 15 
age at death 
(years) 
Correlation 
Coefficient 
-.025 -.075 -.312 -.428 .175 .136 
P (2-tailed) .930 .775 .239 .087 .532 .630 
N 15 17 16 17 15 15 
age of onset 
of disease 
(years) 
Correlation 
Coefficient 
-.686
**
 -.401 -.279 -.070 .238 -.646
**
 
P (2-tailed) .005 .111 .295 .791 .392 .009 
N 15 17 16 17 15 15 
duration of 
disease 
(years) 
Correlation 
Coefficient 
-.636
*
 -.129 -.006 .012 .309 -.582
*
 
P (2-tailed) .011 .622 .983 .962 .262 .023 
N 15 17 16 17 15 15 
lifetime 
quantity of 
fluphenazine 
or 
equivalent 
(mg) 
Correlation 
Coefficient 
-.604
*
 .261 .295 .130 .446 -.395 
P (2-tailed) .017 .312 .267 .618 .096 .145 
N 15 17 16 17 15 15 
severity of 
substance 
abuse 
Correlation 
Coefficient 
-.510 .110 .298 .162 .020 -.337 
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Continuous Variables: qPCR Non-Parametric Correlations (non-neurogenic hippocampal 
formation) 
  DCX DPYSL2 FEZ1 NDEL1 NEUROD1 PDE4B 
P (2-tailed) .052 .673 .262 .536 .942 .219 
N 15 17 16 17 15 15 
severity of 
alcohol 
abuse 
Correlation 
Coefficient 
-.412 .272 .322 .066 .206 -.085 
P (2-tailed) .127 .291 .224 .800 .461 .764 
N 15 17 16 17 15 15 
PH Correlation 
Coefficient 
-.369 -.350 -.023 -.031 -.436 -.304 
P (2-tailed) .176 .169 .934 .905 .105 .271 
N 15 17 16 17 15 15 
mass of 
brain (g) 
Correlation 
Coefficient 
.131 .158 .141 .247 -.061 -.061 
P (2-tailed) .643 .544 .601 .340 .830 .830 
N 15 17 16 17 15 15 
post-mortem 
interval 
(hours) 
Correlation 
Coefficient 
.100 .201 .234 .214 .014 -.011 
P (2-tailed) .722 .438 .383 .410 .960 .970 
N 15 17 16 17 15 15 
STORAGE 
(DAYS) 
Correlation 
Coefficient 
-.900
**
 .140 .400 .110 .529
*
 -.411 
P (2-tailed) .000 .593 .125 .673 .043 .128 
N 15 17 16 17 15 15 
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3-H Table showing the results of Mann-Whitney U testing of dichotomous 
demographic and clinical variables for effects on the gene expression 
normalised relative quantities in the anterior parahippocampal region 
Dichotomous Variables: qPCR Non-Parametric Testing (non-neurogenic hippocampal 
formation) 
  DCX DPYSL2 FEZ1 NDEL1 NEUROD1 PDE4B 
female N 8 9 8 9 8 8 
Mean 
Rank 
9.00 7.44 6.38 6.89 6.88 9.25 
Sum of 
Ranks 
72.00 67.00 51.00 62.00 55.00 74.00 
male N 7 8 8 8 7 7 
Mean 
Rank 
6.86 10.75 10.63 11.38 9.29 6.57 
Sum of 
Ranks 
48.00 86.00 85.00 91.00 65.00 46.00 
Total N 15 17 16 17 15 15 
 
Mann-
Whitney 
U 
20.000 22.000 15.000 17.000 19.000 18.000 
 
Wilcoxon 
W 
48.000 67.000 51.000 62.000 55.000 46.000 
 
Z -.926 -1.347 -1.785 -1.828 -1.042 -1.157 
 
p (2-
tailed) 
.355 .178 .074 .068 .298 .247 
Death by 
suicide: yes 
N 6 6 6 6 4 6 
Mean 
Rank 
6.67 8.50 8.00 9.83 7.75 5.50 
Sum of 
Ranks 
40.00 51.00 48.00 59.00 31.00 33.00 
no N 9 11 10 11 11 9 
Mean 
Rank 
8.89 9.27 8.80 8.55 8.09 9.67 
Sum of 
Ranks 
80.00 102.00 88.00 94.00 89.00 87.00 
Total N 15 17 16 17 15 15 
 
Mann-
Whitney 
U 
19.000 30.000 27.000 28.000 21.000 12.000 
 
Wilcoxon 
W 
40.000 51.000 48.000 94.000 31.000 33.000 
 
Z -.943 -.302 -.325 -.503 -.131 -1.768 
 
p (2-
tailed) 
.346 .763 .745 .615 .896 .077 
With 
Psychosis 
N 6 7 7 7 6 6 
Mean 
Rank 
4.50 11.14 10.86 10.14 10.67 6.00 
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Dichotomous Variables: qPCR Non-Parametric Testing (non-neurogenic hippocampal 
formation) 
  DCX DPYSL2 FEZ1 NDEL1 NEUROD1 PDE4B 
Sum of 
Ranks 
27.00 78.00 76.00 71.00 64.00 36.00 
Without 
Psychosis 
N 9 10 9 10 9 9 
Mean 
Rank 
10.33 7.50 6.67 8.20 6.22 9.33 
Sum of 
Ranks 
93.00 75.00 60.00 82.00 56.00 84.00 
Total N 15 17 16 17 15 15 
 
Mann-
Whitney 
U 
6.000 20.000 15.000 27.000 11.000 15.000 
 
Wilcoxon 
W 
27.000 75.000 60.000 82.000 56.000 36.000 
 
Z -2.475 -1.464 -1.747 -.781 -1.886 -1.414 
 
p (2-
tailed) 
.013 .143 .081 .435 .059 .157 
Hemisphere: 
right 
N 9 9 8 9 7 9 
Mean 
Rank 
6.22 8.78 8.25 10.11 9.14 5.56 
Sum of 
Ranks 
56.00 79.00 66.00 91.00 64.00 50.00 
left N 6 8 8 8 8 6 
Mean 
Rank 
10.67 9.25 8.75 7.75 7.00 11.67 
Sum of 
Ranks 
64.00 74.00 70.00 62.00 56.00 70.00 
Total N 15 17 16 17 15 15 
 
Mann-
Whitney 
U 
11.000 34.000 30.000 26.000 20.000 5.000 
 
Wilcoxon 
W 
56.000 79.000 66.000 62.000 56.000 50.000 
 
Z -1.886 -.192 -.210 -.962 -.926 -2.593 
  
p (2-
tailed) 
.059 .847 .834 .336 .355 .010 
3.7.2.3 Quantitative IHC Data 
3-I Table of the Spearman’s rank correlations of demographic and clinical 
variables with the protein density values in sections of anterior hippocampus. 
Asterisk indicates p < 01, double asterisk indicates, p < 05 
Continuous Variables: IHC Non-Parametric Correlations 
 
 121 
Spearman's Rho 
Relative 
FEZ1 
(APh 
Grey 
Matter) 
Relative 
FEZ1 
(APh 
White 
Matter) 
Relative 
FEZ1 
(Dentate 
Gyrus) 
Absolute 
NEUROD1 
(APh Grey 
Matter) 
Absolute 
NEUROD1 
(APh 
White 
Matter) 
Absolute 
NEUROD1 
(Dentate 
Gyrus) 
  age at death 
(years) 
Correlation 
Coefficient 
-.015 -.326
*
 -.066 
.105 .144 -.098 
P (2-tailed) 
.920 .022 .654 
.512 .361 .551 
N 50 49 49 41 42 39 
age of onset 
of disease 
(years) 
Correlation 
Coefficient 
-.035 .123 -.198 
.027 .054 .111 
P (2-tailed) 
.810 .402 .173 
.869 .735 .501 
N 50 49 49 41 42 39 
duration of 
disease 
(years) 
Correlation 
Coefficient 
-.150 -.270 -.105 
-.056 -.009 -.192 
P (2-tailed) 
.298 .061 .471 
.728 .956 .242 
N 50 49 49 41 42 39 
lifetime 
quantity of 
fluphenazine 
or 
equivalent 
(mg) 
Correlation 
Coefficient 
-.060 -.098 .108 
-.100 -.185 -.132 
P (2-tailed) 
.677 .505 .459 
.534 .240 .424 
N 50 49 49 41 42 39 
severity of 
substance 
abuse 
Correlation 
Coefficient 
-.157 .025 -.162 
-.214 -.053 -.130 
P (2-tailed) 
.276 .864 .267 
.179 .737 .431 
N 50 49 49 41 42 39 
severity of 
alcohol 
abuse 
Correlation 
Coefficient 
.020 .015 -.068 
-.210 -.088 -.030 
P (2-tailed) 
.892 .918 .641 
.187 .581 .856 
N 50 49 49 41 42 39 
PH Correlation 
Coefficient 
-.040 -.232 .022 
-.324
*
 -.179 .002 
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Continuous Variables: IHC Non-Parametric Correlations 
 
Spearman's Rho 
Relative 
FEZ1 
(APh 
Grey 
Matter) 
Relative 
FEZ1 
(APh 
White 
Matter) 
Relative 
FEZ1 
(Dentate 
Gyrus) 
Absolute 
NEUROD1 
(APh Grey 
Matter) 
Absolute 
NEUROD1 
(APh 
White 
Matter) 
Absolute 
NEUROD1 
(Dentate 
Gyrus) 
P (2-tailed) 
.782 .108 .880 
.039 .256 .991 
N 50 49 49 41 42 39 
mass of 
brain (g) 
Correlation 
Coefficient 
.002 .124 .047 
.038 -.237 .103 
P (2-tailed) 
.988 .395 .751 
.816 .131 .531 
N 50 49 49 41 42 39 
post-mortem 
interval 
(hours) 
Correlation 
Coefficient 
-.152 .243 .056 
.071 -.099 .005 
P (2-tailed) 
.292 .092 .704 
.658 .532 .976 
N 50 49 49 41 42 39 
STORAGE 
(DAYS) 
Correlation 
Coefficient 
.156 -.147 -.111 
-.085 .072 -.013 
P (2-tailed) 
.278 .315 .449 
.596 .653 .936 
N 50 49 49 41 42 39 
 
3-J Table showing the results of Mann-Whitney U testing of dichotomous 
demographic and clinical variables for effects on protein density values in 
section of anterior hippocampus. 
Dichotomous Variables: IHC Non-Parametric Testing 
 
  
Relative 
FEZ1 
(APh 
Grey 
Matter) 
Relative 
FEZ1 
(APh 
White 
Matter) 
Relative 
FEZ1 
(Dentate 
Gyrus) 
Absolute 
NEUROD1 
(APh Grey 
Matter) 
Absolute 
NEUROD1 
(APh 
White 
Matter) 
Absolute 
NEUROD1 
(Dentate 
Gyrus) 
female N 22 22 21 17 17 15 
Mean 
Rank 23.73 25.23 24.52 
22.53 24.41 19.33 
Sum of 
Ranks 522.00 555.00 515.00 
383.00 415.00 290.00 
male N 28 27 28 24 25 24 
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Dichotomous Variables: IHC Non-Parametric Testing 
 
  
Relative 
FEZ1 
(APh 
Grey 
Matter) 
Relative 
FEZ1 
(APh 
White 
Matter) 
Relative 
FEZ1 
(Dentate 
Gyrus) 
Absolute 
NEUROD1 
(APh Grey 
Matter) 
Absolute 
NEUROD1 
(APh 
White 
Matter) 
Absolute 
NEUROD1 
(Dentate 
Gyrus) 
Mean 
Rank 26.89 24.81 25.36 
19.92 19.52 20.42 
Sum of 
Ranks 753.00 670.00 710.00 
478.00 488.00 490.00 
Total N 50 49 49 41 42 39 
 
Mann-
Whitney 
U 
269.000 292.000 284.000 
178.000 163.000 170.000 
 
Wilcoxon 
W 522.000 670.000 515.000 
478.000 488.000 290.000 
 
Z -.762 -.101 -.202 -.688 -1.268 -.289 
 
p (2-
tailed) .446 .920 .840 
.491 .205 .773 
Death by 
suicide: yes 
N 18 18 17 13 12 11 
Mean 
Rank 23.56 25.67 24.53 
14.46 19.17 18.64 
Sum of 
Ranks 424.00 462.00 417.00 
188.00 230.00 205.00 
no N 32 31 32 28 30 28 
Mean 
Rank 26.59 24.61 25.25 
24.04 22.43 20.54 
Sum of 
Ranks 851.00 763.00 808.00 
673.00 673.00 575.00 
Total N 50 49 49 41 42 39 
 
Mann-
Whitney 
U 
253.000 267.000 264.000 
97.000 152.000 139.000 
 
Wilcoxon 
W 424.000 763.000 417.000 
188.000 230.000 205.000 
 
Z -.707 -.249 -.168 -2.381 -.780 -.468 
 
p (2-
tailed) .479 .803 .867 
.017 .436 .640 
With 
Psychosis 
N 24 23 23 21 21 20 
Mean 
Rank 24.79 24.30 27.52 
18.95 20.14 18.15 
Sum of 
Ranks 595.00 559.00 633.00 
398.00 423.00 363.00 
Without 
Psychosis 
N 26 26 26 20 21 19 
Mean 
Rank 26.15 25.62 22.77 
23.15 22.86 21.95 
Sum of 
Ranks 680.00 666.00 592.00 
463.00 480.00 417.00 
Total N 50 49 49 41 42 39 
 124 
Dichotomous Variables: IHC Non-Parametric Testing 
 
  
Relative 
FEZ1 
(APh 
Grey 
Matter) 
Relative 
FEZ1 
(APh 
White 
Matter) 
Relative 
FEZ1 
(Dentate 
Gyrus) 
Absolute 
NEUROD1 
(APh Grey 
Matter) 
Absolute 
NEUROD1 
(APh 
White 
Matter) 
Absolute 
NEUROD1 
(Dentate 
Gyrus) 
 
Mann-
Whitney 
U 
295.000 283.000 241.000 
167.000 192.000 153.000 
 
Wilcoxon 
W 595.000 559.000 592.000 
398.000 423.000 363.000 
 
Z -.330 -.321 -1.162 -1.122 -.717 -1.040 
 
p (2-
tailed) .741 .749 .245 
.262 .473 .299 
Hemisphere: 
right 
N 23 22 22 18 19 18 
Mean 
Rank 25.48 24.14 21.82 
18.94 21.16 21.39 
Sum of 
Ranks 586.00 531.00 480.00 
341.00 402.00 385.00 
left N 27 27 27 23 23 21 
Mean 
Rank 25.52 25.70 27.59 
22.61 21.78 18.81 
Sum of 
Ranks 689.00 694.00 745.00 
520.00 501.00 395.00 
Total N 50 49 49 41 42 39 
 
Mann-
Whitney 
U 
310.000 278.000 227.000 
170.000 212.000 164.000 
 
Wilcoxon 
W 586.000 531.000 480.000 
341.000 402.000 395.000 
 
Z -.010 -.382 -1.407 -.972 -.164 -.704 
 
p (2-
tailed) .992 .703 .159 
.331 .870 .481 
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4 GENOTYPE ANALYSIS 
 Once the full complement of cerebellar DNA samples were extracted and 
verified for purity and yield, discrimination assays were performed (Figs. 4-2 to 
4-22). Genotype experiments were repeated twice, except for in the case of the 
rare variant DISC1 rs3737597 where only two experiments were performed. For 
the rest, sample genotype was determined on the basis of at least three 
technical replicates of normalised relative fluorescence units (RFUs). There 
were no discrepancies between repeat experiments. In the first round of 
experiments, some samples did not produce did not produce amplification 
curves, these samples were re-analysed in a ‘missing samples’ analysis 
performed in duplicate (Figs). 
 Marginal levels of non-specific fluorescence, produced by two of the 
‘Genotyping Assays’, proved to be obstructive towards the sole usage of either 
threshold cycle number or absolute RFU to determine genotype. An RFU 
normalization strategy, forwarded by Livak and colleagues250(Fig 4-1), was 
therefore utilised. This controlled for the marginal nonspecific fluorescence, and 
minor variations in starting sample quantity (data not shown). Normalised RFU 
clusters were then sequestered on an axis plot (membership of the intermediate 
cluster denoting heterozygosity) in order to make allele calls. In order to check 
the results, genotype was also determined using threshold cycle during the 2nd 
experiment for DISC1 rs6675281 (Fig 4-7). 
 
4-1 Adapted from Livak et al.250 Formula for normalizing RFUs for the purposes of allelic 
discrimination using the 5’ nuclease assay. 
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 When only 2 clusters were present, 4 non-template control wells were 
sequentially re-analysed as samples to indicate an expected normalized 
fluorescence value for probes complimentary to non-present alleles, allowing for 
a genotype determination between the two groups. The cycle which provided 
the most distinct clustering across all assays was found to be cycle number 45 
(5 extra cycles then recommended by the reagent suppliers). 
 All SNPs analysed in this study were found to be in Hardy-Weinberg 
Equilibrium (HWE; χ2, p > .05) with the Stanley Consortium allele frequencies. 
HWE was therefore also tested using HapMap Central European (CEU) allele 
frequencies (4-A Table to 4-R Table). This method exploits HWE to ‘screen’ for 
distorted SNPs in population samples251. 
4.1 DISC1 Locus 
  
4.1.1 rs3738401 
 For the rs3738401 assay, the Allele 1 VIC fluorophore was attached to 
the probe complimentary to the minor A allele; the Allele 2 FAM fluorophore was 
attached to the major G allele (Fig 4-2 to 4-5). The Stanley Consortium 
frequencies of the DISC1 rs3738401 alleles were A = .36, G = .64. The HapMap 
frequencies of the DISC1 rs3738401 alleles are A = .36, G = .64. The allelic 
discrimination analysis results were found to be in HWE with the expected 
Stanley Consortium allele frequencies for this sample (χ2, p = .98) (4-B Table) 
and the HapMap allele frequencies (χ2, p = 0.96) (4-C Table). The allelic 
discrimination repeat experiments for this SNP were in concordance. 
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4-2 Scatter plot of the raw data obtained from the 1st analysis of the DISC1 rs3738401 SNP. 
The normalised relative fluorescence unit (NRFU) at cycle 45 is demonstrated for each 
fluorophore. 
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4-3 Scatter plot of the raw data obtained from the 2nd analysis of the DISC1 rs3738401. The 
normalised relative fluorescence unit (NRFU) at cycle 45 is demonstrated for each fluorophore. 
4-4 Scatter plot of the raw data obtained from the 3rd analysis of the DISC1 rs3738401. The 
normalised relative fluorescence unit (NRFU) at cycle 45 is demonstrated for each fluorophore. 
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4-5 Scatter plot of the raw data obtained from the analysis of DISC1 rs3738401 in samples 
missing from the 1
st
 experiment. Each previously missing sample was run in duplicate, the 
normalised relative fluorescence unit (NRFU) at cycle 45 is demonstrated for each fluorophore. 
4-A Table demonstrating the genotype calls from each experiment for DISC1 rs3738401, 
samples that were missing from the 1
st
 experiment are highlighted in grey 
AL ID No. 1st 2nd 3rd 
Missing 
Samples (in 
duplicate) 
1 GA GA GA   
2 GA GA GA   
3   AA AA AA 
4 GG GG GG   
5 GA GA GA   
6 GA GA GA   
7 GA GA GA   
8 GG GG GG   
9 GA GA GA   
10 GG GG GG   
11 GG GG GG   
12 GG GG GG   
13 AA AA AA   
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AL ID No. 1st 2nd 3rd 
Missing 
Samples (in 
duplicate) 
14   GG GG GG 
15 GA GA GA   
16 GA GA GA   
17 GA GA GA   
18 GG GG GG   
19   GG GG GG 
20 AA AA AA   
21 GA GA GA   
22 GA GA GA   
23 GA GA GA   
24 GG GG GG   
25 GG GG GG   
26 GG GG GG   
27 GG GG GG   
28 GA GA GA   
29 GG GG GG   
30 GA GA GA   
31 AA AA AA   
32   AA AA AA 
33 GA GA GA   
34 GA GA GA   
35 GA GA GA   
36 GG GG GG   
37 AA AA AA   
38 GA GA GA   
39 GA GA GA   
40 
 
GG GG GG 
41 GG GG GG   
42 GA GA GA   
43 GA GA GA GA 
44 GG GG GG   
45 GG GG GG   
46   GG GG GG 
47   GG GG GG 
48 GG GG GG   
49 GG GG GG   
50 GA GA GA   
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AL ID No. 1st 2nd 3rd 
Missing 
Samples (in 
duplicate) 
51 AA AA AA   
52   GG GG GG  
53 GA GA GA   
54 GA GA GA   
55 AA AA AA   
56 GA GA GA   
57 GA GA GA   
58 GG GG GG   
59 GA GA GA   
60 GG GG GG   
 
4-B Table showing the Stanley Consortium allele frequency Hardy-Weinberg equilibrium data 
for DISC1 rs3738401 
DISC1 rs3738401; N = 60; Stanley MAF = .36 
 
AA GA 
 
GG 
Observed 8 27 
 
25 
Expected 8 28 
 
25 
 
χ2 test p = .98 
4-C Table showing the HapMap allele frequency Hardy-Weinberg equilibrium data for DISC1 
rs3738401 
DISC1 rs3738401; N = 60; HapMap MAF = .36 
 
AA GA 
 
GG 
Observed 8 27 
 
25 
Expected 8 28 
 
24 
 
χ2 test p = .96 
4.1.2 rs6675281 
 For the rs6675281 assay, the Allele 1 VIC fluorophore was attached to 
the probe complimentary to the major C allele; the Allele 2 FAM fluorophore 
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was attached to the minor T allele (Figs. 4-6 to 4-9). The Stanley Consortium 
frequencies of the DISC1 rs6675281 alleles were T = .13, C = .87. The HapMap 
frequencies of the DISC1 6675281 alleles are T = .16, C = .84. The allelic 
discrimination analysis results were found to be in Hardy-Weinberg Equilibrium 
(HWE) with the expected Stanley Consortium allele frequencies for this sample 
(χ2, p = .53) (4-E Table) and the HapMap allele frequencies (χ2, p = 0.35) (4-F 
Table). The allelic discrimination repeat experiments for this SNP were in 
concordance.. 
 
4-6 Scatter plot of the raw data obtained from the 1st analysis of DISC1 rs6675281. The 
normalised relative fluorescence unit (NRFU) at cycle 45 is demonstrated for each fluorophore. 
 133 
 
4-7 Scatter plot of the raw data obtained from the 2nd analysis of DISC1 rs6675281. Threshold 
Cycles (Cq) are demonstrated for each fluorophore. 
4-8 Scatter plot of the raw data obtained from the 3rd  analysis of DISC1 rs6675281. The 
normalised relative fluorescence unit (NRFU) at cycle 45 is demonstrated for each fluorophore. 
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4-9 Scatter plot of the raw data obtained from the analysis of DISC1 rs6675281 in samples 
missing from the 1
st
 experiment. Each previously missing sample was run in duplicate, the 
normalised relative fluorescence unit (NRFU) at cycle 45 is demonstrated for each fluorophore.. 
4-D Table demonstrating the genotype calls from each experiment for DISC1 rs6675281, 
samples that were missing from the 1
st
 experiment are highlighted in grey 
AL ID No. 
1st 
Experiment 2nd  3rd 
Missing 
Samples (in 
duplicate) 
1 CC CC CC   
2 CC CC CC   
3     CC CC 
4 CC CC CC   
5 CT CT CT   
6 CC CC CC   
7 CC CC CC   
8 CC CC CC   
9 CC CC CC   
10 TT TT TT   
11 CC CC CC   
12 CC CC CC   
13 CC CC CC   
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AL ID No. 
1st 
Experiment 2nd  3rd 
Missing 
Samples (in 
duplicate) 
14     CT CT 
15 CC CC CC   
16 CC CC CC   
17 CC CC CC   
18 CC CC CC   
19     CC CC 
20 CC CC CC   
21 CC CC CC   
22 CC CC CC   
23 CC CC CC   
24 
  
CT CT 
25 CC CC CC   
26 CT CT CT   
27 CT CT CT   
28 CC CC CC   
29 CC CC CC   
30 CC CC CC   
31 CC CC CC   
32     CC CC 
33 CC CC CC   
34 CC CC CC   
35 CT CT CT   
36 CC CC CC   
37 CT CT CT   
38 CC CC CC   
39 CC CC CC   
40 CT CT CT   
41 CC CC CC   
42 CC CC CC   
43 TT TT TT   
44 CC CC CC   
45 CC CC CC   
46     CC CC 
47     CC CC 
48 CC CC CC   
49 CT CT CT   
50 CT CT CT   
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AL ID No. 
1st 
Experiment 2nd  3rd 
Missing 
Samples (in 
duplicate) 
51 CC CC CC   
52     CC CC 
53 CT CT CT   
54 CC CC CC   
55 CC CC CC   
56 CC CC CC   
57     CC CC 
58     CC CC 
59     CT CT 
60     CC CC 
4-E Table showing the Stanley Consortium allele frequency Hardy-Weinberg equilibrium data 
for DISC1 rs6675281 
DISC1 rs6675281; N = 60; Stanley MAF = .13 
 
TT 
 
CT 
 
CC 
Observed 2 
 
12 
 
45 
Expected 1 
 
14 
 
45 
 
χ2 test p = .53 
4-F Table the HapMap allele frequency Hardy-Weinberg equilibrium data for DISC1 rs6675281 
DISC1 rs6675281; N = 60; HapMap MAF = .16 
 
TT 
 
CT 
 
CC 
Observed 2 
 
12 
 
45 
Expected 1 
 
16 
 
43 
 
χ2 test p = .35 
4.1.3 rs3737597 
 For the rs3737597 assay, the Allele 1 VIC fluorophore was attached to 
the probe complimentary to the minor A allele; the Allele 2 FAM fluorophore was 
attached to the major G allele (Fig. 4-10 to 4-11). The Stanley Consortium 
frequencies of the DISC1 rs3737597 alleles were A = .02, G = .98. The HapMap 
frequencies of the DISC1 rs3737597 alleles are A = .04, G = 0.95. All samples 
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except two were determined to be homozygous for the major allele(4-G Table). 
The allelic discrimination analysis results were found to be in Hardy-Weinberg 
Equilibrium (HWE) with the expected Stanley Consortium allele frequencies for 
this sample (χ2, p = .85) (4-H Table) and the HapMap allele frequencies (χ2, p = 
.35) (4-I Table). The allelic discrimination repeat experiments for this SNP were 
in concordance. 
 
4-10 Scatter plot of the raw data obtained from the 1st analysis of DISC1 rs3737597. The 
normalised relative fluorescence unit (NRFU) at cycle 45 is demonstrated for each fluorophore. 
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4-11 Scatter plot of the raw data obtained from the 2nd analysis of DISC1 rs3737597. The 
normalised relative fluorescence unit (NRFU) at cycle 45 is demonstrated for each fluorophore. 
4-G Table demonstrating the genotype calls from each experiment for DISC1 rs3737597, 
samples that were missing from the 1
st
 experiment are highlighted in grey 
AL ID No. 
1st 
Experiment 2nd 
1 GG GG 
2 GG GG 
3   GG 
4 GG GG 
5 GG GG 
6 GG GG 
7 GG GG 
8 GG GG 
9 GG GG 
10 GG GG 
11 GG GG 
12 GG GG 
13 GG GG 
14   GG 
15 GG GG 
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AL ID No. 
1st 
Experiment 2nd 
16 GG GG 
17 GG GG 
18 GG GG 
19   GA 
20 GG GG 
21 GG GG 
22 GG GG 
23 GG GG 
24 
 
GG 
25 GG GG 
26 GG GG 
27 GG GG 
28 GG GG 
29 GG GG 
30 GG GG 
31 GA GA 
32   GG 
33 GG GG 
34 GG GG 
35 GG GG 
36 GG GG 
37 GG GG 
38 GG GG 
39 GG GG 
40 GG GG 
41 GG GG 
42 GG GG 
43 GG GG 
44 GG GG 
45 GG GG 
46   GG 
47   GG 
48 GG GG 
49 GG GG 
50 GG GG 
51 GG GG 
52   GG 
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AL ID No. 
1st 
Experiment 2nd 
53 GG GG 
54 GG GG 
55 GG GG 
56 GG GG 
57 GG GG 
58 GG GG 
59 GG GG 
60 GG GG 
 
4-H Table showing the Stanley Consortium allele frequency Hardy-Weinberg equilibrium data 
for DISC1 rs3737597 
DISC1 rs3737597; N = 60; Stanley MAF = .02 
 
AA GA 
 
GG 
Observed 0 2 
 
58 
Expected 0.02 2.97 
 
58 
 
χ2 test p = .85 
 
4-I Table showing the HapMap allele frequency Hardy-Weinberg equilibrium data for DISC1 
rs3737597 
DISC1 rs3737597; N = 60; HapMap MAF = .04 
 
AA GA 
 
GG 
Observed 0 2 
 
58 
Expected 0.1 5 
 
54.8 
 
χ2 test p = .35 
4.1.4 rs821616 
 For the rs821616 assay, the Allele 1 VIC fluorophore was attached to the 
probe complimentary to the major A allele; the Allele 2 FAM fluorophore was 
attached to the minor T allele (Fig. 4-12 to 4-15). The Stanley Consortium 
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frequencies of the DISC1 rs821616 alleles were T = .78, A = .23. The HapMap 
frequencies of the DISC1 rs821616 alleles are T = 0.31, A = 0.69. The complete 
allelic discrimination analysis results were found to be in Hardy-Weinberg 
Equilibrium (HWE) with the expected Stanley Consortium allele frequencies for 
this sample (χ2, p = .76) (4-K Table) and the HapMap allele frequencies (χ2, p = 
0.11) (4-L Table). The allelic discrimination repeat experiments for this SNP were 
in concordance. 
 
4-12 Scatter plot of the raw data obtained from the 1st analysis of DISC1 rs821616. The 
normalised relative fluorescence unit (NRFU) at cycle 45 is demonstrated for each fluorophore. 
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4-13 Scatter plot of the raw data obtained from the 2nd analysis of DISC1 rs821616. The 
normalised relative fluorescence unit (NRFU) at cycle 45 is demonstrated for each fluorophore. 
4-14 Scatter plot of the raw data obtained from the 3rd analysis of DISC1 rs821616. The 
normalised relative fluorescence unit (NRFU) at cycle 45 is demonstrated for each fluorophore. 
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4-15 Scatter plot of the raw data obtained from the analysis of DISC1 rs821616 in samples 
missing from the 1
st
 experiment. Each previously missing sample was run in duplicate, the 
normalised relative fluorescence unit (NRFU) at cycle 45 is demonstrated for each fluorophore. 
4-J Table demonstrating the genotype calls from each experiment for DISC1 rs821616, 
samples that were missing from the 1
st
 experiment are highlighted in grey 
AL ID No. 
1st 
Experiment 2nd 3rd 
Missing 
Samples (in 
duplicate) 
1 AT AT AT   
2 AA AA AA   
3     AT AT 
4 AA AA AA   
5 AA AA AA   
6 AA AA AA   
7 AA AA AA   
8 AA AA AA   
9 AT AT AT   
10 AA AA AA   
11 AA AA AA   
12 AA AA AA   
13 AA AA AA   
 144 
AL ID No. 
1st 
Experiment 2nd 3rd 
Missing 
Samples (in 
duplicate) 
14     AT AT 
15 AA AA AA   
16 AT AT AT   
17 AT AT AT   
18 AA AA AA   
19     TT TT 
20 AA AA AA   
21 AT AT AT   
22 AT AT AT   
23 AT AT AT   
24 
  
AA AA 
25 AA AA AA   
26 AA AA AA   
27 AA AA AA   
28 AA AA AA   
29 AT AT AT   
30 AT AT AT   
31 AT AT AT   
32     AA AA 
33 AT AT AT   
34 AT AT AT   
35 AA AA AA   
36 AA AA AA   
37 AA AA AA   
38 AA AA AA   
39 AA AA AA   
40 AA AA AA   
41 AT AT AT   
42 AA AA AA   
43 AT AT AT   
44 AT AT AT   
45 AA AA AA   
46     AT AT 
47     AA AA 
48 AT AT AT   
49 AT AT AT   
50 AT AT AT   
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AL ID No. 
1st 
Experiment 2nd 3rd 
Missing 
Samples (in 
duplicate) 
51 AA AA AA   
52     AA AA 
53 AA AA AA   
54 AT AT AT   
55 AA AA AA   
56 AA AA AA   
57 AA AA AA   
58 AT AT AT   
59 TT TT TT   
60 AA AA AA   
 
4-K Table showing the Stanley Consortium allele frequency Hardy-Weinberg equilibrium data 
for DISC1 rs821616 
DISC1 rs821616; N = 60; Stanley MAF = .23 
 
TT 
 
AT 
 
AA 
Observed 2 
 
23 
 
35 
Expected 3 
 
21 
 
36 
 
χ2 test p = .76 
4-L Table showing the HapMap allele frequency Hardy-Weinberg equilibrium data for DISC1 
rs821616 
DISC1 rs821616; N = 60; HapMap MAF = .31 
 
TT 
 
AT 
 
AA 
Observed 2 
 
23 
 
35 
Expected 6 
 
26 
 
29 
 
χ2 test p = .12 
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4.2 Schizophrenia-susceptibility Genes 
4.2.1 Regulatory-associated Protein of MTOR (RPTOR) SNP 
rs2289759 
 For the RPTOR rs2289759 assay, the Allele 1 VIC fluorophore was 
attached to the probe complimentary to the major A allele; the Allele 2 FAM 
fluorophore was attached to the minor G allele (Fig. 4-16 to 4-18). The Stanley 
Consortium frequencies of the RAPTOR rs2289759 alleles were G = .33, A = 
.67. The HapMap frequencies of the rs2289759 alleles are G = 0.22, A = 0.78. 
The complete allelic discrimination analysis results were found to be in Hardy-
Weinberg Equilibrium (HWE) with the expected Stanley Consortium allele 
frequencies for this sample (χ2, p = .90) (4-N Table). However the results were 
not in HWE with the HapMap allele frequencies (χ2, p = 0.02) (4-O Table). The 
allelic discrimination repeat experiments for this SNP were in concordance.. 
 
4-16 Scatter plot of the raw data obtained from the 1st analysis of RPTOR rs2289759. The 
normalised relative fluorescence unit (NRFU) at cycle 45 is demonstrated for each fluorophore. 
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4-17 Scatter plot of the raw data obtained from the 2nd analysis of RPTOR rs2289759. The 
normalised relative fluorescence unit (NRFU) at cycle 45 is demonstrated for each fluorophore. 
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4-18 Scatter plot of the raw data obtained from the analysis of RPTOR rs2289759 in samples 
missing from the 1
st
 experiment. Each previously missing sample was run in duplicate, the 
normalised relative fluorescence unit (NRFU) at cycle 45 is demonstrated for each fluorophore. 
4-M Table demonstrating the genotype calls from each experiment for RPTOR rs2289759, 
samples that were missing from the 1
st
 experiment are highlighted in grey 
AL ID No. 1st Experiment 2nd 
Missing 
samples (in 
duplicate) 
1 AG AG   
2 AG AG   
3   AA AA 
4 AG AG   
5 AA AA   
6 GG GG   
7 AA AA   
8 AG AG   
9 AA AA   
10 AA AA   
11 AG AG   
12 AA AA   
13 AG AG   
14   AA AA 
15 AG AG   
16 GG GG   
17 AG AG   
18 AA AA   
19   AG AG 
20 AA AA   
21 AA AA   
22 AA AA   
23 AG AG   
24 
 
AG AG 
25 AA AA   
26 AG AG   
27 AA AA   
28 AA AA   
29 AG AG   
30 AG AG   
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AL ID No. 1st Experiment 2nd 
Missing 
samples (in 
duplicate) 
31 GG GG   
32   AG AG 
33 AA AA   
34 AG AG   
35 AA AA   
36 AG AG   
37 AA AA   
38 AA AA   
39 AG AG   
40 AG AG   
41 AG AG   
42 GG GG   
43 AA AA   
44 AG AG   
45 AG AG   
46   AA AA 
47   GG GG 
48 AA AA   
49 AA AA   
50 AG AG   
51 AG AG   
52   AA AA 
53 AG AG   
54 AA AA   
55 AG AG   
56 AG AG   
57 AA AA   
58 AA AA   
59 AG AG   
60 GG GG   
 
4-N Table showing the Stanley Consortium allele frequency Hardy-Weinberg equilibrium data 
for RPTOR rs2289759 
RPTOR rs2289759; N = 60; Stanley MAF = .33 
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GG 
 
GA 
 
AA 
Observed 6 
 
28 
 
26 
Expected 27 
 
27 
 
7 
 
χ2 test p = .90 
4-O Table showing the HapMap allele frequency Hardy-Weinberg equilibrium data for RPTOR 
rs2289759. 
RPTOR rs2289759; N = 60; HapMap MAF = .22 
 
GG 
 
GA 
 
AA 
Observed 6 
 
28 
 
26 
Expected 3 
 
21 
 
36 
 
χ2 test p = .02 
4.2.2 Brain-derived Neurotrophic Factor (BDNF) SNP rs6265 
 For the BDNF rs6265 assay, the Allele 1 VIC fluorophore was attached 
to the probe complimentary to the major G allele; the Allele 2 FAM fluorophore 
was attached to the minor A allele (Fig. 4-19 to 4-22). The Stanley Consortium 
frequencies of the BDNF rs6265 alleles were G = .83, A = .17.  The HapMap 
frequencies of the rs6265 alleles are G = 0.81, A = 0.20. The complete allelic 
discrimination analysis results were found to be in Hardy-Weinberg Equilibrium 
(HWE) with the expected Stanley Consortium allele frequencies for this sample 
(χ2, p = .59) (4-Q Table) and the HapMap allele frequencies (χ2, p = 0.33) (4-R 
Table). The allelic discrimination repeat experiments for this SNP were in 
concordance. 
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4-19 Scatter plot of the raw data obtained from the 1st analysis of BDNF rs6265. The 
normalised relative fluorescence unit (NRFU) at cycle 45 is demonstrated for each fluorophore. 
Large annotated bold shapes surround data clusters used to make allele calls. 
4-20 Scatter plot of the raw data obtained from the 2nd analysis of BDNF rs6265. The 
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normalised relative fluorescence unit (NRFU) at cycle 45 is demonstrated for each fluorophore. 
Large annotated bold shapes surround data clusters used to make allele calls. 
4-21 Scatter plot of the raw data obtained from the 3rd analysis of BDNF rs6265. The 
normalised relative fluorescence unit (NRFU) at cycle 45 is demonstrated for each fluorophore. 
Large annotated bold shapes surround data clusters used to make allele calls. 
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4-22 Scatter plot of the raw data obtained from the analysis of BDNF rs6265 in samples 
missing from the 1
st
 experiment. Each previously missing sample was run in duplicate, the 
normalised relative fluorescence unit (NRFU) at cycle 45 is demonstrated for each fluorophore. 
Large annotated bold shapes surround data clusters used to make allele calls. 
4-P Table demonstrating the genotype calls from each experiment for BDNF rs6265, samples 
that were missing from the 1
st
 experiment are highlighted in grey 
AL ID No. 
1st 
Experiment 2nd) 3rd 
Missing 
samples (in 
duplicate) 
1 GG GG GG   
2 GG GG GG   
3   GG GG GG 
4 GG GG GG   
5 GA GA GA   
6 GG GG GG   
7 GG GG GG   
8 GG GG GG   
9 GA GA GA   
10 GG GG GG   
11 GG GG GG   
12 GA GA GA   
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AL ID No. 
1st 
Experiment 2nd) 3rd 
Missing 
samples (in 
duplicate) 
13 GG GG GG   
14   GG GG GG 
15 GG GG GG   
16 GG GG GG   
17 GA GA GA   
18 GG GG GG   
19   GG GG GG 
20 GG GG GG   
21 GG GG GG   
22 GG GG GG   
23 GG GG GG   
24 
 
GG GG GG 
25 GA GA GA   
26 GG GG GG   
27 GA GA GA   
28 GG GG GG   
29 AA AA AA   
30 GG GG GG   
31 GG GG GG   
32   GG GG GG 
33 GG GG GG   
34 AA AA AA   
35 GA GA GA   
36 GG GG GG   
37 GA GA GA   
38 GG GG GG   
39 GA GA GA   
40 GG GG GG   
41 GA GA GA   
42 GG GG GG   
43 GG GG GG   
44 GA GA GA   
45 GG GG GG   
46   GG GG GG 
47   AA AA AA 
48 GA GA GA   
49 GG GG GG   
 155 
AL ID No. 
1st 
Experiment 2nd) 3rd 
Missing 
samples (in 
duplicate) 
50 GG GG GG   
51 GG GG GG   
52   GA GA GA 
53 GG GG GG   
54 GG GG GG   
55 GG GG GG   
56 GG GG GG   
57 GG GG GG   
58 GA GA GA   
59 GG GG GG   
60 GG GG GG   
 
4-Q Table showing the Stanley Consortium allele frequency Hardy-Weinberg equilibrium data 
for BDNF rs6265 
BDNF rs6265; N = 60; Stanley MAF = .17 
 
TT 
 
AT 
 
AA 
Observed 3 
 
14 
 
43 
Expected 2 
 
17 
 
42 
 
χ2 test p = .60 
 
4-R Table showing the HapMap allele frequency Hardy-Weinberg equilibrium data for BDNF 
SNP rs6265 
BDNF rs6265; N = 60; HapMap MAF = .20 
 
TT 
 
AT 
 
AA 
Observed 3 
 
14 
 
43 
Expected 2 
 
19 
 
39 
 
χ2 test p = .33 
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5 QUANTITATIVE PCR (qPCR) 
 Bar graphs are used to illustrate differences between diagnostic groups 
as these were assumed to be different based on the sample collection strategy 
(Stanley Consortium samples are matched across diagnosis). This is also 
consistent with a priori hypotheses of the current study. Scatter plots are used 
to illustrate data of mixed diagnostic composition i.e. genotype data. 
5-A Table of the anterior parahippocampal normalised relative quantity data from 
each diagnostic category. Asterisk indicates where the Levene’s Test of Equality 
of Error Variances was violated (p < 05), double asterisk indicates, p < 05 when 
controlling for demographic and clinical variables.; bpd = bipolar disorder, mdd 
= major depressive disorder, con = controls, scz = schizophrenia 
qPCR mRNA Transcript Data (anterior parahippocampal region) 
Diagnosis     DCX DPYSL2 FEZ1 NDEL1 NEUROD1 PDE4B 
bpd N Original 15 15 15 15 15 15 
    Received 15 15 15 15 15 15 
   Pre-
outlier 
10 10 10 10 10 10 
    No. of 
Outliers 
2 2 3 1 0 0 
  N Valid 8 8 7 9 10 10 
  Mean   0.002302 0.564427 0.388825 0.08214 0.129759 0.039532 
  Median   0.00169 0.522815 0.467074 0.021545 0.102625 0.003148 
  Std. 
Deviation 
  0.002537 0.478916 0.265368 0.119132 0.12337 0.060764 
post-hoc to controls (Bonferroni) p 1 0.089 < .001 0.756 1 1 
mdd N Original 15 15 15 15 15 15 
    Received 13 13 13 13 13 13 
   Pre-
outlier 
7 7 7 7 6 7 
    No. of 
Outliers 
2 0 1 1 0 1 
  N Valid 5 7 6 6 6 6 
  Mean   0.002794 0.780422 1.266084 0.067273 0.244612 0.015869 
  Median   0.00246 0.680171 1.423946 0.045725 0.153497 0.013599 
  Std. 
Deviation 
  0.001537 0.495491 0.481025 0.061356 0.252577 0.015162 
post-hoc to controls (Bonferroni) p 1 0.434 0.112 1 0.231 1 
con N Original 15 15 15 15 15 15 
    Received 13 13 13 13 13 13 
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qPCR mRNA Transcript Data (anterior parahippocampal region) 
Diagnosis     DCX DPYSL2 FEZ1 NDEL1 NEUROD1 PDE4B 
   Pre-
outlier 
9 9 9 9 9 9 
    No. of 
Outliers 
2 0 0 2 1 0 
  N Valid 7 9 9 7 8 9 
  Mean   0.00294 1.412732 2.33967 0.019646 0.080498 0.043987 
  Median   0.002408 1.076593 2.482221 0.020171 0.043837 0.005378 
  Std. 
Deviation 
  0.002021 0.969235 1.362233 0.009832 0.074491 0.060516 
post-hoc to controls (Bonferroni) p - - - - - - 
scz N Original 15 15 15 15 15 15 
    Received 2 2 2 2 2 2 
   Pre-
outlier 
9 9 9 9 9 9 
    No. of 
Outliers 
0 1 1 1 2 0 
  N Valid 9 8 8 8 7 9 
  Mean   0.031855 0.760888 0.818269 0.081087 0.077237 0.016265 
  Median   0.010494 0.571892 0.849782 0.10291 0.068748 0.015058 
  Std. 
Deviation 
  0.034427 0.541494 0.315812 0.062216 0.073327 0.012586 
post-hoc to controls (Bonferroni) p 0.042 0.334 0.004 0.854 1 1 
Kruskal-
Wallis 
Pre-
outlier H 7.482 1.828 6.194 1.893 2.804 1.695 
    p 0.058 0.609 0.103 0.595 0.423 0.638 
  Valid H 17.256 5.122 15.036 2.691 3.387 1.797 
    p 0.001 0.163 0.002 0.442 0.336 0.616 
ANOVA Valid F 4.616* 2.559* 8.789* 1.036* 2.01* .856* 
    p 0.011** 0.072 
< 
.001** 0.393 0.136 0.474 
 
5-B Table of the anterior parahippocampal normalised relative quantity data from 
each diagnostic category. Asterisk indicates where the Levene’s Test of Equality 
of Error Variances was violated (p < 05), double asterisk indicates, p < 05 when 
controlling for demographic and clinical variables.; bpd = bipolar disorder, mdd 
= major depressive disorder, con = controls, scz = schizophrenia 
qPCR mRNA Transcript Data (non-neurogenic hippocampal formation) 
Diagnosis     DCX DPYSL2 FEZ1 NDEL1 NEUROD1 PDE4B 
bpd N Original 15 15 15 15 15 15 
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qPCR mRNA Transcript Data (non-neurogenic hippocampal formation) 
Diagnosis     DCX DPYSL2 FEZ1 NDEL1 NEUROD1 PDE4B 
    Received 15 15 15 15 15 15 
   Pre-
outlier 
4 4 4 4 4 4 
    No. of 
Outliers 
1 0 0 0 1 1 
  N Valid 3 4 4 4 3 3 
  Mean   0.000252 0.433572 2.146806 0.013207 0.060532 0.000383 
  Median   0.000226 0.384002 1.969353 0.012563 0.076985 0.000348 
  Std. 
Deviation 
  0.00012 0.355288 1.919553 0.010717 0.045039 0.000103 
post-hoc to controls (Bonferroni) p 0.048 1 0.436 1 1 0.504 
mdd N Original 15 15 15 15 15 15 
    Received 10 10 10 10 10 10 
   Pre-
outlier 
4 4 4 4 3 4 
    No. of 
Outliers 
0 0 0 0 0 0 
  N Valid 4 4 4 4 3 4 
  Mean   0.001749 0.195381 0.102841 0.008231 0.120305 0.000491 
  Median   0.001337 0.119725 0.085903 0.009201 0.053324 0.000444 
  Std. 
Deviation 
  0.001757 0.192848 0.048234 0.005777 0.150405 0.000373 
post-hoc to controls (Bonferroni) p 0.211 1 1 1 1 0.41 
con N Original 15 15 15 15 15 15 
    Received 13 13 13 13 13 13 
   Pre-
outlier 
5 5 5 5 5 5 
    No. of 
Outliers 
0 0 1 0 0 0 
  N Valid 5 5 4 5 5 5 
  Mean   0.004957 0.412305 0.575156 0.007222 0.044911 0.005115 
  Median   0.003904 0.475955 0.569149 0.007343 0.032727 0.003411 
  Std. 
Deviation 
  0.002927 0.253147 0.520381 0.002113 0.041384 0.00564 
post-hoc to controls (Bonferroni) p - - - - - - 
scz N Original 15 15 15 15 15 15 
    Received 13 13 13 13 13 13 
   Pre-
outlier 
4 4 4 4 4 4 
    No. of 
Outliers 
1 0 0 0 0 1 
  N Valid 3 4 4 4 4 3 
  Mean   0.000362 0.68069 0.979931 0.010828 0.437323 0.00048 
  Median   0.000284 0.467003 0.757242 0.009133 0.222644 0.000257 
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qPCR mRNA Transcript Data (non-neurogenic hippocampal formation) 
Diagnosis     DCX DPYSL2 FEZ1 NDEL1 NEUROD1 PDE4B 
  Std. 
Deviation 
  0.002927 0.253147 0.520381 0.002113 0.041384 0.00564 
post-hoc to controls (Bonferroni) p 0.054 1 1 1 0.518 0.539 
Kruskal-
Wallis 
Pre-
outlier H 4.529 2.537 6.324 0.949 3.044 4.88 
    p 0.21 0.469 0.097 0.814 0.385 0.181 
  Valid H 8.736 2.537 6.441 0.949 3.263 7.29* 
    p 0.033 0.469 0.092 0.814 0.353 0.063 
ANOVA Valid F 5.071* 0.832 2.395* .522* 1.408* 2.073* 
    p 0.019 0.5 0.119 0.675 0.292 0.162 
 
5-C Table showing the results of the non-parametric testing of minor carrier 
allele status effects on mRNA transcript levels in the anterior parahippocampal 
region 
qPCR Minor Allele Carrier Status Data (anterior parahippocampal region) 
  DCX DPYSL2 FEZ1 NDEL1 NEUROD1 PDE4B 
DISC1 
rs3738401 
minor 
allele 
carriers 
N 20 18 18 20 18 21 
Mean 
Rank 
15.85 14.28 13.00 15.40 14.67 15.71 
Sum of 
Ranks 
317.00 257.00 234.00 308.00 264.00 330.00 
Non-
carriers 
N 9 14 12 10 13 13 
Mean 
Rank 
13.11 19.36 19.25 15.70 17.85 20.38 
Sum of 
Ranks 
118.00 271.00 231.00 157.00 232.00 265.00 
Total N 29 32 30 30 31 34 
 
Mann-
Whitney 
U 
73.000 86.000 63.000 98.000 93.000 99.000 
 
Wilcoxon 
W 
118.000 257.000 234.000 308.000 264.000 330.000 
 
Z -.801 -1.519 -1.905 -.088 -.961 -1.329 
 
p (2-
tailed) 
.423 .129 .057 .930 .337 .184 
DISC1 
rs6675281 
minor 
allele 
carriers 
N 7 7 7 8 8 9 
Mean 
Rank 
16.29 16.86 17.57 17.25 14.25 18.33 
Sum of 
Ranks 
114.00 118.00 123.00 138.00 114.00 165.00 
Non- N 22 25 23 22 23 25 
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qPCR Minor Allele Carrier Status Data (anterior parahippocampal region) 
  DCX DPYSL2 FEZ1 NDEL1 NEUROD1 PDE4B 
carriers Mean 
Rank 
14.59 16.40 14.87 14.86 16.61 17.20 
Sum of 
Ranks 
321.00 410.00 342.00 327.00 382.00 430.00 
Total N 29 32 30 30 31 34 
 
Mann-
Whitney 
U 
68.000 85.000 66.000 74.000 78.000 105.000 
 
Wilcoxon 
W 
321.000 410.000 342.000 327.000 114.000 430.000 
 
Z -.459 -.114 -.711 -.657 -.632 -.293 
 
p (2-
tailed) 
.646 .909 .477 .511 .527 .770 
DISC1 
rs821616 
minor 
allele 
carriers 
N 11 13 11 12 11 14 
Mean 
Rank 
17.55 20.00 17.55 13.17 13.82 21.07 
Sum of 
Ranks 
193.00 260.00 193.00 158.00 152.00 295.00 
Non-
carriers 
N 18 19 19 18 20 20 
Mean 
Rank 
13.44 14.11 14.32 17.06 17.20 15.00 
Sum of 
Ranks 
242.00 268.00 272.00 307.00 344.00 300.00 
Total N 29 32 30 30 31 34 
 
Mann-
Whitney 
U 
71.000 78.000 82.000 80.000 86.000 90.000 
 
Wilcoxon 
W 
242.000 268.000 272.000 158.000 152.000 300.000 
 
Z -1.259 -1.746 -.968 -1.185 -.991 -1.750 
 
p (2-
tailed) 
.208 .081 .333 .236 .322 .080 
DISC1 
rs3737597 
minor 
allele 
carriers 
N 1 1 1 1 0
a
 1 
Mean 
Rank 
22.00 28.00 19.00 3.00 0.00 26.00 
Sum of 
Ranks 
22.00 28.00 19.00 3.00 0.00 26.00 
Non-
carriers 
N 28 31 29 29 31 33 
Mean 
Rank 
14.75 16.13 15.38 15.93 16.00 17.24 
Sum of 
Ranks 
413.00 500.00 446.00 462.00 496.00 569.00 
Total N 29 32 30 30 31 34 
 
Mann-
Whitney 
U 
7.000 4.000 11.000 2.000 
 
8.000 
 
Wilcoxon 
W 
413.000 500.000 446.000 3.000 
 
569.000 
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qPCR Minor Allele Carrier Status Data (anterior parahippocampal region) 
  DCX DPYSL2 FEZ1 NDEL1 NEUROD1 PDE4B 
 
Z -.837 -1.246 -.404 -1.444 
 
-.866 
 
p (2-
tailed) 
.403 .213 .686 .149 
 
.386 
BDNF 
rs6265 
minor 
allele 
carriers 
N 8 9 8 9 9 10 
Mean 
Rank 
21.25 17.44 15.88 18.67 12.11 21.60 
Sum of 
Ranks 
170.00 157.00 127.00 168.00 109.00 216.00 
Non-
carriers 
N 21 23 22 21 22 24 
Mean 
Rank 
12.62 16.13 15.36 14.14 17.59 15.79 
Sum of 
Ranks 
265.00 371.00 338.00 297.00 387.00 379.00 
Total N 29 32 30 30 31 34 
 
Mann-
Whitney 
U 
34.000 95.000 85.000 66.000 64.000 79.000 
 
Wilcoxon 
W 
265.000 371.000 338.000 297.000 109.000 379.000 
 
Z -2.440 -.356 -.141 -1.290 -1.523 -1.550 
 
p (2-
tailed) 
.015 .722 .888 .197 .128 .121 
RAPTOR 
rs2289759 
minor 
allele 
carriers 
N 16 16 16 16 15 17 
Mean 
Rank 
14.88 17.69 18.00 13.63 17.73 16.94 
Sum of 
Ranks 
238.00 283.00 288.00 218.00 266.00 288.00 
Non-
carriers 
N 13 16 14 14 16 17 
Mean 
Rank 
15.15 15.31 12.64 17.64 14.38 18.06 
Sum of 
Ranks 
197.00 245.00 177.00 247.00 230.00 307.00 
Total N 29 32 30 30 31 34 
 
Mann-
Whitney 
U 
102.000 109.000 72.000 82.000 94.000 135.000 
 
Wilcoxon 
W 
238.000 245.000 177.000 218.000 230.000 288.000 
 
Z -.088 -.716 -1.663 -1.247 -1.028 -.327 
  
p (2-
tailed) 
.930 .474 .096 .212 .304 .744 
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5-D Table showing the results of the non-parametric testing of minor carrier 
allele status effects on mRNA transcript levels in the non-neurogenic 
hippocampal formation 
qPCR Minor Allele Carrier Status Data (non-neurogenic hippocampal formation) 
  DCX DPYSL2 FEZ1 NDEL1 NEUROD1 PDE4B 
DISC1 
rs3738401 
minor 
allele 
carriers 
N 9 10 9 10 9 9 
Mean 
Rank 
7.00 10.80 9.00 9.00 10.22 8.33 
Sum of 
Ranks 
63.00 108.00 81.00 90.00 92.00 75.00 
Non-
carriers 
N 6 7 7 7 6 6 
Mean 
Rank 
9.50 6.43 7.86 9.00 4.67 7.50 
Sum of 
Ranks 
57.00 45.00 55.00 63.00 28.00 45.00 
Total N 15 17 16 17 15 15 
 
Mann-
Whitney 
U 
18.000 17.000 27.000 35.000 7.000 24.000 
 
Wilcoxon 
W 
63.000 45.000 55.000 63.000 28.000 45.000 
 
Z -1.061 -1.757 -.476 0.000 -2.357 -.354 
 
p (2-
tailed) 
.289 .079 .634 1.000 .018 .724 
DISC1 
rs6675281 
minor 
allele 
carriers 
N 3 3 3 3 2 3 
Mean 
Rank 
10.33 6.67 6.33 8.00 4.50 8.00 
Sum of 
Ranks 
31.00 20.00 19.00 24.00 9.00 24.00 
Non-
carriers 
N 12 14 13 14 13 12 
Mean 
Rank 
7.42 9.50 9.00 9.21 8.54 8.00 
Sum of 
Ranks 
89.00 133.00 117.00 129.00 111.00 96.00 
Total N 15 17 16 17 15 15 
 
Mann-
Whitney 
U 
11.000 14.000 13.000 18.000 6.000 18.000 
 
Wilcoxon 
W 
89.000 20.000 19.000 24.000 9.000 96.000 
 
Z -1.010 -.882 -.874 -.378 -1.189 0.000 
 
p (2-
tailed) 
.312 .378 .382 .705 .234 1.000 
DISC1 
rs821616 
minor 
allele 
carriers 
N 4 5 5 5 5 4 
Mean 
Rank 
9.25 6.40 7.60 8.00 5.80 9.75 
Sum of 
Ranks 
37.00 32.00 38.00 40.00 29.00 39.00 
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qPCR Minor Allele Carrier Status Data (non-neurogenic hippocampal formation) 
  DCX DPYSL2 FEZ1 NDEL1 NEUROD1 PDE4B 
Non-
carriers 
N 11 12 11 12 10 11 
Mean 
Rank 
7.55 10.08 8.91 9.42 9.10 7.36 
Sum of 
Ranks 
83.00 121.00 98.00 113.00 91.00 81.00 
Total N 15 17 16 17 15 15 
 
Mann-
Whitney 
U 
17.000 17.000 23.000 25.000 14.000 15.000 
 
Wilcoxon 
W 
83.000 32.000 38.000 40.000 29.000 81.000 
 
Z -.653 -1.370 -.510 -.527 -1.347 -.914 
 
p (2-
tailed) 
.514 .171 .610 .598 .178 .361 
DISC1 
rs3737597 
minor 
allele 
carriers 
N 0
a
 0
a
 0
a
 0
a
 0
a
 0
a
 
Mean 
Rank 
0.00 0.00 0.00 0.00 0.00 0.00 
Sum of 
Ranks 
0.00 0.00 0.00 0.00 0.00 0.00 
Non-
carriers 
N 15 17 16 17 15 15 
Mean 
Rank 
8.00 9.00 8.50 9.00 8.00 8.00 
Sum of 
Ranks 
120.00 153.00 136.00 153.00 120.00 120.00 
Total N 15 17 16 17 15 15 
 
Mann-
Whitney 
U             
 
Wilcoxon 
W             
 
Z             
 
p (2-
tailed)             
BDNF 
rs6265 
minor 
allele 
carriers 
N 5 6 6 6 6 5 
Mean 
Rank 
7.60 5.83 7.67 8.83 6.17 6.80 
Sum of 
Ranks 
38.00 35.00 46.00 53.00 37.00 34.00 
Non-
carriers 
N 10 11 10 11 9 10 
Mean 
Rank 
8.20 10.73 9.00 9.09 9.22 8.60 
Sum of 
Ranks 
82.00 118.00 90.00 100.00 83.00 86.00 
Total N 15 17 16 17 15 15 
 
Mann-
Whitney 
U 
23.000 14.000 25.000 32.000 16.000 19.000 
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qPCR Minor Allele Carrier Status Data (non-neurogenic hippocampal formation) 
  DCX DPYSL2 FEZ1 NDEL1 NEUROD1 PDE4B 
 
Wilcoxon 
W 
38.000 35.000 46.000 53.000 37.000 34.000 
 
Z -.245 -1.910 -.542 -.101 -1.296 -.735 
 
p (2-
tailed) 
.806 .056 .588 .920 .195 .462 
RAPTOR 
rs2289759 
minor 
allele 
carriers 
N 11 11 10 11 10 11 
Mean 
Rank 
9.64 7.73 6.70 8.36 6.90 8.64 
Sum of 
Ranks 
106.00 85.00 67.00 92.00 69.00 95.00 
Non-
carriers 
N 4 6 6 6 5 4 
Mean 
Rank 
3.50 11.33 11.50 10.17 10.20 6.25 
Sum of 
Ranks 
14.00 68.00 69.00 61.00 51.00 25.00 
Total N 15 17 16 17 15 15 
 
Mann-
Whitney 
U 
4.000 19.000 12.000 26.000 14.000 15.000 
 
Wilcoxon 
W 
14.000 85.000 67.000 92.000 69.000 25.000 
 
Z -2.350 -1.407 -1.952 -.704 -1.347 -.914 
  
p (2-
tailed) 
.019 .159 .051 .482 .178 .361 
 
 
5.1 DISC1 Binding Partners 
5.1.1 DPYSL2 
5.1.1.1 Confounding Factors 
 Demographic and clinical variables found to exhibit correlations with 
DPYSL2 mRNA transcript levels in the anterior parahippocampal (APh) region, 
significant or otherwise, included duration of disease (rs = -.35, p = .053), 
lifetime fluphenazine dosage (rs = -.31, p = .087) and qPCR analysis plate (rs = -
.33, p = .066). The negative correlation of DPYSL2 mRNA transcript levels with 
disease duration, fluphenazine dosage and qPCR analysis plate were all 
experimental concerns and were therefore adopted as significant confounding 
factors for DCX mRNA transcript levels in this region. 
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 When the dichotomous clinical and demographic variables were tested 
for an effect on DPYSL2 mRNA transcript levels, subjects with an episode of 
psychosis in their medical history exhibited a trend towards lower APh mRNA 
abundance (Mdn = .57), when compared to subjects without an episode (Mdn = 
.98), U = 78.0, p = .062. Psychosis was therefore also adopted as a significant 
confounding factor for APh DPYSL2 mRNA transcript levels. No correlations or 
other significant effects of demographic and clinical variables were detected in 
the non-neurogenic HF. 
5.1.1.2 Effect of Diagnosis 
 Upon analysis of variance (ANOVA) testing between diagnostic groups, 
Levene’s Test of Equality of Error Variances was found to be violated in the 
APh region, F(3,28) = 6.21, p = .002. Nevertheless, the results of the ANOVA 
were accepted with confidence. This was because the group exhibiting the 
largest standard deviation (SD) consisted of the largest sample (CON, N = 8, 
SD = .97); and smallest sample group exhibited one of the lowest SD values 
(MDD, N = 6, SD = .50). This pattern of divergent variances has the tendency of 
reducing the F value and thus making the test more conservative. 
 The ANOVA results suggested a trend towards a main effect of 
diagnosis, F(3,28) = 2.60, p = .072. Post-hoc analysis using Fisher’s Least 
Significant Difference (LSD) revealed this to be a function of lower mean mRNA 
transcript levels in BPD (M = .56, SD = .48) when compared to CON (M = 1.41, 
SD = .97). However, these results did not survive Bonferroni correction. Trends 
towards a reduction in both MDD (M = .78, SD = .50) and SCZ (M = .76, SD = 
.54) were also detected when each were respectively compared with CON. 
However, these also did not survive Bonferroni correction (Fig 5-1). Kruskal-
Wallis testing failed to detect a main effect of diagnosis. 
 Each of the adopted significant confounding factors were included as 
covariates in an ANCOVA analysis between the diagnostic groups. In all cases, 
except for qPCR analysis plate, when the identified confounding factor was 
controlled for, the trend towards a main effect of diagnosis was not evident. 
When controlling for the effect of qPCR analysis plate, the trend towards a main 
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effect was detected but slightly adjusted, F(3,27) = 2.33, p = .097. No main 
effect was diagnosis was observed when mRNA transcript levels in the non-
neurogenic HF were analysed under either ANOVA or Kruskal-Wallis testing 
conditions (Fig. 5-2). 
 
5-1 Bar graph showing DPYSL2 mRNA transcript levels across diagnosis in the anterior 
parahippocampal region. † denotes LSD p < .1; †† denotes LSD p < .05. BPD = Bipolar 
Disorder (N = 8), MDD = Major Depressive Disorder (N = 7), SCZ = Schizophrenia (N = 8), CON 
= controls (N = 9). 
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5-2 Bar graph showing DPYSL2 mRNA transcript levels across diagnosis in the non-
neurogenic hippocampal formation. BPD = Bipolar Disorder (N = 4), MDD = Major Depressive 
Disorder (N = 4), SCZ = Schizophrenia (N = 4), CON = controls (N = 5). 
5.1.1.3 Genotype Effects 
 Mann-Whitney U tests of each minor allele, using the dominant effect 
model, suggested marginal effects of DISC1 rs821616 in the APh region. Minor 
allele carriers were found to exhibit a trend towards higher mRNA transcript 
levels in the APh region (Mdn = 1.03) when compared to non-carriers (Mdn = 
.55), U = 78.0, p = .081 (Fig 5-3). As no effect of diagnosis was detected in this 
region, the rs821616 minor allele was re-analysed under parametric conditions. 
Upon t-testing, no significant difference in DPYSL2 mRNA transcript levels was 
detected between DISC1 rs821616 minor allele carriers (M = 1.14, SD = .76, N 
= 13) and non-carriers (M = .73, SD = .67, N = 29), t(30) = 1.595, p = .121. 
 The results of a 4×2 ANOVA with diagnosis and DISC1 rs821616 minor 
allele carrier status as between-subjects factors could not be confidently 
reported as the Levene’s Test for Equality of Error Variances was violated, 
F(7,24) = 3.30, p = .013. Notwithstanding this, no significant interaction between 
the 2 between-subjects factors was detected. Therefore, the results of t testing 
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was adopted as representing the effect of the DISC1 rs821616 minor allele in 
the APh region. No other significant effects of minor alleles were detected in this 
region. 
 
5-3 Scatter plot showing the DPYSL2 mRNA transcript levels of rs821616 minor allele carriers 
in the anterior parahippocampal region 
 In the non-neurogenic HF, a trend towards an effect of DISC1 SNP 
rs3738401 and BDNF SNP rs6265 minor allele carrier status was detected. For 
rs3738401, minor allele carriers were found to exhibit marginally higher mRNA 
transcript levels (Mdn = .51) when compared to non-carriers (Mdn = .13), U = 
17.0, p = .079 (Fig 5-4). As no effect of diagnosis was detected in this region, 
the rs3738401 minor allele was re-analysed under parametric conditions. Upon 
t-testing, no significant difference in DPYSL2 mRNA transcript levels was 
detected between DISC1 rs3738401 minor allele carriers (M = .56, SD = .49, N 
= 10) and non-carriers (M = .24, SD = .25, N = 7), t(15) = 1.58, p = .135. In 
order to protect against any artefacts of multiple comparisons, a 4×2 ANOVA 
analysis was attempted, However due to inadequate sample size in the non-
neurogenic HF, the results of the 4×2 ANOVA, with diagnosis and DISC1 
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rs3738401 as between-subjects factors could not be reported; the principal 
results of the nonparametric tests were therefore adopted. 
  
5-4 Scatter plot showing the DPYSL2 mRNA transcript levels of rs3738401 minor allele carriers 
in the non-neurogenic hippocampal formation 
 For rs6265, minor allele carriers were found to exhibit marginally lower 
mRNA transcript levels in the non-neurogenic HF (Mdn = .10) when compare to 
non-carriers (Mdn = .48), U = 14.0, p = .056 (Fig 5-5). Upon t-testing, no 
significant difference in DPYSL2 mRNA transcript levels was detected between 
BDNF rs6265 minor allele carriers (M = .21, SD = .26, N = 6) and non-carriers 
(M = .55, SD = .47, N = 11), t(15) = -1.64, p = .123. In order to protect against 
any artefacts of multiple comparisons, a 4×2 ANOVA analysis was attempted, 
However due to inadequate sample size in the non-neurogenic HF, the results 
of the 4×2 ANOVA, with diagnosis and BDNF rs6265 as between-subjects 
factors could not be reported; the principal results of the nonparametric tests 
were therefore adopted. Mann-Whitney U testing detected no other significant 
effects of minor alleles in this region 
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5-5 Scatter plot showing the DPYSL2 mRNA transcript levels of BDNF rs6265 minor allele 
carriers in the non-neurogenic hippocampal formation 
5.1.2 FEZ1 
5.1.2.1 Confounding Factors 
 Demographic and clinical variables found to exhibit correlations with 
FEZ1 mRNA transcript levels in the APh region included duration of disease (rs 
= -.56, p = .001), days of storage (rs = -.44, p = .014), lifetime fluphenazine 
dosage (rs = -.60, p < .001) and age of disease onset (rs = -.41, p = .025). The 
negative correlations of FEZ1 mRNA transcript levels with disease duration, 
storage days, fluphenazine dosage and disease onset were all significant 
experimental concerns. Therefore, these were all adopted as significant 
confounding factors for FEZ1 mRNA transcript levels in this region. 
 When dichotomous variables were tested for an effect on FEZ1 mRNA 
transcript levels in the APh region, psychosis and brain hemisphere were found 
to exert a significant effect. Subjects with an episode of psychosis in their 
medical history exhibited significantly lower APh mRNA abundance (Mdn = .54), 
when compared to subjects without an episode (Mdn = 1.63), U = 30.0, p = 
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.001. Additionally, left hemisphere FEZ1 mRNA abundance (Mdn = 1.42) was 
found to be significantly lower than right hemisphere FEZ1 mRNA abundance 
(Mdn = .54), U = 46.0, p = .012. Each were therefore adopted as significant 
confounding factors for FEZ1 APh mRNA transcript levels. 
 In the non-neurogenic HF, no demographic or clinical variables were 
found to exhibit correlations with FEZ1 mRNA transcript levels. When the 
dichotomous clinical and demographic variables were tested for an effect on 
FEZ1 mRNA transcript levels in this region, gender and psychosis were found 
to exert modest effects. Males were found to exhibit a trend towards higher 
FEZ1 mRNA transcript levels (Mdn = 1.18) than females (Mdn = .19), U = 15.0, 
p = .074. For psychosis in the non-neurogenic HF, subjects with an episode of 
psychosis in their medical history exhibited a trend towards higher mRNA 
transcript levels (Mdn = 1.29), when compared to subjects without an episode 
(Mdn = .16), U = 15, p = .081. 
5.1.2.2 Effect of Diagnosis 
 When homogeneity of variance was tested across diagnostic groups for 
FEZ1 mRNA transcript levels in the APh region, The Levene’s Test of Equality 
of Error Variances result was found to be significant, F(3,26) = 7.50, p = .001. 
Nevertheless, the analysis of FEZ1 mRNA abundance was conducted under 
parametric ANOVA conditions and accepted. This was due to the variance 
heterogeneity being ascribed to the largest group (CON, N = 9, SD = 1.362) 
having a larger standard deviation when compared to the remaining diagnostic 
groups (BPD, N = 7, SD = .265; MDD, N = 6, SD = .481; SCZ, N = 8, SD = 
.316). This tends to make the resultant F value smaller, and thus the ANOVA 
test more conservative. 
 Upon ANOVA testing between diagnostic groups, a main effect of 
diagnosis on FEZ1 mRNA transcript levels in the APh region was detected, 
F(3,26) = 8.79, p < .001 (Fig 5-6). Post hoc analyses using Bonferroni criterion 
for significance indicated that average FEZ1 mRNA abundance was 
significantly lower in BPD (M = .39, SD = .27. p = .004) and SCZ (M = .82, SD = 
.32, p < .001) when compared to CON (M = 2.34, SD = 1.36). This represented 
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an 83% reduction in BPD FEZ1 mRNA transcript levels and a 65% reduction in 
SCZ FEZ1 mRNA transcript levels when each was compared to CON subjects 
in the APh region. Kruskal-Wallis testing also detected a main effect of 
diagnosis, H(3) = 15.036, p = .002. 
 Each of the continuous variables adopted as significant confounding 
factors were included as covariates in an ANCOVA retesting between 
diagnostic groups. When controlling for the effect of fluphenazine dosage, a 
significant main effect of diagnosis was still detected, F(3,25) = 6.50, p = .002. 
Pair-wise comparisons, using Bonferroni-adjusted alpha levels, indicated FEZ1 
mRNA transcript levels to significantly reduced in BPD (p = .001) and SCZ (p = 
.036) when compared to CON subjects. When the effects of storage days were 
controlled for, a main effect of diagnosis on the FEZ1 mRNA abundance was 
also still observed, F(3,25) = 5.89, p = .003. Furthermore, the significant 
reduction in both BPD and SCZ, when compared to CON, sustained (p = .003 
and p = .030 respectively). 
 After controlling for the effects of disease duration, though the significant 
main effect was detected, F(3,25) = 3.94, p = .020, not all of the pair wise 
comparisons sustained upon Bonferroni correction. A significant reduction in 
BPD mRNA transcript levels when compared to CON was still evident (p = 
.013); however the reduction in SCZ mRNA transcript levels ceased to be 
significant. Also, when the effects of disease onset were controlled for, though 
the main effect of diagnosis was still evident, F(3,25) = 3.50, p = .030, the pair 
wise comparisons did not survive Bonferroni correction. 
 This was interrogated further by grouping SCZ and BPD diagnosis 
categories together by their clinical history of psychosis. The effect of psychosis 
was then analysed with disease onset as a covariate. Upon ANCOVA analysis, 
marginal variance heterogeneity was detected by Levene’s Test, F(1,28) = 3.98, 
p = .056. However, a main effect of psychosis was observed, F(1,27) = 9.44, p 
= .005. Subjects with a history of psychosis (M = .62, SD = .36) exhibited 
significantly lower FEZ1 mRNA transcript levels values when compared to 
subjects without (M = 1.91, SD = 1.20, p < .001) (Fig 5-8). 
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 The dichotomous variables identified as significant confounding factors 
were included as covariates in ANCOVA models to retest FEZ1 mRNA 
transcript levels in the APh region. When the effect of brain hemisphere was 
controlled for, main effect of diagnosis was still evident, F(3,25) = 7.24, p = 
.001. When compared to the APh region FEZ1 mRNA transcript levels in CON, 
using Bonferroni correction for significance, the reduced mRNA transcript levels 
in SCZ sustained (p = .004), as did the reduced mRNA abundance in BPD (p = 
.003). 
 The effect of psychosis as a covariate in an ANCOVA test of diagnosis 
could not be fully analysed. This was due to psychosis being a discriminating 
factor between BPD and SCZ versus MDD and CON groups. It was established 
however, that the main effect of diagnosis sustained, F(2,26) = 3.673, p = .039. 
Pair-wise comparisons, using Bonferroni-adjusted alpha levels, did indicate 
lower FEZ1 mRNA transcript levels in MDD when compared to CON (p = .037). 
 When FEZ1 mRNA abundance was examined in the non-neurogenic HF, 
Levene’s Homogeneity of Variance Test was not satisfied F(3,12) = 16.086, p < 
.001. Under nonparametric conditions, Levene’s Test was satisfied and a trend 
towards a significant difference in FEZ1 mRNA transcript levels between the 
diagnostic groups was detected, H(3) = 6.44, p = .092. When interrogated for 
pair wise differences using Mann-Whitney testing, this difference was ascribed 
to FEZ1 mRNA transcript levels in MDD (Mdn = .086), exhibiting significantly 
lower values when compared to BPD (Mdn = 1.97, U = 0.00, p = .021) (Fig 5-7) 
and a trend towards lower values when compared to CON (Mdn = .57, U = 2.00, 
p = .083). 
 In an attempt to control for the effects of confounding factors on FEZ1 
mRNA transcript levels in the non-neurogenic HF, each of the adopted 
significant confounding factors in this region were included as covariates in 
ANCOVA retesting between the diagnostic groups. When controlling for the 
effects of psychosis, Levene’s Testing of Equality of Error Variance detected the 
variance heterogeneity between diagnostic groups to be a trend, [F(3,12) = 
2.89, p = .080)]. Notwithstanding this, no main effect of diagnosis was detected. 
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 When the effects of gender were controlled for, The Levene’s Test of 
Equality of Error Variances was satisfied and a main effect of diagnosis was 
detected, F(3,8) = 11.404, p = .003. FEZ1 mRNA transcript levels were found to 
be marginally higher in BPD (M = 2.14, SD = 1.91) when compared to MDD (M 
= .10, SD = .05, p = .054). Furthermore, males were found to exhibit a 
significantly higher level of FEZ1 mRNA abundance than females, F(1,8) = 
22.953, p = .001., This was qualified by an interaction between gender and 
diagnosis, F(3,8) = 8.73, p = .007. Due to inadequate sample size the results of 
a 4×2 ANOVA with diagnosis and gender as between-subjects factors could not 
be reported. 
 
5-6 Bar graph showing FEZ1 mRNA transcript levels across diagnosis in the anterior 
parahippocampal region. ** denotes p < .05 (Bonferroni-adjusted) when controlling for the 
effects of confounding variables; ‡‡ denotes p < .05 (Bonferroni-adjusted). BPD = Bipolar 
Disorder (N = 7), MDD = Major Depressive Disorder (N = 6), SCZ = Schizophrenia (N = 8), CON 
= controls (N = 9). 
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5-7 Bar graph showing FEZ1 mRNA transcript levels across diagnosis in the non-neurogenic 
hippocampal formation. †† denotes Mann-Whitney U and post hoc  ANOVA LSD  p < .05. BPD 
= Bipolar Disorder (N = 4), MDD = Major Depressive Disorder (N = 4), SCZ = Schizophrenia (N 
= 4), CON = controls (N = 4). 
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5-8 Bar graph showing FEZ1 mRNA transcript levels in the anterior parahippocampal region 
and history of psychosis. ** denotes p < .05 (Bonferroni-adjusted) when controlling for the 
effects of disease onset. With psychosis (N = 15), without psychosis (N = 15). 
5.1.2.3 Genotype Effects 
 Mann-Whitney U testing of minor allele carrier status suggested marginal 
effects of DISC1 SNP rs3738401 and RAPTOR SNP rs2289759 in the APh 
region. For rs3738401, minor allele carriers were found to exhibit a trend 
towards lower mRNA transcript levels (Mdn = .71) when compared to non-
carriers (Mdn = 1.45), U = 63.0, p = .057 (Fig 5-9). For RAPTOR SNP 
rs2289759, FEZ1 mRNA abundance was found to be marginally increased in 
minor allele carriers (Mdn = 1.33) when compared to non-carriers (Mdn = .61), 
U = 72.0, p = .096 (Fig 5-10). Mann-Whitney U tests detected no other 
significant effects of minor alleles in this region. 
 As a significant effect of diagnosis was previously detected under 
ANOVA testing in this region, 4×2 ANOVA analyses were performed in order to 
protect against artefacts of multiple comparisons. In the APh region, the 4×2 
ANOVA with diagnosis and DISC1 rs3738401 minor allele carrier status as 
between-subjects factors detected the main effect of diagnosis, F(3,22) = 5.93, 
p = .004, but not minor allele carrier status, F(1,22) = .87, p = .361. This was not 
qualified by an interaction between diagnosis and rs3738401 minor allele carrier 
status, F(3,22) = 1.65, p = .207. Although Levene’s Test for Equality of Error 
Variances detected a trend towards heterogeneity of variances between groups, 
F(7,22) = 2.36, p = .059, this analysis was adopted as representing the effect of 
the DISC1 rs3738401 minor allele in the APh region. 
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5-9 Scatter plot of FEZ1 mRNA transcript levels in rs3738401 minor allele carriers in the 
anterior parahippocampal region 
 The results of the 4×2 ANOVA with diagnosis and RAPTOR rs2289759 
minor allele carrier status as between-subjects factors could not be confidently 
reported as the Levene’s test for homogeneity of variances was violated 
between groups., F(7,24) = 3.30, p = .013; the principal results of nonparametric 
testing were therefore adopted. Notwithstanding this, no significant interaction 
between the 2 between-subjects factors was detected in the APh region. 
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5-10 Scatter plot of FEZ1 mRNA transcript levels in RAPTOR rs32289759 minor allele carriers 
in the anterior parahippocampal region 
 In the non-neurogenic HF, a trend towards an effect of RAPTOR SNP 
rs2289759 minor allele carrier status was detected. Minor allele carriers (Mdn = 
.13) were found to exhibit a trend towards lower mRNA transcript levels when 
compared to non-carriers (Mdn = 1.02), U = 12.0, p = .051 (Fig 5-11). As no 
significant main effect of diagnosis was perceived in this region, the rs2289759 
minor allele was re-analysed under parametric conditions. Upon t-testing, no 
significant difference in FEZ1 mRNA transcript levels was detected between 
RAPTOR rs2289759 minor allele carriers (M = .60, SD = .99, N = 10) and non-
carriers (M = .1.54, SD = .1.58, N = 6), t(14) = -1.479, p = 1.61. Mann-Whitney 
U tests detected no other significant effects of minor alleles in this region. 
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5-11 Scatter plot of FEZ1 mRNA transcript levels in RAPTOR rs2289759 minor allele carriers in 
the non-neurogenic hippocampal formation 
5.1.3 NDEL1 
5.1.3.1 Confounding Factors 
 Demographic and clinical variables found to exhibit correlations with 
NDEL1 mRNA transcript levels in the APh region, significant or otherwise, 
included RQI (rs = -.51, p = .004), brain pH (rs = -.37, p = .045), no. of storage 
days (rs = .50, p = .005) and PMI (rs = .345, p = .062). The negative correlation 
of NDEL1 mRNA transcript levels with pH; and the positive correlation with PMI, 
were both experimental concerns and were thusly adopted as significant 
confounding factors for NDEL1 mRNA transcript levels in this region. The 
positive correlation of NDEL1 mRNA transcript levels with storage days; and the 
negative correlation with RQI, were both dismissed on the basis of theoretical 
invalidity. No effects of dichotomous variables on NDEL1 mRNA transcript 
levels were detected in the APh region. 
 In the non-neurogenic HF, only age at death was found to exhibit a 
correlation with NDEL1 mRNA transcript levels (rs = -.43, p = .087). The 
 181 
negative correlation of NDEL1 mRNA abundance with age at death was an 
experimental concern, and thus adopted as a significant confounding factor for 
NDEL1 mRNA transcript levels in the non-neurogenic HF. Of the dichotomous 
variables, only gender was found to exert a modest effect on NDEL1 mRNA 
transcript levels. Males were found to exhibit marginally higher mRNA transcript 
levels (Mdn = .013) than their female counterparts (Mdn = .006), U =17.0, p = 
.068. The effect of gender was therefore also adopted as a significant 
confounding factor for NDEL1 mRNA transcript levels in this region. 
5.1.3.2 Effect of Diagnosis 
 When NDEL1 mRNA abundance was examined in the APh region, 
Levene’s Homogeneity of Variance Test was violated, F(3,26) = 5.08, p = .007. 
Under nonparametric conditions, The Levene’s Test was satisfied. Kruskal-
Wallis testing however, revealed no main effect of diagnosis. When attempting 
to control for the effects of each significant confounding factor on NDEL1 mRNA 
transcript levels, the variance heterogeneity, observed in the parametric a priori 
hypotheses tests, sustained. This precluded confident reporting of ANCOVA 
tests in this region. Notwithstanding this, when controlling for the effects of the 
adopted significant confounding factors, no main effect of diagnosis was 
observed (Fig 5-12).  
 Upon ANOVA testing between diagnostic groups in the non-neurogenic 
HF, Levene’s Test of Equality of Error Variances was found to be violated, 
F(3,13) = 3.69, p = .040. Under nonparametric conditions, The Levene’s Test 
detected a trend towards variance heterogeneity, F(3,13) = 2.98, p = .070. 
Nevertheless, Kruskal-Wallis testing failed to detect a significant main effect of 
diagnosis. 
 In an attempt to control for the effects confounding factors on NDEL1 
mRNA transcript levels in the non-neurogenic HF, each of the adopted 
significant confounding factors in this region were included as covariates in 
separate ANCOVA retests of a main effect of diagnosis. When controlling for 
the effects of either age at death or gender, Levene’s Testing of Equality of 
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Error Variance was satisfied but no main effect of diagnosis was detected (Fig 
5-13). 
  
5-12 Bar graph showing NDEL11 mRNA transcript levels across diagnosis in the anterior 
parahippocampal region. BPD = Bipolar Disorder (N = 9), MDD = Major Depressive Disorder (N 
= 6), SCZ = Schizophrenia (N = 8), CON = controls (N = 7).  
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5-13 Bar graph showing NDEL1 mRNA transcript levels across diagnosis in the non-
neurogenic hippocampal formation. BPD = Bipolar Disorder (N = 4), MDD = Major Depressive 
Disorder (N = 4), SCZ = Schizophrenia (N = 4), CON = controls (N = 5). 
5.1.3.3 Genotype Effects 
 Mann-Whitney U tests failed to detect significant effects of any minor 
alleles in either the non-neurogenic HF or APh region. 
 
5.1.4 PDE4B 
5.1.4.1 Confounding Factors 
 The only demographic or clinical variable found to exhibit a correlation, 
significant or otherwise, with APh PDE4B mRNA abundance was qPCR 
analysis plate (rs = -.38, p = .027). The negative correlation of PDE4B mRNA 
transcript levels with qPCR plate no. was an experimental concern, and thus 
adopted as a significant confounding factor for PDE4B mRNA transcript levels 
in the APh region. Of the dichotomous variables, only brain hemisphere was 
found to exert an effect on PDE4B mRNA transcript levels in the APh region. 
Left hemisphere PDE4B mRNA abundance (Mdn = .011) was found to be 
significantly higher than right hemisphere PDE4B mRNA abundance (Mdn = 
.004), U = 86.0, p = .074. The effect of brain hemisphere was therefore also 
adopted as a significant confounding factor for PDE4B mRNA transcript levels 
in this region. 
 In the non-neurogenic HF, significant correlations were detected when 
PDE4B mRNA abundance was compared with age at onset of disease (rs = -
.65, p = .009), duration of disease (rs = -58, p = .023); a trend was detected with 
and RQI (rs = -.44, p = .099). The negative correlation of PDE4B mRNA 
transcript levels with RQI was dismissed on the basis of theoretical invalidity. 
The negative correlations with disease onset and disease duration on the other 
hand, were experimental concerns and thus adopted as experimental 
confounds. 
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 When dichotomous variables were tested for an effect on PDE4B mRNA 
transcript levels in the non-neurogenic HF, subjects who died by suicide 
exhibited a trend towards lower mRNA transcript levels (Mdn = .0003), when 
compared to subjects who did not (Mdn = .0009), U = 12.0, p = .077. There was 
also an effect detected when brain hemisphere was tested, left hemisphere 
PDE4B mRNA transcript levels (Mdn = .001) was found to be significantly 
higher than right hemisphere PDE4B mRNA transcript levels (Mdn = .0003), U = 
5.00, p = .010. The effects of brain hemisphere and death by suicide were 
therefore adopted as significant confounding factors for PDE4B mRNA 
transcript levels in this region. 
5.1.4.2 Effect of Diagnosis 
 When homogeneity of variance was tested across diagnostic groups for 
PDE4B mRNA transcript levels in the APh region, The Levene’s Test of Equality 
of Error Variances result was found to be significant, F(3,30) = 13.0, p < .001. 
Under nonparametric conditions, the variance heterogeneity was detected as a 
trend, F(3,30) = 2.75, p = .060, but no significant effect of diagnosis upon 
Kruskal-Wallis testing was detected (Fig 5-14). 
 In the non-neurogenic HF, when PDE4B mRNA abundance was 
investigated, The Levene’s Homogeneity of Variance Test was not satisfied 
F(3,11) = 4.29, p = .031. Kruskal-Wallis testing detected a trend towards an 
effect of diagnosis, H(3) = 7.29, p = .063, however the non-parametric 
equivalent of the Levene’s Test was also violated, F(3,11) = .4.90, p = .021. 
Therefore, The Brown-Forsythe Test was used to test the effect of diagnosis on 
PDE4B mRNA transcript levels in the non-neurogenic HF. Under these 
conditions, no significant effect of diagnosis was observed (Fig 5-15). 
 In an attempt to control for the effects confounding factors on PDE4B 
mRNA transcript levels in the APh region, each of the adopted significant 
confounding factors in this region were included as covariates in separate 
ANCOVA retests of a main effect of diagnosis. When controlling for the effects 
of the adopted covariates, the significant variance heterogeneity observed in the 
parametric a priori hypotheses tests sustained. This same was observed when 
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attempting to control for the effects of identified confounding factors for PDE4B 
mRNA transcript levels in the non-neurogenic HF. This precluded confident 
reporting of ANCOVA test results. 
  
5-14 Bar graph showing PDE4B mRNA transcript levels across diagnosis in the anterior 
parahippocampal region. BPD = Bipolar Disorder (N = 10), MDD = Major Depressive Disorder 
(N = 6), SCZ = Schizophrenia (N = 7), CON = controls (N = 9). 
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5-15 Bar graph showing PDE4B mRNA transcript levels across diagnosis in the non-
neurogenic hippocampal formation. BPD = Bipolar Disorder (N = 3), MDD = Major Depressive 
Disorder (N = 4), SCZ = Schizophrenia (N = 3), CON = controls (N = 5). 
5.1.4.3 Genotype Effects 
 Mann-Whitney U tests of each minor allele, using the dominant effect 
model, suggested marginal effects of DISC1 rs821616 in the APh region. Minor 
allele carriers were found to exhibit a trend towards higher mRNA transcript 
levels in the APh region (Mdn = .026) when compared to non-carriers (Mdn = 
.005), U = 90.0, p = .080 (Fig 5-16). As no effect of diagnosis was detected in 
this region, the rs821616 minor allele was re-analysed under parametric 
conditions. Upon t-testing, PDE4B mRNA transcript levels of DISC1 rs821616 
minor allele carriers (M = .051, SD = .056, N = 14) were found to be significantly 
higher than non-carriers (M = .016, SD = .031, N = 20), t(19) = 2.4128, p = .047 
(Fig 5-16); Levene’s test indicated unequal variances (F = 14.902, p = .001), so 
degrees of freedom were adjusted from 32 to 19. 
 In order to protect against artefacts of multiple comparisons, a 4×2 
ANOVA analysis was performed. However, results of the 4×2 ANOVA, with 
diagnosis and DISC1 rs821616 minor allele carrier status as between-subjects 
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factors, could not be confidently reported as the Levene’s Test for Equality of 
Error Variances was violated, F(7,26) = 3.30, p = .004; the principal results of 
nonparametric testing were therefore adopted. Notwithstanding this, no 
significant interaction between the 2 between-subjects factors was detected. 
Mann-Whitney U testing detected no other significant effects of minor alleles in 
this region. 
 In the non-neurogenic HF, no significant effects of the minor alleles were 
detected upon Mann-Whitney U testing. 
  
5-16 Scatter plot showing the PDE4B mRNA transcript levels of rs821616 minor allele carriers 
in the anterior parahippocampal region 
5.2 Neurogenesis-related Genes 
5.2.1 DCX 
5.2.1.1 Confounding Factors 
 The demographic and clinical variables found to exhibit significant 
correlations with DCX mRNA transcript levels in the APh region included PMI (rs 
= .47, p = .007) and no. of storage days (rs = .36, p = .044).  A correlation trend 
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was detected between DCX mRNA transcript levels and lifetime fluphenazine 
dosage (rs = -.36, p = .056). The positive correlations of DCX mRNA transcript 
levels with storage days and PMI were both dismissed on the basis of 
theoretical invalidity. The negative correlation of DCX mRNA transcript levels 
with fluphenazine dosage was however an experimental concern. Fluphenazine 
dosage was thusly adopted as a significant confounding factor for DCX mRNA 
transcript levels in the APh region. 
 Of the dichotomous variables, only psychosis was found to exert a 
modest effect on DCX mRNA transcript levels in the APh region. Subjects with 
an episode of psychosis in their medical history exhibited a trend towards lower 
APh mRNA transcript levels (Mdn = .007), when compared to subjects without 
an episode (Mdn = .002), U = 62.0, p = .077. Psychosis was therefore also 
adopted as a significant confounding factor in the analysis of APh DCX mRNA 
transcript levels. 
 In the non-neurogenic HF, the variables found to exhibit significant 
correlations with DCX mRNA transcript levels included qPCR analysis plate no. 
(rs = .93, p < .001), age of onset (rs = -.69, p = .005), duration of disease (rs = 
.64, p = .011), lifetime fluphenazine dosage (rs = -.60, p = .017) and no. of 
storage days (rs = -.90, p < .001); a correlation trend with substance abuse 
severity (rs = -.51, p = .052) was also detected. Each of these correlations were 
deemed to be experimental concerns. They were each therefore adopted as 
significant confounding factors for DCX mRNA transcript levels in the non-
neurogenic HF. 
 When the dichotomous variables were tested for an effect on DCX 
mRNA transcript levels in this region, significant or otherwise, brain hemisphere 
and psychosis were found to exert effects. Left hemisphere DCX mRNA 
transcript levels (Mdn = .003) was found to be marginally higher than right 
hemisphere DCX mRNA transcript levels (Mdn = .0004), U = 11.0, p = .059. For 
psychosis, subjects with an episode of psychosis in their medical history 
exhibited significantly lower mRNA transcript levels in the non-neurogenic HF 
(Mdn = .0003), when compared to subjects without an episode (Mdn = .003), U 
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= 6.00, p = .013. Each of these variables were therefore adopted as significant 
confounding factors for DCX mRNA transcript levels in the non-neurogenic HF. 
5.2.1.2 Effect of Diagnosis 
 When mRNA transcript levels were compared across diagnostic 
categories, a main effect of diagnosis on APh DCX mRNA abundance was 
detected, F(3,25) = 4.616, p = .011. Upon pair wise comparison, this was found 
to reflect higher DCX mean mRNA transcript levels in SCZ (M = .031, SD = 
.034) in comparison to other diagnostic categories. Mean mRNA transcript 
levels in was significantly higher in SCZ when compared to both CON (M = 
.003, SD = .002, p = .042) and BPD (M = .002, SD = .003, p = .028). When 
compared to MDD (M = .003, SD = .002), the reduced DCX mRNA transcript 
levels in comparison to SCZ was detected as a trend, p = .080. Kruskal-Wallis 
testing also detected a significant main effect of diagnosis, H(3) = 17.256, p = 
.001. 
 Before conducting ANOVA tests for DCX mRNA transcript levels in the 
APh region, Levene’s Test of Equality of Error Variances was found to be 
violated, F(3,25) = .20.30, p < .001. However, this was attributed to the largest 
group (SCZ, N = 9) having a much larger standard deviation than BPD (N = 8) 
and SCZ (N = 7); with the smallest group, MDD (N = 5), having the smallest 
standard deviation. This has the effect of making the reported F value smaller, 
and thus the ANOVA test more conservative. Therefore, the results of the 
ANOVA tests on APh region DCX mRNA transcript levels were accepted. 
 Each of the demographic or clinical variables adopted as significant 
confounding factors were included as covariates in an ANCOVA retesting 
between diagnostic groups. When fluphenazine dosage was added as a 
covariate in an ANCOVA test, a trend towards an interaction between 
hemisphere and diagnosis was detected F(1,23) = 2.98, p = .098. 
Notwithstanding this, the main effect of diagnosis was significant, F(3,23) = 
10.25., p < .001. Pair-wise comparisons, using Bonferroni-adjusted alpha levels, 
indicated DCX mRNA transcript levels to be significantly reduced in CON (p = 
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.001), BPD (p = .002) and MDD (p = .002) when compared to SCZ subjects (Fig 
5-17). 
 As psychosis was a discriminating factor between BPD and SCZ versus 
MDD and CON groups, the effect of psychosis as a covariate in an ANCOVA 
test of diagnosis could not be fully analysed. It was established however, that 
the main effect of diagnosis sustained, F(2,25) = 4.84, p = .017; pair wise 
comparisons, using Bonferroni-adjusted alpha levels, indicated lower DCX 
mRNA transcript levels in BPD when compared to SCZ (p = .037). 
 When DCX mRNA transcript levels in the non-neurogenic HF were 
measured, Levene’s Test for Homogeneity of Variances was violated, F(3,11) = 
4.15, p = .034. This variance heterogeneity was determined to be caused by the 
largest group (CON, N = 5, M = .005, SD = .003) having the largest SD and the 
smallest groups having the smallest SD (BPD, N = 3, M = .0002, SD = .0001; 
SCZ, N = 3, M = .0003, SD = .0001). Thusly, the main effect of diagnosis, 
detected upon ANOVA testing, was accepted, F(3,11) = 5.07, p = .019. Post-
hoc analysis, using Bonferroni-adjusted alpha levels, revealed significantly 
lower DCX mRNA transcript levels in BPD (p = .048) and a trend towards lower 
mRNA transcript levels in SCZ (p = .054) when each were compared to CON 
(Fig 5-18). Kruskal-Wallis testing also detected a significant main effect of 
diagnosis, H(3) = 8.736, p = .033. 
 Each of the continuous variables adopted as significant confounding 
factors were included as covariates in an ANCOVA retesting between 
diagnostic groups. When controlling for the effect of disease onset age, qPCR 
plate analysis no., no. of storage days and duration of disease, the significant 
main effect of diagnosis was no longer significant. When the effects of alcohol 
abuse were controlled for, the main effect of diagnosis on the DCX mRNA 
abundance was also detected as a trend, F(3,10) = 3.237, p = .069, no 
significant pair-wise differences upon Bonferroni correction were detected. 
 When the effects of fluphenazine dosage were controlled for, the main 
effect of diagnosis on the DCX mRNA abundance was detected as a trend, 
F(3,10) = 3.529, p = .056. Pair-wise comparisons, using Bonferroni adjusted 
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alpha levels, indicated marginally lower non-neurogenic HF DCX mRNA 
transcript levels in BPD when compared to CON (p = .080). The diagnosis-
discriminating nature of psychosis notwithstanding, when controlling for its 
effect on DCX mRNA transcript levels, the main effect of diagnosis sustained, 
F(2,11) = 2.89, p = .098. The pair wise comparisons, using Bonferroni-adjusted 
alpha levels, were able to detect lower DCX mRNA transcript levels in MDD 
when compared to CON (p = .070). 
 When brain hemisphere was added as a covariate in an ANCOVA test, 
the interaction between hemisphere and diagnosis was found to be significant 
F(2,8) = 12.89, p = .003; as was the main effect of diagnosis, F(2,8) = 19.99, p 
= .001. Despite the detected interaction, the low sample size in the non-
neurogenic HF precluded a 4×2 ANOVA with diagnosis and brain hemisphere. 
  
5-17 Bar graph showing DCX mRNA transcript levels across diagnosis in the anterior 
parahippocampal region. *** denotes p < .05 (Bonferroni-adjusted) against all groups when 
controlling for the effects of confounding variables. BPD = Bipolar Disorder (N = 8), MDD = 
Major Depressive Disorder (N = 5), SCZ = Schizophrenia (N = 9), CON = controls (N = 7). 
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5-18 Bar graph showing DCX mRNA transcript levels across diagnosis in the non-neurogenic 
hippocampal formation. ‡ denotes p < .1 (Bonferroni-adjusted), ‡‡ denotes p < .05 (Bonferroni-
adjusted). BPD = Bipolar Disorder (N = 3), MDD = Major Depressive Disorder (N = 4), SCZ = 
Schizophrenia (N = 3), CON = controls (N = 5).  
 
5.2.1.3 Genotype Effects 
 In the APh region, Mann-Whitney U tests of minor allele carrier status in 
suggested a significant effect of BDNF SNP rs6265. Minor allele carriers were 
found to exhibit significantly higher mRNA transcript levels in the APh region 
(Mdn = .008) when compared to non-carriers (Mdn = .003), U = 34.0, p = .015 
(Fig 5-19). As a significant main effect of diagnosis was detected in this region, 
the rs6265 minor allele was re-analysed under parametric conditions. Upon t-
testing, DCX mRNA transcript levels of BDNF rs6265 minor allele carriers (M = 
.032, SD = .038, N = 8) were found to be marginally higher than non-carriers (M 
= .004, SD = .004, N = 21), t(7) = 2.05, p = .079 (Fig 5-19); Levene’s test 
indicated unequal variances (F = 84.1, p < .001), so degrees of freedom were 
adjusted from 27 to 7. 
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 In order to protect against artefacts of multiple comparisons, a 4×2 
ANOVA analysis was performed. However, results of the 4×2 ANOVA, with 
diagnosis and BDNF rs6265 minor allele carrier status as between-subjects 
factors, could not be confidently reported as the Levene’s Test for Equality of 
Error Variances was violated, F(6,22) = 12.652, p < .001; the principal results of 
nonparametric testing were therefore adopted. Notwithstanding this, no 
significant interaction between the 2 between-subjects factors was detected. 
Mann-Whitney U testing detected no other significant effects of minor alleles in 
this region. 
 
5-19 Scatter plot of DCX mRNA transcript levels in BDNF rs6265 minor allele carriers in the 
non-neurogenic hippocampal formation 
  In the non-neurogenic HF, Mann-Whitney U tests of minor allele carrier 
status suggested a significant effect of RAPTOR SNP rs2289759. The DCX 
mRNA transcript levels of minor allele carriers were found to be significantly 
increased in minor allele carriers (Mdn = .002) when compared to non-carriers 
(Mdn = .0002), U = 4.00, p = .019 (Fig 5-20). As no significant main effect of 
diagnosis was perceived in this region, the rs2289759 minor allele was re-
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analysed under parametric conditions. Upon t-testing, DCX mRNA transcript 
levels of RAPTOR rs2289759 minor allele carriers (M = .003, SD = .003, N = 
11) were found to be significantly higher than non-carriers (M = .0002, SD = 
.0001, N = 4), t(10) = 3.162, p = 010. (Fig 5-20); Levene’s test indicated 
unequal variances (F = 5.332, p = .038), so degrees of freedom were adjusted 
from 13 to 10. 
 In order to protect against artefacts of multiple comparisons in the non-
neurogenic HF, a 4×2 ANOVA analysis was attempted, However, due to 
inadequate sample size the results of the 4×2 ANOVA with diagnosis and 
RAPTOR SNP rs2289759 as between-subjects factors could not be reported;  
the principal results of the nonparametric tests were therefore adopted. Mann-
Whitney U testing detected no other significant effects of minor alleles in this 
region. 
 
5-20 Scatter plot of DCX mRNA transcript levels in RAPTOR rs2289759 minor allele carriers in 
the non-neurogenic hippocampal formation 
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5.2.2 NEUROD1 
5.2.2.1 Confounding Factors 
 The demographic and clinical variables found to exhibit significant 
correlations with NEUROD1 mRNA transcript levels in the APh region included 
brain pH (rs = -.37, p = .041) and alcohol abuse severity (rs = .38, p = .038). The 
negative correlation of NEUROD1 mRNA transcript levels with pH and the 
positive correlation with alcohol abuse were both experimental concerns. They 
were each therefore adopted as significant confounding factors for NEUROD1 
mRNA transcript levels in the APh region. 
 When dichotomous variables were tested for an effect on NEUROD1 
mRNA transcript levels, left hemisphere exhibited a trend towards lower APh 
mRNA transcript levels (Mdn = .13), when compared to right hemisphere mRNA 
transcript levels (Mdn = .050), U = 66.0, p = .052. Brain hemisphere was 
therefore also adopted as a significant confounding factor in the analysis of APh 
NEUROD1 mRNA transcript levels. 
 In the non-neurogenic HF, the continuous variables found to exhibit 
significant correlations with NEUROD1 mRNA transcript levels included qPCR 
analysis plate no. (rs = -.53, p = .041) and no. of storage days (rs = .53, p = 
.043); a correlation trend was detected with lifetime fluphenazine dosage (rs = -
.44, p = .096). The negative correlations of NEUROD1 mRNA transcript levels 
with qPCR plate no. and fluphenazine dosage were both experimental 
concerns. Each was therefore adopted significant confounding factors for 
NEUROD1 mRNA transcript levels in this region. The positive correlation of 
NEUROD1 mRNA transcript levels with storage days on the other hand, was 
dismissed on the basis of theoretical invalidity 
 Of the dichotomous variables, only psychosis was found to exert a 
modest effect on NEUROD1 mRNA transcript levels in the non-neurogenic HF. 
Subjects with an episode of psychosis in their medical history exhibited a trend 
towards higher APh mRNA transcript levels (Mdn = .098), when compared to 
subjects without an episode (Mdn = .032), U = 11.0, p = .059. Psychosis was 
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also adopted as a significant confounding factor in the analysis of NEUROD1 
mRNA transcript levels in the non-neurogenic HF. 
5.2.2.2 Effect of Diagnosis 
 When NEUROD1 mRNA abundance was examined in the APh region, 
The Levene’s Test of Equality of Error Variances was violated, F(3,27) = 3.83, p 
= .021. When NEUROD1 mRNA abundance was examined in the non-
neurogenic HF, The Levene’s Test was again violated, F(3,11) = 4.98, p = .020. 
Under nonparametric conditions, Levene’s testing detected homogenous 
variances for both regions, but Kruskal-Wallis testing failed to detect any 
significant effect of diagnosis on NEUROD1 mRNA transcript levels in either the 
non-neurogenic HF or APh region. 
 When attempting to control for the effects of the identified confounding 
factors for NEUROD1 mRNA transcript levels, the significant variance 
heterogeneity observed in the parametric a priori hypotheses tests sustained; 
except for in the case of alcohol abuse severity in the APh region and qPCR 
analysis plate in the non-neurogenic HF. This largely precluded confident 
reporting of ANCOVA test results. 
 When controlling for the effects of alcohol abuse severity in the APh 
region, variance heterogeneity was detected as a trend, F(3,27) = 2.75, p = 
.062. Notwithstanding this, no main effect of diagnosis on NEUROD1 mRNA 
abundance was in the APh region was observed (Fig 5-21). In the non-
neurogenic HF, when controlling for the effects of qPCR analysis plate, 
marginal variance heterogeneity was detected, F(3,11) = 2.73, p = .095. 
Notwithstanding this, no main effect of diagnosis on NEUROD1 mRNA 
abundance in the non-neurogenic HF was observed (Fig 5-22). 
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5-21 Bar graph showing NEUROD1 mRNA transcript levels across diagnosis in the anterior 
parahippocampal region. BPD = Bipolar Disorder (N = 10), MDD = Major Depressive Disorder 
(N = 6), SCZ = Schizophrenia (N = 7), CON = controls (N = 8). 
  
5-22 Bar graph showing NEUROD1 mRNA transcript levels across diagnosis in the non-
neurogenic hippocampal formation. BPD = Bipolar Disorder (N = 3), MDD = Major Depressive 
Disorder (N = 3), SCZ = Schizophrenia (N = 4), CON = controls (N = 5). 
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5.2.2.3 Genotype Effects 
 In the APh region, no significant effects of minor alleles were observed 
when the dominant effect model was assessed via Mann-Whitney U testing. In 
the non-neurogenic HF, results of Mann-Whitney U testing of this dominant 
effect model suggested a significant effect of the DISC1 rs3738401 minor allele. 
Minor allele carriers presented significantly higher NEUROD1 mRNA transcript 
levels in the non-neurogenic HF (Mdn = .095) when compared to non-carriers 
(Mdn = .018), U = 7.00, p = .018 (Fig 5-23). As no effect of diagnosis was 
detected in this region, the rs3738401 minor allele was re-analysed under 
parametric conditions. Upon t-testing, no significant difference in NEUROD1 
mRNA transcript levels was detected between DISC1 rs3738401 minor allele 
carriers (M = .26, SD = .40, N = 9) and non-carriers (M = .56, SD = .49, N = 9), 
t(13) = 1.37, p = .193. 
 In order to protect against any artefacts of multiple comparisons, a 4×2 
ANOVA analysis was attempted, However due to inadequate sample size in the 
non-neurogenic HF, the results of the 4×2 ANOVA, with diagnosis and DISC1 
rs3738401 as between-subjects factors could not be reported; the principal 
results of the nonparametric tests were therefore adopted. Mann-Whitney U 
testing detected no other significant effects of minor alleles in this region. 
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5-23 Scatter plot showing the NEUROD1 mRNA transcript levels of rs3738401 minor allele 
carriers in the non-neurogenic hippocampal formation 
5.3 Regional Analysis 
 Comparisons of mRNA transcript levels between the non-neurogenic HF 
and APh region were conducted via non-parametric independent samples 
testing. Initial Mann-Whitney U tests detected regional mRNA transcript levels 
differences across all genes except NEUROD1. 
 PDE4B mRNA abundance was found to be significantly lower in the non-
neurogenic HF (Mdn = .0005) when compared to levels in the APh region (Mdn 
= .007; U = 60.0, p < .001). DCX mRNA transcript levels in the non-neurogenic 
HF (Mdn = .0009) was also found to be significantly lower than in the APh 
region (Mdn = .004; U = 131.0, p = .032). Non-neurogenic HF mRNA transcript 
levels of DPYSL2 (Mdn = .230) was also found to be significantly lower than in 
the APh region (Mdn = .761; U = 147.0, p = .009). 
 Results from these tests were accepted if the non-parametric equivalent 
of the Levene’s Test for Equal variances was satisfied, and no correlation 
between APh region and non-neurogenic HF  mRNA abundance was detected. 
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These conditions were not satisfied for NDEL11 and FEZ1. The homogeneity of 
variances condition was violated for NDEL1, F(1,45) = 6.69, p = .013. In the 
case of FEZ1, a trend towards heterogeneous variances was detected, F(1,44) 
= 3.577, p = .065; a correlation between APh region and non-neurogenic HF 
gene mRNA abundance was also detected, rs = -.608, p = .036. 
 In both instances, mRNA transcript levels differences across region was 
reanalysed via paired-Wilcoxon rank testing. For NDEL1, non-neurogenic HF 
mRNA transcript levels (Mdn = .008) was found to be significantly lower than 
APh region mRNA transcript levels (Mdn = .027; Z = -2.20, p = .028). For FEZ1, 
no significant difference between regions was observed. 
 
5-24 Graph showing mRNA transcript levels of DCX, DPYSL2, FEZ1, NDEL1 NEUROD1 and 
PDE4B mRNA in the anterior parahippocampal (APh) region and the non-neurogenic 
hippocampal formation (HF). †† denotes p < .05, NRQ = normalised relative quantity 
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6 QUANTITATIVE IMMUNOHISTOCHEMISTRY 
 In the assessment of protein density, the effects of diagnosis and minor 
allele carriers status was examined in each region of interest (ROI) separately. 
The demographic and clinical variables were also examined separately for each 
ROI. Due to experimental constraints, no technical replicates were performed 
during the examination of NEUROD1 protein density. When analysing FEZ1 
and NEUROD1 protein density in the APh grey and white matter, signal 
saturation forced the comparisons of different areas within these broadly 
defined ROIs. This was not a factor in the analysis dentate gyrus protein 
density. 
6-A Table of the anterior hippocampus protein density levels from each 
diagnostic category. Asterisk indicates where the Levene’s Test of Equality of 
Error Variances was violated (p < 05), double asterisk indicates, p < 05 when 
controlling for demographic and clinical variables.; bpd = bipolar disorder, mdd 
= major depressive disorder, con = controls, scz = schizophrenia 
IHC Protein Density Data 
Diagnosis     
Absolute 
NEUROD1 
(APh Grey 
Matter) 
Absolute 
NEUROD1 
(APh 
White 
Matter) 
Absolute 
NEUROD1 
(Dentate 
Gyrus) 
Relative 
FEZ1 
(APh 
Grey 
Matter) 
Relative 
FEZ1 
(APh 
White 
Matter) 
Relative 
FEZ1 
(Dentate 
Gyrus) 
bpd N Original 15 15 15 15 15 15 
    Received 15 15 15 15 15 15 
   Pre-
outlier 
12 12 11 15 15 14 
    No. of 
Outliers 
0 0 0 0 0 0 
  N Valid 12 12 11 15 15 14 
  Mean   755.6421 471.4695 2035.272 1.0734 1.3395 1.1192 
  Median   760.0842 500.2249 1748.306 1.031 1.2309 1.0537 
  Std. 
Deviation 
  238.9986 147.9751 965.1086 0.21725 0.26775 0.18796 
post-hoc to controls (Bonferroni) p 0.865 1 1 0.846 1 1 
mdd N Original 15 15 15 15 15 15 
    Received 10 10 10 10 10 10 
   Pre-
outlier 
8 8 7 10 10 10 
    No. of 
Outliers 
1 1 0 0 0 0 
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IHC Protein Density Data 
Diagnosis     
Absolute 
NEUROD1 
(APh Grey 
Matter) 
Absolute 
NEUROD1 
(APh 
White 
Matter) 
Absolute 
NEUROD1 
(Dentate 
Gyrus) 
Relative 
FEZ1 
(APh 
Grey 
Matter) 
Relative 
FEZ1 
(APh 
White 
Matter) 
Relative 
FEZ1 
(Dentate 
Gyrus) 
  N Valid 7 7 7 10 10 10 
  Mean   1030.133 515.5843 2439.039 1.2049 1.4116 1.15 
  Median   932.6944 483.5322 2573.919 1.2178 1.36 1.136 
  Std. 
Deviation 
  228.1784 96.03043 945.5413 0.21904 0.22344 0.23372 
post-hoc to controls (Bonferroni) p 1 1 1 1 1 1 
con N Original 15 15 15 15 15 15 
    Received 13 13 13 13 13 13 
   Pre-
outlier 
11 11 9 12 12 12 
    No. of 
Outliers 
1 0 0 0 0 0 
  N Valid 10 11 9 12 12 12 
  Mean   985.263 569.7127 2250.039 1.2035 1.3662 1.2182 
  Median   1138.16 460.4171 2147.771 1.1789 1.3867 1.1989 
  Std. 
Deviation 
  376.2874 260.1768 996.3947 0.19968 0.19923 0.21298 
post-hoc to controls (Bonferroni) p - - - - - - 
scz N Original 15 15 15 15 15 15 
    Received 13 13 13 13 13 13 
   Pre-
outlier 
12 12 12 13 13 13 
    No. of 
Outliers 
0 0 0 0 1 0 
  N Valid 12 12 12 13 12 13 
  Mean   1002.904 500.6704 2279.839 1.1765 1.4535 1.2397 
  Median   1036.032 448.3012 2110.524 1.1288 1.4201 1.1656 
  Std. 
Deviation 
  482.9859 240.1595 932.1107 0.2558 0.22017 0.18903 
post-hoc to controls (Bonferroni) p 1 1 1 1 1 1 
Diagnosis 
Pre-
outlier H 5.177 0.38 0.896 2.818 2.01 3.202 
Kruskal-
Wallis   p 
0.159 0.944 0.827 0.421 0.57 
0.362 
  Valid H 3.883 0.787 0.896 2.818 1.264 3.202 
  
 
p 0.274 0.853 0.827 0.421 0.738 0.362 
ANOVA Valid F 1.365 0.457 0.274 1.051 0.606 0.994 
    p 0.268 0.714 0.844 0.379 0.614 0.404 
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6-B Table showing the results of the non-parametric testing of minor carrier 
allele status effects on protein density levels in sections of anterior 
hippocampus 
IHC Minor Allele Carrier Status Data 
  
Relative 
FEZ1 
(APh 
Grey 
Matter) 
Relative 
FEZ1 
(APh 
White 
Matter) 
Relative 
FEZ1 
(Dentate 
Gyrus) 
Absolute 
NEUROD1 
(APh Grey 
Matter) 
Absolute 
NEUROD1 
(APh 
White 
Matter) 
Absolute 
NEUROD1 
(Dentate 
Gyrus) 
DISC1 
rs3738401 
minor 
allele 
carriers 
N 32 32 31 24 26 24 
Mean 
Rank 
23.13 24.13 22.90 18.58 23.00 19.54 
Sum of 
Ranks 
694.00 724.00 687.00 446.00 598.00 469.00 
Non-
carriers 
N 18 17 18 17 16 15 
Mean 
Rank 
25.53 23.76 25.94 24.41 19.06 20.73 
Sum of 
Ranks 
434.00 404.00 441.00 415.00 305.00 311.00 
Total N 50 49 49 41 42 39 
 
Mann-
Whitney 
U 
229.000 251.000 222.000 146.000 169.000 169.000 
 
Wilcoxon 
W 
694.000 404.000 687.000 446.000 305.000 469.000 
 
Z -.576 -.089 -.731 -1.535 -1.010 -.318 
 
p (2-
tailed) 
.565 .929 .465 .125 .312 .751 
DISC1 
rs6675281 
minor 
allele 
carriers 
N 14 14 14 13 13 12 
Mean 
Rank 
24.00 25.36 24.14 26.69 21.77 22.25 
Sum of 
Ranks 
336.00 355.00 338.00 347.00 283.00 267.00 
Non-
carriers 
N 36 35 35 28 29 27 
Mean 
Rank 
24.00 23.42 23.94 18.36 21.38 19.00 
Sum of 
Ranks 
792.00 773.00 790.00 514.00 620.00 513.00 
Total N 50 49 49 41 42 39 
 
Mann-
Whitney 
U 
231.000 212.000 229.000 108.000 185.000 135.000 
 
Wilcoxon 
W 
792.000 773.000 790.000 514.000 620.000 513.000 
 
Z 0.000 -.442 -.047 -2.073 -.095 -.822 
 
p (2-
tailed) 
1.000 .659 .963 .038 .924 .411 
DISC1 N 22 22 21 18 18 17 
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IHC Minor Allele Carrier Status Data 
  
Relative 
FEZ1 
(APh 
Grey 
Matter) 
Relative 
FEZ1 
(APh 
White 
Matter) 
Relative 
FEZ1 
(Dentate 
Gyrus) 
Absolute 
NEUROD1 
(APh Grey 
Matter) 
Absolute 
NEUROD1 
(APh 
White 
Matter) 
Absolute 
NEUROD1 
(Dentate 
Gyrus) 
rs821616 
minor 
allele 
carriers 
Mean 
Rank 18.82 23.14 20.19 
15.78 15.61 18.00 
Sum of 
Ranks 414.00 509.00 424.00 
284.00 281.00 306.00 
Non-
carriers 
N 28 27 28 23 24 22 
Mean 
Rank 30.75 26.52 28.61 
25.09 25.92 21.55 
Sum of 
Ranks 861.00 716.00 801.00 
577.00 622.00 474.00 
Total N 50 49 49 41 42 39 
 
Mann-
Whitney 
U 
161.000 256.000 193.000 
113.000 110.000 153.000 
 
Wilcoxon 
W 414.000 509.000 424.000 
284.000 281.000 306.000 
 
Z -2.873 -.824 -2.041 -2.469 -2.694 -.963 
 
p (2-
tailed) .004 .410 .041 
.014 .007 .336 
DISC1 
rs3737597 
minor 
allele 
carriers 
N 2 2 2 2 2 2 
Mean 
Rank 
25.50 26.50 26.00 9.50 5.50 18.50 
Sum of 
Ranks 
51.00 53.00 52.00 19.00 11.00 37.00 
Non-
carriers 
N 48 47 47 39 40 37 
Mean 
Rank 
23.93 23.89 23.91 21.59 22.30 20.08 
Sum of 
Ranks 
1077.00 1075.00 1076.00 842.00 892.00 743.00 
Total N 50 49 49 41 42 39 
 
Mann-
Whitney 
U 
42.000 40.000 41.000 16.000 8.000 34.000 
 
Wilcoxon 
W 
1077.000 1075.000 1076.000 19.000 11.000 37.000 
 
Z -.158 -.264 -.211 -1.392 -1.890 -.191 
 
p (2-
tailed) 
.874 .792 .833 .164 .059 .849 
BDNF 
rs6265 
minor 
allele 
carriers 
N 14 13 14 11 12 11 
Mean 
Rank 31.00 27.77 30.36 
24.91 27.67 20.91 
Sum of 
Ranks 434.00 361.00 425.00 
274.00 332.00 230.00 
Non- N 36 36 35 30 30 28 
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IHC Minor Allele Carrier Status Data 
  
Relative 
FEZ1 
(APh 
Grey 
Matter) 
Relative 
FEZ1 
(APh 
White 
Matter) 
Relative 
FEZ1 
(Dentate 
Gyrus) 
Absolute 
NEUROD1 
(APh Grey 
Matter) 
Absolute 
NEUROD1 
(APh 
White 
Matter) 
Absolute 
NEUROD1 
(Dentate 
Gyrus) 
carriers Mean 
Rank 23.36 24.00 22.86 
19.57 19.03 19.64 
Sum of 
Ranks 841.00 864.00 800.00 
587.00 571.00 550.00 
Total N 50 49 49 41 42 39 
 
Mann-
Whitney 
U 
175.000 198.000 170.000 
122.000 106.000 144.000 
 
Wilcoxon 
W 841.000 864.000 800.000 
587.000 571.000 550.000 
 
Z -1.664 -.815 -1.660 -1.265 -2.060 -.312 
 
p (2-
tailed) .096 .415 .097 
.206 .039 .755 
RAPTOR 
rs2289759 
minor 
allele 
carriers 
N 26 26 26 21 21 20 
Mean 
Rank 
24.42 25.04 26.08 18.57 18.76 18.25 
Sum of 
Ranks 
586.00 601.00 652.00 390.00 394.00 365.00 
Non-
carriers 
N 24 23 23 20 21 19 
Mean 
Rank 
23.57 22.91 21.64 23.55 24.24 21.84 
Sum of 
Ranks 
542.00 527.00 476.00 471.00 509.00 415.00 
Total N 50 49 49 41 42 39 
 
Mann-
Whitney 
U 
266.000 251.000 223.000 159.000 163.000 155.000 
 
Wilcoxon 
W 
542.000 527.000 476.000 390.000 394.000 365.000 
 
Z -.213 -.532 -1.109 -1.330 -1.446 -.983 
  
p (2-
tailed) 
.831 .595 .268 .183 .148 .325 
 
6.1 FEZ1 Protein Density 
 In the APh grey matter, none of demographic and clinical variables were 
adopted as significant confounding variables for FEZ1 protein density. 
Furthermore, ANOVA testing of the mean relative FEZ1 protein densities in 
each of the ROIs revealed no significant main effect of diagnosis. Mann-
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Whitney testing of minor allele carrier statuses suggested an effect of the 
DISC1 rs821616 SNP. DISC1 rs821616 minor allele carriers (Mdn = 1.23) 
exhibited lower levels of FEZ1 protein density in the grey matter when compare 
to major allele homozygotes (Mdn = 1.41, U = 160, p = .004). 
 As no significant main effect of diagnosis was detected in this region, the 
rs821616 minor allele was re-analysed under parametric conditions. Upon t-
testing, the relative FEZ1 protein density of DISC1 rs821616 minor allele 
carriers (M = 1.06, SD = .20, N = 22) was found to be significantly reduced 
when compared to non-carriers (M = 1.23, SD = .21, N = 28), t(48) = -2.933, p = 
.005. Mann-Whitney and t tests on all other minor alleles revealed no significant 
effects on FEZ1 protein density were detected in this region. 
 In the dentate gyrus, DISC1 rs821616 minor allele carriers (Mdn = 1.22) 
exhibited lower levels of FEZ1 protein density in the grey matter when compare 
to major allele homozygotes (Mdn = 1.28, U = .193, p = .041). Upon t-testing, 
the relative FEZ1 density of DISC1 rs821616 minor allele carriers (M = 1.11, SD 
= .16, N = 21), was also detected as significantly lower than in non-carriers (M = 
1.24, SD = .22, N = 28), t(47) = -2.425, p = .019; Levene’s test indicated 
unequal variances (F = 4.342, p = .043), so degrees of freedom were adjusted 
from 46.9 to 47. Analysis of the demographic and clinical variables in the 
dentate gyrus revealed no significant confounding variables for FEZ1 protein 
density. Mann-Whitney U and t tests on all other minor alleles revealed no 
significant effects on FEZ1 protein density were detected in this region. 
 In the APh white matter, the demographic and clinical variable of age at 
death (rs = -.326, p = .022) exhibited a significant correlation with FEZ1 protein 
destiny; duration of disease (rs = -.270, p = .061) and PMI (rs = .243, p = .092) 
exhibited marginal correlations. These were therefore adopted as significant 
confounding variables. Nevertheless, no significant main effect of diagnosis was 
detected under ANOVA testing. There were also no effects of the minor alleles 
subjected to Mann-Whitney U and t tests in this ROI. 
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6.1.1 DISC1 rs821616 
 In order to protect against artefacts of multiple comparisons, 4×2 ANOVA 
analyses with diagnosis and DISC1 rs821616 minor allele carrier status as 
between-subjects factors were performed on the results derived from tests in 
the grey matter and dentate gyrus ROIs. In the grey matter, the 4×2 ANOVA 
detected no significant main effect of diagnosis, F(3,42) = 1.67, p = .189, but a 
significant effect of minor allele carrier status, F(1,42) = .8,553 p = .006. This 
effect was not qualified by an interaction between diagnosis and rs821616 
minor allele carrier status, F(3,42) = 1.801, p = .162. The assessment within 
subjects, based on the estimated marginal means, revealed the significant 
effect of DISC1 rs821616 to be specific to both SCZ [F(1,42) = 10.716, p = .002] 
and BPD [F(1,42) = 4.433, p = .041]; minor allele carriers exhibiting significantly 
lower FEZ1 protein density levels than the non carriers in both groups. 
 Sufficiently protected from artefacts of multiple comparisons, and the 
potential for an interaction between diagnosis and DISC1 rs821616 minor allele 
status, t test were performed separately within each diagnostic group. Upon t 
testing within diagnoses, the FEZ1 density of rs821616 minor allele carriers in 
the grey matter demonstrated a 27.2% reduction in SCZ (t(11) = -3.671, p = 
.004) and a 19.2% reduction in BPD (t(13) = -2.197, p = .047) (Fig 6-1). No 
significant effects were observed in the MDD or CON groups. 
 208 
 
6-1 Bar graph showing the results of the within-group comparisons of grey matter FEZ1 protein 
density levels across DISC1 rs821616 minor allele carrier status from slides of anterior 
hippocampus. * denotes p < .05 (t-tests within groups); BPD = Bipolar Disorder (N, carriers = 6, 
non-carriers = 9), MDD = Major Depressive Disorder (N, carriers = 5, non-carriers = 5), SCZ = 
Schizophrenia (N, carriers = 6, non-carriers = 7), CON = controls (N, carriers = 5, non=carriers = 
7) 
 In the dentate gyrus, similar results were observed, The 4×2 ANOVA 
detected no significant main effect of diagnosis, F(3,41) = 1.50, p = .230, but a 
significant effect of minor allele carrier status, F(1,41) = .5,026, p = .030. This 
effect was not qualified by an interaction between diagnosis and rs821616 
minor allele carrier status, F(3,41) = 1.801, p = .162. The assessment within 
subjects, based on the estimated marginal means, revealed the significant 
effect of DISC1 rs821616 in the dentate gyrus to be specific to both SCZ 
[F(1,42) = 4.309, p = .044] and BPD [F(1,42) = 5.029, p = .030]; minor allele 
carriers exhibiting significantly lower FEZ1 protein density levels than the non 
carriers in both groups. 
 Upon t testing within diagnoses, the FEZ1 density of rs821616 minor 
allele carriers in the dentate gyrus was reduced by 16.5% in SCZ (t(11) = -
2.540, p = .027) and 19.9% in BPD (t(11) = -2.845, p = .004) (Fig 6-2). No 
significant effects were observed in the MDD or CON groups. Levene’s test 
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indicated unequal variances between minor allele carriers and non-carriers in 
the BPD group (F = 5.878, p = .032), degrees of freedom were therefore 
adjusted from 12 to 11. 
 
6-2 Bar graph showing the results of the within-group comparisons of dentate gyrus FEZ1 
protein density levels across DISC1 rs821616 minor allele carrier status from slides of anterior 
hippocampus. * denotes p < .05 (t-tests within groups); BPD = Bipolar Disorder (N, carriers = 5, 
non-carriers = 9), MDD = Major Depressive Disorder (N, carriers = 5, non-carriers = 5), SCZ = 
Schizophrenia (N, carriers = 6, non-carriers = 7), CON = controls (N, carriers = 5, non=carriers = 
7) 
6.2 NEUROD1 Protein Density 
 In the APh grey matter, the demographic and clinical variable found to 
exhibit a significant correlation with NEUROD1 protein density was brain pH (rs 
= -.32, p = .039). From the dichotomous demographic and clinical variables, 
suicide was detected to have a significant effect on NEUROD1 protein density; 
subjects with the reported cause of death as suicide exhibited lower NEUROD1 
protein density levels (Mdn = 793), when compared to non-suicide counterparts 
(Mdn = 1040, U = 97.0, p = .017). Suicide and brain pH therefore adopted as 
adopted significant confounding variables for grey matter NEUROD1 protein 
density. No other significant effects of demographic and clinical variables were 
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observed in this ROI. Under ANOVA testing, no significant main effect of 
diagnosis in the APh grey matter was detected. 
 Mann-Whitney U testing of minor allele carrier statuses suggested an 
effect of two DISC1 SNPs. Minor allele carriers of the rs6675281 SNP (Mdn = 
1135) exhibited significantly higher absolute NEUROD1 protein density levels 
when compared to non-carriers (Mdn = 899, U = 108, p = .038). As no 
significant main effect of diagnosis was detected in this region, the rs6675281 
minor allele was re-analysed under parametric conditions. Upon t-testing, minor 
allele carriers (M = 1087, SD = 289 N = 13) exhibited marginally higher absolute 
NEUROD1 protein density levels in the grey matter when compared to non-
carriers carriers (M = 858, SD = 377, N = 28), t(39) = 1.93, p = .061 (Fig 6-3). 
 
6-3 Scatter plot showing the NEUROD1 protein density levels in the anterior parahippocampal 
grey matter of DISC1 rs6675281 minor allele carriers from slides of anterior hippocampus 
 Minor allele carriers of the DISC1 rs821616 SNP (Mdn = 797) exhibited 
significantly lower absolute NEUROD1 protein density levels when compared to 
non-carriers (Mdn = 1051, U = 113.0, p = .014). As no significant main effect of 
diagnosis was detected in this region, the rs821616 minor allele was re-
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analysed under parametric conditions. Upon t-testing, minor allele carriers (M = 
764, SD = 315 N = 18) exhibited significantly lower absolute NEUROD1 protein 
density levels in the grey matter when compared to non-carriers carriers (M = 
1061, SD = 352, N = 23), t(39) = -2.81, p = .008 (Fig 6-4). No other significant 
effects of minor alleles were detected in this region. 
 
6-4 Scatter plot showing the NEUROD1 protein density levels in the anterior parahippocampal 
grey matter of DISC1 rs821616 minor allele carriers from slides of anterior hippocampus 
 In the APh white matter, no demographic or clinical variables were 
adopted as significant confounding factors for NEUROD1 protein density. 
Additionally, ANOVA testing revealed no significant main effect of diagnosis in 
this region. When the effect of minor allele carrier statuses were assessed in 
the white matter, DISC1 rs821616 minor allele carriers were found to exhibit 
significantly lower absolute NEUROD1 protein density levels (Mdn = 425) when 
compared non-carriers carriers (Mdn = 558, U = 110.0, p = .007). 
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6-5 Scatter plot showing the NEUROD1 protein density levels in the anterior parahippocampal 
white matter of DISC1 rs821616 minor allele carriers from slides of anterior hippocampus 
 As no significant main effect of diagnosis was detected in this region, the 
rs821616 minor allele was re-analysed under parametric conditions. Upon t-
testing, minor allele carriers (M = 419, SD = 125, N = 18) exhibited significantly 
lower absolute NEUROD1 protein density levels in the grey matter when 
compared to non-carriers carriers (M = 583, SD = 221, N = 24), t(39) = -2.82, p 
= .007. No other significant effects of minor alleles were detected in this region. 
Marginal reductions in NEUROD1 protein density were predicted by the rare 
rs3737597 DISC1 SNP; minor allele carriers exhibiting significantly lower 
absolute NEUROD1 protein density levels when compared to non-carriers (U = 
8.00, p = .058). However, this was based on only 2 minor allele carriers. 
Consequently, upon t testing this effect was no longer detected as significant, 
t(40) = -1.53, p = .134. 
 In the dentate gyrus, no demographic or clinical variables were adopted 
as significant confounding factors for NEUROD1 protein density. Nevertheless, 
ANOVA testing revealed no significant main effect of diagnosis. There was also 
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no significant effect of minor allele carrier status detected in this ROI under t 
testing or Mann-Whitney U conditions. 
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7 DISCUSSION 
 The noteworthy findings of this report include; significant reductions of 
APh FEZ1 mRNA transcript levels in SCZ and BPD, significant reductions of 
FEZ1 protein density in the APh grey matter and dentate gyrus of DISC1 
rs821616 minor allele carriers diagnosed with SCZ and BPD, increased APh 
DCX mRNA abundance in SCZ, and increased NEUROD1 mRNA transcript 
levels in the non-neurogenic HF of DISC1 rs3738401 minor allele carriers. The 
findings of significantly reduced NEUROD1 protein density levels associated 
with the DISC1 rs821616 minor allele in both the APh grey and white matter, 
were not based on technical replicates. These were therefore not a focus of 
these discussions. 
7.1 Genotype Analysis 
 The results show that at each non-synonymous SNP, the Stanley 
Consortium sample is in Hardy-Weinberg Equilibrium (HWE; χ², p≥0.05) with 
both the Stanley Consortium and HapMap allele frequencies. This is an 
indication of genotype analysis authenticity and, notwithstanding the mixed 
diagnostic composition of the sample, also suggests the absence of any 
genotype frequency distortions in our sample251. 
 DISC1 SNPs have exhibited associations to schizophrenia and BPD (see 
1.8), though there is less evidence of a DISC1 association to MDD. The 
association between the DISC1 locus and schizophrenia is likely to be a 
complex interplay between SNPs252. Therefore the absence of any genotype 
frequency distortions was not necessarily unexpected for a sample of this size. 
 Though all allele distributions were all found to be in HWE with HapMap 
allele frequencies, the. rs821616 SNP exhibited a χ2 alpha value of p = .012. 
This is intriguing as the rs821616 allele has been demonstrated to predict lower 
expression of DISC1 binding partners FEZ1 and NDEL1 in homozygotes204. It 
lies proximal to the predicted binding region of NDEL1 and has also been 
shown to exhibit epistatic interactions with the G allele of the rs1361768 SNP in 
this gene. 
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 This risk allele has also been associated in with reduced hippocampal 
grey matter volume, and deficits in episodic and working memory253. A larger 
sample size would offer the statistical power necessary to further interrogate the 
existence of genotype distortions at this locus in relation to mental illness. This 
may contribute to the evidence suggesting that this locus mediates risk for 
psychiatric phenotypes. 
7.2 Gene Expression 
7.2.1 DCX 
7.2.1.1 DCX and schizophrenia 
 The results reported here are suggestive of an increase in the 
transcription of the DCX gene in the APh region of subjects diagnosed with 
schizophrenia. DCX is a gene with well characterized roles in the migration and 
neurite outgrowth of newborn neurons141; 254. However, evidence is beginning 
emerge that, quite apart from its neurogenic roles, DCX also functions in mature 
neurons255. Despite this, a scant number of studies have directly investigated 
DCX function in schizophrenia. DCX has primarily been utilised in psychiatric 
research as a marker for neurogenesis in tissues, distinguished from the BrdU-
labelling which is used to measure neural progenitor proliferation. Accordingly, 
there are limitations in the ability to parallel these results with previous research. 
 For example, a role for DCX in the subtle migration dynamics of newborn 
neurons has been forwarded by the animal studies of Kvajo and colleague256. In 
a mutant mouse model of the DISC1 t(1:11) translocation, though they detected 
lower overall numbers of DCX-positive neurons, the proportion of these neurons 
in the outer granule cell layer was increased in the mutant mice. The outer 
region of the granule cell layer is the destination of tangentially migrating 
neurons generated from the inner layer. Interestingly, Kvajo and colleagues256 
were unable to detect concomitant increases in NeuN, a mature neuron marker. 
Taken with the SCZ-like behavioural deficits observed, this indicates a role for 
DCX as an indicator of uncoordinated migration (i.e. occurring without neuronal 
maturation) in SCZ neurobiology. 
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 However, there are limitations to the extent to which this data can be 
interpreted. Firstly, the mutant mice expressed a truncated form of the mouse 
Disc1. This truncation was intended to mimic the genomic disruption present in 
the original DISC1 t(1:11) translocation, however their deletion variant 
introduced a premature stop codon in exon 7 whereas the original truncation 
point has been demonstrated to reside between exons 8 and 9. Secondly, Kvajo 
and colleagues detected these results in the dentate, a neurogenic subfield of 
the mammalian hippocampus. The results report in the present study relate to 
the APh region which does not host neurogenesis. 
 Recent work has illustrated this duality of DCX expression in the 
mammalian brain. Kremer and colleagues255 report a constitutive expression of 
DCX in non-neurogenic regions of the brain. However, they did not find this 
non-neurogenic expression to be significantly altered upon environmental 
stimulation of neurogenesis in adult rodents. This was in direct contrast to the 
increase in DCX expression observed in the neurogenic niche of the dentate. 
This demonstrates that, in non-neurogenic regions, DCX expression may 
operate independently of adult neurogenesis. 
 It therefore follows that the SCZ-associated increase in DCX mRNA 
transcript levels observed in the APh region reflects an increased burden on the 
DCX-dependent processes occurring in mature neurons. Extrapolating from the 
neurodevelopment roles of DCX, this would implicate mature neuronal migration 
and axon growth. This would speculatively associate schizophrenia with 
disturbances in the neuroplasticity of the adult brain. It would also be consistent 
with some of the SCZ cytoarchitectural findings such as abnormal neuronal 
clustering in the entorhinal cortex29; 30, and reduced synaptic marker expression 
in the temporal lobe35; 39. However, such distinct findings are likely the result of 
changes actuated early in development, which would be relevant if the 
abnormal expression of DCX detected in this study could be confidently 
reported for a neurogenic region of the brain. Unfortunately, due to sample 
sizes in the neurogenic HF dissections, the data does not support such an 
interpretation. 
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 This also limits the correlations that can be made with the post-mortem 
findings reported by Fung and colleagues257 . In their study, they were unable to 
detect differences in DCX expression levels between subjects with 
schizophrenia/schizoaffective disorder and normal controls in the dorsolateral 
prefrontal cortex (DLPFC). However, in the schizophrenia group they were able 
to detect evidence of a negative correlation between numbers of DLPFC 
interstitial white matter neurons (IWMNs) and DCX expression levels. Having 
previously reported a significant increase in IWMN density in SCZ258, and a 
negative correlation of grey matter somatostatin expression with IWMN density, 
they understood this to reflect a failure of interneurons to migrate from white 
matter tracts into the cortex during development. 
 That the results indicate defects in neuro-plasticity is further evidenced 
by the finding that the RPTOR rs2289759 minor allele is associated with 
increased hippocampal DCX transcript levels. The RPTOR protein is a major 
constituent of the mTORC1 complex which regulates synaptic protein 
translation259. It acts downstream of the neurotrophin BDNF in the PI3K-Akt 
signalling cascade260; important in the formation of memories261. There is 
evidence that the minor G allele of the rs2289759 RPTOR SNP promotes the 
expression of a RPTOR splice variant with limited mTOR substrate binding 
capacity262. Substrate binding is critical to mTORC1 function, the inhibition of 
which has been demonstrated to result in impairments to long-term 
potentiation263. 
 Our additional finding in the schizophrenia cohort, of an increased level 
of parahippocampal DCX transcript in BDNF rs6265 minor allele carriers, further 
implicates the BDNF signalling pathway. BDNF serves as a major regulator of 
synaptic transmission and plasticity in numerous brain regions264. The minor A 
allele of the BDNF rs6265 SNP has been associated to deficits in episodic 
memory and reduced hippocampal activation in humans265. This demonstrates 
that, as with the RPTOR rs2289759 SNP in the hippocampus, the minor allele 
of a polymorphism previously associated to memory processing defects, may 
also be associated to an increase in DCX expression. It is interesting that both 
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these genotype-mediated effects involve genes in the BDNF-mTORC1 
signalling pathway but manifest in separate brain regions. As Kendler266 has 
recently argued, this may reflect the different levels at which a molecular 
pathway may impact on disease risk.. 
7.2.1.2 Implications for DCX as a Neurogenesis Marker 
 As a putative marker for neurogenesis, these results, along with the work 
of Kremer and Colleagues255, raise important questions regarding the 
interpretation of DCX expression in post-mortem studies. Couillard-Despres and 
colleagues267 demonstrated that DCX expression in adult neurogenic regions 
does not overlap with either nestin; a marker for pluripotent neural stem cells, or 
GFAP; a marker for astrocytes. This was taken as strong evidence that DCX 
expression is specific to new-born neurons. However, there is now a growing 
appreciation that DCX is expressed in non-neurogenic pools, operating 
independent of neurogenesis. This behoves caution when interpreting DCX 
expression data from post-mortem tissues and also explains the apparent 
disparity between the increase of DCX expression, detected in this study, and 
previous reports of reduced adult neurogenesis in SCZ (see 1.4.4). 
 In addition to this, the extent to which DCX expression accurately reflects 
neurogenesis is also under scrutiny. Merz and colleagues268 have recently 
demonstrated that the absence of Dcx expression in migrating neurons does 
not necessarily result in ‘heterotopic’ positioning of neurons within the 
mammalian adult brain. Their results, when taken with the findings of previous 
reports254; 269, indicate that DCX plays a critical role in the early stages of 
migration; but a ‘dispensable’ one in the latter stages. 
 Accordingly, researchers have argued against the use of solitary markers 
for neurogenesis in immunohistological studies137. However, for quantitative 
studies, the accurate targeting of specific brain regions and subfields will aid the 
accurate interpretation of results. This approach has previously been explored 
by Altar and colleagues150 who used laser-capture micro-dissection (LCM) to 
profile neurogenic gene expression. 
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7.2.2 FEZ1 
7.2.2.1 FEZ1 and Psychosis 
 The data reported in this study strongly suggest that expression of the 
FEZ1 gene is reduced in the major psychoses. Not only were FEZ1 mRNA 
transcript levels in the APh region found to be significantly reduced in both SCZ 
and BPD, but the FEZ1 protein reductions, found existing in the brains of minor 
allele carriers of the DISC1 rs821616 SNP, were revealed to be specific to the 
SCZ and BPD groups. This is consistent with the findings of Lipska and 
colleagues204 which demonstrated FEZ mRNA reductions in the hippocampus 
and DLPFC of SCZ sufferers. Lipska and colleagues204 also reported evidence 
that the DISC1 rs821616 minor allele predicts reductions in FEZ1 mRNA in the 
context of a SCZ diagnosis. This is consistent with the findings of reduced FEZ1 
protein density in rs821616 minor allele carriers reported in this study. Genetic 
association of the FEZ1 gene has identified two adjacent loci exhibiting 
nominally significant associations to SCZ, but not BPD, in the Japanese 
population222. Further studies have yet to replicate this finding223; 270, including a 
second study in a Japanese cohort224. 
7.2.2.2 Impact of Reduced FEZ1 Expression 
 There have been previously reported examples of FEZ1 insufficiency 
correlating to indicators of psychosis. Fez1 knockdown mice, when subjected to 
behavioural tests, have been shown to exhibit hyperactivity traits and 
demonstrate an increased sensitivity to psycho-stimulation of the mesolimbic 
dopaminergic system271. Researchers have postulated that these behavioural 
abnormalities correspond to psychiatric endophenotypes271. Hyperactivity is a 
proposed endophenotype in psychiatric conditions, including SCZ272, and 
increased dopaminergic sensitivity directly correlates to the hyper-functioning 
dopamine system observed in SCZ and BPD patients. These findings therefore 
implicate FEZ1 expression in behavioural and neurochemical correlates of 
psychosis. 
 Previously demonstrated roles of FEZ1 include a participation in dendritic 
outgrowth218 and microtubule transport219. It would be reasonable to expect that 
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reduced FEZ1 expression might correspond to deficits in these aspects of cell 
biology. Accordingly, Fujita and colleagues report that FEZ1-deficient PC12 
cells show reduced levels of NGF-induced neurite extension. This is somewhat 
consistent with the decreased neuronal soma size and reduced synaptic marker 
density observed in SCZ. They also found that these cells exhibited defects in 
the anterograde transport of mitochondria along axons218. Mitochondrial 
transport is thought to be critical in neural differentiation, providing energy for 
neurite development. 
 Abnormalities in mitochondrial morphology have also been detected in 
FEZ1-deficient PC12 cells219, and there is evidence to suggest that 
mitochondrial changes operate as a neurobiological correlate of both BPD and 
SCZ273. This implicates FEZ1 reductions in the mitochondrial disturbances 
associated with these disorders. Interestingly, mitochondria-related 
disturbances are gaining increasing relevance in the molecular basis of 
psychiatric disorders. Mitochondrial DNA (mtDNA) mutations have been linked 
to BPD and SCZ, as have mtDNA polymorphisms274-276 and subjects with 
mitochondrial disorders have been reported to present psychotic symptoms277. 
 Of course, FEZ1 also participates on the microtubule transport of other 
cargoes, including neurotransmitter vesicles. Therefore, the mechanism by 
which reduced FEZ1 expression may mediate risk for SCZ and BPD is open to 
further speculation. For example, the previous genetic association of FEZ1 to 
SCZ was detected in a locus which translates to the N-terminal portion of the 
protein. This portion of the protein has been reported to be involved in the 
axonal targeting activity of the UNC76 ortholog, which has been demonstrated 
to functionally overlap with human FEZ1217. It is an intriguing possibility that 
reduced FEZ1 expression translates to deficits in the axonal targeting activity of 
FEZ1 highlighted by the genetic association studies. This would retard 
anterograde transport of cargoes including mitochondria and neurotransmitters, 
reducing the capacity of neurons to accurately extend processes and maintain 
active synaptic contacts. This is one means by which FEZ1 expression 
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reductions could contribute to the abnormalities observed in the major 
psychoses. 
 Further evidence of FEZ1‘s role in psychiatric disorders is reported by Yu 
and colleagues278. Their study reported the results of a microarray expression 
analysis of 11,214 genes in human astrocyte-derived cells treated with the 
classic mood stabilisers, lithium, valproic acid, carbamazepine, and lamotrigine. 
The results were then confirmed with follow-up qPCR analysis. Intriguingly, they 
found FEZ1 to be the only gene for which expression levels were significantly 
increased in response to each of the 4 drug regimens. This provides a direct 
link between the treatment of mood disorders, including BPD, and a regulation 
of cellular FEZ1 expression levels. Whereas the previously discussed evidence 
demonstrates a correlation between FEZ1 expression and psychotic pathology, 
these results appear to implicate increased FEZ1 expression in therapeutic 
recovery. 
 BPD and SCZ are distinctly characterised psychotic disorders; however 
there is a growing appreciation of the extent to which they overlap. Reviews of 
the genetic association literature highlight many of the most strongly supported 
SCZ susceptibility genes as being associated to BPD279. More recently, The 
International Schizophrenia Consortium used a novel form of GWAS analyses 
to corroborate the polygenic theory of SCZ. However, they were also able to 
demonstrate a substantial overlap between the polygenic component of SCZ 
and BPD67. 
 This suggests that though these disorders are understood to manifest 
divergently, there is a strong possibility that aspects of the underlying molecular 
mechanisms are shared. This would explain the findings in this study of reduced 
FEZ1 expression in the merged SCZ and BPD psychosis group. It would also 
be consistent with the results of FEZ1-silencing studies, which correlate to both 
SCZ and BPD neurobiology. 
 Specifically, acute psychosis; a feature of both SCZ and BPD, is thought 
to be associated to an elevation in striatal dopamine neurotransmission280. 
FEZ1 expression is prominent in the mammalian striatum, where it is 
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predominantly found in inhibitory GABA neurons271. Reductions in FEZ1 
expression, and its reported consequences, may induce subtle alterations to the 
brain’s capacity to appropriately regulate neurotransmission. When related to 
the striatum, this may have substantial implications for our understanding of the 
acute psychosis phase. Whether any pathological relationship between reduced 
FEZ1 expression in the APh region and psychosis is causal or secondary in 
nature requires further investigation. Genome-wide and animal model studies, 
incorporating both SCZ- and BPD- related phenotypes, will be invaluable in this 
regard. 
7.2.2.3 FEZ1 and DISC1 rs821616 
 The analysis of the data indicates that reductions in the amount of FEZ1 
protein exist in the brains of carriers of the minor allele of common DISC1 
variant rs821616. This minor T allele encodes an amino acid change in the 
gene product from serine, encoded by the major A allele, to cysteine. The 
expression reduction was detected in the grey matter and dentate gyrus of 
slides encompassing the anterior hippocampus. 
 There is previous evidence to suggest that variation in DISC1 predicts 
reductions in FEZ1 expression. Lipska and colleagues204 reported that variation 
at 3 DISC1 loci which, in the context of a schizophrenia diagnosis, coincided 
with reduced FEZ1 expression. Schizophrenia subjects homozygous for SCZ-
associated alleles at 2 silent intronic SNPs (hCV219779 and rs821597), and the 
non-synonymous SNP highlighted in this study (rs821616), were found to 
exhibit significantly lower levels of FEZ1 expression in the hippocampus. In the 
DLPFC these effects were only associated with rs821597 and rs821616. 
 This provides evidence that the non-synonymous SNP rs821616 can 
exert influences on the expression of FEZ1 in both cortical and sub-cortical 
regions. However, whereas previous studies have demonstrated an effect on 
FEZ1 mRNA204, the results reported here indicate that these effects may 
manifest at the protein level. This has a further relevance for a SNP which 
moderates an amino acid substitution. 
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 There is evidence to suggest that this amino acid substitution coincides 
with a wide array of neurocognitive, neuroanatomical and cytoarchitectural 
alterations. These may shed light on the nature of dysregulated FEZ1 mRNA 
and protein expression visited by this particular DISC1 variant. 
7.2.2.3.1 DISC1 rs821616 and Neuroanatomy 
 The reports of an effect of DISC1 rs821616 on grey matter volume have 
been mixed. In one of the first studies to analyse the potential for an effect of 
this SNP on temporal cortical neuroanatomy, Calicott and colleagues253 were 
able to highlight significant enlargements in hippocampal grey matter volumes 
of subjects homozygous for the minor T allele (when compared to the A allele 
homozygotes). However, in 2008, Di Giorgio and colleagues281 reported 
reductions in the grey matter volume of minor T allele carriers when compared 
to their A allele-homozygous counterparts. 
 More recent studies concord with the theory that it is the rs821616 major 
A allele which is associated with reduced temporal region brain volumes. 
Raznahan and colleagues282, associate minor T allele carriers with thicker 
cortices in temporal regions encompassing the inferior, middle and superior 
temporal gyri. Knickmeyer and colleagues283, associate T allele carrier status 
with increased brain volume in the lateral APh region. 
 These results would appear to contradict the findings reported in this 
current study. However, the complexity involved in directly translating the effect 
of genetic variation on brain volume is demonstrated by a recent study by Trost 
and colleagues284. Here, the researchers were able to demonstrate that T allele 
carriers exhibit both reductions and enlargements in grey matter volume, 
sometimes in the same brain region. 
 They report the minor T allele as being associated with reductions in the 
grey matter volume in the left middle frontal gyrus. However, they also detect 
grey matter volume reductions in A allele homozygotes in this region. These 
somewhat contradictory findings were recapitulated in the right middle frontal 
gyrus. However, the Montreal Neurological Institute (MNI) coordinates of the 
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left- and right-sided T allele-associated reductions (-33 37 43 and 36 62-4 
respectively) differ slightly from those of the left- and right-sided A allele 
homozygosity-associated reductions (-24 48 1 and 32 34 30). 
 The results therefore suggest that minor shifts in brain region may 
profoundly affect the observed influence of DISC1 rs821616 variation on brain 
volume. This, to some degree, corresponds with the findings here in this study 
that DISC1 rs821616 minor T allele affects FEZ1 protein density in the grey 
matter of coronal sections of the APh region, but not the white matter. 
 Brain structure consists of a voluminous array of connections. It is highly 
likely that that any effects of the rs821616 SNP manifest in multiple forms at the 
level of brain volume. The observance of these effects may be contingent on 
brain region and/or level of neural circuitry and much more. It is therefore likely 
to be useful for researchers to analyse subtler measures of brain function for 
clues as to the relationship between genetic variation and gene expression. 
7.2.2.3.2 DISC1 rs821616 and Brain Function 
 In their early study into DISC1 variation, Callicott and colleagues253 were 
able to report the results of a series of cognitive tests. They detected subjects 
homozygous for the rs821616 A allele as exhibiting significantly different brain 
activity levels than their minor T allele-carrying counterparts. During the neutral 
scene encoding of the declarative memory task, A allele homozygosity was 
associated with bilateral reductions in blood oxygen levels in the hippocampal 
formation. Interestingly, the A allele was also associated with decreased 
hippocampal grey matter volume in this study. However, Callicott and 
colleagues253 also detected A allele homozygosity to be associated with 
increased bilateral hippocampal activity during the N-back working memory 
task. 
 Conversely in the Di Giorgio study281, A allele homozygosity was found to 
coincide with an increase in hippocampal bilateral blood oxygen levels during 
memory encoding of the declarative memory task. In thus study, the A allele 
was found to be associated with greater parahippocampal gyrus volume. 
 226 
 This suggests that not only do the effects of DISC1 variation seemingly 
manifest divergently at the level of brain volume, but also at the level of brain 
activity (as measured by blood oxygen levels). This may reflect that the effect of 
DISC1 variation on brain activity is subject other influences. 
 For example, in SCZ and BPD patients Prata and colleagues285 detected 
no significant difference between A allele homozygotes and minor T allele 
carriers in prefrontal brain activation levels during verbal fluency testing. This 
was despite previously detecting decreased prefrontal activation in healthy 
minor T allele carriers during the same task in a previous study286. The 
researchers speculated that this may reflect the interaction of DISC1 with other 
genes, and/or the environmental risk factors, associated with SCZ and BPD. 
 This may provide clues to the nature of the association between DISC1 
variation and FEZ1 expression detected in this study. Lipska and colleagues 
report an effect of DISC1 rs821616 specific to SCZ subjects, Praha and 
colleagues286 also report an effect of rs821616 that is specific to SCZ. In this 
current study, the effects of rs821616 were more pronounced in psychosis 
sufferers (SCZ and BPD). This suggests that DISC1 rs821616 may moderate 
brain activity and FEZ1 expression in combination with one or more of the risk 
factors associated with SCZ and BPD. 
7.2.2.3.3 FEZ1 and DISC1 function 
 In a comprehensive study on Fez1 and Disc1 function in adult 
neurogenesis, Kang and colleagues287 were able to demonstrate that the 
consequences of Fez1 knockdown partially parallel the effects seen in Disc1 
silencing. In both cases, significant increases in neuron soma size and dendritic 
arborisation are observed. However, in Disc1 knockdown further effects of 
aberrant neuron positioning and ectopic neurite extension were also detected. 
 The alterations observed upon Fez1 knockdown were susceptible to 
recovery by wild type FEZ1 rescue vectors. Taken together with the interaction 
between FEZ1 and DISC1 proteins, and their evidence of functional synergy 
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between the two, Kang and colleagues287 proposed that FEZ1 and DISC1 
interact to regulate dendritic growth. 
 The potential for variation at the rs821616 locus to regulate DISC1, and 
thus FEZ1 function, is not entirely without basis. For example, though the 
rs821616 SNP does not lie within the purported FEZ1 binding site of DISC1, it 
does reside within the oligomerisation site. DISC1 has been demonstrated to 
organise into dimers and then oligomers, the 668-747aa region of DISC1 has 
been shown to be critical for this assembly207. 
 Furthermore, the minor T allele Cys704 protein product, associated with 
reduced FEZ1 protein expression in this study, was demonstrated to be 
associated with increased oligomerisation. The researchers posited that this 
manipulation of oligomerisation dynamics could serve as a regulatory 
mechanism for DISC1 function207. 
 This may have implications for the function and/or expression of DISC1 
binding partners including FEZ1. In their study, Kamiya and colleagues227 were 
able to demonstrate the effect of DISC1 rs821616-mediated oligomerisation on 
NDEL1 binding. DISC1 and NDEL1 binding was demonstrated to be critical to 
neurite outgrowth227. The DISC1 rs821616 SNP was shown to exert a mild 
influence on the DISC1-NDEL1 interaction227. The reported NDEL1 binding 
region does not overlap with this SNP. It is therefore possible that this effect 
does not reflect a direct interference with this interaction. However, it may serve 
as a secondary consequence of altered DISC1 oligomerisation dynamics. 
 This would be consistent with the findings of Narayanan and 
colleagues288. In their study they found that DSIC1 rs821616 altered quaternary 
structural assembly of DISC1 without significantly affecting NDEL1 binding. 
They thusly proposed that altered oligomerisation as the primary regulatory 
mechanism for DISC1 rs821616-associated phenotypes. This phenomenon is 
therefore also likely to persist in FEZ1 binding, with potential ramifications for 
FEZ1 expression. Thus would concord with two independent evidences that 
DISC1 rs821616 exhibits epistatic interactions of with FEZ1 rs12224788287 and 
NDEL1 rs1391768229 in risk for schizophrenia. 
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 The findings reported in this study of reduced FEZ1 protein expression, 
in association with genetic variation at the DISC1 rs821616 SCZ risk locus, is 
consistent with the literature. This locus has been implicated in numerous 
neuroanatomical and neurocognitive alterations. Research is continually 
revealing clues as to the mechanism of these effects. Understanding this 
mechanism is likely to further our understanding of DISC1 and FEZ1 function in 
psychiatric disorders. 
7.2.3 NEUROD1 and DISC1 
 The findings reported in this study suggest that NEUROD1 mRNA 
abundance in the non-neurogenic HF is to some degree contingent on DISC1 
variation at the rs3738401 locus. Carriers of the minor A allele, which encodes 
an amino acid base change from arginine to glutamine, were found to harbour 
reduced expression levels of NEUROD1 transcript when compared to subjects 
homozygous for the major G allele. Though there is limited evidence to suggest 
that genetic variation at this locus acts as an independent risk factor for 
disease289, the minor A allele has been associated to SCZ as part of a 
haplotype marker. 
 There also a paucity of evidence linking NEUROD1 directly to DISC1 
function or vice versa. NEUROD1 protein does not number amongst the many 
reported binding partners of DISC1 213. Despite this, any link between the 
molecular pathways in which these genes participate may offer further insights 
into their functional role in psychiatric disorders. An example of such a potential 
link is found in Wnt signalling. GSK-3β is a prominent signalling molecule in the 
canonical Wnt signalling pathway and is amongst reported binding partners of 
DISC1. The GSK-3β-DISC1 complex is understood to be critical to 
neurogenesis290.This direct interaction between GSK-3β and DISC1 protein has 
been shown to inhibit GSK-3β activity leading to increased intracellular β-
catenin levels291. 
 In the canonical WNT pathway, GSK-3Β functions as part of the Axin 
destruction complex which phosphorylates β-catenin signalling, targeting it for 
ubiquitination. Upon WNT stimulation, members of the axin destruction complex 
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are recruited to the inner plasmalemmal surface, stabilising intracellular β-
catenin. The increased levels of intracellular β-catenin lead directly to the 
transcription of NEUROD1 via its TCF/LEF elements147. Evidence for the direct 
interaction of β-catenin to NEUROD1 regulatory elements has been 
demonstrated by Gao and colleagues145. 
 Interestingly, the Arg264Gln mutation, coded by the DISC1 rs3738401 
SNP, lies proximal to the reported binding region of GSK-3β. It is quite possible 
that this mutation affects the direct interaction between these two proteins, 
reducing the DISC1-mediated inhibition of GSK-3β. This would reduce 
intracellular β-catenin levels and cause a decrease in the transcription of 
NEUROD1. This would be consistent with the evidence presented by Singh and 
colleagues292. In their study, Singh and colleagues were able to demonstrate 
that in all the model systems tested, Zebrafish, Mouse and also in Humans, the 
rs3738401 minor A allele Gln264 DISC1 variant, produced a negative effect on 
WNT signalling. 
 In mouse P19 carcinoma cells, Disc1 knockdown reduced WNT 
signalling, an effect rescued by wild type DISC1 but not Gln264 DISC1. In 
DISC1-deficient N2A cells, Gln264 DISC1 did not stimulate cell proliferation, 
unlike wild-type DISC1. This effect was determined to be dependent on WNT-
signalling; when WNT signalling was inhibited downstream (by dominant-
negative LEF), none of the DISC1 variants were able to stimulate proliferation. 
In HEK293 cells, Gln264 DISC1 was unable to potentiate WNT signalling. It 
also bound GSK-3β to a lesser degree when compared to wild type DISC1 
 These results translated to their in vivo findings. Singh and colleagues292 
were able to demonstrate that Disc1 knockdown resulted in reduced neural cell 
proliferation and early the cell-cycle exit of neurons in mouse brain. These 
effects were rescued by wild-type DISC1, but not Gln264 DISC1. They also 
detected evidence of a dominant negative effect of this DISC1 variant in vivo. 
Gln264 DISC1 was able to significantly influence progenitor proliferation and 
cell-cycle exit, even without Disc1 knockdown. 
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 In order to test the longer term implications of these effects on embryonic 
development the researchers also investigated the ability of the DISC1 protein 
to rescue the severe zebrafish Disc1 knockdown phenotype. When Disc1 is 
silenced in zebrafish, they exhibit altered brain morphology, muscular segment 
defects and axon tract defects. These are characteristics of disturbed WNT 
signalling293. In keeping with their previous observation, whereas wild type 
DISC1 was able to restore much of the developmental deficits, Gln264 DISC1 
was not. 
 In an attempt to translate their findings to human cells, they then tested 
human lymphoblast cell lines derived from bipolar patients homozygous for the 
rs3738401 A or G allele. Cells from subjects expressing Gln264 DISC1 
exhibited lower constitutive TCF/LEF reporter activity. This effect was attributed 
to effectors downstream of WNT signalling as no significant differences in WNT 
receptor levels were detected. Interestingly, TCF/LEF reporter activity was also 
found to be reduced in bipolar patients independent of DISC1 rs3738401 
genotype. 
 In an attempt to further clarify the mechanisms involved in the effects of 
the DISC1 variation on the tested models, GSK-3β phosphorylation and β-
catenin levels were also examined. GSK-3β is regulated by phosphorylation in a 
site-specific fashion. Phoshporylation at the tyrosine 216 residue stimulates 
activity; at serine 9 it is inhibited. Cells derived from subjects homozygous for 
Gln64 DISC1 exhibited higher levels of tyrosine 216 phosphorylation and lower 
levels of β-catenin. This suggests that DISC1 variation at the rs3738401 locus 
regulates WNT signalling via GSK-3β activity. 
 The implications for our understanding of psychiatric disorders are 
evident. Members of the WNT signalling pathway have been reported as 
dysregulated in the hippocampus in psychiatric disorders. TCF4, a downstream 
effector of WNT signalling has been shown to act in concert with NEUROD1 to 
impact on higher-order cognitive processing in mice294. The evidence presented 
by Singh and colleagues292 comprehensively establishes a link between DISC1 
and WNT signalling. Taken together with the role of WNT signalling in 
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NEUROD1 transcription, this evidences a theory whereby DISC1 rs3738401 
impacts on NEUROD1 expression; explaining the results reported in this study. 
 Though no independent association of DISC1 rs3738401 to BPD or SCZ 
has been reported, this does not preclude a role in more subtle aspects of the 
disease state. For example, a strong association with this SNP and resistance 
to drug treatment has recently been reported in two independent populations 
289. Molecular links, such as those highlighted by this study, will hopefully 
contribute to directing future research, increasing our understanding of the role 
this locus plays in psychiatric illness. 
7.2.4 Other Effects 
 The preliminary analysis of the results using Mann-Whitney U test also 
suggested significant effects of dichotomous clinical and demographic 
variables. For the purposes of the current study, the analysis of these effects 
was deemed tertiary to the effects of diagnosis and genotype. Accordingly, 
sample size restricted the ability to fully analyse these effects and sufficiently 
protect against the artefacts of multiple comparisons (with repeated measures 
ANOVA). These results must therefore be interpreted with caution. 
 Nevertheless, noteworthy amongst the findings were significant 
reductions in right hemisphere non-neurogenic HF PDE4B mRNA transcript 
levels and right hemisphere APh FEZ1 mRNA transcript levels (N = 8) when 
compared to the left hemisphere mRNA abundance levels of the same region. 
Though does not correlate to the perceptions of right-sided hyperactivity in 
MDD295, it does however correlate with the suggested lateralisation deficits 
associated with SCZ296; 297. 
 Also detected were reductions in APh FEZ1 and non-neurogenic HF 
DCX mRNA transcript levels in cases with a history of psychosis; when 
compared to those without. The psychosis group was a direct representation of 
a combined SCZ and BPD group. The prospects of an effect of psychosis on 
FEZ1 mRNA in the APh was discussed previously. The effect on DCX however, 
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may also offer further evidence of the growing appreciation of a shared 
molecular basis to these two disorders298. 
 Another interesting detail from the dichotomous demographic and clinical 
variable data was the trend toward an effect of gender on FEZ1 mRNA 
abundance in the non-neurogenic HF. Of all the trends detected, this effect was 
also found to be significant under parametric analysis. Males were found to 
exhibit a significantly higher level of FEZ1 mRNA abundance than females. This 
intrigues, because SCZ has a higher prevalence in males299, but the FEZ1 
expression distortions detected in the current study appear to exhibit a greater 
association with females. Sex-specific effects have been previously reported in 
the DISC1 pathway; these include the under-transmission of a DISC1 haplotype 
in affected females, and 4tag PDE4B SNPs associating with SCZ in females. 
Therefore with potential for a sex-specific effect to moderate FEZ1 mRNA 
abundance in females is not without precedence. 
7.3 Limitations 
 There were a number of limitations encountered whilst conducting the 
current study. Chief amongst these was sample size and thus statistical power. 
The original sample size was reduced due to the tissue availability. However, 
these sample sizes were further reduced for the qPCR analysis in an attempt to 
maintain sufficient RNA quality for accurate quantification. This precluded qPCR 
analysis of the neurogenic HF dissections. For the APh dissections, diagnostic 
group sample sizes ranged from 5 to 10. For the non-neurogenic HF 
dissections, sample group sizes ranged from 3 to 5.  For the quantitative IHC 
assessment sample group sizes ranged from 7 to 15. 
 Though greater group sample sizes would afford greater statistical 
power, the group sizes for the APh dissections and quantitative IHC are 
reasonably informative. The sample sizes in the non-neurogenic HF dissections 
however, are prohibitive to the drawing of accurate conclusions for highly 
heterogeneous disorders like SCZ, MDD and BPD. Future studies may yet 
detect expression abnormalities that have proven beyond data reported here. 
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Laser capture micro-dissection and RNA extraction strategies, such as RNA 
amplification, can provide essential relief in this regard. 
 The reduced statistical power of the qPCR analysis in the APh region 
may go some way to explain the failure to corroborate some of the Lipska and 
colleagues study findings. These include reduced NDEL1 mRNA in SCZ and 
the rs821616-mediated effects on FEZ1 expression at the mRNA level204. 
Conversely, it could be argued that this emphasises the significance of the 
abnormal FEZ1 expression detected in the current study, as similar results were 
previously reported by Lipska and colleagues204. 
 Statistical power due to sample size is familiar problem for post-mortem 
studies. However, this has been mitigated by the use of gene expression quality 
guidelines300 and the robust protections against Type I error utilised, i.e. 
Bonferroni-adjusted alpha levels and the requirement for significant main effects 
to be sustained upon analysis of demographic and clinical variables as 
covariates. This may have increased the risk of Type II error. 
 The further reduction in statistical power visited by outlier removal was 
mitigated by the requirement for outliers to be identified by the Tukey outlier 
labelling rule and a distribution outside 2.5 standard deviations of the mean 
(except for the situations where the Tukey labelling rule could not be applied). 
The proper means of analysing such data whilst maintaining the appropriate 
balance between risk of Type I and Type II errors is still debated. Therefore, 
researchers are better advised to rely on the independent corroboration of 
experimental findings in separate sample sets.  
 For the assessment of quantitative IHC, a major limitation was spots of 
signal saturation apparent on scans of brain sections. These reduced the area 
available for protein density calculations. It also introduced a level of variability 
between cases due to the different locations within perceived ROIs where signal 
saturation was detected in the grey and white matter. The dentate gyrus ROI 
was not affected, due to its relatively small size. The fact that the only significant 
results detected in the quantitative IHC analysis were directly paralleled in both 
the dentate gyrus and APh ROIs suggests that the saturation variability did not 
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affect these specific findings. Despite this, future investigations, using further 
subdivisions of the ROIs used in the present study, may detect effects not 
reported from the current set of data (this could be conducted on the scans 
produced from this present study). 
 Another limitation was the inability to repeat the quantitative IHC 
assessment of NEUROD1 protein. The results indicate that both reductions and 
escalations in NEUROD1 protein density were mediated by DISC1 genotype. 
However, due to experimental constraints, these results could not be 
substantiated in a follow-up experiment. Due to the nature of IHC, large-scale 
assessments of histological slides are generally thought to be semi-quantitative. 
This further necessitates the use of technical replicates for the confident 
reporting of data. Future studies can directly address this limitation, providing 
further evidence of whether DISC1 genotype is associated to NEUROD1 gene 
expression. 
7.4 Conclusions 
 The results of this study suggest that FEZ1, a DISC1 binding partner, is 
aberrantly expressed in the major psychoses relative to controls. The results 
also suggest that DISC1 genotype can exert an influence on the expression of 
FEZ1 at the protein level. The data reported in this study, when examined in the 
context of previous evidences, represents a coherent account of reduced FEZ1 
expression, monitored by DISC1 rs821616 variation, as a feature of psychosis. 
The role of FEZ1, in neuronal migration and microtubule transport, provides 
clues to the mechanisms by which the DISC1 molecular pathway contributes to 
disease. 
 The results also suggest that the mRNA transcript levels of the 
neurogenesis marker DCX, are increased in schizophrenia; the polymorphisms 
of two synaptic plasticity genes are implicated in this increase. In the APh 
region, this is highly suggestive of aberrations in neuroplasticity. However, 
speculation as to the functional implications of abnormal DCX expression may 
be premature. The same applies to the evidence of abnormal NEUROD1 
expression, detected in relation to DISC1 genotype, though future studies with 
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larger sample sizes can help clarify some of these effects. The data reported 
here illuminate the potential mechanisms by which the DISC1 molecular 
pathway may mediate risk for psychiatric illness. This could, in the future, 
directly assist the development of future diagnostic and treatment strategies. 
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9 APPENDICES 
Appendix A Dentate Gyrus Gene Expression 
9-A Table showing recent investigations into dentate gyrus gene expression (pharmacological investigations are shaded grey). 
First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
Namba (2011) NMDA regulates 
migration of newly 
generated neurons. 
Manual dissection of 
DG 
Mouse Disc1 
 
 
 
 
 
 
 
 
 
NDEL1 
Memantine (NMDA 
antagonist): 50mg/kg 
Body weight (B.W.) 
Significant reduction 
in ratio to GAPDH in 
dose-dependent 
manner (p<0.05) 
CPP (NMDA 
antagonist): 10mg/kg 
B.W. Significant 
reduction in ratio to 
GAPDH (p<0.05) 
 
Memantine: 50mg/kg 
qPCR (ΔΔCt); saline 
control; mice injected at 
3 months, killed 1 day 
later: methamphetamine 
2mg/kg B.W. and D-
Cycloserine 30mg/kg 
B.W. produced no 
significant reduction 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
 
 
 
Girdin 
 
 
 
LIS1 
B.W. no significant 
effect (very slight 
increase) 
 
Memantine: 50mg/kg 
B.W. no significant 
effect (very slight 
increase) 
 
Memantine: 50mg/kg 
B.W. no significant 
effect (very slight 
increase) 
Ray (2011) Decreased BDNF, trk-B-
TK+ and GAD67 mRNA 
expression 
Auto-radiographic 
visualisation of DG and 
CA3 from 14µm mid-
hippocampal sections 
GAD67 
 
 
 
DG: 22% reduction in 
SZ mRNA levels 
(p=0.022) 
CA3: No significant 
effect on SZ mRNA 
In-situ hybridization 
(ISH) w/ autoradiogram: 
mean optical density 
(OD) of 3 ROIs in 
hippocampal formation 
subfield; Stanley 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
 
 
 
 
 
BDNF 
 
 
 
 
 
 
 
trkB-TK+ 
levels (p>0.10) 
Fluphenazine: mg 
equivalents exerted 
no significant effect 
on mRNA levels 
 
DG: No significant 
effect on mRNA levels 
(p>0.20) 
CA3: No significant 
effect on mRNA levels 
(p>0.10) 
Fluphenazine: mg 
equivalents exerted 
no significant effect 
on mRNA levels 
 
DG: No significant 
Consortium Study 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
effect on mRNA levels 
(p>0.20) 
CA3: No significant 
effect on mRNA levels 
(p>0.10) 
Fluphenazine: mg 
equivalents exerted 
no significant effect 
on mRNA levels 
Weickert (2008) Reduced DTNBP1 
mRNA 
Medial temporal lobe 
cryo-sectioning, DG 
and CA3 region of 
interest sampling 
DTNBP1 
 
 
 
 
 
 
DG:25% reduction in 
SZ mRNA levels 
(p=0.04) 
CA3: 39% reduction 
in SZ mRNA levels 
(p=0.03) 
Chlorpromazine: 
Dysbindin-1 mRNA 
did not correlate with 
last, daily or lifetime 
ISH diagnostic category 
comparison of auto-
radiographic film 
images using an 
average of 3 slides per 
case/controls; SZ cases 
matched with controls 
(n=10)  
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
 
 
 
Spinophilin 
 
 
 
 
 
 
 
 
 
 
administration 
(p>0.29) 
 
DG: Positive 
correlation with 
DTNBP1 mRNA 
expression in 
DG(p<0.01); ; Trend 
towards positive 
correlation with 
DTNBP1 in CA4 
(p=0.07) 
 
CA3: No positive 
correlation with 
DTNBP1 mRNA 
expression after pH 
correction; Trend 
towards positive 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
 
 
 
 
Synaptophysin 
correlation with 
DTNBP1 in the DG 
(p=0.06) 
 
CA3: Trend towards 
positive correlation 
with DTNBP1 mRNA 
expression in CA3 
(p=0.08) 
Toro (2007) The NR1 NMDA subunit 
and BDNF in temporal 
lobe epilepsy 
Autoradiograph film 
assessment of 3 layers 
of the DG 
NR1 DG: Molecular layer 
NR1 protein levels 
significantly higher in 
TLE sufferers with 
interictal dysphoria 
(p=0.01) 
Immunohistochemistry 
and autoradiography; 
54 hippocampal tissue 
samples from patients 
suffering intractable 
TLE divided into 4 
groups TLE control, 
TLE w/ SZ-like 
symptoms, TLE w/ 
MDD, TLE w/ 
dysphoria;  
 279 
First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
Tian (2007) Immunoreactivity of 43 
kDa growth-associated 
protein 
ROI sampling of CA3 
and inner molecular 
layer of DG 
GAP-43 DG: Trend towards 
correlation with SZ 
and bipolar disorder 
diagnosis with 
reduced GAP-43 
levels [F(3,52)=2.290, 
p=0.089] 
 
CA3: No association 
with SZ diagnosis and 
GAP-43 levels in CA3 
stratum radiatum 
(p=0.308) and stratum 
oriens (p=0.816) 
Immunohistochemistry 
OD readings; Stanley 
Consortium Samples 
Chambers (2005) GAP-43 and 
synaptophysin 
alterations in the DG 
OD of pre-confirmed 
antibody IR was 
measured in the 
dentate gyrus region of 
the medial human 
GAP-43 
 
 
 
DG: Reduced GAP-43 
in inner molecular 
layer (p=0.049) but 
not outer molecular 
layer (p>0.05) 
35 human brains 
(Harvard Brain Tissue 
Resource Centre) 14 
SZ-sufferers, 14 
matched controls, plus 
 280 
First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
hippocampus 
 
Synaptophysin 
 
DG: Reduced 
synaptophysin in 
inner molecular layer 
(p=0.003) and outer 
molecular layer 
(p=0.002) 
7 similarly matched 
BPD controls, minimum 
4 slides used per case 
Rioux and Arnold 
(2005) 
The expression of RAR-
alpha is increased 
Random  sampling and 
optical fractionation of 
dentate granule cells, 
morphologically 
identified from sections 
of  anterior 
hippocampus after 
Nissl staining 
RARα 
 
 
 
 
 
RARγ1 
 
 
Twofold increase in 
the proportion of 
RARα-labelled 
granule cells in SZ 
(n=16, Z=2.8, 
P=0.0045) 
 
No significant change 
in the proportion of 
RARγ1-labelled 
granule cells in SZ 
(n=18, Z=1.6, 
Immunohistochemistry 
OD readings; 10 SZ, 11 
matched controls; 1 
randomly chosen slide 
analysed per subject 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
 
 
RARγ2 
 
 
 
 
RXRβ 
 
 
 
 
 
RXRγ 
P=0.1000) 
 
No significant change 
in the proportion of 
RARγ2-labelled 
granule cells in SZ 
(n=19, Z=1.3, 
P=0.2006) 
 
No significant change 
in the proportion of 
RXRβ-labelled 
granule cells in SZ 
(n=18, Z=0.8, 
P=0.4140) 
 
No significant change 
in the proportion of 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
RXRγ-labelled 
granule cells in SZ 
(n=19, Z=0.3, 
P=0.7751) 
Pantazopoulos (2004) Differences in the 
cellular distribution of 
D1 receptor mRNA 
ROI sampling of DG (4 
boxes for Granule cell 
layer and 2 for CA3) 
D1r CA3: D1 mRNA was 
decreased 21% in SZ 
compared to controls 
(P=0.029); In this 
region 56% of cells 
were D1 mRNA-
negative, a significant 
increase when 
compared to controls 
(P=0.0008) and BPD 
(P=0.009) 
ISH, relative OD; 
Harvard Brain issue 
Resource Centre 16 
controls, 16 SZ, 16 BPD 
plus a comparison 
group of 6 1
st
 degree SZ 
relatives and 6 matched 
controls; 2 sections per 
case analyzed 
Talbot (2004) Dysbindin-1 is reduced 
in intrinsic, 
glutamatergic terminals 
ROI analysis of DG and 
CA2/3 from coronal 
slabs of intermediate 
rostro-caudal levels of 
the HF 
Dysbindin-1 
 
 
 
CA3: 30% mean 
neuropil reduction in 
CA2/3 stratum oriens 
Dysbindin-1 
immunoreactivity 
IHC by net OD (ROI 
minus background); 17 
SZ and 17 matched 
controls, plus Stanley 
Consortium Sample; 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(W=49.0, P=0.003); 
37% mean neuropil 
reduction in CA2/3 
stratum radiatum 
dysbindin-1 
immunoreactivity 
(W=51.5, P=0.0001); 
no dysbindin-1 
reduction in parent 
cells of intrinsic 
glutamatergic input to 
DGiml in SZ 
 
DG: 42% mean 
neuropil reduction in 
DGiml dysbindin-1 
immunoreactivity in 
SZ (W=71.5, 
P=0.0003); 14% 
Dysbindin-1 reduction 
male C3H control mice 
subcutaneously 
implanted with pellet 
(containing polymer or 
polymer + haloperidol 
released as 2mg/kg per 
day), killed 10 weeks 
later for IHC 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
in parent cells of 
intrinsic glutamatergic 
input to DGiml in 
SZ(W=45.5, P=0.03), 
correlating with 
neuropil reductions 
(Spearman r=0.43, 
P=0.01); Stanley 
Consortium SZ cases 
exhibited a mean 
reduction in DGiml 
Dysbindin-1 of 24.9% 
(W=37.0, P=0.035) 
 
Haloperidol: No 
significant affect of 
chronic treatment on 
Dysbindin-1 (P=0.18) 
immunoreactivity in 
DGiml 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
 
VGlut-1 
 
 
 
 
 
 
Haloperidol 
 
DG: 84% mean 
increase in SZ 
(W=47.0, P=0.01); 
correlating inversely 
with Dysbindin-1 
immunoreactivity 
(Spearman r=-0.61, 
P0.0002) 
 
No significant affect of 
chronic treatment on 
VGluT-1 (P=0.20) 
immunoreactivity in 
DGiml 
Nowakowski (2002) Reduction of 
chromogranin B-like 
immunoreactivity 
Immuno-staining 
density assessment of 
dentate gyrus and CA3 
from coronal sections of 
Chromogranin B 
 
 
DG: Significant 
reduction in 
Chromogranin B 
immunoreactivity 
IHC (OD values, 10 
3µm sections per brain); 
17 SZ, 16 control 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
hippocampus 
 
 
 
 
 
Synapsin I 
(inner ml p<0.05; 
outer ml P<0.05) 
 
CA3: Significant 
reduction in 
Chromogranin B 
immunoreactivity 
(P<0.05) 
 
DG: Significant 
reduction in Synapsin 
I immunoreactivity 
(inner ml p<0.05; 
outer ml P<0.05) 
 
CA3: Significant 
reduction in Synapsin 
I immunoreactivity 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
(P<0.01) 
Ilia (2002) Expression of Oct-6, a 
POU III domain TF 
Oct-6 is a POU-III 
domain transcription 
factor active 
developmentally;  
Oct-6 DG: immunoreactivity 
in a subset of neurons 
in the gcl (granule cell 
layer) in dramatic 
contrast with 
comparison control 
specimens; high 
levels of temporal 
lobe western blot 
immuno-staining in 
SZ, compared to very 
little or no staining in 
matched controls 
 
CA3: clear subset of 
pyramidal neurons 
were immunoreactive 
whereas sections 
from the hippocampal 
IHC: Immuno-staining of 
sections of hippocampal 
region, 10 SZ 10 
matched controls; WB: 
Blots of extracts from 
APh region, WB 3 
additional SZ 3 
additional matched 
controls 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
region of 10 control 
comparison subjects 
failed to show any 
staining; high levels of 
temporal lobe western 
blot immuno-staining 
in SZ, compared to 
very little or no 
staining in matched 
controls 
Heckers (2002) Differential hippocampal 
expression of GAD65 
and 67  mRNA 
Microscopic image 
analysis of 
hippocampal sections, 
outlining sectors 
including DG and 
CA2/3 
Glutamic Acid 
Decarboxylase 
(GAD) 
DG+CA3: No 
significant decrease in 
the numerical density 
of GAD65 +ve neurons 
in SZ (F1,14=1.57; 
P=0.23) 
No significant 
decrease in the 
numerical density of 
GAD67 +ve neurons in 
ISH w/ microscopic 
grain counting, 2 10um 
sections per subject 
(inter-slide variability 
controlled) 15 SZ, 15 
BPD, 15 matched con; 
BPD results proved 
significant 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
SZ (F1,14=0.16; 
P=0.70) 
No significant 
decrease in the 
cellular expression of 
GAD65 or GAD67 +ve 
neurons in SZ 
(F1,14=1.65; P=0.22 
and (F1,14=0.005; 
P=0.95 respectively) 
Webster (2002) Regional specificity of 
brain glucocorticoid 
receptor mRNA 
alterations 
Mean optical density 
with ROIs including DG 
gcl and CA3 from mid 
hippocampal sections 
Glucocorticoid 
receptor (GR) 
DG: Significant 
reduction in GR 
mRNA mean values 
(P < 0.01, -43%) 
 
CA3: Significant 
reduction in GR 
mRNA mean values 
(P < 0.01, -42%) 
ISH, calibrated 
densitometric image 
analysis of 
autoradiograms from 
14um sections; Stanley 
Consortium Sample 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
Law (2002)* Asymmetrical 
reductions of 
hippocampal NMDAI 
OD measurements 
taken over DG and CA3 
NMDA receptor 
subunit 1 (NMDAR1) 
DG: Significant left-
sided reductions in 
NMDAR1 mRNA in 
SZ (-61%; p=0.005) 
but not in right side (-
26%, p=0.16), 
hypothesis-testing 
showed SZ diagnosis 
× side interaction not 
significant (F=3.59; 
df=1; p=0.06) and 
reduction remained 
significant when 
expressed as a ratio 
of the significant poly 
A mRNA reductions 
seen in this region 
(p<0.02) 
 
CA3: No significant 
ISH, densitometric 
analysis of 
autoradiographs; 
Stanley Consortium 
Study 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
overall reduction in 
NMDAR1 mRNA in 
SZ (p=0.07), though 
significant reductions 
in left side (p=0.04) 
Fatemi (2000) Reduction in Reelin 
immunoreactivity in 
hippocampus 
Immuno-staining of 
ventral hippocampal 
sections delineated 5 
boundary regions 
including DG 
Reelin DG: significant 
reductions in mean 
reelin positive cell 
numbers in SZ (-42%, 
P<0.05) 
Significant reductions 
adjusted cell densities 
(reelin +ve cell counts 
taking into account 
changes in areas 
measured in controls) 
in SZ (ANOVA, 
P<0.001) 
 
qIHC, cell counting from 
2-4 14um sections per 
subject; Stanley 
Consortium Study 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
CA3: No significant 
reduction seen in 
alveus and whole 
stratum oriens or 
whole strata 
pyramidale, radiatum 
and lucidum  
Crook (2000) Decreased muscarinic 
receptor binding in 
subjects with SZ 
Computerized image 
analysis of all 
hippocampal subfields 
Muscarinic receptor 
binding (M1 and M4) 
DG: significant 
reductions in 
[
3
H]pirenzepine 
binding in SZ 
(p<0.005) 
 
CA3: significant 
reductions in 
[
3
H]pirenzepine 
binding in SZ 
(p<0.0005) 
q-autoradiography, 4 
20um slides per subject 
from left-side 
hippocampal formation; 
15 SZ, 18 con 
:Young (1998) SNAP-25 deficit and OD density reading of SNAP-25 DG: Significant qIHC, image analysis 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
hippocampal 
connectivity in SZ 
hippocampal ROIs incl. 
DG and CA3 
 
 
 
 
 
 
 
 
 
 
 
 
 
Synaptophysin 
reduction in gcl 
immuno-staining 
using 10× microscope  
(percentage area × 
mean pixel intensity) 
in SZ (F=14.79, 
P=0.001) 
When covaried by 
synaptophysin 
immuno-staining, less 
detailed images 
showed significant 
differences between 
SZ and controls (outer 
ml: F=14.46, 
P=0.002) (gcl: 
F=18.65, P=0.0005) 
 
CA3: reductions in 
synaptophysin 
;Frozen samples: 13 SZ 
13con, FFPE 12 SZ 12 
con 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
(P<0.05) did not 
remain significant 
after covariance with 
age and PMI 
 
DG: Significant 
increase in gcl 
immuno-staining 
using 10× microscope 
(percentage area × 
mean pixel intensity) 
in SZ (F=7.29, 
P=0.02) 
Dean (1997) Changes in PKC and 
adenylate cyclase in the 
temporal lobe 
Sections taken from 
hippocampus and DG 
and CA regions 
analysed 
PKC ([
3
H]phorbol 
ester binding) 
 
 
 
DG: Trend towards 
significant decrease in 
SZ (p=0.06) 
 
CA3: no difference in 
whole CA between SZ 
Radioligand assays, 
total minus non-specific 
binding; 20 SZ male 20 
con male, left brain, 3 
20um slides per subject, 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
 
 
AC ([
3
H]forskolin 
binding) 
and con (p>0.05) 
 
DG: Significant 
decrease in SZ 
(p<0.05) 
 
CA: no difference in 
whole CA between SZ 
and con (p>0.05) 
Porter (1997) Distribution of kainite 
receptor subunit 
mRNAs in human 
hippocampus 
Sections taken from 
mid-hippocampus, 
image analysis of 
regions including DG 
and CA3 
KA2 
 
 
 
 
GluR6 
DG: reduction in SZ 
mRNA levels (P<0.05) 
CA3: reduction in SZ 
mRNA levels (P<0.01) 
 
DG: reduction in SZ 
mRNA levels (P<0.05) 
CA3: reduction in SZ 
ISH, densitometric 
readings from 
autoradiograms; 11 SZ, 
13 con; 3-4 10uM 
sections per subject 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
mRNA levels (P<0.05) 
Eastwood (1995) Decreased 
synaptophysin in the 
medial temporal lobe 
Optical density 
readings from 
hippocampal subfield 
regions 
Synaptophysin DG: significant 
reductions in right 
side ml of SZs when 
compared to control 
right side ml (P<0.05); 
intra-group 
asymmetry (greater 
synaptophysin signal 
in the right side ml 
when compared to the 
left in controls, 
P=0.034) not seen in 
SZ 
Immuno-
autoradiography 
densitometric 
quantification of 10um 
medial temporal lobe 
sections, SZ=11, 
matched con=14 
Freedman (1995) Evidence in post-
mortem brain tissue for 
decreased numbers of 
hippocampal nicotinic 
receptors 
Percentage area 
labelling analysis in DG 
and CA3 
Nicotinic cholinergic 
receptors ([
125
I] -α-
bungarotoxin 
binding) 
DG: Significant 
dentate hilus 
reductions in SZ 
(Tukey’s HSD, df=42, 
p<0.01) 
 
Autoradiography, 
computer algorithm 
determination of 
labelling; 8 SZ 8 con, 1 
slide per subject 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
CA3: Significant 
reductions in SZ 
(Tukey’s HSD, df=42, 
p<0.05) 
Eastwood (1995) Decreased expression 
of mRNAs encoding 
non-NMDA glutamate 
receptors 
Separate 
measurements taken 
over DG and CA3 
GluR1 
 
 
 
 
 
 
 
 
 
 
DG:47% (
35
S nCi/g 
tissue equivalent) 
reduction in GluR1 
mRNA in SZ (P<0.01) 
 
CA3: 62% (
35
S nCi/g 
tissue equivalent) 
reduction in GluR1 
mRNA in SZ (P<0.01) 
45% Reduced GluR1 
mRNA abundance per 
neuron (P<0.01) 
 
DG:50% (
35
S nCi/g 
ISH, film 
autoradiography OD 
readings from 18uM 
slides (3 slides per 
subject); 9 SZ, 14 
matched con 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
 
 
 
GluR2 
tissue equivalent) 
reduction in GluR2 
mRNA in SZ (P<0.05) 
 
CA3: 51% (
35
S nCi/g 
tissue equivalent) 
reduction in GluR2 
mRNA in SZ (P<0.02) 
 Approx. 40-45% 
Reduced GluR2 
mRNA abundance per 
neuron (P<0.01) 
 
Lexow (1994)* Alterations in TRH 
receptors in temporal 
lobe of schizophrenics 
Visualisation of 
receptor-binding 
distribution throughout 
hippocampus 
TRH (thyrotrophin-
releasing hormone) 
receptor ([
3
H]MeTRH 
binding) 
DG: significant 
increased specific 
binding in molecular 
layer between SCZ 
and their control, HD, 
ALS and AD 
qAutoradiography; 6 
SZ, 9 con, 4 HD, 4 AD, 
4 ALS; sequential slides 
were used for each 
paired total and 
nonspecific binding 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
counterparts (P<0.003 
by Dunnett’s multiple 
comparison test) 
 
CA3: the density of 
receptor-binding was 
not significantly 
altered 
determination 
Kerwin (1990)* Quantitative auto-
radiographic analysis of 
glutamate binding sites 
Regional analysis of 
hippocampal region 
(incl. DG and CA3) 
Kainate-r ([3H]KA) 
 
 
 
 
 
 
NMDAr 
DG: significant 
bilateral reductions in 
specific binding seen 
in SZ (P<0.01) 
CA3: significant 
bilateral reductions in 
specific binding seen 
in SZ (P<0.01) 
 
DG: no significant 
qAutoradiography, 
specific binding film 
density analysis, 3 
slides per subject;7 SZ 
8 con 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
([3H]glutamate 
binding) 
 
 
 
NMDA Quisqualate 
site ([3H]CNQX 
binding) 
reductions in specific 
binding seen in SZ 
CA3: no significant 
reductions in specific 
binding seen in SZ 
 
DG: no significant 
reductions in specific 
binding seen in SZ 
CA3: significant left-
sided reductions in 
specific binding seen 
in SZ (P<0.05) 
Kiuchi (1989)* Benzodiazepine 
receptors increase in 
post-mortem brain of 
SCZ 
Analysis of 
homogenised sections 
of dentate gyrus and 
CA1-3 
Benzodiazepine 
receptor ([
3
H]-FNT 
binding) 
DG: specific binding 
tended towards an 
increase but not 
significant (P>0.05) 
 
Radio-receptor assays 
of membrane 
homogenates; 10 con, 
13 SZ 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
CA3: specific binding 
in CA1-3 was 
significantly greater in 
SZ than in controls 
Scarr (2007) Altered Hippocampal 
Muscarinic M4, but not 
M1, receptor expression 
Specific binding 
readings taken from 
DG, CA1-3 and  Sub 
(Sub in pirenzepine 
binding only) 
Muscarinic receptor 
binding (M1 and M4) 
 
 
 
 
 
 
 
 
 
DG: decrease in 
[3H]pirenzepine 
binding in tissue from 
subjects with SZ in 
granular molecular 
layer (t=2.81, df=35, 
p=0.008) and 
polymorphic layer 
(t=2.69, df=35, 
p=0.01) 
 
CA3: decrease in 
[3H]pirenzepine 
binding in tissue from 
subjects with SZ 
qAutoradiography; 20 
SZ 20 con, 20um 
sections from left 
hemisphere 
hippocampal blocks, 
(ISH: 15 SZ/con, 12 
10um section) 
 302 
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Contextualisation 
Gene Expression Findings Study Design 
 
 
 
Muscarinic receptor 
mRNA (M1 and M4) 
(t=3.13, df=35, 
p=0.004) 
 
DG AND CA3: 
significant reductions 
in M4 mRNA seen in 
across whole sections 
(F=5.22, df=1,216, 
p=0.02) but no 
significant variation in 
the levels of M4 
mRNA in any 
individual region 
analysed (p=0.135-
0.324) 
Perlman (2005) Alteration in oestrogen 
receptor alpha mRNA 
OD measurements 
taken from DG and 
CA3 
ERα DG: 18.5% reduction 
in mRNA expression 
in SZ (p=0.0121) 
CA3: non-significant 
ISH, auto-radiographic 
calibrated densitometric 
image analysis; Stanley 
consortium study, 2 
14um sections per 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
trend of 9.4% 
reduction in mRNA 
expression in SZ 
Fluphenazine: 
Significant negative 
correlation of mRNA 
density with drug 
exposure found in 
CA3 (r=-0.55, p=0.03) 
but this was 
recapitulated with 
duration of illness (r=-
0.55, p=0.03) 
subject 
Altar (2005) Deficient hippocampal 
neuron expression 
Laser captured dentate 
granule neurons 
 DG: decreases in the 
expression of genes 
encoding energy 
metabolism, 
mitochondrial and 
neuronal functions 
and protein 
Microarray from qPCR, 
2 SZ cohorts (8 SZ 9 
con, 14 SZ 15 con) 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
processing by 
ubiquitin and the 
proteasome 
Zavitsanou (2007) Effects of typical and 
atypical antipsychotics 
on rat brain muscarinic 
receptors 
Regional analysis of 
14um brain sections 
Muscarinic receptors 
(M1/M4)  
 
 
 
([
3
H]pirenzepine 
binding) 
 
 
 
 
 
 
Main effect of 
treatment in DG 
(F=4.479, df=6, 
P0.002) 
 
Haloperidol (typical 
antipsychotic): 37% 
increase in DG 
[
3
H]pirenzepine 
binding in animals 
sacrificed 2h after 
LDA (P=0.001) 
 
Clozapine (atypical 
antipsychotic): 29% 
increase in DG 
Autoradiography; 
Female Sprague 
Dawley rats given 
pellets of haloperidol 
(2mg/kg/day, n=10), 
clozapine 
(1.5mg/kg/day, n=10), 
olanzapine 
(1.2mg/kg/day, n=10) or 
vehicle for 36 days and 
killed (sodium 
pentobarbitone, 
120mk/kg i.p.) 2h or 48h 
after last drug 
administration 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
 
 
 
 
 
 
 
 
M2/M4 ([
3
H]AF-
DX384 binding) 
[
3
H]pirenzepine 
binding in animals 
sacrificed 2h after 
LDA (P=0.022) 
  
Olanzapine (atypical 
antipsychotic): No 
significant effect in 
DG (P>0.05) 
 
Haloperidol (typical 
antipsychotic): No 
significant effect in 
DG (P>0.05) 
 
Clozapine (atypical 
antipsychotic): No 
significant effect in 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
DG (P>0.05) 
 
Olanzapine (atypical 
antipsychotic): No 
significant effect in 
DG (P>0.05) 
Terry (2006) Time-dependent effects 
of haloperidol and 
ziprasidone 
Regional OD analysis 
of 20um interaural 
sections 
NGF 
 
 
 
 
 
 
 
 
Haloperidol: 
Significant increase in 
NGF immunoreactivity 
in DG after 7days 
(p<0.01) and 14days 
(p<0.01) 
administration 
Significant decrease 
in NGF 
immunoreactivity in 
DG after 45days 
(p<0.05) and 90days 
(p<0.001) 
IHC and 
qAutoradiography; Male 
albino Wistar rats 
treated with Haloperidol 
(2mg/kg/day), Zip 
(12mg/kg/day) or 
vehicle dissolved in 
0.1M acetic acid and 
diluted (1:100) in water 
for 7, 14, 45 or 90 days 
then sacrificed 2 weeks 
after last drug exposure 
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Gene Expression Findings Study Design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
administration 
Significant increase in 
NGF immunoreactivity 
in CA3 after 7days 
(p<0.01) and 14days 
(p<0.01) 
administration 
Significant decrease 
in NGF 
immunoreactivity in 
CA3 after 45days 
(p<0.001) and 90days 
(p<0.001) 
administration 
 
Zipra: Significant 
increase in NGF 
immunoreactivity in 
DG after 7days 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(p<0.01) and 14days 
(p<0.05) 
administration 
Significant decrease 
in NGF 
immunoreactivity in 
DG after 90days 
(p<0.001) 
administration 
Significant increase in 
NGF immunoreactivity 
in CA3 after 7days 
(p<0.01) and 14days 
(p<0.01) 
administration 
Significant decrease 
in NGF 
immunoreactivity in 
CA3 after 90days 
(p<0.001) 
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Contextualisation 
Gene Expression Findings Study Design 
 
 
ChAT 
 
 
 
 
 
 
 
 
 
 
 
administration 
 
Haloperidol: 
Significant increase in 
ChAT 
immunoreactivity in 
DG after 7days 
(p<0.05) and 14days 
(p<0.05) 
administration 
Significant decrease 
in ChAT 
immunoreactivity in 
DG after 45days 
(p<0.05) and 90days 
(p<0.001) 
administration 
 
Significant increase in 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ChAT 
immunoreactivity in 
CA3 after 7days 
(p<0.01) and 14days 
(p<0.01) 
administration 
Significant decrease 
in ChAT 
immunoreactivity in 
CA3 after 45days 
(p<0.01) and 90days 
(p<0.001) 
administration 
 
Zpi: Significant 
increase in ChAT 
immunoreactivity in 
DG after 7days 
(p<0.05) and 14days 
(p<0.05) 
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Gene Expression Findings Study Design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
administration 
Significant decrease 
in ChAT 
immunoreactivity in 
DG after 90days 
(p<0.001) 
administration 
 
Significant increase in 
ChAT 
immunoreactivity in 
CA3 after 7days 
(p<0.01) and 14days 
(p<0.05) 
administration 
Significant decrease 
in ChAT 
immunoreactivity in 
CA3 after 90days 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
 
 
 
 
Nicotinic receptors: 
α7 (
125
I-bungarotoxin) 
and α4/β2 
([
3
H]epibatidine) 
 
 
Muscarinic 
receptors: M2 
receptor ([
3
H]AF-
DX384 binding) and 
M1/M4 
([
3
H]pirenzepine 
binding) 
(p<0.001) 
administration 
 
No significant 
differences in binding 
associated with 
different antipsychotic 
treatments in DG and 
CA3 (p>0.05) 
 
No significant 
differences in binding 
associated with 
different antipsychotic 
treatments in DG and 
CA3 (p>0.05) 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
Park (2006) Effects of quetiapine on 
the BDNF expression 
Area of interest OD 
analysis of 10-20um 
sections 
BDNF Quetiapine: significant 
increase in BDNF 
mRNA levels in DG 
(p<0.01) 
No significant effect 
on BDNF mRNA 
levels in CA3 
In both regions 
immobilization stress 
produced a decrease 
(p<0.01) which was 
rescued by drug 
administration 
(p<0.01) 
ISH, 10 section per 
animal; Male Sprague-
Dawley rats treated with 
vehicle (0.8% glacial 
acetic acid, 1ml/kg i.p.) 
or quetiapine (10mg/kg 
i.p.) both with and 
without immobilization 
stress for 3 weeks and 
sacrificed 24h after last 
treatment 
Terry (2005) Chronic exposure to 
typical or atypical 
antipsychotics in 
rodents 
Regional analysis of 
16um sagittal sections 
DISCREPANCY 
BETWEEN BINDING 
TABLE AND WRITTEN 
Nicotinic receptors: 
α7 (
125
I-bungarotoxin) 
Risperidone: 
Significant slight 
reductions in ventral 
DG binding density 
after 90 days of drug 
qAutoradiography; Male 
albino Wistar rats 
treated with Haloperidol 
(2mg/kg/day), 
chlorpromazine 
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Contextualisation 
Gene Expression Findings Study Design 
RESULTS SECTION 
REGARDING 90 DAY 
RIS TREATMENT 
(ventral DG or 
polymorphic DG) 
treatment (P<0.01) 
After 180 days of 
treatment significant 
reductions in medial 
CA2/CA3 (P<0.01) 
and lateral DG (12%, 
P<0.01) 
 
Olanzapine: 
Significant slight 
reductions in ventral 
DG binding density 
after 90 days of drug 
treatment (P<0.01) 
 
Other drugs: No 
significant differences 
of binding levels in 
HAL, CPZ or OPZ 
(10mg/kg/day), 
risperidone 
(2.5mg/kg/day) or 
olanzapine 
(10mg/kg/day) orally in 
drinking water for 90 or 
180 days + a 2 week 
washout period then 
killed 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
treatments groups at 
either 90 or 180 days 
of treatment 
Parikh (2004) Modulation of nerve 
growth factor and 
choline 
acetyltransferase 
expression 
Regional OD analysis 
of 20um (40um for 
ChAT IHC) coronal 
interaural sections 
NGF 
 
 
 
 
 
 
 
 
 
 
 
Haloperidol: 
Significant reductions 
in mean OD of 
stained cells in the 
DG (1mg/kg/day, -
18%, P<0.01; 
2mg/kg/day, -32%, 
P<0.001) and CA3 
(1mg/kg/day, -24%, 
P<0.01; 2mg/kg/day, -
39%, P<0.001) 
 
Risperidone: No 
significant effect on 
mean OD values 
 
qIHC; Male albino 
Wistar rats treated with 
Haloperidol 
(1/2mg/kg/day), 
Risperidone 
(1.25/2.5mg/kg/day), 
Olanzapine 
(5/10mg/kg/day) or 
vehicle dissolved in 
0.1M acetic acid diluted 
(1:100) in water for 45 
days 
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ChAT 
Olanzapine: 
Significant increases 
in mean OD of 
stained cells in the 
DG (5mg/kg/day, 
14%, P<0.05; 
10mg/kg/day, 18%, 
P<0.05) and CA3 
(5mg/kg/day, 19%, 
P<0.05; 10mg/kg/day, 
22%, P<0.05) 
 
Haloperidol: 
Significant reductions 
in fibre pixel density of 
stained neurons in 
DG (1mg/kg/day, -
24%, P<0.05; 
2mg/kg/day, -34%, 
P<0.01) and CA3 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
(1mg/kg/day, -20%, 
P<0.05; 2mg/kg/day, -
28%, P<0.01) 
 
Risperidone: No 
significant effect on 
fibre pixel densities 
 
Olanzapine: 
Significant increases 
in fibre pixel density of 
stained neurons in 
DG (5mg/kg/day, 
16%, P<0.05; 
10mg/kg/day, 18%, 
P<0.05) and CA3 
(5mg/kg/day, 17%, 
P<0.05; 10mg/kg/day, 
34%, P<0.01) 
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Contextualisation 
Gene Expression Findings Study Design 
Lipska (2001) BDNF mRNA 
expression in rat 
hippocampus and 
prefrontal cortex 
Regional analysis of 
DG and CA3 in 20um 
sections 
BDNF Haloperidol: Acute 
treatment produced 
significant reduction in 
DG (21%, 
0.5mg/kg/day) 
Chronic treatment 
produced significant 
reductions in DG 
(19%, 0.5mg/kg/day;  
33%, 1mg/kg/day) 
Chronic treatment 
produced significant 
reductions in CA3 
(both 0.5 and 1 
mg/kg/day, P<0.05), 
acute treatment 
produced no 
significant effect in 
CA3 
ISH and 
qAutoradiography, Male 
Sprague-Dawley pups 
give drug regime for 28 
days (Acute = full dose 
given on 28
th
 day), 
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Clozapine 
(10mg/kg/day): Acute 
treatment produced 
significant 55% 
reduction in DG 
Chronic treatment 
produced significant 
30% reduction in DG 
No significant 
reductions in CA3 
Tarazi (1996)* Regulation of ionotropic 
glutamate receptors 
OD regional analysis of 
16um coronal sections 
NMDA-R (
3
H-MK801 
binding) / AMPA-R 
(
3
H-CNQX binding) / 
Kainite-R (
3
H-kainic 
acid binding) 
SCH23390: sub-
chronic treatment 
showed a trend 
towards an increase 
in MK801 binding in 
the hippocampal 
formation reaching 
statistical significance 
In vitro 
qAutoradiography; Male 
Sprague-Dawley rats 
treated with haloperidol 
(1.5mg/kg/day), 
raclopride 
(10mg/kg/day), 
clozapine 
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First Author (Year) Title (Abbreviation) Adult-NG 
Contextualisation 
Gene Expression Findings Study Design 
in the DG [+30, 
F=16.3, P<0.005 (10 
df)]; no significant 
effects on  receptor 
binding in CA3/DG of 
chronic treatment 
 
Clozapine: No 
significant effects on 
receptor in CA3/DG of 
chronic or sub-chronic 
treatment 
 
Raclopride: No 
significant effects on 
receptor binding in 
CA3/DG of chronic or 
sub-chronic treatment 
 
(25mg/kg/day) or 
SCH23390 
(0.5mg/kg/day) in 
drinking water 
(SCH23390 given 
subcutaneously) for 28 
days (sub-chronic) or 8 
months (chronic), 
animals decapitated 
immediately after LDA 
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Contextualisation 
Gene Expression Findings Study Design 
Haloperidol: No 
significant effects on 
receptor binding in 
CA3/DG of chronic or 
sub-chronic treatment 
Ossowska (2011) Chronic treatments with 
haloperidol and 
clozapine alter the level 
of NMDA-R1 mRNA in 
the rat brain 
Regional analysis of 
hippocampal formation 
subfields in 10um 
coronal sections 
NMDA-R1 mRNA 
(radio-labelled 
oligonucleotide 
binding) 
Haloperidol: 
elevations in the OD 
levels were observed 
in DG, CA3 and CA1; 
however, only in the 
CA1 region were 
these significant 
 
Clozapine: No 
changes in OD levels 
were observed across 
any hippocampal 
formation subfields 
Auto-radiographic 
analysis, 10 Male 
Wistar rats, treated with 
either haloperidol 
(1mg/kg/day), clozapine 
(30mg/kg/day) or 
drinking for 3 months 
then sacrificed 5 days 
after LDA, a inter-
hemispheric mean was 
used 
Abe (2001) Effects of single and Regional analysis of mGluRs 1-5 (radio- PCP: an almost 20% Autoradiography, Male 
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Contextualisation 
Gene Expression Findings Study Design 
repeated phencyclidine 
administration on the 
expression of 
metabotropic glutamate 
receptor 
OD fro DG and CA3 labelled 
oligonucleotide 
binding) 
decrease in mGluR5 
mRNA binding 
observed in DG 
(p=0.004) and CA3 
(p0.002) 1hr after 
single administration; 
decreases in mGluR5 
and mGluR2 binding 
24hr after a single 
administration and 
mGluR5 after 14 days 
administration were 
not significant 
Wistar rats, treated with 
daily i.p. injections of 
PCP (7.5mg/kg) for 
either 1 day and 
sacrificed 1 hr after LDA 
or 14 days and 
sacrificed 24hr after 
LDA, saline was used 
as a control 
Numachi (2004) Psychostimulant alters 
expression of DNA 
Methyltransferase 
(Dnmt) mRNA in the Rat 
Brain 
OD readings from 
14mm coronal sections 
Dnmt2 
 
 
 
 
MAP: 27-39% mRNA-
binding reductions 
seen in DG (P<0.01), 
CA3 (P<0.0001) and 
CA1 (P<0.0001) 24hr 
after drug 
administration 
ISH, Male Wistar Rats 
(7 wks old)) injected w/ 
MAP hydrochloride 
(4mg/kg) and sacrificed 
0, 1, 3, 9, and 24hr after 
drug administration 
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Reelin 
 
MAP: significant 
mRNA reductions 
were only observed in 
the frontal cortex 3hr 
after administration 
(P<0.03) 
Hammonds (2009) Effects of 4-week 
Treatment with Lithium 
and Olanzapine on 
Levels of BDNF, Bcl2 
and phosphorylated 
CREB 
Manual dissection of 
DG 
BDNF 
 
 
 
 
 
 
Bcl-2 
 
Lithium: 4-week 
treatment increased 
levels in DG 
(P=0.016) 
Olanzapine: 4week 
treatment increased 
levels in DG 
(P=0.054) 
 
Lithium: 4-week 
treatment increased 
ELISA, Male Sprague 
Dawley rats, Li-
carbonate pellets 
(0.24%), olanzapine in 
tap water (1.5-2mg/kg) 
or control water and 
pellets for 4 weeks,  
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pCREB 
levels in DG 
(P<0.001) and CA1 
(P=0.025) 
Olanzapine: 4-week 
treatment increased 
levels in DG 
(P<0.001) and 
(P<0.001) 
 
Lithium: 4-week 
treatment increased 
levels in DG 
(P=0.001) and CA1 
(P=0.001) 
Olanzapine: 4-week 
treatment increased 
levels in DG 
(P=0.002) and CA1 
(P=0.003) 
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Appendix B Anterior Hippocampus Coronal Sections 
 Scans of haematoxylin and eosin stained slides of anterior hippocampus coronal sections (provided by the Stanley 
Consortium). 
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Appendix C Parallel Outlier Analyses 
9-B Table of the Spearman’s rank correlations of demographic and clinical variables with the gene expression normalised 
relative quantities (italic headings) in the anterior parahippocampal region (APh), the non-neurogenic hippocampal formation 
(HF) and protein density levels from sections of anterior hippocampus. Asterisk indicates p < 01, double asterisk indicates, p < 
05 
Continuous Variables: Non-Parametric Correlations (w/ Outliers Incl.) 
  
DC
X 
(AP
h) 
DPYS
L2 
(APh) 
FEZ
1 
(AP
h) 
NDE
L1 
(APh
) 
NEURO
D1 
(APh) 
PDE
4B 
(APh
) 
DCX 
(non-
neuroge
nic HF) 
DPYSL
2 (non-
neuroge
nic HF) 
FEZ1 
(non-
neuroge
nic HF) 
NDEL1 
(non-
neuroge
nic HF) 
NEURO
D1 
(non-
neuroge
nic HF) 
PDE4B 
(non-
neuroge
nic HF) 
Absolut
e 
NEURO
D1 
(APh 
Grey 
Matter) 
Absolut
e 
NEURO
D1 
(APh 
White 
Matter) 
Absolut
e 
NEURO
D1 
(Dentat
e 
Gyrus) 
Relati
ve 
FEZ1 
(APh 
Grey 
Matte
r) 
Relati
ve 
FEZ1 
(APh 
White 
Matte
r) 
Relati
ve 
FEZ1 
(Dent
ate 
Gyrus
) 
  qPCR 
Plate 
(APh) 
Correlat
ion 
Coeffici
ent 
-
.390
*
 
-.359
*
 
-
.229 
-.166 -.022 
-
.404
*
 
-.150 -.191 -.368 -.704
**
 .446 .479 .097 -.202 .280 -.016 .048 .190 
P (2-
tailed) .021 .034 .185 .341 .905 .016 .626 .532 .215 .007 .127 .098 .611 .284 .167 .929 .794 .305 
N 35 35 35 35 32 35 13 13 13 13 13 13 30 30 26 32 32 31 
RQI 
(APh) 
Correlat
ion 
Coeffici
ent 
-
.508
**
 
-.172 
-
.357
*
 
-
.620
**
 
-.077 -.314 -.278 .179 .110 .168 .085 -.391 .129 -.002 .268 .234 .148 .248 
P (2-
tailed) .002 .331 .038 .000 .682 .071 .358 .559 .720 .584 .782 .187 .506 .990 .195 .205 .426 .186 
N 34 34 34 34 31 34 13 13 13 13 13 13 29 29 25 31 31 30 
qPCR 
Plate 
(non-
neurogen
ic HF) 
Correlat
ion 
Coeffici
ent 
-
.280 
.361 
.671
*
 
-.462 -.265 .711
**
 .677
**
 -.119 -.184 -.089 -.612
*
 .251 -.226 .365 -.378 -.464 .040 -.144 
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Continuous Variables: Non-Parametric Correlations (w/ Outliers Incl.) 
  
DC
X 
(AP
h) 
DPYS
L2 
(APh) 
FEZ
1 
(AP
h) 
NDE
L1 
(APh
) 
NEURO
D1 
(APh) 
PDE
4B 
(APh
) 
DCX 
(non-
neuroge
nic HF) 
DPYSL
2 (non-
neuroge
nic HF) 
FEZ1 
(non-
neuroge
nic HF) 
NDEL1 
(non-
neuroge
nic HF) 
NEURO
D1 
(non-
neuroge
nic HF) 
PDE4B 
(non-
neuroge
nic HF) 
Absolut
e 
NEURO
D1 
(APh 
Grey 
Matter) 
Absolut
e 
NEURO
D1 
(APh 
White 
Matter) 
Absolut
e 
NEURO
D1 
(Dentat
e 
Gyrus) 
Relati
ve 
FEZ1 
(APh 
Grey 
Matte
r) 
Relati
ve 
FEZ1 
(APh 
White 
Matte
r) 
Relati
ve 
FEZ1 
(Dent
ate 
Gyrus
) 
P (2-
tailed) .355 .226 .012 .112 .405 .006 .003 .649 .480 .733 .012 .332 .437 .200 .183 .061 .880 .582 
N 13 13 13 13 12 13 17 17 17 17 16 17 14 14 14 17 17 17 
RQI 
(non-
neurogen
ic HF) 
Correlat
ion 
Coeffici
ent 
.052 .041 .044 .122 -.232 .177 -.236 -.303 -.494
*
 .004 -.033 -.403 .210 .454 -.007 .394 .022 .049 
P (2-
tailed) .865 .893 .886 .692 .467 .563 .361 .237 .044 .989 .905 .109 .470 .103 .982 .118 .933 .851 
N 13 13 13 13 12 13 17 17 17 17 16 17 14 14 14 17 17 17 
age at 
death 
(years) 
Correlat
ion 
Coeffici
ent 
-
.001 
.161 .128 .128 -.121 .140 -.080 -.075 -.223 -.428 -.028 -.004 .088 .144 -.098 -.015 -.260 -.066 
P (2-
tailed) .995 .355 .462 .465 .510 .422 .761 .775 .389 .087 .918 .989 .576 .357 .551 .920 .068 .654 
N 35 35 35 35 32 35 17 17 17 17 16 17 43 43 39 50 50 49 
age of 
onset of 
disease 
(years) 
Correlat
ion 
Coeffici
ent 
.154 -.044 
-
.233 
.182 .142 .045 -.585
*
 -.401 -.348 -.070 .186 -.552
*
 .034 .020 .111 -.035 .144 -.198 
P (2-
tailed) .378 .802 .177 .294 .437 .796 .014 .111 .171 .791 .491 .022 .829 .899 .501 .810 .317 .173 
N 35 35 35 35 32 35 17 17 17 17 16 17 43 43 39 50 50 49 
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Continuous Variables: Non-Parametric Correlations (w/ Outliers Incl.) 
  
DC
X 
(AP
h) 
DPYS
L2 
(APh) 
FEZ
1 
(AP
h) 
NDE
L1 
(APh
) 
NEURO
D1 
(APh) 
PDE
4B 
(APh
) 
DCX 
(non-
neuroge
nic HF) 
DPYSL
2 (non-
neuroge
nic HF) 
FEZ1 
(non-
neuroge
nic HF) 
NDEL1 
(non-
neuroge
nic HF) 
NEURO
D1 
(non-
neuroge
nic HF) 
PDE4B 
(non-
neuroge
nic HF) 
Absolut
e 
NEURO
D1 
(APh 
Grey 
Matter) 
Absolut
e 
NEURO
D1 
(APh 
White 
Matter) 
Absolut
e 
NEURO
D1 
(Dentat
e 
Gyrus) 
Relati
ve 
FEZ1 
(APh 
Grey 
Matte
r) 
Relati
ve 
FEZ1 
(APh 
White 
Matte
r) 
Relati
ve 
FEZ1 
(Dent
ate 
Gyrus
) 
duration 
of 
disease 
(years) 
Correlat
ion 
Coeffici
ent 
.028 -.183 
-
.276 
.218 -.066 -.018 -.375 -.129 -.114 .012 .272 -.325 -.075 -.028 -.192 -.150 -.203 -.105 
P (2-
tailed) .873 .292 .109 .208 .721 .918 .138 .622 .663 .962 .309 .203 .631 .861 .242 .298 .158 .471 
N 35 35 35 35 32 35 17 17 17 17 16 17 43 43 39 50 50 49 
lifetime 
quantity 
of 
fluphena
zine or 
equivalen
t (mg) 
Correlat
ion 
Coeffici
ent 
.072 -.102 
-
.449
**
 
.107 .006 -.159 -.472 .261 .206 .130 .477 -.297 -.170 -.137 -.132 -.060 -.038 .108 
P (2-
tailed) .682 .561 .007 .540 .974 .362 .056 .312 .428 .618 .062 .248 .277 .381 .424 .677 .793 .459 
N 35 35 35 35 32 35 17 17 17 17 16 17 43 43 39 50 50 49 
severity 
of 
substanc
e abuse 
Correlat
ion 
Coeffici
ent 
-
.134 
-.168 
-
.228 
-.105 .107 -.197 -.524
*
 .110 .237 .162 .178 -.387 -.251 -.025 -.130 -.157 .001 -.162 
P (2-
tailed) .444 .335 .189 .547 .560 .257 .031 .673 .359 .536 .510 .124 .105 .872 .431 .276 .994 .267 
N 35 35 35 35 32 35 17 17 17 17 16 17 43 43 39 50 50 49 
severity 
of alcohol 
abuse 
Correlat
ion 
Coeffici
ent 
-
.133 
.229 
-
.039 
.005 .331 -.181 -.427 .272 .200 .066 .326 -.167 -.267 -.070 -.030 .020 -.036 -.068 
P (2-
tailed) .447 .186 .823 .977 .064 .299 .088 .291 .441 .800 .217 .523 .084 .654 .856 .892 .803 .641 
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Continuous Variables: Non-Parametric Correlations (w/ Outliers Incl.) 
  
DC
X 
(AP
h) 
DPYS
L2 
(APh) 
FEZ
1 
(AP
h) 
NDE
L1 
(APh
) 
NEURO
D1 
(APh) 
PDE
4B 
(APh
) 
DCX 
(non-
neuroge
nic HF) 
DPYSL
2 (non-
neuroge
nic HF) 
FEZ1 
(non-
neuroge
nic HF) 
NDEL1 
(non-
neuroge
nic HF) 
NEURO
D1 
(non-
neuroge
nic HF) 
PDE4B 
(non-
neuroge
nic HF) 
Absolut
e 
NEURO
D1 
(APh 
Grey 
Matter) 
Absolut
e 
NEURO
D1 
(APh 
White 
Matter) 
Absolut
e 
NEURO
D1 
(Dentat
e 
Gyrus) 
Relati
ve 
FEZ1 
(APh 
Grey 
Matte
r) 
Relati
ve 
FEZ1 
(APh 
White 
Matte
r) 
Relati
ve 
FEZ1 
(Dent
ate 
Gyrus
) 
N 35 35 35 35 32 35 17 17 17 17 16 17 43 43 39 50 50 49 
PH Correlat
ion 
Coeffici
ent 
-
.135 
.130 
-
.064 
-
.359
*
 
-.268 -.122 -.326 -.350 -.115 -.031 -.257 -.332 -.299 -.176 .002 -.040 -.222 .022 
P (2-
tailed) .440 .457 .715 .034 .137 .485 .201 .169 .660 .905 .336 .192 .051 .259 .991 .782 .121 .880 
N 35 35 35 35 32 35 17 17 17 17 16 17 43 43 39 50 50 49 
mass of 
brain (g) 
Correlat
ion 
Coeffici
ent 
.131 .095 .129 .014 .346 .027 .028 .158 .128 .247 .041 -.106 -.004 -.208 .103 .002 .080 .047 
P (2-
tailed) .454 .589 .461 .938 .053 .877 .914 .544 .626 .340 .879 .687 .979 .180 .531 .988 .581 .751 
N 35 35 35 35 32 35 17 17 17 17 16 17 43 43 39 50 50 49 
post-
mortem 
interval 
(hours) 
Correlat
ion 
Coeffici
ent 
.389
*
 
-.032 .222 .192 -.123 .212 .302 .201 .209 .214 -.018 .292 .080 -.117 .005 -.152 .251 .056 
P (2-
tailed) .021 .855 .199 .269 .502 .222 .238 .438 .421 .410 .948 .255 .610 .456 .976 .292 .079 .704 
N 35 35 35 35 32 35 17 17 17 17 16 17 43 43 39 50 50 49 
STORAG
E 
(DAYS) 
Correlat
ion 
Coeffici
ent 
.424
*
 
-.192 
-
.266 
.554
**
 -.191 -.005 -.654
**
 .140 .194 .110 .612
*
 -.267 -.106 .024 -.013 .156 -.108 -.111 
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Continuous Variables: Non-Parametric Correlations (w/ Outliers Incl.) 
  
DC
X 
(AP
h) 
DPYS
L2 
(APh) 
FEZ
1 
(AP
h) 
NDE
L1 
(APh
) 
NEURO
D1 
(APh) 
PDE
4B 
(APh
) 
DCX 
(non-
neuroge
nic HF) 
DPYSL
2 (non-
neuroge
nic HF) 
FEZ1 
(non-
neuroge
nic HF) 
NDEL1 
(non-
neuroge
nic HF) 
NEURO
D1 
(non-
neuroge
nic HF) 
PDE4B 
(non-
neuroge
nic HF) 
Absolut
e 
NEURO
D1 
(APh 
Grey 
Matter) 
Absolut
e 
NEURO
D1 
(APh 
White 
Matter) 
Absolut
e 
NEURO
D1 
(Dentat
e 
Gyrus) 
Relati
ve 
FEZ1 
(APh 
Grey 
Matte
r) 
Relati
ve 
FEZ1 
(APh 
White 
Matte
r) 
Relati
ve 
FEZ1 
(Dent
ate 
Gyrus
) 
P (2-
tailed) .011 .269 .123 .001 .296 .978 .004 .593 .456 .673 .012 .300 .499 .876 .936 .278 .455 .449 
N 35 35 35 35 32 35 17 17 17 17 16 17 43 43 39 50 50 49 
 
9-C Table showing the results of Mann-Whitney U testing of dichotomous demographic and clinical variables for effects on the 
gene expression normalised relative quantities (italic headings) in the anterior parahippocampal region (APh), the non-
neurogenic hippocampal formation (HF) and protein density levels from section of anterior hippocampus 
Dichotomous Variables: Non-Parametric Tests (w/ Outliers Incl.) 
  
DCX 
(APh) 
DPYS
L2 
(APh) 
FEZ1 
(APh) 
NDEL
1 
(APh) 
NEURO
D1 
(APh) 
PDE4
B 
(APh) 
DCX 
(non-
neuroge
nic HF) 
DPYSL
2 (non-
neuroge
nic HF) 
FEZ1 
(non-
neuroge
nic HF) 
NDEL1 
(non-
neuroge
nic HF) 
NEURO
D1 
(non-
neuroge
nic HF) 
PDE4B 
(non-
neuroge
nic HF) 
Absolut
e 
NEURO
D1 
(APh 
Grey 
Matter) 
Absolut
e 
NEURO
D1 
(APh 
White 
Matter) 
Absolut
e 
NEURO
D1 
(Dentat
e 
Gyrus) 
Relati
ve 
FEZ1 
(APh 
Grey 
Matte
r) 
Relati
ve 
FEZ1 
(APh 
White 
Matte
r) 
Relati
ve 
FEZ1 
(Dent
ate 
Gyrus
) 
female N 15 15 15 15 14 15 9 9 9 9 9 9 18 18 15 22 22 21 
Mean 
Rank 18.40 14.33 18.20 17.40 14.71 20.20 10.00 7.44 7.44 6.89 7.78 10.22 23.67 24.06 19.33 23.73 25.23 24.52 
Sum 
of 
Ranks 
276.0
0 
215.0
0 
273.0
0 
261.0
0 
206.00 
303.0
0 
90.00 67.00 67.00 62.00 70.00 92.00 426.00 433.00 290.00 
522.0
0 
555.0
0 
515.0
0 
male N 20 20 20 20 18 20 8 8 8 8 7 8 25 25 24 28 28 28 
Mean 
Rank 17.70 20.75 17.85 18.45 17.89 16.35 7.88 10.75 10.75 11.38 9.43 7.63 20.80 20.52 20.42 26.89 25.71 25.36 
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Dichotomous Variables: Non-Parametric Tests (w/ Outliers Incl.) 
  
DCX 
(APh) 
DPYS
L2 
(APh) 
FEZ1 
(APh) 
NDEL
1 
(APh) 
NEURO
D1 
(APh) 
PDE4
B 
(APh) 
DCX 
(non-
neuroge
nic HF) 
DPYSL
2 (non-
neuroge
nic HF) 
FEZ1 
(non-
neuroge
nic HF) 
NDEL1 
(non-
neuroge
nic HF) 
NEURO
D1 
(non-
neuroge
nic HF) 
PDE4B 
(non-
neuroge
nic HF) 
Absolut
e 
NEURO
D1 
(APh 
Grey 
Matter) 
Absolut
e 
NEURO
D1 
(APh 
White 
Matter) 
Absolut
e 
NEURO
D1 
(Dentat
e 
Gyrus) 
Relati
ve 
FEZ1 
(APh 
Grey 
Matte
r) 
Relati
ve 
FEZ1 
(APh 
White 
Matte
r) 
Relati
ve 
FEZ1 
(Dent
ate 
Gyrus
) 
Sum 
of 
Ranks 
354.0
0 
415.0
0 
357.0
0 
369.0
0 
322.00 
327.0
0 
63.00 86.00 86.00 91.00 66.00 61.00 520.00 513.00 490.00 
753.0
0 
720.0
0 
710.0
0 
Total N 35 35 35 35 32 35 17 17 17 17 16 17 43 43 39 50 50 49 
 
Mann-
Whitn
ey U 
144.0
00 
95.00
0 
147.0
00 
141.0
00 
101.000 
117.0
00 
27.000 22.000 22.000 17.000 25.000 25.000 195.000 188.000 170.000 
269.0
00 
302.0
00 
284.0
00 
 
Wilcox
on W 
354.0
00 
215.0
00 
357.0
00 
261.0
00 
206.000 
327.0
00 
63.000 67.000 67.000 62.000 70.000 61.000 520.000 513.000 290.000 
522.0
00 
555.0
00 
515.0
00 
 
Z 
-.200 -1.833 -.100 -.300 -.950 
-
1.100 
-.866 -1.347 -1.347 -1.828 -.688 -1.058 -.739 -.911 -.289 -.762 -.117 -.202 
 
p (2-
tailed) .841 .067 .920 .764 .342 .271 .386 .178 .178 .068 .491 .290 .460 .362 .773 .446 .907 .840 
Death by 
suicide: 
yes 
N 9 9 9 9 8 9 6 6 6 6 5 6 13 13 11 18 18 17 
Mean 
Rank 17.11 12.78 15.33 17.22 14.38 16.22 6.67 8.50 8.17 9.83 9.20 5.50 14.46 18.69 18.64 23.56 25.67 24.53 
Sum 
of 
Ranks 
154.0
0 
115.0
0 
138.0
0 
155.0
0 
115.00 
146.0
0 
40.00 51.00 49.00 59.00 46.00 33.00 188.00 243.00 205.00 
424.0
0 
462.0
0 
417.0
0 
no N 26 26 26 26 24 26 11 11 11 11 11 11 30 30 28 32 32 32 
Mean 
Rank 18.31 19.81 18.92 18.27 17.21 18.62 10.27 9.27 9.45 8.55 8.18 10.91 25.27 23.43 20.54 26.59 25.41 25.25 
Sum 
of 
Ranks 
476.0
0 
515.0
0 
492.0
0 
475.0
0 
413.00 
484.0
0 
113.00 102.00 104.00 94.00 90.00 120.00 758.00 703.00 575.00 
851.0
0 
813.0
0 
808.0
0 
Total N 35 35 35 35 32 35 17 17 17 17 16 17 43 43 39 50 50 49 
 
Mann-
Whitn
ey U 
109.0
00 
70.00
0 
93.00
0 
110.0
00 
79.000 
101.0
00 
19.000 30.000 28.000 28.000 24.000 12.000 97.000 152.000 139.000 
253.0
00 
285.0
00 
264.0
00 
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Dichotomous Variables: Non-Parametric Tests (w/ Outliers Incl.) 
  
DCX 
(APh) 
DPYS
L2 
(APh) 
FEZ1 
(APh) 
NDEL
1 
(APh) 
NEURO
D1 
(APh) 
PDE4
B 
(APh) 
DCX 
(non-
neuroge
nic HF) 
DPYSL
2 (non-
neuroge
nic HF) 
FEZ1 
(non-
neuroge
nic HF) 
NDEL1 
(non-
neuroge
nic HF) 
NEURO
D1 
(non-
neuroge
nic HF) 
PDE4B 
(non-
neuroge
nic HF) 
Absolut
e 
NEURO
D1 
(APh 
Grey 
Matter) 
Absolut
e 
NEURO
D1 
(APh 
White 
Matter) 
Absolut
e 
NEURO
D1 
(Dentat
e 
Gyrus) 
Relati
ve 
FEZ1 
(APh 
Grey 
Matte
r) 
Relati
ve 
FEZ1 
(APh 
White 
Matte
r) 
Relati
ve 
FEZ1 
(Dent
ate 
Gyrus
) 
 
Wilcox
on W 
154.0
00 
115.0
00 
138.0
00 
155.0
00 
115.000 
146.0
00 
40.000 51.000 49.000 94.000 90.000 33.000 188.000 243.000 205.000 
424.0
00 
813.0
00 
417.0
00 
 
Z -.302 -1.774 -.906 -.264 -.740 -.604 -1.407 -.302 -.503 -.503 -.397 -2.111 -2.592 -1.137 -.468 -.707 -.061 -.168 
 
p (2-
tailed) .763 .076 .365 .792 .459 .546 .159 .763 .615 .615 .692 .035 .010 .255 .640 .479 .952 .867 
With 
Psychosi
s 
N 17 17 17 17 15 17 7 7 7 7 7 7 21 21 20 24 24 23 
Mean 
Rank 17.88 15.59 12.29 18.24 15.47 15.41 5.86 11.14 11.00 10.14 11.43 7.29 18.95 21.14 18.15 24.79 25.38 27.52 
Sum 
of 
Ranks 
304.0
0 
265.0
0 
209.0
0 
310.0
0 
232.00 
262.0
0 
41.00 78.00 77.00 71.00 80.00 51.00 398.00 444.00 363.00 
595.0
0 
609.0
0 
633.0
0 
Without 
Psychosi
s 
N 18 18 18 18 17 18 10 10 10 10 9 10 22 22 19 26 26 26 
Mean 
Rank 18.11 20.28 23.39 17.78 17.41 20.44 11.20 7.50 7.60 8.20 6.22 10.20 24.91 22.82 21.95 26.15 25.62 22.77 
Sum 
of 
Ranks 
326.0
0 
365.0
0 
421.0
0 
320.0
0 
296.00 
368.0
0 
112.00 75.00 76.00 82.00 56.00 102.00 548.00 502.00 417.00 
680.0
0 
666.0
0 
592.0
0 
Total N 35 35 35 35 32 35 17 17 17 17 16 17 43 43 39 50 50 49 
 
Mann-
Whitn
ey U 
151.0
00 
112.0
00 
56.00
0 
149.0
00 
112.000 
109.0
00 
13.000 20.000 21.000 27.000 11.000 23.000 167.000 213.000 153.000 
295.0
00 
309.0
00 
241.0
00 
 
Wilcox
on W 
304.0
00 
265.0
00 
209.0
00 
320.0
00 
232.000 
262.0
00 
41.000 75.000 76.000 82.000 56.000 51.000 398.000 444.000 363.000 
595.0
00 
609.0
00 
592.0
00 
 
Z 
-.066 -1.353 
-
3.201 
-.132 -.585 
-
1.452 
-2.147 -1.464 -1.366 -.781 -2.170 -1.171 -1.555 -.437 -1.040 -.330 -.058 -1.162 
 
p (2-
tailed) .947 .176 .001 .895 .558 .146 .032 .143 .172 .435 .030 .242 .120 .662 .299 .741 .954 .245 
Hemisph N 13 13 13 13 12 13 9 9 9 9 8 9 19 19 18 23 23 22 
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Dichotomous Variables: Non-Parametric Tests (w/ Outliers Incl.) 
  
DCX 
(APh) 
DPYS
L2 
(APh) 
FEZ1 
(APh) 
NDEL
1 
(APh) 
NEURO
D1 
(APh) 
PDE4
B 
(APh) 
DCX 
(non-
neuroge
nic HF) 
DPYSL
2 (non-
neuroge
nic HF) 
FEZ1 
(non-
neuroge
nic HF) 
NDEL1 
(non-
neuroge
nic HF) 
NEURO
D1 
(non-
neuroge
nic HF) 
PDE4B 
(non-
neuroge
nic HF) 
Absolut
e 
NEURO
D1 
(APh 
Grey 
Matter) 
Absolut
e 
NEURO
D1 
(APh 
White 
Matter) 
Absolut
e 
NEURO
D1 
(Dentat
e 
Gyrus) 
Relati
ve 
FEZ1 
(APh 
Grey 
Matte
r) 
Relati
ve 
FEZ1 
(APh 
White 
Matte
r) 
Relati
ve 
FEZ1 
(Dent
ate 
Gyrus
) 
ere: right Mean 
Rank 16.46 17.77 13.62 18.08 12.00 13.77 6.44 8.78 9.22 10.11 9.88 5.56 20.16 22.16 21.39 25.48 25.26 21.82 
Sum 
of 
Ranks 
214.0
0 
231.0
0 
177.0
0 
235.0
0 
144.00 
179.0
0 
58.00 79.00 83.00 91.00 79.00 50.00 383.00 421.00 385.00 
586.0
0 
581.0
0 
480.0
0 
left N 22 22 22 22 20 22 8 8 8 8 8 8 24 24 21 27 27 27 
Mean 
Rank 18.91 18.14 20.59 17.95 19.20 20.50 11.88 9.25 8.75 7.75 7.13 12.88 23.46 21.88 18.81 25.52 25.70 27.59 
Sum 
of 
Ranks 
416.0
0 
399.0
0 
453.0
0 
395.0
0 
384.00 
451.0
0 
95.00 74.00 70.00 62.00 57.00 103.00 563.00 525.00 395.00 
689.0
0 
694.0
0 
745.0
0 
Total N 35 35 35 35 32 35 17 17 17 17 16 17 43 43 39 50 50 49 
 
Mann-
Whitn
ey U 
123.0
00 
140.0
00 
86.00
0 
142.0
00 
66.000 
88.00
0 
13.000 34.000 34.000 26.000 21.000 5.000 193.000 225.000 164.000 
310.0
00 
305.0
00 
227.0
00 
 
Wilcox
on W 
214.0
00 
231.0
00 
177.0
00 
395.0
00 
144.000 
179.0
00 
58.000 79.000 70.000 62.000 57.000 50.000 383.000 525.000 395.000 
586.0
00 
581.0
00 
480.0
00 
 
Z 
-.683 -.102 
-
1.946 
-.034 -2.102 
-
1.878 
-2.213 -.192 -.192 -.962 -1.155 -2.983 -.856 -.073 -.704 -.010 -.107 -1.407 
  
p (2-
tailed) .495 .918 .052 .973 .036 .060 .027 .847 .847 .336 .248 .003 .392 .942 .481 .992 .915 .159 
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